mitoxantrone profile

Mitoxantrone is a synthetic anthracenedione antineoplastic agent. Its synthesis involves a multi-step process, starting from anthraquinone. It acts by inhibiting DNA topoisomerase II, an enzyme essential for DNA replication and repair. This inhibition leads to double-strand DNA breaks, ultimately causing cell death. Mitoxantrone is used in the treatment of various cancers, including acute non-lymphocytic leukemia, breast cancer, and multiple myeloma. Its importance lies in its ability to target rapidly dividing cells, making it effective against cancers. The study of mitoxantrone continues to focus on optimizing its therapeutic efficacy, reducing its side effects, and exploring its potential applications in other diseases. This ongoing research aims to improve patient outcomes and develop novel therapeutic strategies.'

Mitoxantrone: An anthracenedione-derived antineoplastic agent. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

mitoxantrone : A dihydroxyanthraquinone that is 1,4-dihydroxy-9,10-anthraquinone which is substituted by 6-hydroxy-1,4-diazahexyl groups at positions 5 and 8. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

ID Source	ID
PubMed CID	4212
CHEMBL ID	58
CHEBI ID	50729
SCHEMBL ID	3000
MeSH ID	M0013954

Synonym
smr001549953
mitoxantrone, mitoxantrone hydrochloride, mitoxantrone dihydrochloride, mitoxanthrone hydrochloride
BIDD:PXR0181
9,10-anthracenedione, 1,4-dihydroxy-5,8-bis((2-((2-hydroxyethyl)amino)ethyl)amino)-
1,4-dihydroxy-5,8-bis(5-hydroxy-3-azapentylamino)anthrachinon
mitoxantronum [inn-latin]
5,8-bis((2-((2-hydroxyethyl)amino)ethyl)amino)-1,4-dihydroxyanthraquinone
mitoxantrone [inn]
1,4-dihydroxy-5,8-bis(2-((2-hydroxyethyl)amino)ethylamino)-9,10-anthracenedione
mitozantrone
anthraquinone, 5,8-bis((2-((2-hydroxyethyl)amino)ethyl)amino)-1,4-dihydroxy-
brn 2795126
mitoxanthrone ,
mitoxantrona [inn-spanish]
nsc 279836
ccris 7604
mitoxantron
MLS001333711 ,
AKOS005564036
AB00053716-18
AB00053716-19
BRD-K21680192-300-05-2
ksc-19-204
KUC108634N
smr000058480
MIX ,
1,4-dihydroxy-5,8-bis({2-[(2-hydroxyethyl)amino]ethyl}amino)-9,10-anthracenedione
KBIO1_000516
DIVK1C_000516
NCI60_002535
NCI60_002276
SPECTRUM_001655
BSPBIO_003160
lopac-m-6545
cas-70476-82-3
NCGC00015693-01
NCGC00015693-02
LOPAC0_000779
IDI1_000516
nsc301739
dhad
nsc299195
1,4-dihydroxy-5,8-bis[[2-[(2-hydroxyethyl)amino]ethyl]amino]-9,10-anthracenedione
nsc279836
1,4-dihydroxy-5,8-bis[2-(2-hydroxyethylamino)ethylamino]anthracene-9,10-dione
dhaq (diacetate salt)
9, 1,4-dihydroxy-5,8-bis[[2-[(2-hydroxyethyl)amino]ethyl] amino]-
mls002703044 ,
mitoxantrone (free base)
nsc-279836
BPBIO1_000627
PRESTWICK3_000385
NEURO_000153
SPECTRUM5_001205
mitoxantronum
1,4-dihydroxy-5,8-bis({2-[(2-hydroxyethyl)amino]ethyl}amino)anthracene-9,10-dione
mitoxantrona
CHEBI:50729 ,
dhaq
AB00053716
65271-80-9
mitoxantrone
1,4-bis(2-(2-hydroxyethylamino)ethyl)amino)-5,8-dihydroxyanthraquinone
DB01204
2FUM
SMP2_000179
KBIO2_002135
KBIO2_007271
KBIO2_004703
KBIO3_002660
KBIOSS_002135
KBIOGR_001531
SPBIO_002490
SPECTRUM2_000908
PRESTWICK1_000385
NINDS_000516
SPECTRUM4_000866
SPECTRUM3_001590
PRESTWICK0_000385
SPBIO_000756
PRESTWICK2_000385
BSPBIO_000569
NCGC00162251-01
HMS2090D05
BRD-K21680192-300-07-8
NCGC00015693-04
SR-01000076001-7
sr-01000076001
VU0244399-2
misostol
CHEMBL58
misostol (tn)
mitoxantrone (inn)
D08224
STK631833
9,10-anthracenedione, 1,4-dihydroxy-5,8-bis[[2-[(2-hydroxyethyl)amino]ethyl]amino]-
CCG-36371
NCGC00015693-03
NCGC00015693-06
NCGC00015693-05
BRD-K21680192-001-01-5
BCP9000931
unii-bz114nvm5p
mitoxantrone [inn:ban]
bz114nvm5p ,
FT-0630752
BRD-K21680192-001-11-4
S1889
NCGC00015693-08
BRD-K21680192-300-10-2
BRD-K21680192-300-12-8
gtpl7242
1,4-dihydroxy-5,8-bis({2-[(2-hydroxyethyl)amino]ethyl}amino)-9,10-dihydroanthracene-9,10-dione
1,4-bis[2-(2-hydroxyethylamino)ethylamino]-5,8-dihydroxyanthraquinone
1,4-dihydroxy-5,8-bis[[2-(2-hydroxyethylamino)ethyl]amino]anthraquinone
1,4-bis[2-(2-hydroxyethylamino)-ethylamino]-5,8-dihydroxyanthraquinone
mitoxantrone [iarc]
mitoxantrone [vandf]
mitoxantrone [mi]
mitoxantrone [who-dd]
HY-13502
SCHEMBL3000
AB00053716-22
DTXSID4046947 ,
immunex (salt/mix)
1,4-dihydroxy-5,8-bis-[[2-[(2-hydroxyethyl)amino]ethyl]amino]anthraquinone
mitoxantrone hydrochloride (salt/mix)
1,4-bis[2-(2-hydroxyethylamino)ethylamino]-5,8-bis(oxidanyl)anthracene-9,10-dione;hydrochloride
cid_4212
bdbm67690
1,4-dihydroxy-5,8-bis[2-(2-hydroxyethylamino)ethylamino]-9,10-anthraquinone;hydrochloride
cid_5458171
1,4-dihydroxy-5,8-bis[2-(2-hydroxyethylamino)ethylamino]anthracene-9,10-dione;hydrochloride
AB00053716_24
AB00053716_23
HMS3655E20
SBI-0050757.P003
SW196745-6
1,4-dihydroxy-5,8-bis(2-(2-hydroxyethylamino)ethylamino)anthracene-9,10-dione
mitoxantrone; 1,4-dihydroxy-5,8-bis({2-[(2-hydroxyethyl)amino]ethyl}amino)anthra-9,10-quinone
M3133
1,4-dihydroxy-5,8-bis[[2-[(2-hydroxyethyl)amino]ethyl]amino]anthracene-9,10-dione
SY226320
mfcd00242942
FT-0672423
1,4-dihydroxy-5,8-bis((2-((2-hydroxyethyl)amino)ethyl)amino)anthracene-9,10-dione
AS-35321
Q239426
BCP02861
BRD-K21680192-300-09-4
SDCCGSBI-0050757.P004
mitoxantrone free base
NCGC00015693-23
65271-80-9 (free base)
NCGC00015693-13
mitoxantrone base
EN300-117257
1,4-dihydroxy-5,8-bis((2-((2-hydroxyethyl)amino)ethyl)amino)-9,10-anthracenedione
1,3-dihydroxy-5,8-bis((2-((2-hydroxyethyl)amino)ethyl)amino)-9, 10-anthracenedione
mitoxantronum (inn-latin)
l01db07
mitoxantrona (inn-spanish)
dtxcid2026947
mitoxantrone (iarc)
dihydroxyanthracenedione
1,4-dihydroxy-5,8-bis((2-((2-hydroxyethyl)amino)ethyl)amino)-9, 10-anthroquinone

Excerpt	Reference	Relevance
"Mitoxantrone is an anticancer anthracenedione that can be activated by formaldehyde to generate covalent drug-DNA adducts. "	( Formaldehyde-activated WEHI-150 induces DNA interstrand crosslinks with unique structural features. Collins, JG; Cutts, SM; Evison, BJ; Kelso, C; Konda, SK; Medan, J; Phillips, DR; Pumuye, PP; Sleebs, BE; Watson, K, 2020)	2
"Mitoxantrone (MTX) is a topoisomerase II inhibitor used to treat a wide range of tumors and multiple sclerosis but associated with potential neurotoxic effects mediated by hitherto poorly understood mechanisms. "	( Chemobrain: mitoxantrone-induced oxidative stress, apoptotic and autophagic neuronal death in adult CD-1 mice. Bastos, ML; Capela, JP; Carvalho, F; Costa, VM; Dias-Carvalho, A; Fernandes, E; Ferreira, M; Ferreira, R; Reis-Mendes, A; Sá, SI, 2022)	2.54
"Mitoxantrone (MTX) is an antineoplastic agent used to treat advanced breast cancer, prostate cancer, acute leukemia, lymphoma and multiple sclerosis. "	( Autophagy (but not metabolism) is a key event in mitoxantrone-induced cytotoxicity in differentiated AC16 cardiac cells. Carvalho, F; Costa, VM; de Lourdes Bastos, M; Reis-Mendes, A; Remião, F; Sousa, E, 2023)	2.61
"Mitoxantrone (MXN) is a synthetic anthracenedione oncogenic therapy. "	( An eco-friendly matrix-augmented fluorescence spectroscopic approach for the analysis of mitoxantrone, an oncogenic therapy; application to the dosage form and biological matrices. Abourehab, MAS; Derayea, SM; Eltoukhi, WE; Hamad, AA; Hassan, YF; Mohammed, BS, 2023)	2.57
"Mitoxantrone (MX) is a robust chemotherapeutic with well-characterized applications in treating certain leukemias and advanced breast and prostate cancers. "	( Design, synthesis, and evaluation of a mitoxantrone probe (MXP) for biological studies. Borgstahl, GEO; Natarajan, A; Singh, S; Wallin, S, 2023)	2.62
"Mitoxantrone (MTX) is a topoisomerase II inhibitor that binds and intercalates with DNA, being used in the treatment of several cancers and multiple sclerosis."	( A Clinically Relevant Dosage of Mitoxantrone Disrupts the Glutathione and Lipid Metabolic Pathways of the CD-1 Mice Brain: A Metabolomics Study. Carvalho, F; Costa, VM; Dias-Carvalho, A; Fernandes, E; Guedes de Pinho, P; Margarida-Araújo, A; Pereira, SA; Reis-Mendes, A; Sá, SI; Sequeira, CO, 2023)	1.92
"Mitoxantrone is a chemotherapeutic agent approved for various diseases. "	( A case of mitoxantrone extravasation. Chang, A, 2020)	2.4
"Mitoxantrone (MTX) is a synthetic compound used as a second line chemotherapeutic drug for prostate cancer. "	( Mitoxantrone triggers immunogenic prostate cancer cell death via p53-dependent PERK expression. Huo, H; Li, B; Li, C; Lian, F; Liu, F; Liu, Q; Qi, Z; Sun, H; Wang, Y; Wei, W; Ying, K; Zhang, Y, 2020)	3.44
"Mitoxantrone (MTX) is an antitumor drug that can block type II topoisomerase."	( miR-130-3p Promotes MTX-Induced Immune Killing of Hepatocellular Carcinoma Cells by Targeting EPHB4. Jia, M; Shao, L; Ye, Q, 2021)	1.34
"Mitoxantrone (MXT) is an androstenedione that is used to treat cancers and progressive forms of multiple sclerosis; however, its use is limited by its cardiotoxicity. "	( Pituitary adenylate cyclase-activating polypeptide (PACAP) protects against mitoxantrone-induced cardiac injury in mice. Bradley, J; Burn, B; Chuang, G; Coy, DH; Maderdrut, JL; Subramaniam, V; Varner, KJ; Xia, H, 2017)	2.13
"Mitoxantrone (MIT) is an anticancer agent with photosensitive properties that is commonly used in various cancers. "	( Polymeric mixed micelles loaded mitoxantrone for overcoming multidrug resistance in breast cancer via photodynamic therapy. Cai, Y; Chen, M; Li, Z; Yu, H; Zhao, Y; Zhou, H, 2017)	2.18
"Mitoxantrone (MTX) is an antracycline antibiotic that is used in oncologic treatment of breast, prostate, liver, ovarian and stomach cancer."	( BLOOD COUNT IN PATIENTS WITH MULTIPLE SCLEROSIS TREATED WITH MITOXANTRONE IN SHORT TIME OBSERVATION. Pastuszak, Z; Piusinska-Macoch, R; Stepien, A; Tomczykiewicz, K, 2016)	1.4
"Mitoxantrone (MTO) is a topoisomerase II inhibitor which has been used to treat various forms of cancer either as a solo chemotherapy regimen or as a component in cocktail treatments. "	( Tobacco mosaic virus delivery of mitoxantrone for cancer therapy. Lin, RD; Steinmetz, NF, 2018)	2.2
"Mitoxantrone (MTX) is an antitumor agent that causes cardiotoxicity in 18 % patients. "	( The metabolic profile of mitoxantrone and its relation with mitoxantrone-induced cardiotoxicity. Arbo, MD; Costa, VM; de Freitas, V; de Lourdes Bastos, M; de Pinho, PG; Palmeira, C; Remião, F; Rossato, LG; Vilain, L, 2013)	2.14
"Mitoxantrone is a promising antitumor drug having considerably reduced cardiotoxicity as compared to anthracyclines. "	( NMR-based structure of anticancer drug mitoxantrone stacked with terminal base pair of DNA hexamer sequence d-(ATCGAT)2. Awasthi, P; Barthwal, R; Dogra, S; Nair, MS; Pradeep, TP; Tripathi, S, 2014)	2.11
"Mitoxantrone is an effective disease-modifying therapy in multiple sclerosis (MS), but its use is limited by cardiotoxicity. "	( Subclinical myocardial dysfunction in multiple sclerosis patients remotely treated with mitoxantrone: evidence of persistent diastolic dysfunction. Goggin, C; Joyce, E; Lynch, T; Mahon, N; McGorrian, C; Melling, J; Mulroy, E; O'Rourke, K; Scott, J, 2013)	2.05
"Mitoxantrone (MTX) is a chemotherapeutic agent that emerged as an alternative to anthracycline therapy. "	( Therapeutic concentrations of mitoxantrone elicit energetic imbalance in H9c2 cells as an earlier event. Costa, VM; de Lourdes Bastos, M; Palmeira, C; Remião, F; Rolo, A; Rossato, LG; Vilas-Boas, V, 2013)	2.12
"Mitoxantrone (MTX) is a chemotherapeutic agent, which presents late irreversible cardiotoxicity. "	( Mitochondrial cumulative damage induced by mitoxantrone: late onset cardiac energetic impairment. Amado, F; Arbo, M; Costa, VM; Dallegrave, E; de Lourdes Bastos, M; Dinis-Oliveira, RJ; Duarte, JA; Ferreira, R; Palmeira, C; Remião, F; Rossato, LG; Silva, R, 2014)	2.11
"Mitoxantrone (MTX) is an antineoplastic agent that can induce hepato- and haematotoxicity. "	( Cumulative mitoxantrone-induced haematological and hepatic adverse effects in a subchronic in vivo study. Arbo, M; Costa, VM; Dallegrave, E; de Lourdes Bastos, M; Dinis-Oliveira, RJ; Duarte, JA; Palmeira, C; Remião, F; Rossato, LG; Santos-Silva, A, 2014)	2.23
"Mitoxantrone is a reasonable replacement for daunorubicin in times of drug shortage."	( Mitoxantrone as a substitute for daunorubicin during induction in newly diagnosed lymphoblastic leukemia and lymphoma. Bergsagel, J; Cooper, T; Daves, M; Keller, F; Lew, G; Nickel, RS; Sabnis, H, 2014)	2.57
"Mitoxantrone is an antineoplastic agent approved for clinical use in the secondary progressive phase of multiple sclerosis (MS). "	( [Mitoxantrone - an anthraquinone antibiotic with antitumor activity applied for the treatment of multiple sclerosis]. Szwed, M, 2014)	2.76
"Mitoxantrone is an immunosuppressive drug approved for aggressive relapsing and progressive multiple sclerosis. "	( The current role of mitoxantrone in the treatment of multiple sclerosis. Cocco, E; Marrosu, MG, 2014)	2.17
"Mitoxantrone is a conventional agent for relapsed or refractory acute lymphoblastic leukemia (ALL). "	( Clinical efficacy of mitoxantrone and Ara-C with or without etoposide salvage chemotherapy in adult patients with relapsed or refractory acute lymphoblastic leukemia: retrospective multicenter study of the Korean Adult ALL Working Party. Ahn, JS; Chung, JS; Jo, DY; Joo, YD; Jung, SH; Kim, DY; Kim, I; Lee, JJ; Lee, KH; Moon, JH; Park, S; Shin, HJ; Sohn, SK; Song, IC; Yang, DH, 2015)	2.18
"Mitoxantrone is a synthetic anthracenedione originally developed to improve the therapeutic profile of the anthracyclines and is commonly applied in the treatment of breast and prostate cancers, lymphomas, and leukemias. "	( Mitoxantrone, More than Just Another Topoisomerase II Poison. Cutts, SM; Evison, BJ; Phillips, DR; Sleebs, BE; Watson, KG, 2016)	3.32
"Mitoxantrone (MXT) is an anticancer drug structurally related to anthracyclines, such as doxorubicin (DOX). "	( Influence of nucleotide excision repair on mitoxantrone cytotoxicity. Busatto, FF; de Souza, LK; Rocha, JC; Saffi, J, 2016)	2.14
"Mitoxantrone (MIT) is a chemotherapeutic agent with promising anticancer efficacy. "	( Vitamin E succinate-conjugated F68 micelles for mitoxantrone delivery in enhancing anticancer activity. Chen, M; Fan, L; He, C; Li, H; Li, P; Liu, Y; Wan, JB; Wu, M; Xu, Y, 2016)	2.13
"Mitoxantrone is a highly cytotoxic antineoplastic drug, however, its poor penetration of the blood-brain barrier has limited its role in the treatment of brain cancers. "	( Safety, feasibility, and optimization of intra-arterial mitoxantrone delivery to gliomas. Bigio, IJ; Bruce, JN; Cooke, J; Ellis, JA; Emala, CW; Joshi, S; Singh-Moon, RP; Wang, M, 2016)	2.12
"Mitoxantrone (MTX) is an antineoplastic agent used to treat several types of cancers and on multiple sclerosis, which shows a high incidence of cardiotoxicity. "	( Naphthoquinoxaline metabolite of mitoxantrone is less cardiotoxic than the parent compound and it can be a more cardiosafe drug in anticancer therapy. Bastos, ML; Carvalho, F; Carvalho, RA; Costa, VM; Gomes, AS; Pinto, M; Reis-Mendes, A; Remião, F; Sousa, E, 2017)	2.18
"Mitoxantrone is a synthetic anticancer drug used clinically in the treatment of different types of cancer. "	( Mitoxantrone-Surfactant Interactions: A Physicochemical Overview. Enache, M; Enache, MI; Toader, AM, 2016)	3.32
"Mitoxantrone (MTO) is a potent drug used to treat breast cancer; however, efforts to expand its clinical applicability have been restricted because of its high risk for cardiotoxicity. "	( Mitoxantrone- and Folate-TPGS2k Conjugate Hybrid Micellar Aggregates To Circumvent Toxicity and Enhance Efficiency for Breast Cancer Therapy. Chen, M; Guissi, NE; Li, H; Ping, Q; Semcheddine, F; Su, Z; Xu, Y, 2017)	3.34
"Mitoxantrone is an effective drug used for acute leukemias."	( [Effects of mitoxantrone on the activity of human protein kinase CK2 holoenzyme]. Chen, XW; Li, CM; Liang, NC; Lin, XC; Liu, XG, 2008)	1.45
"Mitoxantrone is a strong inhibitor of recombinant human protein kinase CK2 in vitro. "	( [Effects of mitoxantrone on the activity of human protein kinase CK2 holoenzyme]. Chen, XW; Li, CM; Liang, NC; Lin, XC; Liu, XG, 2008)	2.17
"Mitoxantrone (MTX) is a clinically used antitumor anthracycline, which is made available to the target tissues by transport protein human serum albumin (HSA). "	( Interaction of mitoxantrone with human serum albumin: spectroscopic and molecular modeling studies. Islam, B; Khan, AU; Khan, SN; Subbarao, N; Sultan, A; Yennamalli, R, 2008)	2.14
"Mitoxantrone (MX) is a potent immunosuppressant for the treatment of active MS."	( Mitoxantrone does not restore the impaired suppressive function of natural regulatory T cells in patients suffering from multiple sclerosis. A longitudinal ex vivo and in vitro study. Diener, HC; Grosse-Wilde, H; Kreuzfelder, E; Kumar, M; Limmroth, V; Putzki, N, 2009)	2.52
"Mitoxantrone is a potent antitumor drug, widely used in the treatment of various cancers. "	( Studies on the binding affinity of anticancer drug mitoxantrone to chromatin, DNA and histone proteins. Hajihassan, Z; Rabbani-Chadegani, A, 2009)	2.05
"Mitoxantrone is an approved disease modifying agent for treatment of multiple sclerosis (MS). "	( Efficacy and safety of mitoxantrone, as an initial therapy, in multiple sclerosis: experience in an Indian tertiary care setting. Geeta, S; Hundalani, SG; Menon, S; Singhal, BS, )	1.88
"Mitoxantrone (MTX) is a synthetic antineoplastic cytotoxic drug, active both on proliferative and non-proliferative cells. "	( Mitoxantrone: benefits and risks in multiple sclerosis patients. Comi, G; Martinelli, V; Radaelli, M; Rodegher, M; Straffi, L, 2009)	3.24
"Mitoxantrone is a cytotoxic drug with immune modulatory properties used in the treatment of progressive forms of multiple sclerosis (MS). "	( Mitoxantrone treatment in multiple sclerosis induces TH2-type cytokines. Bröker, BM; Dressel, A; Rosenberg, S; Skrzipek, S; Vogelgesang, A, 2010)	3.25
"Mitoxantrone (MTX) is an immunosuppressive drug approved for multiple sclerosis (MS) treatment."	( Comparative study of mitoxantrone efficacy profile in patients with relapsing-remitting and secondary progressive multiple sclerosis. Comi, G; Esposito, F; Martinelli Boneschi, F; Martinelli, V; Moiola, L; Radaelli, M; Rocca, MA; Rodegher, M; Sormani, MP, 2010)	2.12
"Mitoxantrone is an anticancer agent that acts as a topoisomerase II poison, however, it can also be activated by formaldehyde to form DNA adducts. "	( New anthracenedione derivatives with improved biological activity by virtue of stable drug-DNA adduct formation. Bilardi, RA; Buck, DP; Collins, JG; Cutts, SM; Evison, BJ; Mansour, OC; Nudelman, A; Phillips, DR; Rephaeli, A; Sleebs, BE; Watson, KG, 2010)	1.8
"Mitoxantrone (MX) is a potent immunosuppressant that is licensed as escalation therapy for the treatment of active multiple sclerosis (MS)."	( Stability of cognitive functions under mitoxantrone therapy in patients with progressive multiple sclerosis: a pilot analysis. Gold, R; Klotz, P; Lee, DH; Linker, RA; Schröder, A, 2011)	2.08
"Mitoxantrone is a cytotoxic drug approved for the treatment of MS with adverse effects associated potentially with an increased level of oxidative stress."	( Paraoxonase 1 activity in multiple sclerosis patients during mitoxantrone therapy. Bartosik-Psujek, H; Beltowski, J; Jamroz-Wisniewska, A; Stelmasiak, Z, 2013)	1.35
"Mitoxantrone is an anthracycline analog with presumed better antineoplastic activity and lesser toxicity."	( A comparison of the in vitro genotoxicity of anticancer drugs idarubicin and mitoxantrone. Błasiak, J; Gloc, E; Warszawski, M, 2002)	1.26
"Mitoxantrone is an anticancer agent for which it is important to know the concentration in blood during therapy. "	( Quantitative analysis of mitoxantrone by surface-enhanced resonance Raman scattering. MacMillan, D; McCardle, C; McLaughlin, C; Smith, WE, 2002)	2.06
"Mitoxantrone is a drug with potent in vitro activity against malignant brain tumor cell lines; however, its effectiveness as a systemic agent has been hampered by poor central nervous system penetration and dose-limiting myelosuppression. "	( Local delivery of mitoxantrone for the treatment of malignant brain tumors in rats. Brem, H; DiMeco, F; Li, KW; Olivi, A; Tyler, BM; Wolf, AS, 2002)	2.09
"Mitoxantrone is a recently approved drug for patients with secondary progressive multiple sclerosis (SPMS). "	( Rapid onset mitoxantrone-induced cardiotoxicity in secondary progressive multiple sclerosis. Abbey, EE; Avasarala, JR; Clifford, DB; Cross, AH; Siegel, BA; Singer, BA, 2003)	2.14
"Mitoxantrone is an anthracenedione, which is active in NHL and its toxicity profile may be more favorable than doxorubicin with respect to alopecia, mucositis and cardiotoxicity."	( A randomized trial comparing intensified CNOP vs. CHOP in patients with aggressive non-Hodgkin's lymphoma. Angelopoulou, MK; Bourantas, KL; Christopoulos, G; Grigorakis, V; Kalmantis, T; Kokkinis, G; Korantzis, J; Michalis, E; Mihalakeas, I; Pangalis, GA; Papayiannis, A; Repousis, P; Roussou, P; Siakantaris, MP; Stamatellou, M; Stefanoudakis, E; Symeonidis, A; Vassilakopoulos, TP; Vrakidou, E, 2003)	1.04
"Mitoxantrone is an antineoplastic agent that exerts a potent immunosuppresive effect, including suppression of B cell immunity and reduction of T cell numbers. "	( [Mitoxantrone]. Montalban, X; Pericot, I, )	2.48
"Mitoxantrone (Mx) is a drug well known for its antiproliferative properties and is used clinically in oncology and in the treatment of relapsing multiple sclerosis."	( The effect of mitoxantrone on anti-pig immunization in baboons. Ashton-Chess, J; Barreau, N; Blancho, G; Boulday, G; Edan, G; Le Berre, L; Minault, D; Petzold, T; Roussel, JC; Soulillou, JP, 2003)	1.4
"As mitoxantrone is a recently approved immunosuppressant for managing multiple sclerosis, the number of patients treated with this effective but potentially cardiotoxic anthracenedione derivative will increase substantially. "	( Non-invasive functional and biochemical assessment of mitoxantrone cardiotoxicity in patients with multiple sclerosis. Beer, M; Ertl, G; Gold, R; Hahn, D; Köstler, H; Sandstede, J; Spindler, M; Strotmann, J; Voelker, W; Weilbach, F, 2003)	1.19
"Mitoxantrone is an immunosuppressive drug usually delivered in severe relapsing remitting multiple sclerosis. "	( [Acute heart failure in a patient treated by mitoxantrone for multiple sclerosis]. Ali Chérif, A; Eusebio, A; Feuillet, L; Guedj, E; Malikova, I; Mundler, O; Pelletier, J, 2003)	2.02
"Mitoxantrone is a rescue therapy reserved to patients with an aggressive, rapidly progressive form of the disease."	( A comparison of the benefits of mitoxantrone and other recent therapeutic approaches in multiple sclerosis. Gonsette, RE, 2004)	1.33
"Mitoxantrone is a member of the anthracendione family developed to treat malignancies and increasingly used to treat multiple sclerosis (MS). "	( Rationale for the use of mitoxantrone in multiple sclerosis. Edan, G; Le Page, E; Morrissey, S, 2004)	2.07
"Mitoxantrone (MX) is a cytotoxic drug with proven clinical efficacy in active multiple sclerosis (MS). "	( Mitoxantrone induces cell death in peripheral blood leucocytes of multiple sclerosis patients. Chan, A; Gold, R; Toyka, KV; Weilbach, FX, 2005)	3.21
"Mitoxantrone is a synthetic anthracenedione recently approved by the FDA for the treatment of worsening relapsing-remitting (RR), secondary progressive (SP), and progressive relapsing (PR) multiple sclerosis (MS). "	( Review of mitoxantrone in the treatment of multiple sclerosis. Herndon, R; Jeffery, DR, 2004)	2.17
"Mitoxantrone is an approved drug for patients with worsening relapsing-remitting, secondary progressive and progressive relapsing multiple sclerosis (MS). "	( Severe delayed heart failure in three multiple sclerosis patients previously treated with mitoxantrone. Goffette, S; Morandini, E; Sindic, CJ; van Pesch, V; Vanoverschelde, JL, 2005)	1.99
"Mitoxantrone is an useful and clinically effective drug in MS and its major limitation is the potencial cardiotoxicity due to cumulative dose (140 mg)."	( Mitoxantrone in secondarily progressive multiple sclerosis: a series of 18 patients. Arruda, WO; de Oliveira, Mde S; Montú, MB; Ramina, R, 2005)	2.49
"Mitoxantrone (MX) is an immunosupressant drug used in secondarily progressive multiple sclerosis (SPMS) and in relapsing-remitting multiple sclerosis (RRMS). "	( Acute myeloid leukaemia induced by mitoxantrone: case report. Arruda, WO; de Oliveira, Mde S; Montú, MB; Ramina, R, 2005)	2.05
"Mitoxantrone is an anti-neoplastic anthracenedione derivative that, based on its immunosuppressive properties, is approved for the treatment of severe forms of relapsing-remitting or secondary progressive multiple sclerosis (MS). "	( Multiple sclerosis: Mitoxantrone promotes differential effects on immunocompetent cells in vitro. Archelos, JJ; Hartung, HP; Hemmer, B; Kieseier, BC; Neuhaus, O; Stüve, O; Wiendl, H, 2005)	2.09
"Mitoxantrone is a synthetic anthracenedione, recently approved for the treatment of worsening multiple sclerosis, which is known to induce cardiotoxicity."	( Evaluation of the myocardial performance index for early detection of mitoxantrone-induced cardiotoxicity in patients with multiple sclerosis. Borghetti, A; Montanari, E; Moruzzi, P; Pattoneri, P; Pelà, G; Pesci, I, 2007)	1.29
"Mitoxantrone is an antineoplastic drug, recently approved for treatment of multiple sclerosis."	( Mitoxantrone-induced cardiotoxicity in patients with multiple sclerosis. Etemadifar, M; Hamzehloo, A, 2006)	2.5
"Mitoxantrone is an antineoplastic agent also used for the treatment of multiple sclerosis (MS). "	( In vivo effects of mitoxantrone on the production of pro- and anti-inflammatory cytokines by peripheral blood mononuclear cells of secondary progressive multiple sclerosis patients. Angelucci, F; Batocchi, AP; Caggiula, M; Frisullo, G; Mirabella, M; Nociti, V; Patanella, K; Sancricca, C; Tonali, PA, 2006)	2.1
"Mitoxantrone is a DNA topoisomerase II poison commonly used for the treatment of hormone-refractory prostate cancer. "	( Mitoxantrone-related acute myeloblastic leukaemia in a patient with metastatic hormone-refractory prostate cancer. Bouscary, D; Dômont, J; Goldwasser, F; Martinez, V; Mir, O, 2007)	3.23
"Mitoxantrone is an antineoplastic agent considered a potential human teratogen because of its mechanism of action and is classified by the US Food and Drug Administration in pregnancy category risk D. "	( The first case of mitoxantrone exposure in early pregnancy. Batocchi, AP; Caruso, A; Cavaliere, AF; De Santis, M; Rosati, P; Straface, G, 2007)	2.12
"Mitoxantrone (MXR) is a prototypical substrate for the ABCG2 (bcrp1) efflux transporter and is often used as a positive control in bcrp-mediated transport studies. "	( Mitoxantrone permeability in MDCKII cells is influenced by active influx transport. Elmquist, WF; Pan, G, )	3.02
"Mitoxantrone (MTX) is a water-soluble anticancer drug that poorly penetrates the BBB."	( Optical method for real-time monitoring of drug concentrations facilitates the development of novel methods for drug delivery to brain tissue. A'Amar, O; Bigio, IJ; Joshi, S; Reif, R; Wang, M, )	0.85
"Mitoxantrone (MTX) is an antineoplastic agent approved for treatment of secondary progressive and rapidly worsening relapsing-remitting multiple sclerosis (MS). "	( Mitoxantrone treatment in multiple sclerosis: a 5-year clinical and MRI follow-up. Borriello, G; Buttinelli, C; Clemenzi, A; Denaro, F; Fieschi, C; Pozzilli, C, 2007)	3.23
"Mitoxantrone is a similar anticancer agent with an anthracenedion structure that has been shown to be significantly less cardiotoxic."	( Mechanisms responsible for reduced cardiotoxicity of mitoxantrone compared to doxorubicin examined in isolated guinea-pig heart preparations. Chugun, A; Hara, Y; Nagasawa, H; Sasaki, T; Takagishi, K; Temma, K; Tsurimaki, C; Uchide, T; Ueno, S, 2008)	1.32
"Mitoxantrone is a DNA-topoisomerase 2 inhibitor used as a single agent for treatment of relapsing-remitting or progressive multiple sclerosis (MS). "	( Acute promyelocytic leukemia after mitoxantrone therapy for multiple sclerosis. Baer, MR; Barcos, M; Chadha, MK; Heyman, MR; Ramkumar, B; Sait, SN, 2008)	2.07
"Mitoxantrone is an active and relatively non-toxic agent which merits further assessment prior to its incorporation in first-line therapy of acute leukaemia."	( Sequential studies on the role of mitoxantrone in the treatment of acute leukaemia. Ho, AD; Ma, DD; Prentice, HG; Robbins, G, 1983)	1.27
"Mitoxantrone appears to be an effective and well-tolerated agent for breast cancer."	( A comparative trial of mitoxantrone and doxorubicin in patients with minimally pretreated breast cancer. Gochnour, D; Neidhart, JA; Roach, RW; Steinberg, JA; Young, D, 1984)	1.3
"Mitoxantrone is a relatively new synthetic anthracenedione derivative with intercalating properties. "	( Mitoxantrone in relapsed and refractory acute leukemia. Ho, AD; Ma, DD; Prentice, HG; Robbins, G, 1984)	3.15
"Mitoxantrone (NSC-301739) is a synthetic amino anthraquinone DNA intercalater active in several experimental tumor systems. "	( Phase I study of mitoxantrone on a daily X 5 schedule. Goldsmith, MA; Greenspan, EM; Holland, JF; Jaffrey, IH; Ohnuma, T, 1984)	2.05
"Mitoxantrone is an active, well-tolerated new drug in the treatment of advanced breast cancer, but cardiotoxicity may occur in a proportion of patients."	( Mitoxantrone in advanced breast cancer--a phase II study with special attention to cardiotoxicity. Coleman, RE; Knight, RK; Maisey, MN; Rubens, RD, 1984)	2.43
"Mitoxantrone is an anthracenedione, showing structural similarities to doxorubicin. "	( An EORTC phase II study of mitoxantrone in solid tumors and lymphomas. Armand, JP; Bastit, P; Cappelaere, P; De Jager, R; Earl, H; Fargeot, P; Keiling, R; Renard, J; Rubens, R; van Glabbeke, M, 1984)	2.01
"Mitoxantrone is an active, well tolerated drug in the treatment of advanced breast cancer and merits further evaluation."	( Mitoxantrone (Novantrone) as single agent and in combination chemotherapy in the treatment of advanced breast cancer. Bozek, T; Pavlidis, N; Smith, IE; Stuart-Harris, R, 1983)	2.43
"Mitoxantrone is an active well-tolerated agent in the treatment of advanced breast carcinoma, but the risk of neutropenia requires careful supervision."	( Mitoxantrone: an active new agent in the treatment of advanced breast cancer. Bozek, T; Pavlidis, NA; Smith, IE; Stuart-Harris, RC, 1984)	2.43
"Mitoxantrone is a synthetic anthraquinone that was developed through the doxorubicin analog program in hopes of retaining anticancer activity with less cardiotoxicity. "	( Cardiac evaluation of mitoxantrone. Balcerzak, SP; Bashore, TA; Neidhart, JA; Unverferth, BJ; Unverferth, DV, 1983)	2.02
"Mitoxantrone (DAD) is a new agent which intercalates into DNA. "	( Phase I trial of mitoxantrone by 24-hour continuous infusion. Anderson, KC; Canellos, GP; Cohen, GI; Frei, E; Garnick, MB; Israel, M; Meshad, MW; Modest, E; Pegg, WJ, 1983)	2.05
"Mitoxantrone is a promising new agent developed in an attempt to find drugs with a broad spectrum of antitumor activity and devoid of cardiotoxicity. "	( Potential cardiotoxicity with mitoxantrone. Blumenschein, G; Bodey, G; Schell, FC; Valdivieso, M; Yap, HY, 1982)	2
"Mitoxantrone appears to be a well-tolerated and clinically active agent against advanced breast carcinoma."	( Mitoxantrone: a phase II study in the treatment of patients with advanced breast carcinoma and other solid tumours. Smith, IE; Stuart-Harris, RC, 1982)	2.43
"Mitoxantrone is an anthracenedion (an anthracycline-related class of compounds) of increased clinical use, which may benefit from selective circadian timing."	( Circadian changes in mitoxantrone toxicity in mice: relationship with plasma pharmacokinetics. Bizi, E; Hallek, M; Lemaigre, G; Lévi, F; Metzger, G; Tampellini, M, 1994)	1.33
"Mitoxantrone is an effective drug against ovarian cancer cells in vitro and is an attractive agent for IP therapy because of its very low peritoneal clearance."	( Intraperitoneal mitoxantrone as consolidation treatment for patients with ovarian carcinoma in pathologic complete remission. Audhuy, B; Barats, JC; Bergerat, JP; Dellenbach, P; Duclos, B; Dufour, P; Giron, C; Oberling, F; Renaud, R; Ritter, J, 1994)	1.36
"Mitoxantrone is an effective and safe agent for the post-TUR adjuvant intravesical therapy."	( Intravesical mitoxantrone for superficial bladder tumors. Arikan, N; Yaman, LS; Yaşar, B; Yurdakul, T; Zissis, NP, 1994)	1.38
"Mitoxantrone hydrochloride is an anthracenodione that has been reported to be useful when used intracavitary for malignant effusion due to gynaecological malignancies."	( Mitoxantrone for malignant pleural effusion due to metastatic sarcoma. Holmes, EC; Kelly, J; Rosen, G, 1993)	2.45
"Mitoxantrone (MIT) is a new anthraquinone anti-cancer agent. "	( [Preoperative intra-arterial injection of mitoxantrone for locally advanced breast cancer]. Hirayama, R; Ichikawa, W; Mishima, Y; Miyanaga, T; Nihei, Z; Sawai, S; Shoji, Y; Yamashita, T; Yoshinaga, K, 1993)	1.99
"Mitoxantrone is an anthraquinone derivative that has demonstrated encouraging preclinical and clinical activity against a variety of human carcinoma cell lines and malignancies. "	( A phase I-II trial of mitoxantrone by hepatic arterial infusion in patients with hepatocellular carcinoma or colorectal carcinoma metastatic to the liver. Abbruzzese, J; Ajani, JA; Carrasco, CH; Charnsangavej, C; Jones, DV; Levin, B; Patt, YZ; Wallace, S, 1993)	2.04
"Mitoxantrone is an anthraquinone structurally related to the anthracycline drugs doxorubicin and daunorubicin. "	( Reversible cardiopathy after accidental overdose of mitoxantrone. DeWolf, D; Hachimi-Idrissi, S; Otten, J; Schots, R; Van Belle, SJ, )	1.82
"Mitoxantrone is a good candidate for local or regional administration because (1) its metabolism is mainly hepatic, (2) it has a steep dose-response curve for multiple solid tumors, and (3) its fixation in tissues is sustained without vesicant effects after extravasation."	( Pharmacokinetics and antitumor effects of mitoxantrone after intratumoral or intraarterial hepatic administration in rabbits. Ardouin, P; Bognel, C; Dzodic, R; Gouyette, A; Munck, JN; Ramirez, LH; Rougier, P; Vassal, G; Zhao, Z, 1996)	1.28
"Mitoxantrone is an effective and well-tolerated regimen in elderly breast cancer patients presenting with comorbid conditions."	( Mitoxantrone in elderly women with advanced breast cancer: a phase II study. Biancardi, V; Campora, E; Gasco, M; Repetto, L; Rosso, R; Simoni, C; Venturino, A, )	2.3
"Mitoxantrone is a new antineoplastic that differs from bleomycin in that it binds to membranes."	( Comparison of mitoxantrone and tetracycline as pleural sclerosing agents in rabbits. Despars, JA; Gruer, SE; Light, RW; Sassoon, C; Vargas, FS; Wang, NS, 1996)	1.38
"Mitoxantrone is an agent with potential to cause t-AML and t-MDS and which is being used increasingly in the treatment of breast cancer."	( Myelodysplasia and acute myeloid leukaemia following adjuvant chemotherapy for breast cancer using mitoxantrone and methotrexate with or without mitomycin. Cremin, P; Daly, PA; Flattery, M; McCann, SR, 1996)	1.23
"Mitoxantrone is an intravenous anthracenedione structurally related to the anthracycline antibiotics. "	( Mitoxantrone in the treatment of acute myelogenous leukemia: a review. Archimbaud, E; Thomas, X, 1997)	3.18
"Mitoxantrone (M) is a synthetic aminoanthraquinone with anti-leukemic activity in patients with daunorubicin (D) resistant acute leukemia. "	( Sequential mitoxantrone, daunorubicin, and cytosine arabinoside for patients with newly diagnosed acute myelocytic leukemia. Cuttner, J; Davis, RB; Gottlieb, A; Holland, JF; Martelo, O; Paciucci, PA, 1997)	2.13
"Mitoxantrone (MIT) is a new anthraquinone anticancer agent. "	( [Intra-arterial injection therapy of mitoxantrone for locally advanced breast cancer]. Ichikawa, W; Iida, S; Miyanaga, T; Nihei, Z; Nishi, N; Osanai, T; Shimizu, C; Sugihara, K; Togo, S; Uetake, H; Yamashita, T, 1998)	2.02
"Mitoxantrone is an anthracenedione with low cardiotoxicity, and seems to be effective when combined with vinorelbine after prior exposure to anthracyclines."	( First-line vinorelbine-mitoxantrone combination in metastatic breast cancer patients relapsing after an adjuvant anthracycline regimen: results of a phase II study. Le Cesne, A; Le Chevalier, T; Llombart-Cussac, A; Pivot, X; Rhor-Alvarado, A; Spielmann, M; Tursz, T, )	1.16
"Mitoxantrone (Novantrone) is an anthracene derivative that has demonstrated antitumor activity in patients with breast cancer, ovarian cancer, acute leukemia, and lymphoma."	( A phase I trial of vinorelbine in combination with mitoxantrone in patients with refractory solid tumors. Bigley, J; Burris, HA; Dieras, V; Eckardt, JR; Hardy, J; Hohneker, J; Jones, SF; Peacock, NW; Rodriguez, GI; Smith, L; Von Hoff, DD, 1998)	1.27
"Mitoxantrone is an anthracenedione anti-neoplastic agent that has recently been shown to be effective in ameliorating disease activity in multiple sclerosis (MS) as indicated by clinical and MRI data. "	( [Mitoxantrone (Novantron) in therapy of severe multiple sclerosis. A retrospective study of 15 patients]. Cursiefen, S; Flachenecker, P; Rieckmann, P; Toyka, KV, 1999)	2.66
"Mitoxantrone is an active agent in lymphoma that is not generally used in first-line treatment."	( CN3OP: an active regimen in patients with relapsed/refractory Hodgkin's lymphoma. Kraszewska, E; Krzyzanowska, JB; Lampka, E; Meder, J; Miśkiewicz, Z; Romejko-Jarosińska, J; Walewski, J, 2000)	1.03
"Mitoxantrone is a minimally toxic chemotherapeutic agent, which justifies its current indication in hormone-resistant advanced prostate cancer."	( [Value of mitoxantrone in metastatic hormone-resistant prostate cancer]. Dunet, F; Grise, P; Hellot, MF; Khalaf, A; Moussu, J; Pfister, C, 2002)	2.16
"Mitoxantrone is a dihydroxyanthracenedione derivative which as intravenous mono- and combination therapy has demonstrated therapeutic efficacy similar to that of standard induction and salvage treatment regimens in advanced breast cancer, non-Hodgkin's lymphoma, acute nonlymphoblastic leukaemia and chronic myelogenous leukaemia in blast crisis; it appears to be an effective alternative to the anthracycline component of standard treatment regimens in these indications. "	( Mitoxantrone. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the chemotherapy of cancer. Balfour, JA; Chrisp, P; Faulds, D; Langtry, HD, 1991)	3.17
"Mitoxantrone is a new anthracenodione derivative with a high antineoplastic activity in proliferative diseases of the haemopoietic system. "	( [Preliminary results of the treatment of acute leukemia with mitoxantrone]. Apel, D; Hołowiecki, J; Konecki, R; Lawniczek, T; Maj, S; Mariańska, B; Mazur, J; Pałynyczko, G; Rozmysłowicz, T; Rudzka, E, 1991)	1.97
"Mitoxantrone is an anthracene derivative that acts as a cytostatic in a variety of cancers. "	( Novel assay method for mitoxantrone in plasma, and its application in cancer patients. Chang, SP; Chen, KY; Hu, OY; Law, CK; Song, YB, 1990)	2.03
"Mitoxantrone is an active agent in the treatment of acute leukemia and demonstrates incomplete cross resistance with duanorubicin."	( Mitoxantrone for refractory and relapsed acute leukemia. Bernasconi, C; Bezwoda, WR; de Bock, R; Hutchinson, RM; Mandelli, F; Winfield, DA, 1990)	2.44
"Mitoxantrone is a substituted anthraquinone with considerable activity against human acute leukemia. "	( Continuous infusion mitoxantrone in relapsed acute nonlymphocytic leukemia. Choi, KE; Daley, KM; Kaminer, LS; Larson, RA, 1990)	2.05
"Mitoxantrone (MTX) is a recently synthesized antitumor intercalative molecule, currently in use in chemotherapy. "	( Theoretical design of novel, 4 base pair selective derivatives of mitoxantrone. Gresh, N; Kahn, PH, 1990)	1.96
"Mitoxantrone (DHAQ) is a new anti-cancer agent. "	( [Ion-paired high performance liquid chromatographic determination of mitoxantrone hydrochloride injection]. Guo, P; Song, H; Wu, C, 1990)	1.96
"Mitoxantrone is a synthetic anthraquinone that is active in the therapy of a number of malignancies. "	( Mitoxantrone: potential for use in intensive therapy. Herzig, R; LeMaistre, CF, 1990)	3.16
"Mitoxantrone is a new effective antineoplastic agent with activity against a wide range of tumors. "	( Accidental overdose of mitoxantrone in three patients. Büchner, T; Essink, M; Hiddemann, W; Huhn, D; Jung, M; Koppensteiner, R; Marosi, L; Martin, T; Minar, E; Siegert, W, 1989)	2.03
"Mitoxantrone is an antitumor agent that was synthesized to try to develop a doxorubicinlike drug with a better therapeutic index. "	( Mitoxantrone: its development and role in clinical practice. Weiss, RB, 1989)	3.16
"Mitoxantrone is a compound that is related to the anthracyclines but has a different mechanism of action."	( Phase I and II agents in cancer therapy: I. Anthracyclines and related compounds. Fuks, JZ; Wadler, S; Wiernik, PH, )	0.85
"Mitoxantrone is an important new agent with antitumor activity in leukemia, lymphoma, and breast cancer."	( Mitoxantrone: a novel anthracycline derivative. Eble, M; Koeller, J, 1988)	2.44
"Mitoxantrone is an effective agent in refractory NHL and should be taken into consideration in the design of salvage regimens."	( Mitoxantrone: an active agent in refractory non-Hodgkin's lymphomas. Bajetta, E; Bonadonna, G; Buzzoni, R; Valagussa, P, 1988)	2.44
"Mitoxantrone is a synthetic aminoanthraquinone we have previously reported to be effective for patients with acute leukemia in relapse. "	( Mitoxantrone and ara-C in previously treated patients with acute myelogenous leukemia. Cuttner, J; Dutcher, JP; Holland, JF; Paciucci, PA; Strauman, JJ; Wiernik, PH, 1987)	3.16
"Mitoxantrone is an anthraquinone antineoplastic agent with structural similarities to doxorubicin. "	( Mitoxantrone. Poirier, TI, 1986)	3.16
"Mitoxantrone is an anthracenedione derivative with structural and functional similarities to doxorubicin."	( Inhibition of endogenous respiration in rat heart slices as a measure of mitoxantrone cardiac toxicity. Cini-Neri, G; Neri, B, 1986)	1.22
"Mitoxantrone thus appears to be a promising drug for the treatment of acute leukemia."	( [A phase II study of mitoxantrone in acute leukemia. Hanshin Cooperative Study Group of Hematological Disorders]. Horiuchi, A; Kawagoe, H; Kitani, T; Masaoka, T; Nagai, K; Oguma, S; Shibata, H; Yasunaga, K; Yonezawa, T, 1986)	1.31
"Mitoxantrone (Novantrone), is an anthracenedione which in preclinical studies demonstrated a spectrum of antitumor activity similar to the anthracyclines, but with less cardiotoxicity. "	( Mitoxantrone: an overview of safety and toxicity. Bernstein, T; Cartwright, K; Dukart, G; Goldberg, J; Posner, LE, 1985)	3.15
"Mitoxantrone is a new active anthracene-based, DNA intercalator which is undergoing widespread clinical testing for antitumor efficacy in man."	( Lack of experimental vesicant activity for the anticancer agents cisplatin, melphalan, and mitoxantrone. Alberts, DS; Dorr, RT; Soble, M, 1986)	1.21
"Mitoxantrone (DHAD) is a recently developed cancer chemotherapeutic drug proposed as a possible substitute for the older established chemotherapeutic, doxorubicin (adriamycin, or ADR). "	( Comparative toxicity of mitoxantrone and doxorubicin on hematopoietic stem cells. Buffo, MJ; Kociban, DL; OKunewick, JP, 1985)	2.02
"Mitoxantrone is an anthracenedione with structural similarities to adriamycin but without the amino-sugar moiety on the parent molecule. "	( [Mitoxantrone in the treatment of relapsed and refractory malignant lymphoma]. Hiraki, S; Kimura, I; Miyamoto, H; Murashima, M; Ohnoshi, T; Toyata, K; Ueno, K; Ueoka, H; Yamane, T, 1985)	2.62
"Mitoxantrone is a new anthracenedione derivative that suppresses cell proliferation in the T-47D human breast tumor cell line as revealed by colony-forming assay in soft agar and growth study in monolayer culture. "	( Growth and ultrastructural responses of T-47D human breast tumor cells to treatment with mitoxantrone. Ballou, RJ; Safa, AR; Tseng, MT, 1985)	1.93

Excerpt	Reference	Relevance
"The mitoxantrone molecule has an intense binding energy of - 880.536 kcal/mol with AKT1 protein, while the XFE molecule shows a binding energy value of - 83.569 kcal/mol."	( Investigation of the inhibitory behavior of XFE and mitoxantrone molecules in interaction with AKT1 protein: a molecular dynamics simulation study. Abasi Joozdani, F; Amiran, MR; Taghdir, M, 2023)	1.64
"Mitoxantrone has a broad anti-tumour activity including lymphoma with potentially less cardiotoxicity than doxorubicin, which may be of particular importance in elderly patients. "	( CNOP (mitoxantrone) chemotherapy is inferior to CHOP (doxorubicin) in the treatment of patients with aggressive non-Hodgkin lymphoma (meta-analysis). Ahlbom, A; Anders, A; Andersson, T; Björkholm, M; Eva, O; Magnus, B; Ösby, E; Tomas, A, 2008)	2.27
"Mitoxantrone also has a very favorable toxicity profile with significantly less nausea and vomiting, alopecia, and stomatitis as compared with anthracyclines."	( A phase I trial of vinorelbine in combination with mitoxantrone in patients with refractory solid tumors. Bigley, J; Burris, HA; Dieras, V; Eckardt, JR; Hardy, J; Hohneker, J; Jones, SF; Peacock, NW; Rodriguez, GI; Smith, L; Von Hoff, DD, 1998)	1.27
"Mitoxantrone has a role in the treatment of MS patients with frequent exacerbations and rapid disease progression."	( A double-blind clinical trial of mitoxantrone versus methylprednisolone in relapsing, secondary progressive multiple sclerosis. Beguin, C; Carton, H; D'Hooghe, MB; Dooms, G; Lissoir, F; Sindic, CJ; van de Wyngaert, FA, 2001)	1.31
"Mitoxantrone also has a much slower dissociation rate from poly[d(G-C)]2 than from poly[d(A-T)]2, but its dissociation from both polymers exhibits biphasic kinetics."	( Stopped-flow kinetic analysis of the interaction of anthraquinone anticancer drugs with calf thymus DNA, poly[d(G-C)].poly[d(G-C)], and poly[d(A-T)].poly[d(A-T)]. Krishnamoorthy, CR; Lown, JW; Smith, JC; Wilson, WD; Yen, SF, 1986)	0.99
"Mitoxantrone has proved efficacy in treatment of multiple sclerosis (MS). "	( Does physical exercise improve or deteriorate treatment of multiple sclerosis with mitoxantrone? Experimental autoimmune encephalomyelitis study in rats. Abdallah, DM; El Achy, S; El-Abhar, HS; El-Emam, MA; Gowayed, MA, 2022)	2.39
"The mitoxantrone molecule has an intense binding energy of - 880.536 kcal/mol with AKT1 protein, while the XFE molecule shows a binding energy value of - 83.569 kcal/mol."	( Investigation of the inhibitory behavior of XFE and mitoxantrone molecules in interaction with AKT1 protein: a molecular dynamics simulation study. Abasi Joozdani, F; Amiran, MR; Taghdir, M, 2023)	1.64
"Mitoxantrone (MTX) has been used as an effective disease modifying treatment (DMT) in multiple sclerosis (MS). "	( Mitoxantrone in relapsing-remitting and rapidly progressive multiple sclerosis: Ten-year clinical outcomes post-treatment with mitoxantrone. Foo, EC; Ford, HL; Lily, O; Russell, M, 2020)	3.44
"Mitoxantrone (MITOX) has been used to treat patients with aggressive multiple sclerosis (MS) for decades. "	( Clinical follow-up of 411 patients with relapsing and progressive multiple sclerosis 10 years after discontinuing mitoxantrone treatment: a real-life cohort study. Chartier, N; Dahan, C; Debouverie, M; Epstein, J; Guillemin, F; Mathey, G; Michaud, M; Pittion-Vouyovitch, S; Soudant, M, 2018)	2.13
"Mitoxantrone (MTX) has been shown to reduce progression of disability and number of clinical exacerbations in patients with progressive multiple sclerosis (MS). "	( The N-terminal pro-brain natriuretic peptide as a marker of mitoxantrone-induced cardiotoxicity in multiple sclerosis patients. Kamińska, AM; Kochanowski, J; Kwieciński, H; Opolski, G; Podlecka-Piętowska, A; Zakrzewska-Pniewska, B, 2014)	2.09
"Mitoxantrone has been extensively used as a disease-modifying therapy for multiple sclerosis. "	( Long-term risk of leukaemia or cardiomyopathy after mitoxantrone therapy for multiple sclerosis. Goggin, C; Joyce, E; Lynch, T; Mahon, N; Melling, J; Mulroy, E; O'Rourke, K; Scott, J, 2012)	2.07
"Mitoxantrone has been approved by the FDA for the treatment of multiple sclerosis (MS). "	( Mitoxantrone repression of astrocyte activation: relevance to multiple sclerosis. Burns, SA; Chavis, JA; Drew, PD; Hensley, LL; Lee Archer, R; Tull, CA, 2012)	3.26
"Mitoxantrone has not gained widespread acceptance in the veterinary community, primarily due to its cost and single-dose packaging in a volume that exceeds the needs of the majority of veterinary cancer patients."	( Evaluation of the in vitro cytotoxicity of mitoxantrone following repeated freeze-thaw cycles. Mauldin, GN; Truax, R, 2002)	1.3
"Mitoxantrone (MX) has been approved by the Food and Drug Administration (FDA) for the treatment of patients with worsening relapsing-remitting (RR) or secondary progressive (SP) multiple sclerosis (MS). "	( Mitoxantrone in progressive multiple sclerosis: when and how to treat? Gonsette, RE, 2003)	3.2
"Mitoxantrone has gained largest acceptance."	( Clinical practice of immunosuppressive treatments in multiple sclerosis: results of a second international questionnaire. Hommes, OR; Weiner, HL, 2004)	1.04
"Mitoxantrone (MX) has been approved by the Food and Drug Administration for the treatment of rapidly progressive multiple sclerosis (MS). "	( Pixantrone (BBR2778): a new immunosuppressant in multiple sclerosis with a low cardiotoxicity. Dubois, B; Gonsette, RE, 2004)	1.77
"Mitoxantrone (MTZ) has been shown to be effective in the treatment of newly diagnosed acute myeloblastic leukemia (AML). "	( A randomized trial of continuous infusion versus bolus mitoxantrone in combination with cytarabine in newly diagnosed patients with acute myeloblastic leukemia. Canpinar, H; Kansu, E; Kars, A; Koc, Y; Oyan, B; Tekuzman, G, 2004)	2.01
"Mitoxantrone (mitox) has been shown to be effective for secondary progressive (SP) and relapsing-remitting multiple sclerosis (MS). "	( [The effect of combined mitoxantrone and methylprednisolone therapy in primary and secondary progressive multiple sclerosis. An applied study in 65 patients]. Brandt, T; Gross, A; Hohlfeld, R; Jahn, K; Strupp, M; Zingler, VC, 2005)	2.08
"Mitoxantrone has been approved by the Food and Drug Administration for HRCAP."	( Phase II trial of tesmilifene plus mitoxantrone and prednisone for hormone refractory prostate cancer: high subjective and objective response in patients with symptomatic metastases. Brandes, LJ; Klapp, K; Lieskovsky, G; Quinn, DI; Raghavan, D; Ramsey, EW; Snyder, T; Styles, E; Tsao-Wei, D, 2005)	1.33
"Mitoxantrone (MX) has been shown to be moderately effective in reducing the clinical outcome measures of disease activity in multiple sclerosis (MS) patients."	( Mitoxantrone for multiple sclerosis. Capra, R; Comi, G; Martinelli Boneschi, F; Rovaris, M, 2005)	3.21
"Mitoxantrone has been shown to reduce relapses, the number of new lesions visualised on magnetic resonance imaging and stop or reduce the progression of the disease in many patients treated."	( The cardiac effects of mitoxantrone: do the benefits in multiple sclerosis outweigh the risks? Murray, TJ, 2006)	1.37
"Mitoxantrone has activity similar to that of doxorubicin, is less cardiotoxic, and is widely used to treat prostate cancer."	( Phase II study of mitoxantrone and ketoconazole for hormone-refractory prostate cancer. Bergan, RC; Eklund, J; Gallot, L; Jovanovic, B; Kozloff, M; Mariott, M; Pins, M; Robin, E; Schilder, L; Starr, A; Vlamakis, J, 2006)	1.39
"Mitoxantrone (MX) has demonstrated efficacy in multiple sclerosis (MS), but its immunologic mechanisms of action are poorly understood. "	( Immunological studies of mitoxantrone in primary progressive MS. Cotleur, AC; Fox, RJ; Lee, JC; Pelfrey, CM; Zamor, N, 2006)	2.08
"Mitoxantrone has been approved by the FDA for worsening relapsing remitting and secondary progressive Multiple Sclerosis. "	( Sequential maintenance treatment with glatiramer acetate after mitoxantrone is safe and can limit exposure to immunosuppression in very active, relapsing remitting multiple sclerosis. Boggild, M; Das, K; Jacob, A; Ramtahal, J, 2006)	2.02
"Mitoxantrone has recently been shown to be effective in ameliorating multiple sclerosis activity and reducing the relapse rate."	( Mitoxantrone reduced disability in Iranian patients with multiple sclerosis. Etemadifar, M; Hamzehloo, A, 2007)	2.5
"Mitoxantrone (MTZ) has potent in vitro activity against malignant glioma cell lines, but it cannot be used effectively as a systemic agent for the treatment of brain tumors because of its poor central nervous system penetration. "	( Treatment of malignant gliomas with mitoxantrone-loaded poly (lactide-co-glycolide) microspheres. Bozdag, S; Capan, Y; Cetin, M; Dalkara, T; Söylemezoglu, F; Vural, I; Yemisci, M, 2006)	2.05
"Mitoxantrone resistance has been related to the expression of a drug efflux pump breast cancer resistance pump (BCRP) but little is known of the intracellular protein changes. "	( Proteomic analysis to dissect mitoxantrone resistance-associated proteins in a squamous lung carcinoma. Clynes, M; Keenan, J; Murphy, L, )	1.86
"Mitoxantrone has a broad anti-tumour activity including lymphoma with potentially less cardiotoxicity than doxorubicin, which may be of particular importance in elderly patients. "	( CNOP (mitoxantrone) chemotherapy is inferior to CHOP (doxorubicin) in the treatment of patients with aggressive non-Hodgkin lymphoma (meta-analysis). Ahlbom, A; Anders, A; Andersson, T; Björkholm, M; Eva, O; Magnus, B; Ösby, E; Tomas, A, 2008)	2.27
"Mitoxantrone has been administered to more than 4000 patients worldwide. "	( Clinical safety and tolerance of mitoxantrone. Crossley, RJ, 1984)	1.99
"Mitoxantrone has markedly less cardiotoxicity than doxorubicin, and this may be linked to the fact that the drug does not induce free radical formation but inhibits lipid peroxidation."	( Biologic and biochemical effects of mitoxantrone. Durr, FE, 1984)	1.26
"Mitoxantrone has been given to 335 patients in an i.v."	( An EORTC phase II study of mitoxantrone in solid tumors and lymphomas. Armand, JP; Bastit, P; Cappelaere, P; De Jager, R; Earl, H; Fargeot, P; Keiling, R; Renard, J; Rubens, R; van Glabbeke, M, 1984)	1.29
"Mitoxantrone has recently been tested to treat effusions, and preliminary results suggest the high efficacy of this drug in the treatment of peritoneal, pericardial and pleural effusions."	( Management of peritoneal effusions with intracavitary mitoxantrone or bleomycin. Maiche, AG, 1994)	1.26
"Mitoxantrone has been tested recently in the treatment of effusions, and preliminary results suggest high efficacy of this drug in the treatment of peritoneal, pericardial, and pleural effusions."	( Bleomycin and mitoxantrone in the treatment of malignant pleural effusions. A comparative study. Kontkanen, T; Maiche, AG; Möykkynen, K; Porkka, K; Virkkunen, P, 1993)	1.37
"Mitoxantrone has shown moderate activity in advanced epithelial ovarian cancer following intermittent i.v. "	( Continuous mitoxantrone infusion in pretreated epithelial ovarian cancer. Aversa, S; Azzoni, P; Endrizzi, L; Fiorentino, MV; Koussis, H; Nicoletto, MO; Padrini, R; Palumbo, M; Rosabian, A, 1995)	2.12
"Mitoxantrone has demonstrable clinical activity when administered intravenously in a wide range of malignancies. "	( Phase I/II study of intraperitoneal mitoxantrone in refractory ovarian cancer. Aartsen, E; Dubbelman, R; Mandjes, I; McVie, JG; Oza, AM; Soepenberg, O; ten Bokkel Huinink, W, 1994)	2.01
"Mitoxantrone has been shown in vitro to exhibit a steep dose-response relationship with respect to the clonogenic survival of acute myeloid leukemia cells. "	( High-dose mitoxantrone induces programmed cell death or apoptosis in human myeloid leukemia cells. Bhalla, K; Bullock, G; Grant, S; Huang, Y; Ibrado, AM; Mahoney, ME; Ponnathpur, V; Tang, C; Tourkina, E, 1993)	2.13
"Mitoxantrone (MIT) has not been studied as a single agent in children with untreated leukemia. "	( In vitro cytotoxicity of mitoxantrone, daunorubicin and doxorubicin in untreated childhood acute leukemia. de Waal, FC; Hählen, K; Kaspers, GL; Klumper, E; Pieters, R; van Wering, ER; van Zantwijk, I; Veerman, AJ, 1994)	2.03
"Mitoxantrone has also been effective in inducing complete remissions in patients with relapsed or refractory ANLL, mainly in combination with other antineoplastic agents."	( Mitoxantrone: a review of its pharmacological properties and use in acute nonlymphoblastic leukaemia. Dunn, CJ; Goa, KL, 1996)	2.46
"Mitoxantrone also has a very favorable toxicity profile with significantly less nausea and vomiting, alopecia, and stomatitis as compared with anthracyclines."	( A phase I trial of vinorelbine in combination with mitoxantrone in patients with refractory solid tumors. Bigley, J; Burris, HA; Dieras, V; Eckardt, JR; Hardy, J; Hohneker, J; Jones, SF; Peacock, NW; Rodriguez, GI; Smith, L; Von Hoff, DD, 1998)	1.27
"Mitoxantrone has demonstrated therapeutic efficacy in the regional treatment of intraperitoneal malignancies. "	( Evaluation of mitoxantrone-loaded albumin microspheres following intraperitoneal administration to rats. Eichler, HG; Luftensteiner, CP; Paul, B; Schwendenwein, I; Viernstein, H, 1999)	2.11
"Mitoxantrone (MXN) has demonstrated therapeutic efficacy in the intraperitoneal treatment of malignancies. "	( Toxicity of a particulate formulation for the intraperitoneal application of mitoxantrone. Eichler, HG; Luftensteiner, CP; Paul, B; Schwendenwein, I; Viernstein, H; Wölfl, G, 1999)	1.97
"Mitoxantrone has not been compared with palliative care comprising radiotherapy."	( Mitoxantrone: new indication. More risky than beneficial in advanced prostate cancer. , 2001)	2.47
"Mitoxantrone has a role in the treatment of MS patients with frequent exacerbations and rapid disease progression."	( A double-blind clinical trial of mitoxantrone versus methylprednisolone in relapsing, secondary progressive multiple sclerosis. Beguin, C; Carton, H; D'Hooghe, MB; Dooms, G; Lissoir, F; Sindic, CJ; van de Wyngaert, FA, 2001)	1.31
"Mitoxantrone has moderate activity in childhood ALL and should be considered for further trials in less heavily pretreated patients."	( Phase II trial of mitoxantrone in acute lymphocytic leukemia of childhood. A Pediatric Oncology Group study. Estrada, J; Graham, ML; Ragab, AH; Rosen, D; Starling, KA; Wilkenson, RW; Wilkerson, RW, 1991)	1.34
"Mitoxantrone has been reported to lack certain properties that characterize quinone containing antitumor agents that undergo enzymatic reduction. "	( Mechanism(s) for the metabolism of mitoxantrone: electron spin resonance and electrochemical studies. Gutierrez, PL; Nguyen, B, 1990)	2
"Mitoxantrone (6 mg/m2) has been administrated after effusion aspiration."	( [Efficacy and toxicity of intrapleural mitoxantrone: apropos of 18 cases of pleural metastases of breast cancer]. Brun, B; Calitchi, E; Feuilhade, F; Haddad, E; Le Bourgeois, JP; Otzmeguine, Y; Pierquin, B, 1989)	1.27
"Mitoxantrone has activity in HCC and is well tolerated when administered by HAI."	( Hepatic arterial infusion of mitoxantrone in the treatment of primary hepatocellular carcinoma. Blackstein, ME; Evans, WK; Fine, S; Habal, F; Heathcote, J; Kutas, G; Langer, B; Pritchard, KI; Shepherd, FA; Taylor, B, 1987)	1.29
"Mitoxantrone has demonstrated clinical efficacy in the treatment of leukemia, lymphoma, and breast cancer."	( Mitoxantrone: a novel anthracycline derivative. Eble, M; Koeller, J, 1988)	2.44
"Mitoxantrone has been found to fluoresce with excitation maxima at 610 and 660 nm and emission maximum at 685 nm."	( Characterization of the fluorescence of the antitumor agent, mitoxantrone. Bell, DH, 1988)	1.24
"Both mitoxantrone and etoposide have been shown to be active in monotherapy trials of relapsed and refractory acute myelogenous leukemia (AML). "	( Combination of mitoxantrone and etoposide in refractory acute myelogenous leukemia--an active and well-tolerated regimen. Ehninger, G; Freund, M; Ho, AD; Hunstein, W; Illiger, HJ; Lipp, T; Meyer, P, 1988)	1.14
"Mitoxantrone has significant activity in the treatment of metastatic breast cancer, acute leukemias, and non-Hodgkin's lymphoma."	( Mitoxantrone. Poirier, TI, 1986)	2.44
"Mitoxantrone (MIT) has recently been introduced into cancer therapy as a possible substitute for the structurally related drug, adriamycin (ADR), because it causes less cardiotoxicity and fewer gastrointestinal side effects. "	( Comparative in vitro toxicity of mitoxantrone and adriamycin in human granulocyte-macrophage progenitor cells. Brühl, P; Ehninger, G; Heidemann, E; Mergenthaler, HG, 1987)	2
"Mitoxantrone also has a much slower dissociation rate from poly[d(G-C)]2 than from poly[d(A-T)]2, but its dissociation from both polymers exhibits biphasic kinetics."	( Stopped-flow kinetic analysis of the interaction of anthraquinone anticancer drugs with calf thymus DNA, poly[d(G-C)].poly[d(G-C)], and poly[d(A-T)].poly[d(A-T)]. Krishnamoorthy, CR; Lown, JW; Smith, JC; Wilson, WD; Yen, SF, 1986)	0.99

Excerpt	Reference	Relevance
"Mitoxantrone did not cause signs of congestive heart failure in any of the patients."	( Assessment of potential cardiotoxic side effects of mitoxantrone in patients with multiple sclerosis. Brandt, T; Gross, A; Hohlfeld, R; Jahn, K; Nabauer, M; Strupp, M; Zingler, VC, 2005)	1.3
"Mitoxantrone may inhibit the migration of inflammatory cells into and within the central nervous system."	( Inhibition by mitoxantrone of in vitro migration of immunocompetent cells: a possible mechanism for therapeutic efficacy in the treatment of multiple sclerosis. Dehmel, T; Hartung, HP; Kieseier, BC; Kopadze, T; Stüve, O, 2006)	2.14
"Mitoxantrone could cause an intrapleural inflammatory reaction."	( [Therapy of pronounced pleural and pericardial effusion in metastatic breast cancer with local mitoxantrone and radiation therapy. Presentation of the intrapleural cytologic findings during this therapy]. Blohmer, JU; Kohls, A; Lau, HU, 1993)	1.23
"Mitoxantrone displays an improved tolerability profile compared with doxorubicin and other anthracyclines, although myelosuppression may occur more frequently."	( Mitoxantrone. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the chemotherapy of cancer. Balfour, JA; Chrisp, P; Faulds, D; Langtry, HD, 1991)	2.45
"Mitoxantrone displays no activity in patients with advanced carcinoma of the vulva or vagina."	( Mitoxantrone in the treatment of advanced vulvar and vaginal carcinoma. A gynecologic oncology group study. Bundy, BN; Christopherson, WA; Muss, HB, 1989)	2.44
"Mitoxantrone displays minimal activity in patients with advanced non-squamous carcinoma of the cervix."	( Mitoxantrone in the treatment of advanced non-squamous carcinoma of the cervix (a phase II trial of the gynecologic oncology group). Bundy, BN; Homesley, HD; Muss, HB; Wilbanks, G, 1987)	2.44

Excerpt	Reference	Relevance
"41 mitoxantrone-treated PPMS-patients, 155 mitoxantrone-treated RP/SPMS-patients and 43 PPMS-controls were retrospectively assessed for clinical therapy-response and in correlation with four single-nucleotide-polymorphisms in ABCB1- and ABCG2-genes."	( Lack of efficacy of mitoxantrone in primary progressive Multiple Sclerosis irrespective of pharmacogenetic factors: a multi-center, retrospective analysis. Chan, A; Comabella, M; Fleischer, V; Gold, R; Grey Née Cotte, S; Kruse, N; Montalban, X; Salmen Née Stroet, A; Starck, M; von Ahsen, N; Winkelmann, A; Zettl, UK; Zipp, F, 2015)	1.36
"Mitoxantrone treatment increased the ex vivo production of the TH2 cytokines interleukin-4 (IL-4; P < 0.05) and IL-5 (P < 0.001) in phytohemagglutinin-stimulated CD4+ T cells within 18 days of treatment. "	( Mitoxantrone treatment in multiple sclerosis induces TH2-type cytokines. Bröker, BM; Dressel, A; Rosenberg, S; Skrzipek, S; Vogelgesang, A, 2010)	3.25
"Mitoxantrone treatment in MS enhances the inducibility of TH2-type cytokines, which may contribute to its beneficial effects in MS."	( Mitoxantrone treatment in multiple sclerosis induces TH2-type cytokines. Bröker, BM; Dressel, A; Rosenberg, S; Skrzipek, S; Vogelgesang, A, 2010)	3.25
"When mitoxantrone-treated B16-F1 cells were used as antigen to inoculate mice, the mice acquired an ability to suppress proliferation of homologous tumor cells."	( Mitoxantrone-mediated apoptotic B16-F1 cells induce specific anti-tumor immune response. Cao, C; Han, Y; Ren, Y; Wang, Y, 2009)	2.25
"Mitoxantrone treatment induced γH2AX foci and NU7441 increased their longevity (24 h)."	( Mitoxantrone in combination with an inhibitor of DNA-dependent protein kinase: a potential therapy for high risk B-cell chronic lymphocytic leukaemia. Bedwell, C; Crawford, C; Durkacz, BW; Elliott, SL; Evans, P; Mainou-Fowler, T; Mulligan, E; Newton, P; Summerfield, G; Wallis, J; Willmore, E, 2011)	2.53
"Mitoxantrone treatment in MS is associated with long-term major potential harms - leukaemia (LK) and cardiotoxicity (CT)."	( Long-term treatment risks in multiple sclerosis: risk knowledge and risk perception in a large cohort of mitoxantrone-treated patients. Elias, WG; Heesen, C; Hofmann, A; Kasper, J; Köpke, S; Pauly, I; Repenthin, J; Rosenkranz, T; Stellmann, JP; Ufer, F; Weber, T, 2013)	1.33
"Mitoxantrone treatment did not improve the Expanded Disability Status Scale score; however, no further significant deterioration appeared."	( Efficacy of mitoxantrone and intrathecal triamcinolone acetonide treatment in chronic progressive multiple sclerosis patients. Brune, N; Hellwig, K; Hoffmann, V; Lukas, C; Müller, T; Przuntek, H; Schimrigk, S, )	1.23
"On mitoxantrone treatment there was a considerable neurologic recovery."	( 3-methylcrotonyl-CoA carboxylase deficiency and severe multiple sclerosis. Andersen, O; Darin, N; Holme, E; Holmgren, D; Wiklund, LM, 2007)	0.85
"Mitoxantrone treatment induced two partial remissions (patients with metastatic squamous cell carcinomas of the hypopharynx and rectum) and one mixed response (patient with gastric carcinoma)."	( Phase I clinical trial f mitoxantrone: a new anthracenedione anticancer drug. Alberts, DS; Goodman, GE; Griffith, KS; Herman, TS; Murray, E, 1980)	1.29
"Mitoxantrone treatment seems able to improve the clinical course of relapsing remitting multiple sclerosis patients."	( Noninvasive assessment of mitoxantrone cardiotoxicity in relapsing remitting multiple sclerosis. Beni, S; Cartoni, D; De Castro, S; Funaro, S; Gasperini, C; Millefiorini, E; Morino, S; Tallarico, D, 1995)	1.31
"Mitoxantrone treatment and doxorubicin treatment also cause up-regulation of Fas, the cell surface receptor for FasL, in LNCaP cells, but not in DU145 or PC3 cells."	( Fas ligand is constitutively secreted by prostate cancer cells in vitro. Lederman, S; Liu, QY; Omene, C; Rubin, MA; Stein, CA, 1998)	1.02
"Mitoxantrone-treated animals showed moderate cardiotoxic lesions (but not cumulative) and no increase in serum lipids."	( The effect of doxorubicin and its analogue mitoxantrone on cardiac muscle and on serum lipids: an experimental study. Couris, E; Deliconstantinos, G; Dontas, I; Karayannacos, PE; Koutinos, G; Perrea-Kotsarelis, D; Stathopoulos, GP, )	1.12
"Mitoxantrone treated NCI-H69 cells were found to accumulate DNA-protein crosslinks during a 4 hr post-treatment incubation period whereas variant cells maintained depressed levels of crosslinking."	( Mitoxantrone-DNA binding and the induction of topoisomerase II associated DNA damage in multi-drug resistant small cell lung cancer cells. Fox, ME; Morgan, SA; Smith, PJ; Watson, JV, 1990)	2.44
"Treatment with mitoxantrone also led to the appearance of structures resembling agresomes in H1299 cells and to nucleolar segregation in both cell lines."	( Cytoskeletal reorganization and cell death in mitoxantrone-treated lung cancer cells. Gackowska, L; Grzanka, A; Klimaszewska-Wisniewska, A; Pawlik, A; Szczepanski, MA; Zuryn, A, 2016)	1.03
"The treatment with mitoxantrone is limited by the occurrence of infertility, cardiotoxicy and leukaemia."	( Treatment of multiple sclerosis: role of natalizumab. Comi, G, 2009)	0.67
"Cotreatment of mitoxantrone with different concentrations of dexamethasone and indomethacin sensitized parental and resistant MCF-7 cells to mitoxantrone cytotoxicity."	( Evaluation of indomethacin and dexamethasone effects on BCRP-mediated drug resistance in MCF-7 parental and resistant cell lines. Behravan, J; Elahian, F; Kalalinia, F, 2010)	0.7
"Treatment with mitoxantrone in patients with highly relapsing NMO significantly reduces relapse rates, resulting in subsequent functional stabilization or improvement."	( Efficacy and safety of mitoxantrone in patients with highly relapsing neuromyelitis optica. Kim, HJ; Kim, SH; Kim, W; Li, XF; Park, MS; Sohn, EH, 2011)	1.03
"Treatment with mitoxantrone brought about statistically significant decreases in relapse rates, progression of disability, gadolinium-enhancing, and new lesions on T2-weighted MRI."	( Review of mitoxantrone in the treatment of multiple sclerosis. Herndon, R; Jeffery, DR, 2004)	1.07
"Treatment with mitoxantrone is associated with certain adverse events, such as cardiotoxicity."	( Mitoxantrone for multiple sclerosis in clinical practice. Fox, EJ; Rizvi, SA; Zwibel, H, 2004)	2.11
"Treatment with mitoxantrone and cytarabine resulted in two acute myeloid leukemia patients achieving complete remission and one a partial remission; two patients had progressive disease, and one died in induction."	( Mitoxantrone as a single agent and in combination chemotherapy in patients with refractory acute leukemia. Cuttner, J; Holland, JF; Paciucci, PA, 1984)	2.05
"treatment with mitoxantrone had AUCs and plasma peak levels of the drug that were significantly higher than those in non-responders (P = 0.03, Fisher's exact test)."	( Phase I-II intraperitoneal mitoxantrone in advanced pretreated ovarian cancer. Costa, L; Ferrazzi, E; Monfardini, S; Nascimben, O; Nicoletto, MO; Padrini, R; Palumbo, M; Tumolo, S; Vinante, O; Visonà, E, 1993)	0.92
"Treatment with mitoxantrone plus prednisone was associated with greater and longer-lasting improvement in several HQL domains and symptoms than treatment with prednisone alone."	( Health-related quality of life in men with metastatic prostate cancer treated with prednisone alone or mitoxantrone and prednisone. Ernst, DS; Neville, AJ; Osoba, D; Tannock, IF, 1999)	0.87
"treatment with mitoxantrone."	( Clinical pharmacokinetics of mitoxantrone after intraperitoneal administration. Dubbelman, R; McVie, JG; Nagel, JD; ten Bokkel Huinink, WW; Varossieau, FJ, 1992)	0.91
"Mice treated with mitoxantrone at a dose of 0.5 mg/kg daily for the 10 days following immunization did not develop any clinical signs and had minimal pathologic signs of disease."	( Suppression of acute and relapsing experimental allergic encephalomyelitis with mitoxantrone. Knobler, RL; Lavasa, M; Lublin, FD; Viti, C, 1987)	0.82

Excerpt	Reference	Relevance
" Generally, the liposomal application form was more effective and less toxic than the free drug."	( Evaluation of incorporation characteristics of mitoxantrone into unilamellar liposomes and analysis of their pharmacokinetic properties, acute toxicity, and antitumor efficacy. Berger, DP; Berger, MR; Fiebig, HH; Schwendener, RA, 1991)	0.54
" These two DNA intercalators differed significantly in their cytotoxic potential, mitoxantrone being 24-fold more toxic than mAMSA when assayed by the inhibition of clonogenicity."	( Long-term inhibition of DNA synthesis and the persistence of trapped topoisomerase II complexes in determining the toxicity of the antitumor DNA intercalators mAMSA and mitoxantrone. Fox, ME; Smith, PJ, 1990)	0.7
" From June 1988 to December 1989, 27 previously untreated patients with early-staged Hodgkin's disease with adverse features for disease-free survival received combined-modality therapy."	( NOVP: a novel chemotherapeutic regimen with minimal toxicity for treatment of Hodgkin's disease. Cabanillas, F; Hagemeister, FB; Liang, JC; McLaughlin, P; Meistrich, ML; Redman, JR; Rodríguez, MA; Romaguera, JE; Swan, F; Velásquez, WS, 1990)	0.28
" In K562 the sequence Ara-C much greater than MX was significantly more toxic (3."	( Synergistic cytotoxicity of cytosine arabinoside and mitoxantrone for K562 and CFU-GM. Büchner, T; Hiddemann, W; Krehmeier, C; Zühlsdorf, M, 1990)	0.53
" This suggests that mitoxantrone is oxidised to a toxic intermediate by the MFO system."	( The role of reductive and oxidative metabolism in the toxicity of mitoxantrone, adriamycin and menadione in human liver derived Hep G2 hepatoma cells. Duthie, SJ; Grant, MH, 1989)	0.84
" The toxic effects were compared with those of adriamycin (ADR)."	( [A study of acute toxicity of mitoxantrone]. Bao, DY; Li, GR; Liao, J; Liao, NG; Liu, YQ; Miao, SK; Xiao, Y; Zeng, ZX, 1989)	0.57
" These results suggest that intracavity injection of mitoxantrone is feasible and generally safe in most patients."	( [Efficacy and toxicity of intrapleural mitoxantrone: apropos of 18 cases of pleural metastases of breast cancer]. Brun, B; Calitchi, E; Feuilhade, F; Haddad, E; Le Bourgeois, JP; Otzmeguine, Y; Pierquin, B, 1989)	0.8
" The results indicate that reserpine enhances the cytotoxicity of mitoxantrone and adriamycin in mildly toxic concentrations (1 and 10 micrograms respectively), in CML cells."	( Mitoxantrone & adriamycin cytotoxicity enhanced by reserpine in human chronic myeloid leukaemia cells. Advani, SH; Chitnis, MP; Kamath, NS, 1989)	1.96
" Moreover, at low concentrations, ADR was less toxic than MIT in both types of GM-CFCs, but was more toxic than MIT when a concentration of 20 ng/ml was used."	( Comparative in vitro toxicity of mitoxantrone and adriamycin in human granulocyte-macrophage progenitor cells. Brühl, P; Ehninger, G; Heidemann, E; Mergenthaler, HG, 1987)	0.55
" In four randomized trials the adverse experience profile associated with Novantrone was superior to that of Adriamycin with statistically significant lower incidences of mucositis/stomatitis, nausea, vomiting and alopecia."	( Mitoxantrone: an overview of safety and toxicity. Bernstein, T; Cartwright, K; Dukart, G; Goldberg, J; Posner, LE, 1985)	1.71
" In mice, LD10, LD50 and LD90 values were respectively, 26, 35 and 47 mg kg-1 28 days following single intravenous injection and 22, 67 and 206 mg kg-1 14 days after single intraperitoneal injection."	( Preclinical toxicity of the new antineoplastic agent, ametantrone acetate, in mice and dogs. Anderson, JA; de la Iglesia, FA; Fitzgerald, JE; Jayasekara, U; Kim, SN; Watkins, JR, 1986)	0.27
" The spleen weight depression assay indicated that, on a mg/kg basis, DHAD was more toxic to the organ than ADR, with 17."	( Comparative toxicity of mitoxantrone and doxorubicin on hematopoietic stem cells. Buffo, MJ; Kociban, DL; OKunewick, JP, 1985)	0.58
" The most common adverse clinical effects were nausea and vomiting, stomatitis, and alopecia, though the majority of these cases were mild."	( Clinical safety and tolerance of mitoxantrone. Crossley, RJ, 1984)	0.55
" 10-fold less toxic than doxorubicin and caused only minor electrocardiogram (ECG) changes."	( Comparison of cardiotoxicity of two anthracenediones and doxorubicin in rats. Beilstein, AK; Zbinden, G, 1982)	0.26
"Cardiotoxicity is a well recognized side effect of anthracyclines (doxorubicin and epirubicin) or antracenadiones (mitoxantrone) at cumulative or high doses."	( Late cardiac toxicity of doxorubicin, epirubicin, and mitoxantrone therapy for Hodgkin's disease in adults. Arévila, N; Avilés, A; Díaz Maqueo, JC; García, R; Gómez, T; Nambo, MJ, 1993)	0.74
" Neither nanoparticles nor liposomes were able to reduce the toxic side-effects caused by mitoxantrone, namely leucocytopenia."	( Influence of polybutylcyanoacrylate nanoparticles and liposomes on the efficacy and toxicity of the anticancer drug mitoxantrone in murine tumour models. Beck, P; Fichtner, I; Kreuter, J; Reszka, R, )	0.56
" In the FAMP group, a direct correlation was found between the LD50 values of both FAMP and Mitox and the number of synergistic interactions, while the Pearson correlation coefficient was not significant in the Pento group."	( The in vitro cytotoxic effect of mitoxantrone in combination with fludarabine or pentostatin in B-cell chronic lymphocytic leukemia. Brugiatelli, M; Callea, I; Console, G; Filangeri, M; Iacopino, P; Morabito, F; Musolino, C; Oliva, B; Sculli, G; Stelitano, C, )	0.41
" Furthermore, we evaluated the times for hematopoietic reconstitution in a group of five BC patients in the high-risk adjuvant situation who underwent HD chemotherapy and hematopoietic rescue with positive/negative selected stem cells and compared it with our own data from 10 BC patients who, after identical HD therapy, received only positively selected CD34+ cells and 14 patients who, after identical HD therapy, received autografts purged by incubation with toxic ether lipids (ET-18-OCH3)."	( Efficacy and safety of simultaneous immunomagnetic CD34+ cell selection and breast cancer cell purging in peripheral blood progenitor cell samples used for hematopoietic rescue after high-dose therapy. Berdel, WE; Cassens, U; Fietz, T; Hilgenfeld, E; Hoffmann, M; Hoppe, B; Kienast, J; Knauf, WU; Koenigsmann, M; Mohr, M; Sibrowski, W; Thiel, E, 1999)	0.3
"Acute toxic effects of the antineoplastic anthraquinones carminomycin, epirubicin, idarubicin and mitoxantrone were studied in primary cultures of cardiomyocytes, which were isolated from adult rats."	( Anthraquinone-induced cell injury: acute toxicity of carminomycin, epirubicin, idarubicin and mitoxantrone in isolated cardiomyocytes. Andersson, BS; Carlberg, M; Eksborg, S; Sundberg, M; Vidal, RF, 1999)	0.74
" No toxic deaths have occurred."	( Etoposide, mitoxantrone and prednisone: a salvage regimen with low toxicity for refractory or relapsed non-Hodgkin's lymphoma. Budel, L; Doorduijn, JK; Löwenberg, B; Sonneveld, P; Spruit, P; van Der Holt, B; van't Veer, M, 2000)	0.7
" With both P388 and HL-60 cells, cryptolepine proved about four times more toxic than its isomer."	( Cytotoxicity and cell cycle effects of the plant alkaloids cryptolepine and neocryptolepine: relation to drug-induced apoptosis. Bailly, C; Dassonneville, L; Lansiaux, A; Mahieu, C; Pieters, L; Van Miert, S; Wattelet, A; Wattez, N, 2000)	0.31
"Cardiotoxicity, a side-effect that can occur after treatment with an anticancer drug, has severe clinical implications."	( In vitro screening of antitumour agents for cardiotoxicity by means of isolated mouse left atria. Bast, A; Haenen, GR; van Acker, FA; van Acker, SA; van der Vijgh, WJ, )	0.13
" In CD2F1 mice, LEM was significantly less toxic as compared with MTO."	( Improved safety, pharmacokinetics and therapeutic efficacy profiles of a novel liposomal formulation of mitoxantrone. Ahmad, I; Gokhale, PC; Kasid, U; Pei, J; Rahman, A; Zhang, C, )	0.35
" A liver biopsy revealed a grade II toxic hepatitis."	( Methotrexate-associated liver toxicity in a patient with breast cancer: case report and literature review. Bogers, J; Schrijvers, D; van den Brande, J; van Marck, E; van Outryve, S; Vermorken, JB; Wilmes, P, 2002)	0.31
"The toxicity of most drugs is associated with their enzymatic conversion to toxic metabolites."	( Saccharomyces cerevisiae as an eukaryotic cell model to assess cytotoxicity and genotoxicity of three anticancer anthraquinones. Buschini, A; Poli, P; Rossi, C, 2003)	0.32
" Pixantrone (PIX) is an analogue of MX devoid of toxic effects on cardiac tissue and was developed as a replacement for other anthracenediones in cancer patients."	( Pixantrone (BBR2778): a new immunosuppressant in multiple sclerosis with a low cardiotoxicity. Dubois, B; Gonsette, RE, 2004)	0.32
" TMJ is a safe and effective regimen when used as a part of autologous stem cell transplant for patients with HD and NHL."	( High dose chemotherapy with thiotepa, mitoxantrone and carboplatin (TMJ) followed by autologous stem cell support in 100 consecutive lymphoma patients in a single centre: analysis of efficacy, toxicity and prognostic factors. Ahmed, T; Hoang, A; Kancherla, R; Liu, D; Qureshi, Z; Seiter, K; Waheed, F, 2004)	0.59
"Treatment of patients with mitoxantrone for worsening multiple sclerosis (MS) requires careful monitoring for possible adverse events."	( Mitoxantrone treatment of multiple sclerosis: safety considerations. Cohen, BA; Mikol, DD, 2004)	2.06
"5 million adverse drug reaction (ADR) reports for 8620 drugs/biologics that are listed for 1191 Coding Symbols for Thesaurus of Adverse Reaction (COSTAR) terms of adverse effects."	( Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling. Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL, 2004)	0.32
" Glatiramer Acetate appears a safe and effective option for continuing disease modification in patients with relapsing remitting multiple sclerosis treated with Mitoxantrone."	( Sequential maintenance treatment with glatiramer acetate after mitoxantrone is safe and can limit exposure to immunosuppression in very active, relapsing remitting multiple sclerosis. Boggild, M; Das, K; Jacob, A; Ramtahal, J, 2006)	0.77
"To investigate spontaneous reports of TdP present in the public version of the FDA Adverse Event Reporting System (AERS) in the light of what is already known on their TdP-liability."	( Drug-induced torsades de pointes: data mining of the public version of the FDA Adverse Event Reporting System (AERS). De Ponti, F; Moretti, U; Poluzzi, E; Raschi, E, 2009)	0.35
" Cases were represented by TdP reports, whereas non-cases were all reports of adverse drug reactions other than TdP."	( Drug-induced torsades de pointes: data mining of the public version of the FDA Adverse Event Reporting System (AERS). De Ponti, F; Moretti, U; Poluzzi, E; Raschi, E, 2009)	0.35
"Large spontaneous reporting databases represent an important source for signal detection of rare adverse drug reactions (ADR), such as TdP."	( Drug-induced torsades de pointes: data mining of the public version of the FDA Adverse Event Reporting System (AERS). De Ponti, F; Moretti, U; Poluzzi, E; Raschi, E, 2009)	0.35
" The patients were monitored for the adverse effects."	( Efficacy and safety of mitoxantrone, as an initial therapy, in multiple sclerosis: experience in an Indian tertiary care setting. Geeta, S; Hundalani, SG; Menon, S; Singhal, BS, )	0.44
" The adverse events noted in the entire cohort were leucopenia in four patients and asymptomatic reversible decrease in cardiac ejection fraction in one patient."	( Efficacy and safety of mitoxantrone, as an initial therapy, in multiple sclerosis: experience in an Indian tertiary care setting. Geeta, S; Hundalani, SG; Menon, S; Singhal, BS, )	0.44
"To evaluate the incidence and potential predictors of adverse events associated with mitoxantrone at the MS Clinic, University of British Columbia, Canada."	( Cardiotoxicity and other adverse events associated with mitoxantrone treatment for MS. Geddes, J; Isserow, S; Kingwell, E; Koch, M; Leung, B; Rieckmann, P; Tremlett, H, 2010)	0.83
" Generalized estimating equations were used to examine potential predictors of adverse events (graded according to the Common Toxicity Criteria, version 4) in patients with normal baseline and > or =1 follow-up MUGA or laboratory assessment."	( Cardiotoxicity and other adverse events associated with mitoxantrone treatment for MS. Geddes, J; Isserow, S; Kingwell, E; Koch, M; Leung, B; Rieckmann, P; Tremlett, H, 2010)	0.61
"Cytoreduction with 4 courses of R-FM was safe and highly efficient in patients with recurrent/refractory follicular lymphoma who had high tumor burden; however, better consolidation than FM is needed to further improve outcome."	( Efficacy and safety of the combination of rituximab, fludarabine, and mitoxantrone for rituximab-naive, recurrent/refractory follicular non-Hodgkin lymphoma with high tumor burden: a multicenter phase 2 trial by the Groupe d'Etude des Lymphomes de l'Adult Brice, P; Copin, MC; Fermé, C; Feugier, P; Lamy, T; Morschhauser, F; Mounier, N; Sebban, C; Solal-Celigny, P; Tilly, H, 2010)	0.59
" The findings of the present study suggest that FLANG salvage chemotherapy is an effective regimen and that it offers a safe bridge to SCT."	( FLANG salvage chemotherapy is an effective regimen that offers a safe bridge to transplantation for patients with relapsed or refractory acute myeloid leukemia. Cho, BS; Cho, SG; Choi, SM; Eom, KS; Kim, CC; Kim, HJ; Kim, YJ; Lee, DG; Lee, JW; Lee, S; Min, CK; Min, WS, 2011)	0.37
" No patients had serious adverse effects during the mean follow-up period of 41 months after completing therapy."	( Efficacy and safety of mitoxantrone in patients with highly relapsing neuromyelitis optica. Kim, HJ; Kim, SH; Kim, W; Li, XF; Park, MS; Sohn, EH, 2011)	0.68
" The most common adverse effects were hematologic, with 2 patients experiencing treatment-related myelodysplastic syndrome (MDS), evolving to acute myelogenous leukemia (AML) in 1 patient."	( Safety and efficacy of combination therapy with fludarabine, mitoxantrone, and rituximab followed by yttrium-90 ibritumomab tiuxetan and maintenance rituximab as front-line therapy for patients with follicular or marginal zone lymphoma. Bayer, R; Fung, HC; Gregory, SA; Karmali, R; Kassar, M; O'Brien, T; Shammo, JM; Venugopal, P, 2011)	0.61
" Redox inactivity in the face of high cardiac uptake suggests that pixantrone might also be safe in doxorubicin-naïve patients."	( The novel anthracenedione, pixantrone, lacks redox activity and inhibits doxorubicinol formation in human myocardium: insight to explain the cardiac safety of pixantrone in doxorubicin-treated patients. Chello, M; Covino, E; Menna, P; Minotti, G; Paz, OG; Salvatorelli, E; Singer, JW, 2013)	0.39
" Safety and tolerability of fingolimod were evaluated by adverse events monitoring, laboratory tests, and ophthalmological and skin assessment."	( Evaluation of efficacy, safety and tolerability of fingolimod in patients with the relapsing form of multiple sclerosis - 12-month observation. A preliminary report. Maciejek, Z; Niezgodzińska-Maciejek, A; Wawrzyniak, S; Wójcik-Drączkowska, H, )	0.13
" During fingolimod treatment there was no new relapse in any patient and no patient stopped the treatment because of any adverse event."	( Evaluation of efficacy, safety and tolerability of fingolimod in patients with the relapsing form of multiple sclerosis - 12-month observation. A preliminary report. Maciejek, Z; Niezgodzińska-Maciejek, A; Wawrzyniak, S; Wójcik-Drączkowska, H, )	0.13
"In our study patients fingolimod was effective, safe and well tolerated independently of disease activity and previous treatment."	( Evaluation of efficacy, safety and tolerability of fingolimod in patients with the relapsing form of multiple sclerosis - 12-month observation. A preliminary report. Maciejek, Z; Niezgodzińska-Maciejek, A; Wawrzyniak, S; Wójcik-Drączkowska, H, )	0.13
" Two toxic deaths were observed."	( High response rate and acceptable toxicity of a combination of rituximab, vinorelbine, ifosfamide, mitoxantrone and prednisone for the treatment of diffuse large B-cell lymphoma in first relapse: results of the R-NIMP GOELAMS study. Alexis, M; Arakelyan, N; Banos, A; Cartron, G; Courby, S; Damotte, D; Dreyfus, F; Fontan, J; Gressin, R; Gyan, E; Lamy, T; Laribi, K; Le Gouill, S; Maisonneuve, H; Quittet, P; Schmidt-Tanguy, A; Sénécal, D; Solal-Céligny, P; Tournilhac, O, 2013)	0.61
" Thus, a network of multiple-treatments meta-analysis was performed using four clinical outcomes: 'patients free of relapse', 'patients without disease progression', 'patients without MRI progression' and 'patients with adverse events'."	( A network meta-analysis of randomized controlled trials for comparing the effectiveness and safety profile of treatments with marketing authorization for relapsing multiple sclerosis. Bakalos, G; Doxani, C; Grigoriadis, N; Hadjigeorgiou, GM; Miligkos, M; Mprotsis, T; Papadimitriou, D; Ziakas, P; Zintzaras, E, 2013)	0.39
" Regarding 'patients with adverse events', no data were available for all comparisons to make fair inferences."	( A network meta-analysis of randomized controlled trials for comparing the effectiveness and safety profile of treatments with marketing authorization for relapsing multiple sclerosis. Bakalos, G; Doxani, C; Grigoriadis, N; Hadjigeorgiou, GM; Miligkos, M; Mprotsis, T; Papadimitriou, D; Ziakas, P; Zintzaras, E, 2013)	0.39
" One of the treated groups suffered euthanasia on day 22 (MTX22) to evaluate early MTX toxic effects, while the other suffered euthanasia on day 48 (MTX48), to allow the evaluation of MTX late effects."	( Cumulative mitoxantrone-induced haematological and hepatic adverse effects in a subchronic in vivo study. Arbo, M; Costa, VM; Dallegrave, E; de Lourdes Bastos, M; Dinis-Oliveira, RJ; Duarte, JA; Palmeira, C; Remião, F; Rossato, LG; Santos-Silva, A, 2014)	0.79
" Adverse events included nausea and vomiting, fatigue, alopecia, palpitation, cardiomyopathy and mild leukopenia."	( Safety and efficacy of mitoxantrone in pediatric patients with aggressive multiple sclerosis. Abtahi, SH; Afzali, P; Etemadifar, M; Fereidan-Esfahani, M; Murray, RT; Nourian, SM; Ramagopalan, SV, 2014)	0.71
" Continuing research is needed to establish its efficacy and safety profile in a multinational collaboration with careful follow-up of adverse events."	( Safety and efficacy of mitoxantrone in pediatric patients with aggressive multiple sclerosis. Abtahi, SH; Afzali, P; Etemadifar, M; Fereidan-Esfahani, M; Murray, RT; Nourian, SM; Ramagopalan, SV, 2014)	0.71
"The results of our study confirm that MTX therapy is safe for carefully selected and closely monitored MS patients."	( The N-terminal pro-brain natriuretic peptide as a marker of mitoxantrone-induced cardiotoxicity in multiple sclerosis patients. Kamińska, AM; Kochanowski, J; Kwieciński, H; Opolski, G; Podlecka-Piętowska, A; Zakrzewska-Pniewska, B, 2014)	0.64
"Exploring the relationships among adverse events is important because those that arise from a common mechanism are amenable to a common intervention, which can improve symptom management, quality of life, and treatment adherence."	( Identifying Severe Adverse Event Clusters Using the National Cancer Institute's Common Terminology Criteria for Adverse Events. Hershman, DL; Lee, SM; Lim, EA; Moinpour, CM; Unger, J; Zhong, X, 2016)	0.43
"The CTCAE data from a randomized clinical trial conducted by SWOG that compared docetaxel plus estramustine versus mitoxantrone plus predinsone in patients with advanced prostate cancer were used to identify severe adverse event clusters."	( Identifying Severe Adverse Event Clusters Using the National Cancer Institute's Common Terminology Criteria for Adverse Events. Hershman, DL; Lee, SM; Lim, EA; Moinpour, CM; Unger, J; Zhong, X, 2016)	0.64
"A total of 109 adverse event types were captured using the CTCAE."	( Identifying Severe Adverse Event Clusters Using the National Cancer Institute's Common Terminology Criteria for Adverse Events. Hershman, DL; Lee, SM; Lim, EA; Moinpour, CM; Unger, J; Zhong, X, 2016)	0.43
"Several severe adverse event clusters were identified in patients with advanced prostate cancer."	( Identifying Severe Adverse Event Clusters Using the National Cancer Institute's Common Terminology Criteria for Adverse Events. Hershman, DL; Lee, SM; Lim, EA; Moinpour, CM; Unger, J; Zhong, X, 2016)	0.43
"In this article, we review the potential adverse effects and recommended laboratory studies as part of the monitoring strategy following initiation of various first generation DMTs and their recently approved versions."	( Update on monitoring and adverse effects of first generation disease modifying therapies and their recently approved versions in relapsing forms of multiple sclerosis. Cano, CA; Dubey, D; Stüve, O, 2016)	0.43
" MTX was more toxic in equivalent concentrations in all cytotoxicity tests performed [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide reduction, neutral red uptake, and lactate dehydrogenase release assays] and times tested (24 and 48 h)."	( Naphthoquinoxaline metabolite of mitoxantrone is less cardiotoxic than the parent compound and it can be a more cardiosafe drug in anticancer therapy. Bastos, ML; Carvalho, F; Carvalho, RA; Costa, VM; Gomes, AS; Pinto, M; Reis-Mendes, A; Remião, F; Sousa, E, 2017)	0.74
" We analyzed the main outcomes, including the overall survival (OS), progression-free survival (PFS), prostate-specific antigen (PSA) response, tumor response and severe adverse events (AEs)."	( The efficacy and safety comparison of docetaxel, cabazitaxel, estramustine, and mitoxantrone for castration-resistant prostate cancer: A network meta-analysis. Huang, C; Song, P; Wang, Y, 2018)	0.71
"Cardiotoxicity was ascertained through adverse event monitoring over the course of follow-up among 1,022 pediatric patients with acute myeloid leukemia treated in the Children's Oncology Group trial AAML0531."	( Occurrence of Treatment-Related Cardiotoxicity and Its Impact on Outcomes Among Children Treated in the AAML0531 Clinical Trial: A Report From the Children's Oncology Group. Alonzo, T; Aplenc, R; Gamis, A; Gerbing, RB; Getz, KD; Ky, B; Leahy, AB; Leger, KJ; Sack, L; Sung, L; Woods, WG, 2019)	0.51
" Most pediatric oncology treatment groups assume that the hematologic toxicity of anthracycline agents is equivalent to their cardiotoxicity; for example, Children's Oncology Group substitution rules consider daunorubicin and epirubicin isoequivalent to doxorubicin, whereas mitoxantrone and idarubicin are considered 4 to 5 times as toxic as doxorubicin."	( Derivation of Anthracycline and Anthraquinone Equivalence Ratios to Doxorubicin for Late-Onset Cardiotoxicity. Armstrong, GT; Aune, GJ; Chow, EJ; Feijen, EAM; Green, DM; Hudson, MM; Kremer, LCM; Leisenring, WM; Loonen, J; Ness, KK; Oeffinger, KC; Robison, LL; Stratton, KL; van Dalen, EC; van der Pal, HJH; Yasui, Y, 2019)	0.69
" Yet, it may serve as a safe and reliable alternative in cases where the radioactive technique is unavailable."	( Safety and Efficacy of Mitoxantrone Hydrochloride Injection for Identification of Axillary Sentinel Lymph Nodes in Patients with Primary Breast Cancer. Abdelaal, M; Elzayat, I; Monib, S, 2023)	1.22
"Cardiotoxicity is among the most important adverse effects of childhood cancer treatment."	( Acute and early-onset cardiotoxicity in children and adolescents with cancer: a systematic review. Bolier, M; Feijen, EAM; Grotenhuis, HB; Hoesein, FAAM; Kouwenberg, TW; Kremer, LCM; Mavinkurve-Groothuis, AMC; Netea, SA; Slieker, MG; van Dalen, EC, 2023)	0.91

Excerpt	Reference	Relevance
" The drug was quantified in plasma with an HPLC assay and pharmacokinetic analysis was performed with the APIS software."	( Pharmacokinetics of mitoxantrone in cancer patients treated by high-dose chemotherapy and autologous bone marrow transplantation. Blaise, D; Cano, JP; Gaspard, MH; Iliadis, A; Just-Landi, S; Launay-Iliadis, MC; Maraninchi, D; Richard, B; Stoppa, AM; Viens, P, 1992)	0.61
" Median values obtained for the pharmacokinetic parameters of mitoxantrone in peritoneal dialysate were: t1/2 beta (distribution), 56."	( Clinical pharmacokinetics of mitoxantrone after intraperitoneal administration. Dubbelman, R; McVie, JG; Nagel, JD; ten Bokkel Huinink, WW; Varossieau, FJ, 1992)	0.82
" The pharmacokinetic parameters are described adequately by a three-compartment model with a terminal half-life of 71."	( Pharmacokinetic and pharmacodynamic studies with mitoxantrone in the treatment of patients with nasopharyngeal carcinoma. Chang, SP; Chen, KY; Hu, OY; Jian, JM; Law, CK, 1992)	0.54
"Phase I and pharmacokinetic studies were performed in order to evaluate the maximum tolerated dose and the efficiency of 120 h continuous venous infusion (CVI) of mitoxantrone."	( Phase I/II pharmacokinetic study of mitoxantrone by continuous venous infusion in patients with solid tumours and lymphoproliferative diseases. Bugat, R; Canal, P; Chevreau, C; de Forni, M; Huguet, F; Lachau, S; Laurent, G; Roche, H, 1991)	0.75
" This paper reports the pharmacokinetic studies of 3H-mitoxantrone in mice by liquid scintillation."	( [A study on pharmacokinetics of 3H-mitoxantrone in experimental animals]. Bao, D; Fang, Z; Kong, G, 1990)	0.8
" Early pharmacokinetic studies of mitoxantrone in experimental animals using radioactive material showed an extensive tissue distribution and a long terminal plasma half-life."	( Pharmacokinetics and metabolism of mitoxantrone. A review. Blanz, J; Ehninger, G; Proksch, B; Schuler, U; Zeller, KP, 1990)	0.84
"The pharmacokinetic parameters of mitoxantrone in patients with liver metastasis after intra-arterial 2 h and 24 h infusion (dosage 12 mg/m2) were investigated."	( Pharmacokinetics of mitoxantrone in patients after 2 h and 24 h intra-arterial administration. Czejka, MJ; Georgopoulos, A; Jäger, W; Schüller, J, )	0.73
" Pharmacokinetic studies were performed by high-performance liquid chromatography (HPLC) with ultraviolet (UV) detection."	( A phase I pharmacokinetic study of 21-day continuous infusion mitoxantrone. de Vries, EG; Greidanus, J; Mulder, NH; Oosterhuis, B; Sleijfer, DT; Uges, DR; Willemse, PH, 1989)	0.52
" route was studied in a Phase I and pharmacokinetic trial."	( Phase I clinical and pharmacokinetic study of mitoxantrone given to patients by intraperitoneal administration. Alberts, DS; Graham, V; McCloskey, T; McDonald, L; Peng, YM; Rivest, R; Roe, D; Surwit, EA, 1988)	0.53
" Pharmacokinetic and metabolic research is essential to a better understanding of the pharmacological and toxicological activities of drugs and their metabolites."	( Extrapolation of preclinical pharmacokinetic data to therapeutic drug use. Cano, JP; Fabre, G; Rahmani, R; Richard, B, 1988)	0.27
" The pharmacokinetic parameters for ametantrone acetate (CI-881) were characterized in six patients concurrently with the phase I clinical trial."	( Pharmacokinetics of ametantrone acetate (NSC-287513). Balmer, CE; Bender, JF; Grillo-Lopez, AJ; Kuhn, JG; Loesch, DM; Ludden, TM; Von Hoff, DD, 1987)	0.27
" The pharmacokinetic parameters were also defined in five patients who were treated with combination chemotherapy (mitoxantrone 12 mg/m2, methotrexate 30 mg/m2 and vincristine 2 mg)."	( Pharmacokinetics of mitoxantrone in humans following single-agent infusion or intra-arterial injection therapy or combined-agent infusion therapy. de Planque, MM; Deneve, W; McVie, JG; Schoemaker, TJ; Smith, IE; Van Belle, SJ; van Oosterom, AT, 1986)	0.8
" The pharmacokinetic parameters are adequately described by a three-compartment model with a terminal half-life of 214."	( The pharmacokinetics and metabolism of mitoxantrone in man. Ehninger, G; Heinzel, G; Proksch, B; Schiller, E; Weible, KH; Woodward, DL, 1985)	0.54
" Distribution and half-life data provide a pharmacological rationale for the use of mitoxantrone on an intermittent dosing schedule."	( Pharmacology of mitoxantrone: mode of action and pharmacokinetics. Alberts, DS; Bowden, GT; Dalton, WS; Mackel, C; Peng, YM, 1985)	0.84
" There was a large interpatient variability of the area under the time versus concentration curve (AUC) for all three drugs."	( Pharmacokinetics of mitoxantrone, etoposide and cytosine arabinoside in leukemic cells during treatment of acute myelogenous leukemia--relationship to treatment outcome and bone marrow toxicity. Björkholm, M; Gruber, A; Liliemark, E; Liliemark, J; Paul, C; Peterson, C; Tidefelt, U, 1995)	0.61
" Whereas cellular versus plasma maximum concentration ratio was near 1, the area under the concentration +/- time curve ratio reached 100, suggesting a long elimination half-life from cells."	( Plasma and cellular pharmacokinetics of mitoxantrone in high-dose chemotherapeutic regimen for refractory lymphomas. Attal, M; Bugat, R; Canal, P; Chatelut, E; Guichard, S; Houin, G; Huguet, F; Laurent, G; Muller, C; Schlaifer, D, 1993)	0.55
" No significant changes in mean mitoxantrone plasma elimination rates (ie, terminal plasma half-life and total-body clearance rate) occurred as the mitoxantrone dose doubled, indicating linear pharmacokinetics."	( Phase I clinical and pharmacokinetic evaluation of high-dose mitoxantrone in combination with cytarabine in patients with acute leukemia. Ahmed, T; Alberts, DS; Arlin, Z; Baier, M; Baskind, P; Feldman, EJ; Mittelman, A; Peng, YM; Plezia, P, 1993)	0.81
" The pharmacokinetic parameters of DHAQ-PBCA-NP-FDIn and DHAQ-SIn were presented by statistical moment."	( [Study on pharmacokinetics of mitoxantrone polycyanoacrylate nanoparticles freeze-dried injection by HPLC column switching technique]. Liao, GT; Ye, LM; Zhang, ZR, 1995)	0.58
"Two liposomal formulations of mitoxantrone (MTO) were compared with the aqueous solution (free MTO) in terms of their pharmacokinetic behaviour in ICR mice and cytotoxic activity in a nude mouse xenograft model."	( Comparative pharmacokinetic and cytotoxic analysis of three different formulations of mitoxantrone in mice. Hänseler, E; Horber, DH; Rentsch, KM; Schwendener, RA; Wunderli-Allenspach, H, 1997)	0.81
" Pharmacokinetic parameters of f-MTO and 1-MTO were calculated."	( Pharmacokinetic studies of mitoxantrone and one of its metabolites in serum and urine in patients with advanced breast cancer. Hänseler, E; Pestalozzi, BC; Rentsch, KM; Sauter, C; Schwendener, RA; Wunderli-Allenspach, H, 1998)	0.6
"1-MTO had a significantly longer half-life of distribution in the deep (third) compartment and thus a larger area under the curve (AUC) than f-MTO."	( Pharmacokinetic studies of mitoxantrone and one of its metabolites in serum and urine in patients with advanced breast cancer. Hänseler, E; Pestalozzi, BC; Rentsch, KM; Sauter, C; Schwendener, RA; Wunderli-Allenspach, H, 1998)	0.6
"f-MTO and 1-MTO exhibited different distribution patterns in the deep compartment with a significantly increased half-life for 1-MTO."	( Pharmacokinetic studies of mitoxantrone and one of its metabolites in serum and urine in patients with advanced breast cancer. Hänseler, E; Pestalozzi, BC; Rentsch, KM; Sauter, C; Schwendener, RA; Wunderli-Allenspach, H, 1998)	0.6
" LEM also demonstrated favourable pharmacokinetic profiles."	( Improved safety, pharmacokinetics and therapeutic efficacy profiles of a novel liposomal formulation of mitoxantrone. Ahmad, I; Gokhale, PC; Kasid, U; Pei, J; Rahman, A; Zhang, C, )	0.35
" The method was used to successfully quantify mitoxantrone in mouse plasma and tissue samples to support a pharmacokinetic study of LEM-ETU in mice."	( Improved liquid chromatographic method for mitoxantrone quantification in mouse plasma and tissues to study the pharmacokinetics of a liposome entrapped mitoxantrone formulation. Abu-Qare, AW; Ahmad, A; Ahmad, I; Ayoub, JE; Johnson, JL; Khan, S; Wang, YF; Zhang, A, 2004)	0.84
" The recovery of MTO, as well as the precision, linearity, and accuracy of the method for both free and liposomal MTO, appears satisfactory for pharmacokinetic studies."	( Separation of liposome-entrapped mitoxantrone from nonliposomal mitoxantrone in plasma: pharmacokinetics in mice. Ahmad, A; Ahmad, I; Wang, YF, 2005)	0.61
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."	( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. Lombardo, F; Obach, RS; Waters, NJ, 2008)	0.35
"To determine the pharmacokinetic (PK) profile of manganese (Mn) after a 2-hour intravenous infusion of mangafodipir at 5 micromol/kg body weight and to correlate Mn concentrations with oxidative stress, early decrease in serum total bilirubin concentration, and prothrombin time (PT) in chronic alcoholic patients with acute alcoholic hepatitis."	( Pharmacokinetic-pharmacodynamic modeling of manganese after a single intravenous infusion of mangafodipir in patients with acute alcoholic hepatitis. Batteux, F; Debray, M; Hirt, D; Laurent, A; Pavlovic, S; Poupon, J; Richardet, JP; Sogni, P; Treluyer, JM; Urien, S; Weill, B, 2009)	0.35
" This assay was successfully applied in a pharmacokinetic and tissue distribution study of mitoxantrone in mice."	( HPLC analysis of mitoxantrone in mouse plasma and tissues: application in a pharmacokinetic study. An, G; Morris, ME, 2010)	0.92
"The objective of this investigation was to compare the observed biliary clearance (CL(b)) and % of dose excreted in the bile (PD(b)) of mitoxantrone with the predicted values obtained from quantitative structure pharmacokinetic relationship (QSPKR) models."	( Pharmacokinetics and biliary excretion of mitoxantrone in rats. Morris, ME; Yang, X, 2010)	0.83
" Finally, the method was successfully applied to a pharmacokinetic study of mitoxantrone in rats following intravenous administration."	( Determination of mitoxantrone in rat plasma by liquid chromatography-tandem mass spectrometry method: Application to a pharmacokinetic study. He, Z; Ling, G; Pu, X; Sun, J; Sun, Y; Wang, Z; Zhang, P, 2010)	0.93
" The pharmacokinetic comparability of Prolastin-C to Prolastin was assessed in subjects with AAT deficiency."	( Pharmacokinetic comparability of Prolastin®-C to Prolastin® in alpha₁-antitrypsin deficiency: a randomized study. Brantly, ML; Campos, MA; Chapman, KR; Kueppers, F; Sandhaus, RA; Stocks, JM; Strange, C; Turino, G; Wang-Smith, L, 2010)	0.36
" Pharmacokinetic plasma samples were drawn over 7 days following last dose in the first treatment period and over 10 days following the last dose in the second period."	( Pharmacokinetic comparability of Prolastin®-C to Prolastin® in alpha₁-antitrypsin deficiency: a randomized study. Brantly, ML; Campos, MA; Chapman, KR; Kueppers, F; Sandhaus, RA; Stocks, JM; Strange, C; Turino, G; Wang-Smith, L, 2010)	0.36
"09, demonstrating pharmacokinetic equivalence between the 2 products."	( Pharmacokinetic comparability of Prolastin®-C to Prolastin® in alpha₁-antitrypsin deficiency: a randomized study. Brantly, ML; Campos, MA; Chapman, KR; Kueppers, F; Sandhaus, RA; Stocks, JM; Strange, C; Turino, G; Wang-Smith, L, 2010)	0.36
"Prolastin-C demonstrated pharmacokinetic equivalence and a comparable safety profile to Prolastin."	( Pharmacokinetic comparability of Prolastin®-C to Prolastin® in alpha₁-antitrypsin deficiency: a randomized study. Brantly, ML; Campos, MA; Chapman, KR; Kueppers, F; Sandhaus, RA; Stocks, JM; Strange, C; Turino, G; Wang-Smith, L, 2010)	0.36
" The pharmacokinetic study of Mit-lipo and Mit-free was performed on dogs following a single intravenous injection."	( [Pharmacodynamics, pharmacokinetics and tissue distribution of liposomal mitoxantrone hydrochloride]. Li, CL; Li, YH; Wang, CX; Wei, N; Yang, HY; Zhang, L; Zhao, X, 2010)	0.59
" We show the feasibility of real-time, direct pharmacodynamic monitoring by flow cytometry during clinical trials combining intensive chemotherapy and signal transduction inhibitors."	( Single-cell pharmacodynamic monitoring of S6 ribosomal protein phosphorylation in AML blasts during a clinical trial combining the mTOR inhibitor sirolimus and intensive chemotherapy. Carroll, M; Kasner, MT; Luger, SM; Perl, AE; Shank, D, 2012)	0.38
"We conducted a pharmacokinetic (PK) study of mitoxantrone (Novantrone®), a clinically well-established anticancer agent, in mice and developed a mechanism-based PBPK (physiologically based pharmacokinetic) model to describe its disposition."	( A physiologically based pharmacokinetic model of mitoxantrone in mice and scale-up to humans: a semi-mechanistic model incorporating DNA and protein binding. An, G; Morris, ME, 2012)	0.89
" Samples for pharmacokinetic studies were collected."	( Phase I clinical trial of pegylated liposomal mitoxantrone plm60-s: pharmacokinetics, toxicity and preliminary efficacy. Du, P; Gui, L; Han, X; Li, C; Li, N; Liu, P; Shi, Y; Song, Y; Yang, J; Zhang, S; Zhao, X, 2014)	0.66
" The pharmacokinetic profile of plm60-s was remarkably altered."	( Phase I clinical trial of pegylated liposomal mitoxantrone plm60-s: pharmacokinetics, toxicity and preliminary efficacy. Du, P; Gui, L; Han, X; Li, C; Li, N; Liu, P; Shi, Y; Song, Y; Yang, J; Zhang, S; Zhao, X, 2014)	0.66
" Herein, the intracellular pharmacokinetic behavior of D-luciferin was investigated in pancreatic cancer cell lines in real time by using bioluminescence imaging."	( Gemcitabine upregulates ABCG2/BCRP and modulates the intracellular pharmacokinetic profiles of bioluminescence in pancreatic cancer cells. Gu, M; Li, F; Liu, J; Sun, Y; Wei, Y; Xiong, Y; Zhu, L, 2016)	0.43
"The LHRH-MTO-LIPs demonstrated a superior pharmacokinetic profile relative to free MTO."	( Pharmacokinetics, distribution and anti-tumor efficacy of liposomal mitoxantrone modified with a luteinizing hormone-releasing hormone receptor-specific peptide. Feng, W; He, Y; Ren, Y; Song, C; Wang, Y; Zhang, L, 2018)	0.72

Excerpt	Reference	Relevance
"38 patients with advanced breast adenocarcinoma were treated in a phase II study with 5-fluorouracil and high-dose folinic acid combined with cyclophosphamide and mitoxantrone."	( A phase II study of 5-fluorouracil and high-dose folinic acid in combination with cyclophosphamide and mitoxantrone for advanced breast cancer. Aitini, E; Cantore, M; Cavazzini, G; Di Marco, A; Rabbi, C; Rivera, A; Smerieri, F; Togliani, B, 1992)	0.69
"To investigate the effects of mitoxantrone in combination with other anticancer agents, a human T-cell leukemia cell line, MOLT-3, was incubated for 3 days in the presence of two drugs (mitoxantrone and the combined drug) and cell growth inhibition was determined by assay with 3-(4,5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazonium bromide."	( Effects of mitoxantrone in combination with other anticancer agents on a human leukemia cell line. Akutsu, M; Kano, Y; Suda, K; Suzuki, K, 1992)	0.96
" Chronic treatment with these drugs or each combined with ICRF-187 did not change the antioxidant levels relative to the control values."	( Comparative study of doxorubicin, mitoxantrone, and epirubicin in combination with ICRF-187 (ADR-529) in a chronic cardiotoxicity animal model. Alderton, PM; Green, MD; Gross, J, 1992)	0.56
" The low toxicity combined with worthwhile remissions make this an attractive first-line option for elderly patients."	( Phase 2 study of mitozantrone in combination with chlorambucil and prednisolone for relapsed and refractory non-Hodgkins lymphoma. Cotter, FE; Jones, L; Lord, D; Newland, AC, )	0.13
" Neoadjuvant (cytoreductive) chemotherapy combined with early secondary surgical debulking is feasible, with little severe morbidity, and can leave a high proportion of patients free of macroscopic disease."	( Neoadjuvant (cytoreductive) chemotherapy combined with intervention debulking surgery in advanced, unresected epithelial ovarian cancer. Blackledge, G; Chan, KK; Lawton, FG; Luesley, DM; Redman, CW, 1989)	0.28
"To determine optimal dosage, Dihydroxyanthracenedione (DHAD) was given once daily for 3 days at dosage levels of 6, 7, 8, and 10 mg/m2 in combination with a 7-day continuous infusion of cytosine arabinoside (Ara-C)."	( Toxicity evaluation of dihydroxyanthracenedione (DHAD) in combination with cytosine arabinoside (Ara-C). Civin, CI; Krischer, J; Land, VJ; Ragab, AH; Steuber, CP; Vietti, TJ, 1987)	0.27
"The efficacy of mitoxantrone in combination with vinblastine was assessed in 156 patients with metastatic breast cancer who had been treated previously with one or multiple chemotherapeutic regimens."	( Chemotherapy with mitoxantrone in combination with continuous infusion vinblastine for metastatic breast cancer. Blumenschein, GR; Buzdar, AU; Fraschini, G; Hortobagyi, GN; Mann, G; Yap, HY, 1987)	0.95
" Because of the broad spectrum of activity of these DNA binders against murine tumors and due to their promising clinical utility, we have evaluated these agents in combination with a variety of clinically useful antitumor drugs."	( Response of transplantable tumors of mice to anthracenedione derivatives alone and in combination with clinically useful agents. Corbett, TH; Griswold, DP; Laster, WR; Roberts, BJ; Schabel, FM; Trader, MW, 1982)	0.26
" The aim of this study was to assess the response of four mesothelioma cell lines, derived from diffuse asbestos-related pleural malignant mesothelioma, to methotrexate alone and in combination with recombinant IFN-alpha and IFN-gamma."	( Interferon (IFN)-alpha and IFN-gamma in combination with methotrexate: in vitro sensitivity studies in four human mesothelioma cell lines. Hand, A; Linnainmaa, K; Mattson, K; Pelin, K, 1995)	0.29
"High-dose chemotherapy given with autologous bone marrow support has resulted in significant tumor responses in the majority of patients with metastatic breast cancer, a minority of which are durable."	( Dose escalation of mitoxantrone given with thiotepa and autologous bone marrow transplantation for metastatic breast cancer. Adkins, D; Bowers, C; Dunphy, F; Harrison, B; LeMaistre, CF; Spitzer, G, 1993)	0.61
"To determine the maximally tolerated dose of mitoxantrone in combination with cytarabine in patients with acute leukemia and advanced phases of chronic myelogenous leukemia (CML), and to assess the pharmacokinetics of high-dose mitoxantrone in this patient population."	( Phase I clinical and pharmacokinetic evaluation of high-dose mitoxantrone in combination with cytarabine in patients with acute leukemia. Ahmed, T; Alberts, DS; Arlin, Z; Baier, M; Baskind, P; Feldman, EJ; Mittelman, A; Peng, YM; Plezia, P, 1993)	0.79
" Mitoxantrone pharmacokinetics were evaluated by high-performance liquid chromatography (HPLC) in 15 patients given a single dose of mitoxantrone ranging from 40 to 80 mg/m2 in combination with cytarabine."	( Phase I clinical and pharmacokinetic evaluation of high-dose mitoxantrone in combination with cytarabine in patients with acute leukemia. Ahmed, T; Alberts, DS; Arlin, Z; Baier, M; Baskind, P; Feldman, EJ; Mittelman, A; Peng, YM; Plezia, P, 1993)	1.44
"The recommended phase II dose of mitoxantrone is 80 mg/m2 administered over 15 minutes as a single intravenous infusion in combination with cytarabine 3 g/m2/d for 5 days."	( Phase I clinical and pharmacokinetic evaluation of high-dose mitoxantrone in combination with cytarabine in patients with acute leukemia. Ahmed, T; Alberts, DS; Arlin, Z; Baier, M; Baskind, P; Feldman, EJ; Mittelman, A; Peng, YM; Plezia, P, 1993)	0.81
"193 patients with relapsed or refractory acute myeloid leukemia (AML) were entered into a prospective randomized comparison of high-dose versus intermediate dose cytosine arabinoside (AraC) both combined with mitoxantrone (mitox) according to the previously established sequential HD-AraC/mitox regimen (S-HAM)."	( High-dose versus intermediate dose cytosine arabinoside combined with mitoxantrone for the treatment of relapsed and refractory acute myeloid leukemia: results of an age adjusted randomized comparison. Aul, C; Balleisen, L; Bartholomäus, A; Becker, K; Bettelheim, P; Hiddemann, W; Lathan, B; Ludwig, WD; Maschmeyer, G; Schönrock-Nabulsi, R, 1993)	0.71
"The maximum tolerated dose of mitoxantrone (MX) administered alone or combined with whole body hyperthermia (WBH) was determined in this nonrandomized, prospective study in dogs with lymphoma."	( Phase I evaluation of mitoxantrone alone and combined with whole body hyperthermia in dogs with lymphoma. Dewhirst, MW; Gillette, EL; Hauck, ML; Johnson, J; Ogilvie, GK; Page, RL; Price, GS; Thrall, DE, )	0.73
"In this selected group of patients with multiple sclerosis with very active disease, mitoxantrone combined with methylprednisolone was effective in improving both clinical and MRI indices of disease activity over a period of six months whereas methylprednisolone alone was not."	( Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria. Berry, I; Brochet, B; Cabanis, E; Clanet, M; Confavreux, C; Edan, G; Froment, JC; Gandon, JM; Iba-Zizen, MT; Lai, HM; Lubetzki, C; Lyon-Caen, O; Miller, D; Moseley, I; Rolland, Y; Sabouraud, O, 1997)	0.84
"We conducted a randomized, multicenter study of intravenous cyclophosphamide 500 mg/m2 plus fluorouracil 500 mg/m2 combined with either mitoxantrone (Novantrone, Lederle Cyanamid Canada Ltd, Willowdale, Ontario) 10 mg/m2 (CNF) or doxorubicin (Adriamycin, Adria Laboratories of Canada Ltd, Mississauga, Ontario) 50 mg/m2 (CAF) every 3 weeks in advanced breast cancer."	( Cyclophosphamide and fluorouracil combined with mitoxantrone versus doxorubicin for breast cancer: superiority of doxorubicin. Evans, WK; Martz, K; Pritchard, KI; Shepherd, FA; Stewart, DJ; Trudeau, ME; Wilson, JJ; Wilson, KS, 1997)	0.76
" The study was designed to determine the safety and maximally tolerated dose of IV vinorelbine used in combination with a fixed dose of mitoxantrone for the treatment of patients with refractory solid tumors."	( A phase I trial of vinorelbine in combination with mitoxantrone in patients with refractory solid tumors. Bigley, J; Burris, HA; Dieras, V; Eckardt, JR; Hardy, J; Hohneker, J; Jones, SF; Peacock, NW; Rodriguez, GI; Smith, L; Von Hoff, DD, 1998)	0.75
" Because both P-glycoprotein- and platinum-induced resistance appear to be clinically important and can be reversed in vitro with a short exposure of cyclosporin A (CSA) at 2000 and 5000 ng/ml, respectively, we undertook a trial of high-dose chemotherapy with carboplatin (1500mg/m2), mitoxantrone (75 mg/m2), and cyclophosphamide (120 mg/kg) over a 5-day period combined with escalating doses of CSA."	( High-dose chemotherapy combined with escalating doses of cyclosporin A and an autologous bone marrow transplant for the treatment of drug-resistant solid tumors: a phase I clinical trial. Bayer, R; Camarda, M; Kinch, L; Loutfi, S; Peace, D; Rad, N; Sosman, J; Stiff, PJ; Tan, S, 1995)	0.47
"To define the maximum-tolerated dose (MTD) and the dose-limiting toxicities (DLTs) of docetaxel in combination with mitoxantrone in patients with metastatic breast cancer (MBC)."	( Dose-escalation study of docetaxel in combination with mitoxantrone as first-line treatment in patients with metastatic breast cancer. Androulakis, N; Georgoulias, V; Hatzidaki, D; Kakolyris, S; Katsogridakis, K; Kotsakis, T; Kouroussis, C; Mavroudis, D; Samonis, G; Souglakos, J; Vardakis, N; Vlachonikolis, J, 1999)	0.76
"This trial shows the activity of paclitaxel and mitoxantrone in ABC and finds that a dose of 14 mg/m2 of mitoxantrone is the MTD in combination with a fixed dose of 175 mg/m2 of paclitaxel without granulocyte colony stimulating factor (G-CSF)."	( Dose intensification of mitoxantrone in combination with paclitaxel in advanced breast cancer: a phase II study. Acito, L; Angiona, S; Bilancia, D; Costanzo, FD; Fioriti, L; Gasperoni, S; Giustini, L; Manzione, L; Sdrobolini, A; Valenti, L, 1999)	0.87
" These results support that fludarabine in combination with cyclophosphamide and/or mitoxantrone can be highly effective in the treatment of B-CLL."	( In vitro evaluation of fludarabine in combination with cyclophosphamide and/or mitoxantrone in B-cell chronic lymphocytic leukemia. Bellosillo, B; Colomer, D; Gil, J; Montserrat, E; Pons, G; Villamor, N, 1999)	0.76
"Evaluate response, duration of response, and toxicity of paclitaxel in combination with other drugs known to be effective in non-Hodgkin's lymphoma (NHL)."	( Phase II study of paclitaxel in combination with mitoxantrone and ifosfamide/mesna for patients with relapsed or refractory non-Hodgkin's lymphoma after failure to cytarabine/cisplatin combination. Cabanillas, F; Hagemeister, FB; McLaughlin, P; Preti, A; Rodriguez, J; Rodriguez, MA; Romaguera, JE; Sarris, AH; Younes, A, 1999)	0.56
" We analyzed the induction of apoptosis by 2-CdA alone (n=5) and in combination with other drugs in peripheral lymphocytes from 25 patients with leukemic low-grade lymphomas and from 25 healthy volunteers."	( Induction of apoptosis by 2-chloro-2'deoxyadenosine (2-CdA) alone and in combination with other cytotoxic drugs: synergistic effects on normal and neoplastic lymphocytes by addition of doxorubicin and mitoxantrone. Boehrer, S; Chow, KU; Hoelzer, D; Jantschke, P; Martin, H; Mitrou, PS; Napieralski, S; Pourebrahim, F; Ries, J; Rummel, MJ; Stein, J; Weidmann, E, 2000)	0.5
"A dose-escalation study was realized in order to assess the maximally tolerated dose (MTD) of high-dose mitoxantrone in a single injection combined with cytarabine and etoposide (EMA regimen) in refractory or relapsed acute myelogenous leukemia (AML)."	( Dose-escalation study of single dose mitoxantrone in combination with timed sequential chemotherapy in patients with refractory or relapsing acute myelogenous leukemia. Archimbaud, E; Cambier, N; Ecstein-Fraïssé, E; Leblond, V; Pautas, C; Reman, O; Soler-Michel, P; Taksin, AL; Thomas, X; Vekhoff, A, 2000)	0.79
"Main portal branch transection combined with major liver resection and neoadjuvant and adjuvant locoregional immunochemotherapy fulfilled our expectations firstly for increasing the resectability rate and secondly for increasing the overall survival and the disease-free survival."	( Preoperative main portal branch transection combined with liver locoregional transarterial neo and adjuvant immunochemotherapy for patients with hepatocellular carcinoma. Dedemadi, G; Kontis, A; Lygidakis, NJ; Nestoridis, J; Sgourakis, G; Spentzouris, N, )	0.13
" Because its toxicities are minimal and do not overlap with the toxicities of standard chemotherapy, it is an appealing agent to use in combination with chemotherapy."	( Safety of fludarabine, mitoxantrone, and dexamethasone combined with rituximab in the treatment of stage IV indolent lymphoma. Cabanillas, F; Dang, NH; Hagemeister, FB; Lee, MS; McAda, N; McLaughlin, P; Pate, O; Preti, AH; Rodriguez, MA; Romaguera, JE; Sarris, AH; Younes, A, 2000)	0.62
" MV represents a chemotherapy combination with equivalent efficacy to standard FAC/FEC and improved results for patients who have previously received adjuvant chemotherapy."	( Results of a phase III prospective, randomised trial, comparing mitoxantrone and vinorelbine (MV) in combination with standard FAC/FEC in front-line therapy of metastatic breast cancer. Calais, G; Chinet-Charrot, P; Clavère, P; Colin, P; de Gislain, C; Delozier, T; Etienne, PL; Eymard, JC; Ganem, G; Luporsi, E; Maillart, P; Marti, P; Namer, M; Pouillart, P; Prevost, G; Romieu, G; Schraub, S; Serin, D; Soler-Michel, P; Tigaud, D; Trillet-Lenoir, V; Turpin, F; Wendling, JL, 2001)	0.55
"To evaluate the activity and tolerance of docetaxel in combination with mitoxantrone and granulocyte colony-stimulating factor (G-CSF) as front-line treatment in patients with metastatic breast cancer (MBC)."	( Docetaxel in combination with mitoxantrone and granulocyte colony-stimulating factor as front-line chemotherapy in metastatic breast cancer: a multicenter phase II study. Agelaki, S; Alexopoulos, A; Georgoulias, V; Kakolyris, S; Kalbakis, K; Kosmas, C; Kouroussis, C; Malamos, N; Mavroudis, D; Rigatos, G; Sarra, E; Vlachonicolis, J, 2001)	0.83
"Docetaxel in combination with mitoxantrone and G-CSF support is an intensified and active front-line regimen for patients with MBC; despite its hematological toxicity, this regimen merits further comparison with other standard anthracycline- and/or taxane-based combinations."	( Docetaxel in combination with mitoxantrone and granulocyte colony-stimulating factor as front-line chemotherapy in metastatic breast cancer: a multicenter phase II study. Agelaki, S; Alexopoulos, A; Georgoulias, V; Kakolyris, S; Kalbakis, K; Kosmas, C; Kouroussis, C; Malamos, N; Mavroudis, D; Rigatos, G; Sarra, E; Vlachonicolis, J, 2001)	0.89
"A phase II clinical study was performed to evaluate the effectiveness and toxicity of cladribine (2-CdA) combined with mitoxantrone (CM regimen) in the treatment of chronic myeloid leukemia in blastic phase (CML BP)."	( Cladribine combined with mitoxantrone in the treatment of blastic phase of chronic myeloid leukemia. Góra-Tybor, J; Robak, T, 2001)	0.82
" 2-CdA in combination with DOX significantly increased the percentage of annexin V-positive cells, particularly after 48 h of incubation, as compared with DOX used in monotherapy (median AI for 2-CdA+DOX=37."	( Evaluation of apoptosis induced in vitro by cladribine (2-CdA) combined with anthracyclines in lymphocytes from patients with B-cell chronic lymphocytic leukemia. Najder, M; Robak, T; Smolewski, P; Szmigielska-Kaplon, A, 2002)	0.31
"Rituximab, a chimeric monoclonal antibody, produces response rates of up to 73% in patients with previously untreated indolent non-Hodgkin's lymphoma (NHL), and has high activity when combined with chemotherapy."	( Rituximab in combination with CNOP chemotherapy in patients with previously untreated indolent non-Hodgkin's lymphoma. Christodoulou, C; Dimopoulos, M; Economopoulos, T; Fountzilas, G; Hamilos, G; Kalantzis, D; Nicolaides, C; Papageorgiou, E; Pavlidis, N, 2003)	0.32
" Western blot technique combined with videodensitometry was used for Bax and Bcl-2 determination in homogenate, nuclear and postnuclear fractions of mononuclear cells isolated from peripheral blood of B-CLL patients treated with cladribine alone (C), and in combination with cyclophosphamide (CC) or mitoxantrone and cyclophosphamide (CMC)."	( Determination of the in vivo effects of cladribine alone and its combination with cyclophosphamide or cyclophosphamide and mitoxantrone on Bax and Bcl-2 protein expression in B-CLL cells. Blonski, JZ; Hanausek, M; Kilianska, ZM; Kobylinska, A; Robak, T; Walaszek, Z, 2004)	0.71
" This report examines the efficacy of irofulven alone or in combination with mitoxantrone or docetaxel against androgen-independent prostate cancer cell lines."	( Antitumor activity of irofulven monotherapy and in combination with mitoxantrone or docetaxel against human prostate cancer models. MacDonald, JR; Van Laar, ES; Waters, SJ; Weitman, S, 2004)	0.79
"These studies demonstrate that irofulven displays strong activity as monotherapy and in combination with mitoxantrone or docetaxel against androgen-independent prostate cancer in vitro and in vivo; thus, supporting the clinical investigation of irofulven against hormone-refractory prostate cancer."	( Antitumor activity of irofulven monotherapy and in combination with mitoxantrone or docetaxel against human prostate cancer models. MacDonald, JR; Van Laar, ES; Waters, SJ; Weitman, S, 2004)	0.77
" These data provide a proof-of-principle for the clinical use of LErafAON in combination with chemotherapy for cancer treatment."	( Combination with liposome-entrapped, ends-modified raf antisense oligonucleotide (LErafAON) improves the anti-tumor efficacies of cisplatin, epirubicin, mitoxantrone, docetaxel and gemcitabine. Ahmad, I; Dritschilo, A; Gokhale, PC; Kasid, UN; Pei, J; Rahman, A; Zhang, C, 2004)	0.52
" Cladribine is highly effective as a single agent and in combination with mitoxantrone in the treatment of indolent NHL, and its availability broadens the range of therapeutic options for indolent NHL."	( Treatment of indolent non-Hodgkin's lymphoma with cladribine as single-agent therapy and in combination with mitoxantrone. Armitage, JO; Hoelzer, D; Rummel, MJ; Tobinai, K, 2004)	0.77
"From 1998 to 2001, 5 consecutive cases of AML/TMDS entered our hospital and achieved complete remission (CR) with continuous drip infusion of low-dose etoposide and low-dose Ara-C combined with mitoxantrone (MEtA regimen)."	( [Five cases of de novo acute myeloid leukemia with trilineage myelodysplasia (AML/TMDS) achieved CR with the continuous drip infusion of low-dose etoposide and low-dose cytosine arabinoside combined with mitoxantrone (MEtA)]. Furukawa, Y; Kitani, T; Shibano, M; Tsukaguchi, M, 2004)	0.7
"To evaluate the efficacy of postoperative intraperitoneal hyperthermic chemoperfusion (IHCP) combined with intravenous chemotherapy for advanced gastric cancer."	( [Postoperative intraperitioneal hyperthermic chemoperfusion combined with intravenous chemotherapy for 82 advanced gastric cancer patients]. Lu, JF; Lu, WD; Shen, D; Xu, M; Zuo, Y, 2004)	0.32
"Eighty-two patients with stage II - IV gastric cancer were postoperatively randomized into two groups; 46 patients in treatment group who received IHCP combined with intravenous chemotherapy for three times and 36 patients in control group who received intravenous chemotherapy only for six times."	( [Postoperative intraperitioneal hyperthermic chemoperfusion combined with intravenous chemotherapy for 82 advanced gastric cancer patients]. Lu, JF; Lu, WD; Shen, D; Xu, M; Zuo, Y, 2004)	0.32
"Intraperitoneal hyperthermic chemoperfusion combined with intravenous chemotherapy can prolong survival and reduce gastrointestinal side-effect which provides an effective treatment option for advanced gastric cancer."	( [Postoperative intraperitioneal hyperthermic chemoperfusion combined with intravenous chemotherapy for 82 advanced gastric cancer patients]. Lu, JF; Lu, WD; Shen, D; Xu, M; Zuo, Y, 2004)	0.32
" From March 1987 to March 1994, 40 newly diagnosed patients with AML were randomized to receive either bolus or CI-MTZ, administered for 3 days at 10 mg/m2/day in combination with CI-cytarabine for 7 days at 100 mg/m2/day."	( A randomized trial of continuous infusion versus bolus mitoxantrone in combination with cytarabine in newly diagnosed patients with acute myeloblastic leukemia. Canpinar, H; Kansu, E; Kars, A; Koc, Y; Oyan, B; Tekuzman, G, 2004)	0.57
"Docetaxel, a taxane previously approved for the treatment of breast cancer and non-small cell lung cancer, was approved by the United States Food and Drug Administration on May 19, 2004 for use in combination with prednisone for the treatment of metastatic androgen-independent (hormone-refractory) prostate cancer."	( Approval summary: Docetaxel in combination with prednisone for the treatment of androgen-independent hormone-refractory prostate cancer. Abraham, S; Dagher, R; Li, N; Pazdur, R; Rahman, A; Sridhara, R, 2004)	0.32
" When given with prednisone, docetaxel was also shown to reduce pain and serum prostate specific antigen levels and improve quality of life compared with mitoxantrone/prednisone."	( Which drug combination for hormone-refractory prostate cancer? Doggrell, SA, 2005)	0.53
" In this study, the efficacy of lintuzumab in combination with induction chemotherapy was compared with chemotherapy alone in adults with first relapsed or primary refractory acute myeloid leukemia (AML)."	( Phase III randomized multicenter study of a humanized anti-CD33 monoclonal antibody, lintuzumab, in combination with chemotherapy, versus chemotherapy alone in patients with refractory or first-relapsed acute myeloid leukemia. Brandwein, J; Brown, R; Chopra, R; De Angelo, D; Ehmann, WC; Feldman, EJ; Frankel, SR; Jurcic, JC; Kalaycio, M; Miller, C; Moore, J; O'Connor, J; Roboz, GJ; Scheinberg, D; Schulman, P; Stone, R; Wedel, N, 2005)	0.33
"Patients with relapsed or primary resistant AML (duration of first response, zero to 12 months) were randomly assigned to receive either mitoxantrone 8 mg/m(2), etoposide 80 mg/m(2), and cytarabine 1 g/m(2) daily for 6 days (MEC) in combination with lintuzumab 12 mg/m(2), or MEC alone."	( Phase III randomized multicenter study of a humanized anti-CD33 monoclonal antibody, lintuzumab, in combination with chemotherapy, versus chemotherapy alone in patients with refractory or first-relapsed acute myeloid leukemia. Brandwein, J; Brown, R; Chopra, R; De Angelo, D; Ehmann, WC; Feldman, EJ; Frankel, SR; Jurcic, JC; Kalaycio, M; Miller, C; Moore, J; O'Connor, J; Roboz, GJ; Scheinberg, D; Schulman, P; Stone, R; Wedel, N, 2005)	0.53
"In this prospective randomized trial, we compared the efficacy and toxicity of cladribine (2-CdA) alone to 2-CdA combined with cyclophosphamide (CC) or cyclophosphamide and mitoxantrone (CMC) in untreated progressive chronic lymphocytic leukemia (CLL)."	( Cladribine alone and in combination with cyclophosphamide or cyclophosphamide plus mitoxantrone in the treatment of progressive chronic lymphocytic leukemia: report of a prospective, multicenter, randomized trial of the Polish Adult Leukemia Group (PALG C Blonski, JZ; Calbecka, M; Ceglarek, B; Dmoszynska, A; Dwilewicz-Trojaczek, J; Gora-Tybor, J; Jamroziak, K; Kasznicki, M; Kloczko, J; Konopka, L; Kowal, M; Kuliczkowski, K; Robak, T; Skotnicki, AB; Stella-Holowiecka, B; Sulek, K; Tomaszewska, A; Warzocha, K; Zawilska, K, 2006)	0.75
" It is possible that lamivudine combined with chemotherapy may have had a therapeutic effect on ATL in this case."	( [Development of acute type, CD 8 positive adult T-cell leukemia in a carrier of hepatitis B virus--possible therapeutic effect of lamivudine combined with chemotherapy]. Hasegawa, H; Miyagi, T; Nagasaki, A; Nakachi, S; Shinzato, O; Taira, N; Takasu, N; Tomoyose, T, 2006)	0.33
" During 2004 and 2005, 45 patients with newly diagnosed Ph+ ALL were treated in the Group for Research on Adult Acute Lymphoblastic Leukemia (GRAAPH) 2003 study, in which imatinib was started with HAM (mitoxantrone with intermediate-dose cytarabine) consolidation in good early responders (corticosensitive and chemosensitive ALL) or earlier during the induction course in combination with dexamethasone and vincristine in poor early responders (corticoresistant and/or chemoresistant ALL)."	( Imatinib combined with induction or consolidation chemotherapy in patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: results of the GRAAPH-2003 study. Buzyn, A; Cayuela, JM; Chalandon, Y; de Labarthe, A; Delabesse, E; Dombret, H; Escoffre, M; Huguet-Rigal, F; Ifrah, N; Lhéritier, V; MacIntyre, E; Maury, S; Pigneux, A; Réa, D; Reman, O; Rousselot, P; Thomas, X; Vekemans, MC; Vernant, JP; Witz, F, 2007)	0.53
"While gemtuzumab ozogamicin (GTMZ) is commonly used in the treatment of acute myeloid leukemia (AML) in combination with standard chemotherapy agents, the pediatric maximum-tolerated dose (MTD) of GMTZ in combination with chemotherapy has not been determined."	( Safety and efficacy of gemtuzumab ozogamicin in combination with chemotherapy for pediatric acute myeloid leukemia: a report from the Children's Oncology Group. Alonzo, TA; Aplenc, R; Arceci, RJ; Bernstein, I; Buckley, P; Gerbing, RB; Hurwitz, CA; Krimmel, K; Lange, BJ; Sievers, EL; Smith, FO; Wells, RJ, 2008)	0.35
"The Children's Oncology Group AAML00P2 trial sought to define the MTD of GMTZ in combination with cytarabine and mitoxantrone and cytarabine and l-asparaginase chemotherapy regimens."	( Safety and efficacy of gemtuzumab ozogamicin in combination with chemotherapy for pediatric acute myeloid leukemia: a report from the Children's Oncology Group. Alonzo, TA; Aplenc, R; Arceci, RJ; Bernstein, I; Buckley, P; Gerbing, RB; Hurwitz, CA; Krimmel, K; Lange, BJ; Sievers, EL; Smith, FO; Wells, RJ, 2008)	0.56
"The MTD for GMTZ in combination with cytarabine and mitoxantrone was 3 mg/m(2) while the MTD in combination with cytarabine and l-asparaginase was 2 mg/m(2)."	( Safety and efficacy of gemtuzumab ozogamicin in combination with chemotherapy for pediatric acute myeloid leukemia: a report from the Children's Oncology Group. Alonzo, TA; Aplenc, R; Arceci, RJ; Bernstein, I; Buckley, P; Gerbing, RB; Hurwitz, CA; Krimmel, K; Lange, BJ; Sievers, EL; Smith, FO; Wells, RJ, 2008)	0.6
" In vitro, CI-994 in combination with cytarabine (ara-C), daunorubicin and mitoxantrone, resulted in moderate synergism."	( CI-994 (N-acetyl-dinaline) in combination with conventional anti-cancer agents is effective against acute myeloid leukemia in vitro and in vivo. Comijn, EM; Hubeek, I; Kaspers, GJ; Merriman, RL; Padron, JM; Peters, GJ; Van der Wilt, CL, 2008)	0.58
"To evaluate the preliminary efficacy, safety, and impact on quality of life (QoL) of high-dose calcitriol (DN-101) combined with mitoxantrone and glucocorticoids in androgen-independent prostate cancer (AIPC)."	( A phase II study of high-dose calcitriol combined with mitoxantrone and prednisone for androgen-independent prostate cancer. Beer, TM; Chan, JS; Dehaze, DR; Garzotto, M; Pinski, JK; Quinn, DI; Ryan, CW; Sokoloff, M, 2008)	0.8
"This prospective phase II clinical trial evaluated the effects of single-dose mitoxantrone (36 mg/m2 on day 1) in combination with continuous infusion intermediate-dose cytarabine plus etoposide in 25 patients with refractory or early relapsed acute myeloid leukemia (AML)."	( Single-dose mitoxantrone in combination with continuous infusion intermediate-dose cytarabine plus etoposide for treatment of refractory or early relapsed acute myeloid leukemia. Chi, HS; Jang, S; Kang, YA; Kim, DY; Kim, SH; Lee, JH; Lee, KH; Lee, SS; Lee, YS; Lim, SN; Park, CJ; Ryu, SG; Seol, M; Yun, SC, 2009)	0.96
"To observe the clinical efficacy of Chinese drugs combined with chemotherapy in the treatment of acute myeloid leukemia (AML) and to investigate the prognostic relevance of the main parameters in AML treated with integrative medicine."	( Effect and prognostic analysis of treatment for acute myeloid leukemia using Chinese drugs combined with chemotherapy. Hu, NP; Hu, XM; Li, L; Liu, C; Liu, F; Ma, R; Wang, HZ; Xiao, HY; Xu, YG; Yang, XH; Zhang, SS; Zheng, CM, 2009)	0.35
" While clinical efficacy was limited with the viral mutants alone, outcomes were improved in combination with chemotherapeutics."	( Optimisation of replication-selective oncolytic adenoviral mutants in combination with chemotherapeutics. Halldén, G, 2009)	0.35
" The aim of this study was to investigate the cytotoxic effects of this agent in combination with conventional antileukemic agents."	( The cytotoxic effects of gemtuzumab ozogamicin (mylotarg) in combination with conventional antileukemic agents by isobologram analysis in vitro. Akutsu, M; Furukawa, Y; Izumi, T; Kano, Y; Mano, H; Miyawaki, S; Tanaka, M; Tsunoda, S; Yazawa, Y, 2009)	0.35
"The cytotoxic effects of GO in combination with antileukemic agents were studied against human CD33 antigen-positive leukemia HL-60, U937, TCC-S and NALM20 cells."	( The cytotoxic effects of gemtuzumab ozogamicin (mylotarg) in combination with conventional antileukemic agents by isobologram analysis in vitro. Akutsu, M; Furukawa, Y; Izumi, T; Kano, Y; Mano, H; Miyawaki, S; Tanaka, M; Tsunoda, S; Yazawa, Y, 2009)	0.35
"To find the maximum tolerated dose (MTD) of OSI-461 in combination with mitoxantrone in patients with advanced solid tumors."	( A phase I study of OSI-461 in combination with mitoxantrone in patients with advanced solid tumors potentially responsive to mitoxantrone. Boinpally, R; Carducci, MA; Eisenberger, MA; Franke, A; King, S; Pili, R; Porter, J; Resta, LP; Spitz, A; Sweeney, CJ, 2011)	0.86
"This was a Phase I study using cohort dose escalation of OSI-461 dosed orally twice daily in combination with mitoxantrone 12 mg/m(2) given on Day 1 of each 21-day cycle."	( A phase I study of OSI-461 in combination with mitoxantrone in patients with advanced solid tumors potentially responsive to mitoxantrone. Boinpally, R; Carducci, MA; Eisenberger, MA; Franke, A; King, S; Pili, R; Porter, J; Resta, LP; Spitz, A; Sweeney, CJ, 2011)	0.84
" The TTFields were applied alone and in combination with paclitaxel and doxorubicin."	( TTFields alone and in combination with chemotherapeutic agents effectively reduce the viability of MDR cell sub-lines that over-express ABC transporters. Kirson, ED; Palti, Y; Schneiderman, RS; Shmueli, E, 2010)	0.36
"The results indicate that TTFields alone and in combination with paclitaxel and doxorubicin effectively reduce the viability of both wild type and MDR cell sub-lines and thus can potentially be used as an effective treatment of drug resistant tumors."	( TTFields alone and in combination with chemotherapeutic agents effectively reduce the viability of MDR cell sub-lines that over-express ABC transporters. Kirson, ED; Palti, Y; Schneiderman, RS; Shmueli, E, 2010)	0.36
" Here we report greatly improved antitumor efficacy for both attenuated (dl1520) and highly potent (dl922–947) oncolytic mutants in combination with the current standard of care for late-stage hormone-independent prostate cancers, mitoxantrone or docetaxel."	( Efficacy of oncolytic mutants targeting pRb and p53 pathways is synergistically enhanced when combined with cytotoxic drugs in prostate cancer cells and tumor xenografts. Ekblad, M; Halldén, G; Holford, A; Lemoine, NR; Miranda, E; Pizarro, MT; Radhakrishnan, S, 2010)	0.54
"The hepatic organic anion transporting polypeptides (OATPs) influence the pharmacokinetics of several drug classes and are involved in many clinical drug-drug interactions."	( Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions. Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR, 2012)	0.38
"To explore the therapeutic effect of homoharringtonine (HHT) combined with cytarabine (HA regimen) on CML-MBC and its influence on bone marrow CD34+CD7+ cells."	( Homoharringtonine combined with cytarabine to treat chronic myelogenous leukemia in myeloid blast crisis and its impact on bone marrow CD34+CD7+ cells. Deng, Z; Ding, B; Li, Y; Shi, Y; Zho, J, 2014)	0.4
"Reported response rates of transitional cell carcinoma (TCC) in dogs to piroxicam in combination with either mitoxantrone or carboplatin are similar; however, it is unknown whether either drug might provide superior duration of response."	( Randomized phase III trial of piroxicam in combination with mitoxantrone or carboplatin for first-line treatment of urogenital tract transitional cell carcinoma in dogs. Allstadt, SD; Boostrom, B; Rebhun, RB; Rodriguez, CO; Skorupski, KA, 2015)	0.87
"This study did not detect a different in outcome in dogs with TCC treated with either mitoxantrone or carboplatin in combination with piroxicam."	( Randomized phase III trial of piroxicam in combination with mitoxantrone or carboplatin for first-line treatment of urogenital tract transitional cell carcinoma in dogs. Allstadt, SD; Boostrom, B; Rebhun, RB; Rodriguez, CO; Skorupski, KA, 2015)	0.88
"To investigate the efficacy and safety of MA (mitoxantrone and cytarabine) regimen chemotherapy combined with granulocyte-colony stimulating factor (G-CSF)-mobilized family related HLA-haploidentical donor peripheral blood hematopoietic stem cell (G-PBHSC) infusion for the treatment of acute myeloid leukemia (AML) patients aged over 80 years."	( [Clinical Analysis of 4 AML Patients Aged Over 80 Years Treated with Chemotherapy Combined with Haploidentical Hematopoietic Stem Cell Infusion]. Hu, HL; Huang, YJ; Li, J; Liu, J; Sun, WJ; Xi, XQ; Zhao, HX, 2015)	0.68
" We performed an open-label, multi-center, phase II study to investigate the effect and quality of life (QoL) of treatment with vorinostat in combination with fludarabine, mitoxantrone and dexamethasone (V-FND) for relapsed or refractory MCL."	( Results of a phase II study of vorinostat in combination with intravenous fludarabine, mitoxantrone, and dexamethasone in patients with relapsed or refractory mantle cell lymphoma: an interim analysis. Kim, BS; Kim, HJ; Kim, JA; Kim, SJ; Kim, WS; Kong, JH; Park, SK; Park, Y; Shin, DY; Won, JH; Yoon, DH, 2016)	0.85
"In this study, we compared the efficacy of mitoxantrone in combination with intermediate-dose cytarabine (HAM) with that of high-dose cytarabine alone (HiDAC) as consolidation regimens in non-acute promyelocytic leukemia (APL) acute myeloid leukemia patients with favorable and intermediate cytogenetics."	( Comparison of Mitoxantrone in Combination with Intermediate-dose Cytarabine versus High-dose Cytarabine as Consolidation Therapies for Young Non-APL Acute Myeloid Leukemia Patients with Favorable and Intermediate Cytogenetics. Hu, LN; Li, GQ; Lin, HQ; Shen, Q; Sun, XF; Zhang, XY; Zhou, JH, 2018)	1.1
" A phase I trial of the second-generation proteasome inhibitor ixazomib in combination with MEC (mitoxantrone, etoposide, and cytarabine) was conducted in patients with R/R AML."	( A Phase I/II Trial of MEC (Mitoxantrone, Etoposide, Cytarabine) in Combination with Ixazomib for Relapsed Refractory Acute Myeloid Leukemia. Advani, AS; Caimi, P; Carew, J; Carraway, H; Chan, R; Cooper, B; de Lima, M; Elson, P; Gerds, A; Hamilton, B; Kalaycio, M; Little, J; Maciejewski, J; Malek, E; Miron, A; Mukherjee, S; Nazha, A; Pink, J; Sekeres, MA; Sobecks, R; Tomlinson, B; Unger, A; Visconte, V; Wei, W, 2019)	1.03
" The aim of this study was to investigate the cytotoxic and anti-proliferative effects of arvanil and olvanil when administered alone and in combination with cisplatin (CDDP) and mitoxantrone (MTX), using various primary (A375, FM55P) and metastatic (SK-MEL 28, FM55M2) human malignant melanoma cell lines."	( Comparison of the Anticancer Effects of Arvanil and Olvanil When Combined with Cisplatin and Mitoxantrone in Various Melanoma Cell Lines-An Isobolographic Analysis. Drozd, M; Florek-Łuszczki, M; Góralczyk, A; Marzęda, P; Wróblewska-Łuczka, P; Łuszczki, JJ, 2022)	1.13

Excerpt	Reference	Relevance
" Mitoxantrone is poorly absorbed orally and is most commonly administered intravenously."	( Mitoxantrone: a novel anthracycline derivative. Eble, M; Koeller, J, 1988)	2.63
" To avoid the confounding drug transport provided by P-glycoprotein (P-gp), the roles of Bcrp1 in the bioavailability of topotecan and the effect of GF120918 were studied in both wild-type and P-gp-deficient mice and their fetuses."	( Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan. Beijnen, JH; Brinkhuis, RF; Jonker, JW; Maliepaard, M; Schellens, JH; Schinkel, AH; Smit, JW, 2000)	0.31
" When both topotecan and GF120918 were administered orally, the bioavailability (i."	( Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan. Beijnen, JH; Brinkhuis, RF; Jonker, JW; Maliepaard, M; Schellens, JH; Schinkel, AH; Smit, JW, 2000)	0.31
" These results may have therapeutic implications because the antitumor efficacy of ST1481 is in part related to a good bioavailability after oral administration, and the drug is currently under Phase I clinical evaluation."	( A novel 7-modified camptothecin analog overcomes breast cancer resistance protein-associated resistance in a mitoxantrone-selected colon carcinoma cell line. Beggiolin, G; Carenini, N; Carminati, P; De Cesare, M; De Isabella, P; Palumbo, M; Perego, P; Pezzoni, G; Pisano, C; Pratesi, G; Scheffer, GL; Tartaglia, L; Zunino, F, 2001)	0.52
", irinotecan), resulting in increased bioavailability and reduced clearance of these agents."	( Cyclosporin A, tacrolimus and sirolimus are potent inhibitors of the human breast cancer resistance protein (ABCG2) and reverse resistance to mitoxantrone and topotecan. Dai, Y; Gupta, A; Hebert, MF; Mao, Q; Ross, DD; Thummel, KE; Unadkat, JD; Vethanayagam, RR, 2006)	0.54
"The human ATP-binding cassette transporter, ABCG2, confers resistance to multiple chemotherapeutic agents and also affects the bioavailability of different drugs."	( The calcium channel blockers, 1,4-dihydropyridines, are substrates of the multidrug resistance-linked ABC drug transporter, ABCG2. Ambudkar, SV; Bates, SE; Robey, RW; Shukla, S, 2006)	0.33
" The pharmacokinetic study in rats showed that LPG significantly prolonged the circulation time and enhanced the bioavailability of MX."	( Dual-functional liposome for tumor targeting and overcoming multidrug resistance in hepatocellular carcinoma cells. Fan, R; Gan, Y; Guo, S; Li, F; Yu, M; Zhang, X; Zhu, C, 2012)	0.38
" This study investigates the interactions between selected prenylflavonoids and breast cancer resistance protein (BCRP/ABCG2), an efflux transporter important for xenobiotic bioavailability and multidrug resistance (MDR)."	( Hop-derived prenylflavonoids are substrates and inhibitors of the efflux transporter breast cancer resistance protein (BCRP/ABCG2). Birch, NP; Cooney, J; Jensen, D; Li, Y; Paxton, JW; Scheepens, A; Tan, KW, 2014)	0.4
"The ATP-binding cassette transporter G2/breast cancer resistance protein (ABCG2/BCRP) is an efflux protein involved in the bioavailability and milk secretion of endogenous and exogenous compounds, actively affecting milk composition."	( Effect of bovine ABCG2 polymorphism Y581S SNP on secretion into milk of enterolactone, riboflavin and uric acid. Álvarez, AI; Espín, JC; García-Villalba, R; González-Lobato, L; Merino, G; Miguel, V; Otero, JA; Prieto, JG, 2016)	0.43
"Novel nanostructured lipid-carrageenan hybrid carriers (NLCCs) were exploited for controlled delivery of water soluble chemotherapeutic agent mitoxantrone hydrochloride (MTO) with high loading capacity, sustained release property, and potential for improving oral bioavailability and antitumor efficacy."	( Nanostructured lipid-carrageenan hybrid carriers (NLCCs) for controlled delivery of mitoxantrone hydrochloride to enhance anticancer activity bypassing the BCRP-mediated efflux. He, Z; Ling, G; Sun, J; Zhang, P; Zhang, T, 2016)	0.86
" The release in vivo was carried out on the rats, as a result, liposome L3 showed higher bioavailability than traditional intravenous injectable administration, and liposome L3 showed higher elimination ratio after stimulation by ultrasound than L3 without stimulation."	( PLGA nanoparticles introduction into mitoxantrone-loaded ultrasound-responsive liposomes: In vitro and in vivo investigations. Mao, Z; Qi, Q; Xin, Y; Zhan, X, 2017)	0.73
" However, the limited bioavailability of curcumin prevents its use for modulation of the function of these transporters in the clinical setting."	( Synthetic Analogs of Curcumin Modulate the Function of Multidrug Resistance-Linked ATP-Binding Cassette Transporter ABCG2. Ambudkar, SV; Chufan, EE; Fukuda, M; Ishida, M; Iwabuchi, Y; Kanehara, K; Kudoh, K; Murakami, M; Naitoh, T; Ohnuma, S; Shibata, H; Sugisawa, N; Unno, M, 2017)	0.46
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."	( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019)	0.51
" However, it has several disadvantages such as poor water solubility, low bioavailability and low targeting, which seriously restrict its clinical application."	( Delivery of quercetin for breast cancer and targeting potentiation via hyaluronic nano-micelles. Li, M; Lin, K; Liu, Z; Sun, J; Wang, W; Wang, Z; Zhang, S; Zhao, Y; Zhen, Y, 2023)	0.91

Excerpt	Relevance	Reference
" This dosage is only 25% of what a patient with a solid tumour would normally receive during the same time period."	( Treatment of multiple sclerosis with mitoxantrone. Fetzer, U; Kornhuber, HH; Krapf, H; Laufen, H; Mauch, E, 1992)	0.56
"Twelve patients received intrapleural instilments of the cytostatic agent mitoxantrone in a total dosage of 30 mg for locoregional palliative therapy of malignant pleural effusion."	( Local therapy of malignant pleural effusion with mitoxantrone. Opri, F; Torsten, U; Weitzel, H, 1992)	0.77
" As mitoxantrone exhibits a steep dose-response curve against ovarian cancer cells and acute myeloid leukemia cells in vitro, we evaluated the safety and efficacy of high dose mitoxantrone with HiDAc in the treatment of ALL."	( Short course high dose mitoxantrone with high dose cytarabine is effective therapy for adult lymphoblastic leukemia. Ahmed, T; Arlin, ZA; Arnold, P; Baskind, P; Cook, P; Feldman, EJ; Finger, LR; Mittelman, A; Puccio, C; Razis, ED, 1991)	1.15
" All patients were given 4-6 doses of intravesical novantrone at the same dose level at weekly dosing interval."	( Phase I-II evaluation of intravesical novantrone (mitoxantrone) in superficial bladder cancer. Albert, D; Clayton, M; Lamb, D; Lee, M; Sarosdy, M; Sharifi, R; Siami, P; Strub, M, 1991)	0.53
" A steep mitoxantrone dose-response curve was observed, and increases in drug concentrations at both low and high dose ranges were associated with a significant potentiation of anti-leukemic effects."	( Effect of pharmacologically relevant concentrations of mitoxantrone on the in vitro growth of leukemic blast progenitors. Arlin, Z; Feldman, E; Gewirtz, D; Grant, S, 1991)	0.95
"Sixteen patients with advanced adenocarcinoma of the stomach were entered into a phase II study of mitoxantrone at a dosage of either 12 mg/m2 or 14 mg/m2 given at 3 weekly intervals."	( A phase II study of mitoxantrone in advanced gastric cancer. Gill, PG; Levi, JA; Presgrave, P, 1990)	0.82
"In order to reduce the incidence of severe complications noted with regimens containing high-dose cytarabine (HD ARA-C), wer used a combination of mitoxantrone (MTZ) in optimal dosage (12 mg/m2/day for 5 days) and cytarabine in intermediate dosage (1 g/m2 twice daily for 3 or 5 days)."	( Mitoxantrone and intermediate-dose cytarabine in relapsed or refractory acute myeloblastic leukemia. Brière, J; Desablens, B; Ghandour, C; Harousseau, JL; Milpied, N, 1990)	1.92
"Twenty patients with advanced squamous cell carcinomas (SCC) of the head and neck were entered into a phase II study of mitoxantrone at a dosage of either 12 mg/m2 or 14 mg/m2 given at 3 weekly intervals."	( A phase II study of mitoxantrone in advanced squamous cell cancer of the head and neck. Levi, J; Page, J; Wheeler, H; Woods, RL, 1990)	0.81
" Modifications in timing and dosage and the addition of hematopoietic growth factors will be evaluated in subsequent trials."	( Treatment of refractory Hodgkin's disease with high-dose cytosine arabinoside and mitoxantrone in combination. Results of a clinical phase II study of the German Hodgkin Study Group. Hiddemann, W; Kirchner, H; Koch, P; Maschmeyer, G; Ollech-Chwoyka, J; Pflüger, KH; Pfreundschuh, M; Schmitz, N; Tirier, C; Wagner, T, 1990)	0.5
" The dosage of diaziquone was increased for sequential cohorts of seven patients from 20 mg/m2/day to 24 mg/m2/day, and finally to 28 mg/m2/day to determine the maximum tolerated dose for this chemotherapy combination."	( Treatment of relapsed and refractory acute myeloid leukemia with diaziquone and mitoxantrone: a CALGB phase I study. Amrein, PC; Davis, RB; Mayer, RJ; Schiffer, CA, 1990)	0.51
" These features in conjunction with evidence that mitoxantrone displays a dose-response effect in vitro make it an attractive candidate for intensive therapy regimens."	( Mitoxantrone: potential for use in intensive therapy. Herzig, R; LeMaistre, CF, 1990)	1.97
" These results are of particular interest in clinical routines to calculate dosage regimens by Bayesian estimation methods."	( Population pharmacokinetics of mitoxantrone performed by a NONMEM method. Iliadis, A; Launay, MC; Richard, B, 1989)	0.56
"To determine the safety and efficacy of mitoxantrone use in hyperbilirubinemic breast cancer patients, a prospectively determined dosage schedule was evaluated in a multi-center trial."	( Mitoxantrone use in breast cancer patients with elevated bilirubin. Bulcavage, L; Chlebowski, RT; Elashoff, R; Henderson, IC; Rivest, R; Woodcock, T, 1989)	1.99
" Sharp plateaus in the VpmR-5 dose-response curves for Adriamycin-induced DNA strand breaks and cytotoxicity appear to be related to interference with type II topoisomerase-mediated cleavage of DNA at high concentrations of the intercalator."	( Cross-resistance to intercalating agents in an epipodophyllotoxin-resistant Chinese hamster ovary cell line: evidence for a common intracellular target. Glisson, B; Gupta, R; Hodges, P; Ross, W, 1986)	0.27
"The chemistry, pharmacology, pharmacokinetics, clinical efficacy, dosage and administration, and adverse effects of mitoxantrone are reviewed."	( Mitoxantrone: a novel anthracycline derivative. Eble, M; Koeller, J, 1988)	1.93
" Toxicity, particularly alopecia, was appreciably lower in the VMP treated patients, but subclinical cardiotoxicity was seen within the scheduled dosage for both combinations."	( Mitoxantrone versus doxorubicin in combination chemotherapy for advanced carcinoma of the breast. Cornbleet, MA; Hutcheon, AW; Kaye, SB; Kerr, ME; Leonard, RC; Robinson, S; Smyth, JF; Soukop, M; White, G, 1987)	1.72
"To determine optimal dosage, Dihydroxyanthracenedione (DHAD) was given once daily for 3 days at dosage levels of 6, 7, 8, and 10 mg/m2 in combination with a 7-day continuous infusion of cytosine arabinoside (Ara-C)."	( Toxicity evaluation of dihydroxyanthracenedione (DHAD) in combination with cytosine arabinoside (Ara-C). Civin, CI; Krischer, J; Land, VJ; Ragab, AH; Steuber, CP; Vietti, TJ, 1987)	0.27
" The recommended dosage regimen for the treatment of breast carcinoma is 12-14 mg/m2 given intravenously once every 21 days."	( Pharmacokinetics of mitoxantrone in man and laboratory animals. Batra, VK; Morrison, JA; Siverd, NS; Woodward, DL; Yacobi, A, 1986)	0.59
" The combination of mitoxantrone and vinblastine appeared to offer no advantage over single-agent therapy, probably because of the dosage reduction required by the overlapping myelosuppressive toxicity."	( Chemotherapy with mitoxantrone in combination with continuous infusion vinblastine for metastatic breast cancer. Blumenschein, GR; Buzdar, AU; Fraschini, G; Hortobagyi, GN; Mann, G; Yap, HY, 1987)	0.93
" A dosage of 18 mg/m2 was administered as a short intravenous infusion every 3 weeks."	( Novantrone for childhood malignant solid tumors. A pediatric oncology group phase II study. Etcubanas, E; Krance, RA; Mahoney, DH; Patterson, RB; Pratt, CB; Sexauer, C; Vietti, TJ, 1986)	0.27
" MIT dosage was intravenous injection of 3-6 mg/m2/day X 5 consecutive days as a rule."	( [Phase II study of mitoxantrone in patients with acute leukemia]. Hirano, M; Ikeda, Y; Kimura, K; Kobayashi, M; Ohara, K; Ohta, K; Shirakawa, S; Yamada, K; Yoshikawa, H; Yoshikawa, S, 1986)	0.6
" However, there were fewer dosage decreases with CNF."	( A randomized multicenter trial of cyclophosphamide, Novantrone and 5-fluorouracil (CNF) versus cyclophosphamide, Adriamycin and 5-fluorouracil (CAF) in patients with metastatic breast cancer. Bennett, JM; Byrne, P; DeConti, R; Desai, A; Doroshow, J; Krementz, E; Muggia, F; Plotkin, D; Vogel, C; White, C, 1985)	0.27
"Twenty-six evaluable patients with advanced or recurrent squamous cell carcinoma of the uterine cervix were treated with mitoxantrone at a dosage of 12 mg/m2 every 3 weeks."	( Mitoxantrone (NSC 301739) in patients with advanced cervical carcinoma. A phase II study of the Gynecologic Oncology Group. Bundy, B; Hatch, KD; Muss, HB; Sutton, GP, 1985)	1.92
" A 5-day, consecutive intraperitoneal dosing study yielded 28 day, LD10, LD50 and LD90 values of 18, 21 and 26 mg kg-1, respectively, in mice."	( Preclinical toxicity of the new antineoplastic agent, ametantrone acetate, in mice and dogs. Anderson, JA; de la Iglesia, FA; Fitzgerald, JE; Jayasekara, U; Kim, SN; Watkins, JR, 1986)	0.27
" These data provide a pharmacological rationale for use of mitoxantrone on an intermittent dosing schedule."	( Disposition of mitoxantrone in cancer patients. Alberts, DS; Davis, TP; Leigh, S; Peng, YM; Woodward, DL, 1985)	0.87
" Serum samples collected at various time intervals from rats dosed intravenously with mitoxantrone (0."	( Radioimmunoassay for mitoxantrone, a new antitumor agent. Lanzilotti, A; McWilliams, W; Morrison, J; Nicolau, G; Szucs-Myers, V, 1985)	0.81
" Distribution and half-life data provide a pharmacological rationale for the use of mitoxantrone on an intermittent dosing schedule."	( Pharmacology of mitoxantrone: mode of action and pharmacokinetics. Alberts, DS; Bowden, GT; Dalton, WS; Mackel, C; Peng, YM, 1985)	0.84
" Fifty-three evaluable patients were treated with this agent at a dosage of 5 mg/M2/week."	( Phase II study of mitoxantrone in advanced squamous cell carcinoma of the head and neck. A Southeastern Cancer Study Group trial. Birch, R; Gams, R; Velez-Garcia, E; Williams, SD, 1985)	0.6
" Dosage escalations proceeded from 15 mg/m2 to 35 mg/m2."	( A phase I trial of ametantrone acetate (NSC-287513). Bender, JF; Gams, RA; Grillo-López, AJ; Ostroy, F, 1985)	0.27
" Mitoxantrone was given in form of a 30-minute infusion at a dosage of 14 mg/m2."	( [Mitoxantrone in the primary treatment of metastasizing breast cancer]. Dittrich, C; Dudczak, R; Lenzhofer, R; Moser, K; Pirker, P; Rainer, H; Schuster, R, 1984)	2.09
" We have carried out a phase II trial of mitoxantrone using an every three weeks dosing schedule in patients with advanced head and neck cancers."	( Phase II trial of mitoxantrone in head and neck cancer. Aapro, MS; Alberts, DS, 1984)	0.87
"Twenty-six evaluable patients with advanced epithelial ovarian cancer were treated with mitoxantrone at a dosage of 12 mg/m2 every three weeks."	( Mitoxantrone (NSC-301739) in patients with advanced ovarian carcinoma. A phase II study of the Gynecologic Oncology Group. Asbury, R; Bundy, B; Ehrlich, CE; Graham, J; Muss, HB, 1984)	1.93
" However, 24 h after dosing 10."	( Pharmacological disposition of 1,4-dihydroxy-5-8-bis[[2 [(2-hydroxyethyl)amino]ethyl]amino]-9,10-anthracenedione dihydrochloride in the dog. Loo, TL; Lu, K; Savaraj, N, 1984)	0.27
"Combined chemotherapy and radiotherapy in standard dosage is an acceptable approach following mastectomy for patients with extensive nodal involvement at high risk for local recurrence and distant relapse."	( Combined chemotherapy and radiotherapy for patients with breast cancer and extensive nodal involvement. Barraclough, B; Boyages, J; Langlands, AO; Ung, O, 1995)	0.29
" A dose-response relationship characterized body-weight loss and survival rate."	( Circadian changes in mitoxantrone toxicity in mice: relationship with plasma pharmacokinetics. Bizi, E; Hallek, M; Lemaigre, G; Lévi, F; Metzger, G; Tampellini, M, 1994)	0.61
" Once a cumulative dosage of 140 mg/m2 is reached cardiac function tests, including echocardiography with measurement of the left ventricular ejection fraction, should be routinely carried out preceding each treatment administration in all patients."	( [Immunosuppressive therapy of multiple sclerosis with mitoxantrone]. Kornhuber, HH; Mauch, E, 1993)	0.53
" Further studies are needed to explore the potential impact on response and/or toxicity and the requirement of a pharmacokinetic directed adjustment of drug dosage in clinical trials."	( New aspects on the pharmacokinetics of mitoxantrone and its two major metabolites. Hiddemann, W; Kamischke, A; Kaufmann, CC; Schleyer, E; Unterhalt, M, 1994)	0.56
"Seventeen patients with APL were salvaged with ATRA at a dosage of 50 mg/m2/day for 3 months or until complete remission (CR) was achieved; idarubicin (12 mg/m2/day for 4 days) was added if blast plus promyelocyte count either was or reached > or = 10 x 10(3)/microliters."	( All-trans retinoic acid followed by chemotherapy for salvage of refractory or relapsed acute promyelocytic leukemia. Cortes, JE; Estey, E; Hirsh-Ginsberg, C; Kantarjian, H; Keating, M; Koller, C; O'Brien, S; Robertson, LE; Stass, S, 1994)	0.29
" Intraperitoneal mitoxantrone was administered at a dosage of 20-30 mg/mq repeated every 28 days if ascites was still present."	( Mitoxantrone in the treatment of recurrent ascites of pretreated ovarian carcinoma. Berardi, F; Catino, A; de Lena, M; Fioretto, A; Gargano, G; Lorusso, V, 1994)	2.07
"Mitoxantrone has been shown in vitro to exhibit a steep dose-response relationship with respect to the clonogenic survival of acute myeloid leukemia cells."	( High-dose mitoxantrone induces programmed cell death or apoptosis in human myeloid leukemia cells. Bhalla, K; Bullock, G; Grant, S; Huang, Y; Ibrado, AM; Mahoney, ME; Ponnathpur, V; Tang, C; Tourkina, E, 1993)	2.13
" However, in vitro data demonstrate a steep dose-response curve to a variety of agents, most notably mitoxantrone."	( Phase I clinical and pharmacokinetic study of high-dose mitoxantrone combined with carboplatin, cyclophosphamide, and autologous bone marrow rescue: high response rate for refractory ovarian carcinoma. Alberts, DS; Dolan, JR; McCloskey, T; McKenzie, RS; Rad, N; Sosman, JA; Stiff, PJ, 1994)	0.75
" For consolidation with NOVE, rhGM-CSF was given according to the same dosage schedule."	( Idarubicin/cytosine arabinoside and mitoxantrone/etoposide for the treatment of de novo acute myelogenous leukemia. Del Valle, F; Döhner, H; Ehrhardt, R; Fischer, JT; Haas, R; Ho, AD; Huberts, H; Hunstein, W; Kaplan, E; Witt, B, 1993)	0.56
" An increase in the prednisolone dosage led to an improvement."	( Interstitial pneumonitis possibly due to mitoxantrone. Aiso, M; Hagiwara, T; Hayama, T; Horie, T; Kitami, Y; Matsukawa, Y; Ohshima, T; Takeuchi, J, 1993)	0.55
" Although the primary purpose of this study was to determine a clinically useful dosage and to characterize the toxicoses associated with mitoxantrone administration, each cat was monitored for response to treatment."	( Toxicoses and efficacy associated with administration of mitoxantrone to cats with malignant tumors. Atwater, SW; Ciekot, PE; Elmslie, RE; Klein, MK; Moore, AS; Obradovich, JE; Ogilvie, GK; Salmon, MD; Straw, RC; Vail, DM, 1993)	0.73
" All patients received a standard IV dose of mitoxantrone (8 mg/m2) every 3 weeks for a total of seven infusions, with dosage adjustments depending on the hematologic profile at the nadir."	( An open-trial evaluation of mitoxantrone in the treatment of progressive MS. Cauvier, H; Grinwich, KD; Harris, BJ; Hopkins, MB; Karlik, SJ; Lee, DH; Noseworthy, JH; Penman, M; Rice, GP; Vandervoort, MK, 1993)	0.84
" In the trial, the dosage of granisetron tablet was 2 mg once a day, and the drug was given before each chemotherapy for 6 consecutive days."	( [Study on the inhibitory effect of oral granisetron against nausea/vomiting induced by cytosine arabinoside containing chemotherapy for tumors in the hematopoietic organs]. Gondo, H; Harada, M; Matsuishi, H; Omori, F; Otsuka, T; Shibuya, T; Taniguchi, S; Teshima, T; Yamano, Y; Yamazaki, K, 1993)	0.29
" However, because this drug exhibits a steep dose-response curve, a Phase I-II trial of mitoxantrone by hepatic arterial infusion was initiated."	( A phase I-II trial of mitoxantrone by hepatic arterial infusion in patients with hepatocellular carcinoma or colorectal carcinoma metastatic to the liver. Abbruzzese, J; Ajani, JA; Carrasco, CH; Charnsangavej, C; Jones, DV; Levin, B; Patt, YZ; Wallace, S, 1993)	0.82
" Only one patient required a dosage reduction on the basis of toxicity (neutropenia)."	( A phase I-II trial of mitoxantrone by hepatic arterial infusion in patients with hepatocellular carcinoma or colorectal carcinoma metastatic to the liver. Abbruzzese, J; Ajani, JA; Carrasco, CH; Charnsangavej, C; Jones, DV; Levin, B; Patt, YZ; Wallace, S, 1993)	0.6
" In addition, ICRF-187 allowed for 50% greater cumulative dosing in normal mice that, nonetheless, showed extensive histological heart damage 7 wk after dosing."	( Characterization of experimental mitoxantrone cardiotoxicity and its partial inhibition by ICRF-187 in cultured neonatal rat heart cells. Alberts, DS; Dawson, BV; Dorr, RT; Hendrix, M; Shipp, NG, 1993)	0.57
" The dose-response curves of mitoxantrone in a human clonogenic cytotoxicity assay against the RPMI 2780/S human ovarian cell line were virtually identical when the cells were incubated in either 5 or 50% fetal bovine serum, suggesting that protein binding will not significantly impair mitoxantrone-induced tumor cell killing."	( Evidence for persistence of mitoxantrone within the peritoneal cavity following intraperitoneal delivery. Alberts, D; Barakat, R; Brodar, F; Curtin, J; Hakes, T; Jones, W; Lewis, JL; Markman, M; Reichman, B; Rubin, S, 1993)	0.87
" Mitoxantrone is a good candidate for local or regional administration because (1) its metabolism is mainly hepatic, (2) it has a steep dose-response curve for multiple solid tumors, and (3) its fixation in tissues is sustained without vesicant effects after extravasation."	( Pharmacokinetics and antitumor effects of mitoxantrone after intratumoral or intraarterial hepatic administration in rabbits. Ardouin, P; Bognel, C; Dzodic, R; Gouyette, A; Munck, JN; Ramirez, LH; Rougier, P; Vassal, G; Zhao, Z, 1996)	1.47
" For both drugs, a loss of linearity of the IC90 and IC50 dose-response curves was found at maximum concentrations."	( [Comparison of the cytostatic effect of epirubicin and mitoxantrone on native breast carcinoma cells using the ATP tumor chemosensitivity assay]. Brenne, U; Krebs, D; Kurbacher, CM; Kurbacher, JA; Mallmann, P, 1996)	0.54
" Dosage in subsequent cycles was adjusted according to hematologic toxicity."	( A carboplatin-based regimen for the treatment of patients with advanced transitional cell carcinoma of the urothelium. Carroll, PR; Ernest, ML; Fippin, LJ; Small, EJ, 1996)	0.29
" FLANG (27 patients) had a shorter duration (3 days), reduced Ara-C dosage (1 g/sqm) and administration of mitoxantrone (10 mg/sqm) at the end of Ara-C infusion."	( High efficacy of fludarabine-containing therapy (FLAG-FLANG) in poor risk acute myeloid leukemia. Balleari, E; Canepa, L; Carrara, P; Celesti, L; Cerri, R; Clavio, M; Damasio, E; Gatti, AM; Ghio, R; Gobbi, M; Miglino, M; Patrone, F; Pierri, I; Sessarego, M; Vallebella, E, )	0.34
"Echocardiographic reports on 144 adults receiving anthracycline therapy and 18 controls were reviewed for the possible relationship between dosage and ejection fractions."	( [Echocardiographic evaluation of cardiotoxicity induced by anthracycline therapy]. Horikawa, K; Okada, Y; Sano, M, 1997)	0.3
" DHAD dosage could be increased to 18 mg/m2 in 66 out of 317 cycles of chemotherapy (21%)."	( Dose intensification of mitoxantrone in combination with levofolinic acid, fluorouracil, cyclophosphamide and granulocyte colony stimulating factor support in advanced untreated breast cancer patients. A multicentric phase II study of the Southern Italy O Caruso, M; Colucci, G; Durini, E; Gebbia, N; Gebbia, V; Giotta, F; Pezzella, G; Riccardi, F; Romito, S, 1997)	0.6
" No difference in toxicity was observed between the two dosage regimens."	( A randomized trial of high- vs standard-dose mitoxantrone with cytarabine in elderly patients with acute myeloid leukemia. Ahmed, T; Beer, M; Case, DC; Damon, L; Feldman, EJ; Linker, C; Ries, C; Rugo, H; Seiter, K, 1997)	0.56
" Neutropenia is the most common toxicity associated with mitoxantone therapy and may necessitate dosage reduction in some patients."	( Mitoxantrone. A review of its pharmacology and clinical efficacy in the management of hormone-resistant advanced prostate cancer. Spencer, CM; Wiseman, LR, 1997)	1.74
"Although cytosine arabinoside (AraC) represents the most effective single agent in the treatment of adults with acute myeloid leukemia (AML) when given at doses exceeding 200 to 500 mg per application, its optimal dosage is still a matter of controversial discussion."	( Superiority of high-dose over intermediate-dose cytosine arabinoside in the treatment of patients with high-risk acute myeloid leukemia: results of an age-adjusted prospective randomized comparison. Aul, C; Bartholomäus, A; Bettelheim, P; Büchner, T; Hiddemann, W; Kern, W; Ludwig, WD; Maschmeyer, G; Schönrock-Nabulsi, R; Wörmann, B, 1998)	0.3
"In the human clonogenic assay, mitoxantrone possesses among the steepest dose-response curves of any cytotoxic agent against ovarian cancer."	( Phase 2 trial of moderately high dose single agent mitoxantrone in platinum and paclitaxel-refractory ovarian cancer. Belinson, J; Ernst, S; Homesley, H; Kennedy, A; Lichtman, SM; Markman, M; Omura, G; Webster, K, 1998)	0.84
" Data analysis revealed sustained release of mitoxantrone from microspheres into peritoneal fluid in all dosage groups."	( Evaluation of mitoxantrone-loaded albumin microspheres following intraperitoneal administration to rats. Eichler, HG; Luftensteiner, CP; Paul, B; Schwendenwein, I; Viernstein, H, 1999)	0.92
" Applied MXN dosage was equivalent to 30 mg/m2 body surface area."	( Toxicity of a particulate formulation for the intraperitoneal application of mitoxantrone. Eichler, HG; Luftensteiner, CP; Paul, B; Schwendenwein, I; Viernstein, H; Wölfl, G, 1999)	0.53
" No apparent dose-response relationship was observed in our study."	( Phase I/II trial of high dose mitoxantrone in metastatic breast cancer: the M.D. Anderson Cancer Center experience. Buzdar, AU; Cristofanilli, M; Esparza, L; Holmes, FA; Hortobagyi, GN; Neidhart, JA; Valero, V, 1999)	0.59
" The maximal acceptable dosage of mitoxantrone was 10 mg/m2 x 2 due to serious hematologic toxicity."	( Mitoxantrone-DHAP with GM-CSF: an active but myelosuppressive salvage therapy for relapsed/refractory aggressive non-Hodgkin's lymphoma. Berinstein, NL; Franssen, E; Haq, R; Sawka, CA, 1999)	2.03
" We conclude that CBP at a cumulative dosage of 1 g/m2 together with intercalating agents (IDA/MIT) has antileukemic efficacy in elderly patients."	( Continuous-infusion carboplatin in combination with idarubicin or mitoxantrone for high-risk acute myeloid leukemia: a randomised phase II study. Archimbaud, E; Assouline, D; Belhabri, A; Blanc, M; Fière, D; Michallet, M; Thomas, X; Tigaud, JD; Troncy, J; Wattel, E, 1999)	0.54
" On the other hand, bacillus Calmette-Guerin (BCG) currently appears to be the most effective agent for intravesical use, especially in patients with high grade and stage neoplasms but the optimum strain, dosage and duration schedule have not been determined."	( Intravesical therapy of superficial bladder cancer. Melekos, MD; Moutzouris, GD, 2000)	0.31
"The combination CEF using this schedule and dosage in metastatic breast cancer is more effective with less toxicity than CNF, except for alopecia, and was associated with longer survival."	( Phase III trial of cyclophosphamide, epirubicin, fluorouracil (CEF) versus cyclophosphamide, mitoxantrone, fluorouracil (CNF) in women with metastatic breast cancer. Alvarez, E; Buesa, JM; Corral, N; Estaban, E; Estrada, E; Fernández, JL; Lacave, AJ; Muñiz, I; Palacio, I; Vieitez, JM, 1999)	0.52
" These data suggest that the addition of PSC 833 to an M/E regimen for older patients with untreated AML is well tolerated but requires a reduction in M/E dosing to avoid increased toxicity."	( A phase I study of induction chemotherapy for older patients with newly diagnosed acute myeloid leukemia (AML) using mitoxantrone, etoposide, and the MDR modulator PSC 833: a southwest oncology group study 9617. Anderson, JE; Appelbaum, FR; Chauncey, TR; Chen, I; Godwin, JE; Head, DR; Kalaycio, ME; Kopecky, KJ; Kraut, EH; Leith, CP; Luthardt, FW; Moore, DF; Petersdorf, SH; Rankin, C; Shurafa, MS; Willman, CL, 2000)	0.52
"The carboplatin-mitoxantrone combination, at the dosage tested in this study, appears to be well tolerated by elderly patients with advanced ovarian cancer and is associated with an acceptable response rate."	( Elderly ovarian cancer: treatment with mitoxantrone-carboplatin. Amichetti, M; Artioli, G; Azzoni, P; Donach, M; Endrizzi, L; Ferrazzi, E; Monfardini, S; Nicoletto, MO; Prosperi, A; Salvagno, L; Sileni, VC; Talamini, R; Tumolo, S; Veronesi, A; Visonà, E, 2001)	0.93
" Here, in order to determine whether the efficacy of chemotherapy can be enhanced by changing the regimen, we evaluated the effect of the varied timing and dosage of chemotherapy in combination with androgen withdrawal on time to androgen-independent (AI) progression in the human androgen-dependent LNCaP tumour model."	( Optimal timing and dosage of chemotherapy as a combined treatment with androgen withdrawal in the human prostate LNCaP tumour model. Arakawa, S; Hara, I; Hara, S; Kamidono, S; Miyake, H, 2001)	0.31
" The dose-response curve was represented by a second-degree polynomial without absolute term."	( Effect of acetyl-L-carnitine on leukemia L1210 resistant to mitoxantrone. Mĕlka, M; Niang, M, 2000)	0.55
" However, some trials showed that increasing the dosage of anthracyclines within induction therapy improved treatment outcome substantially."	( Intensified double induction therapy with high dose mitoxantrone, etoposide, m-amsacrine and high dose ara-C for elderly acute myeloid leukemia patients aged 61-65 years. Aulitzky, W; Bodenstein, H; Clemens, M; Ehninger, G; Illmer, T; Neubauer, A; Repp, R; Schaich, M; Schäkel, U; Soucek, S; Wandt, H, 2002)	0.57
" Given the potent myelosuppressive activity of mitoxantrone, dosage should be carefully adapted to the body surface and hematological changes."	( Mitoxantrone in progressive multiple sclerosis: when and how to treat? Gonsette, RE, 2003)	2.02
" With the same dosage (2 mg."	( [Preparation of long circulating mitoxantrone liposomes and its pharmacokinetics]. Duan, YS; Yu, BT; Zhang, ZR, 2002)	0.6
" In phase I, on 23 patients entered on study, dose-limiting toxicity occurred at the dosage of 1200 mg m(-2) gemcitabine and 10 mg m(-2) mitoxantrone, with three out of five patients developing grade 4 neutropenia."	( Phase I/II study of gemcitabine plus mitoxantrone as salvage chemotherapy in metastatic breast cancer. Calabrese, P; Caporusso, L; Catino, A; Crucitta, E; D'Amico, C; De Lena, M; Guida, M; Latorre, A; Lorusso, V; Mazzei, A; Sambiasi, D; Schittulli, F; Silvestris, N, 2003)	0.79
" These drugs are at different stages of clinical development and additional clinical data are needed to support their use and devise dosage regimens."	( New and emerging treatment options for multiple sclerosis. Polman, CH; Uitdehaag, BM, 2003)	0.32
" Positive PA317/Tet-on/TRE-BCRP cells, which showed well dose-response in expression of BCRP with different concentration of Dox induction, were selected by both reverse transcriptase-polymerase chain reaction (RT-PCR) and Western blot."	( [Expression establishment and functional analysis of breast cancer resistance protein with doxycycline induced tet regulating system in mouse fibroblast cell line PA317]. Chen, ZC; He, ZM; Yu, YH; Yuan, JH, 2004)	0.32
"5 PA317/Tet-on /TRE-BCRP cell clone showed well dose-response in expression of BCRP with different concentration of Dox induction; its drug-resistance against mitoxantrone has positive correlation with BCRP expression (r=0."	( [Expression establishment and functional analysis of breast cancer resistance protein with doxycycline induced tet regulating system in mouse fibroblast cell line PA317]. Chen, ZC; He, ZM; Yu, YH; Yuan, JH, 2004)	0.52
" Early pilot trials using mitoxantrone were carried out using vastly different dosage regimens and patient populations, which may have resulted in conflicting results."	( Review of mitoxantrone in the treatment of multiple sclerosis. Herndon, R; Jeffery, DR, 2004)	1.03
" This C(i) was designed as a prognostic index by taking the area under the curve as an exact measure of the total dose-response relationship."	( Prediction of individual response to chemotherapy in patients with acute myeloid leukaemia using the chemosensitivity index Ci. Cornely, O; Neurohr, K; Reiser, M; Schinköthe, T; Staib, P; Staltmeier, E, 2005)	0.33
" However, these approaches will not take into account the possible dose-response relationship on each endpoint, and therefore are less specific and may have lower power."	( Multiplicity adjustment for multiple endpoints in clinical trials with multiple doses of an active treatment. Capizzi, T; Luo, X; Quan, H, 2005)	0.33
" Dosing was continued at 5 mg/m2 every third month."	( A pilot trial of combination therapy with mitoxantrone and interferon beta-1b using monthly gadolinium-enhanced magnetic resonance imaging. Burdette, J; Chepuri, N; Durden, D; Jeffery, DR, 2005)	0.59
"MX is moderately effective in reducing the disease progression and the frequency of relapses in patients affected by RR, PR and SP MS in the short-term follow-up (2 years), even if the results are based on trials heterogeneous in terms of drug dosage and inclusion criteria."	( Mitoxantrone for multiple sclerosis. Capra, R; Comi, G; Martinelli Boneschi, F; Rovaris, M, 2005)	1.77
" Given the increased number of early treatment-related deaths, future treatment protocols should aim to reduce chemotherapy dosage or intensity whilst maintaining low rates of resistant and recurrent disease."	( Treatment for myeloid leukaemia of Down syndrome: population-based experience in the UK and results from the Medical Research Council AML 10 and AML 12 trials. de Graaf, SS; Gibson, BE; Hann, IM; Hills, RK; O'Marcaigh, A; Rao, A; Stiller, C; Webb, DK; Wheatley, K, 2006)	0.33
" Dogs underwent laser ablation of the primary tumor and were treated with mitoxantrone at a dosage of 5 mg/m2)every 3 weeks for 4 treatments."	( Evaluation of carbon dioxide laser ablation combined with mitoxantrone and piroxicam treatment in dogs with transitional cell carcinoma. Payton, ME; Tangner, CH; Upton, ML, 2006)	0.81
" GO at a dosage of 3 mg/m2 was administered as a 2-h intravenous infusion on days 1 and 14, cytarabine at 100 mg/m2 on days 1-7, and mitoxantrone at 12 mg/m2 on days 1-3."	( Gemtuzumab ozogamicin with cytarabine and mitoxantrone as a third-line treatment in a poor prognosis group of adult acute myeloid leukemia patients: a single-center experience. Carluccio, P; Giannoccaro, M; Liso, V; Mestice, A; Pastore, D; Rizzi, R; Specchia, G; Spinosa, G, 2007)	0.81
" MITO was administered at a dosage of 8 mg/m(2) monthly for 3 months, then every 3 months, until a dosage of 120 mg/m(2) was reached."	( Intravenous mitoxantrone and cyclophosphamide as second-line therapy in multiple sclerosis: an open-label comparative study of efficacy and safety. Amato, MP; Hakiki, B; Portaccio, E; Siracusa, G; Sorbi, S; Zipoli, V, 2008)	0.72
" The most common reason for reduction of the dosage or for cycle delay in the combined scheme was neutropenia."	( Feasibility and efficacy of chemotherapy with gemcitabine mono and with paclitaxel/mitoxantron in gynaecological cancers. Cordes, T; Fischer, D; Friedrich, M; Lüdders, D; Maass, N; Schroer, A; Villena-Heinsen, C, 2007)	0.34
" Nine patients were enrolled at increasing dosage levels of ara-C (8, 12, and 16 g/m2 per dose level)."	( Phase I trial of FLAGM with high doses of cytosine arabinoside for relapsed, refractory acute myeloid leukemia: study of the Japan Adult Leukemia Study Group (JALSG). Arai, Y; Doki, N; Ishida, F; Kano, Y; Kawai, Y; Komatsu, N; Miyawaki, S; Morii, T; Ogura, M; Ohno, R; Takeshita, A; Usui, N, 2007)	0.34
"The dosing schedule of docetaxel may affect its clinical activity and toxicity profile."	( Biweekly docetaxel-containing chemotherapy may be the optimal schedule. Cai, Y; Hong, X; Hu, X; Li, J; Ou, Z; Shen, Z; Wang, Z; Yang, X; Zhao, X, 2008)	0.35
" However, with MTD dosing this drug ratio is not optimal to produce synergy and future studies using ratiometric dosing are required to confirm these findings."	( Phase I evaluation of gemcitabine, mitoxantrone, and their effect on plasma disposition of fludarabine in patients with relapsed or refractory acute myeloid leukemia. Adams, DJ; Decastro, CM; Gockerman, JP; Moore, JO; Peterson, BL; Petros, WP; Rao, AV; Rizzieri, DA; Sand, GJ; Spasojevic, I; Younis, IR, 2008)	0.62
" Clofarabine dosed at 52 mg/m2 was used in adult patients with refractory ALL to maximize response before allo-HSCT."	( The use of higher dose clofarabine in adults with relapsed acute lymphoblastic leukemia. Brown, AW; McGregor, BA; Osswald, MB; Savona, MR, 2009)	0.35
"These results suggest that the combination of ixabepilone and mitoxantrone is feasible and active in CRPC and requires dosing with pegfilgrastim."	( Phase I study of ixabepilone, mitoxantrone, and prednisone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel-based therapy: a study of the department of defense prostate cancer clinical trials consortium. Beer, TM; Harzstark, AL; Hussain, M; Mathew, P; Pagliaro, LC; Rosenberg, JE; Ryan, CJ; Ryan, CW; Sharib, J; Small, EJ; Smith, DC; Weinberg, VK, 2009)	0.88
" Monitoring and dosing guidelines in the product labeling accompanying this indication include blood counts, liver function, and pregnancy tests at each administration."	( Adherence to recommended dosing and monitoring for mitoxantrone in patients with multiple sclerosis: a healthcare claims database study supplemented with medical records--the RETRO study. Al-Sabbagh, A; Bennett, R; Funch, D; Hillier, J; Norman, H; Seeger, JD; Wong, J, 2010)	0.61
" Adherence to recommended dosing was higher than for recommended monitoring."	( Adherence to recommended dosing and monitoring for mitoxantrone in patients with multiple sclerosis: a healthcare claims database study supplemented with medical records--the RETRO study. Al-Sabbagh, A; Bennett, R; Funch, D; Hillier, J; Norman, H; Seeger, JD; Wong, J, 2010)	0.61
" A dose-response effect was not apparent."	( Cardiotoxicity and other adverse events associated with mitoxantrone treatment for MS. Geddes, J; Isserow, S; Kingwell, E; Koch, M; Leung, B; Rieckmann, P; Tremlett, H, 2010)	0.61
"This was a Phase I study using cohort dose escalation of OSI-461 dosed orally twice daily in combination with mitoxantrone 12 mg/m(2) given on Day 1 of each 21-day cycle."	( A phase I study of OSI-461 in combination with mitoxantrone in patients with advanced solid tumors potentially responsive to mitoxantrone. Boinpally, R; Carducci, MA; Eisenberger, MA; Franke, A; King, S; Pili, R; Porter, J; Resta, LP; Spitz, A; Sweeney, CJ, 2011)	0.84
" In the Phase I part, dose-limiting toxicities occurred in all three patients, given mitoxantrone at the dosage of 10 mg/m(2)/day, and the recommended mitoxantrone dosage was determined to be 8 mg/m(2)/day."	( A phase I/II study of combined chemotherapy with mitoxantrone and uracil/tegafur for advanced hepatocellular carcinoma. Furuse, J; Ikeda, M; Ishii, H; Mitsunaga, S; Morizane, C; Nakachi, K; Okusaka, T; Suzuki, E; Ueno, H, 2011)	0.85
" Pharmacokinetics demonstrated a dose-response for total and unbound plasma flavopiridol unrelated to total protein, albumin, peripheral blast count, or toxicity."	( Phase 1 and pharmacokinetic study of bolus-infusion flavopiridol followed by cytosine arabinoside and mitoxantrone for acute leukemias. Alino, K; Bagain, L; Blackford, A; Briel, J; Carraway, H; Doyle, LA; Gore, SD; Greer, JM; Joseph, B; Karp, JE; Levis, MJ; Mackey, K; McDevitt, MA; Moton-Nelson, D; Resar, LS; Rudek, MA; Smith, BD; Wright, JJ; Zhao, M, 2011)	0.58
" This decrease suggests that daunorubicin, cytosine arabinoside, etoposide and mitoxantrone may impair the metabolism of other active substances metabolized by this isoenzyme, which should be taken into consideration in planning the dosage scheme in individual patients and considering interactions between drugs."	( Influence of anticancer therapy on oxidation phenotype and acetylation phenotype in patients with acute myeloblastic leukemia. Czarnik-Matusewicz, H; Ganczarski, G; Gąsiorowski, J; Głowacka, K; Kuliczkowski, K; Orzechowska-Juzwenko, K; Wiela-Hojeńska, A; Wołowiec, D; Łapiński, Ł, 2011)	0.6
" Herein, we report the response to treatment with a fixed dosing schedule of ME or MEC in 65 patients treated for primary refractory or relapsed AML with intermediate or unfavorable risk cytogenetics."	( Mitoxantrone and etoposide with or without intermediate dose cytarabine for the treatment of primary induction failure or relapsed acute myeloid leukemia. Altman, J; Carlson-Leuer, K; Coyle, K; Frankfurt, O; Mehta, J; Newman, D; Rademaker, AW; Tallman, MS; Trifilio, SM, 2012)	1.82
" Angiogenesis was induced in normal adult rat mesentery by intraperitoneal injection of a low dosage of VEGF-A."	( Low-dosage metronomic chemotherapy and angiogenesis: topoisomerase inhibitors irinotecan and mitoxantrone stimulate VEGF-A-mediated angiogenesis. Albertsson, P; Lennernäs, B; Norrby, K, 2012)	0.6
" We show that real-time flow cytometric quantification of compound-uptake is reliably measured and that analyzing their respective uptake kinetic provides additional valuable information which can be used for improving drug dosage and delivery."	( Utilizing inherent fluorescence of therapeutics to analyze real-time uptake and multi-parametric effector kinetics. Efferth, T; Eichhorn, T; Korn, B; Paulsen, M; Wiench, B, 2012)	0.38
" We aimed to provide a rationale for optimal dosing and scheduling of this anti-CD20 antibody based on pharmacokinetics."	( Rituximab serum concentrations during immuno-chemotherapy of follicular lymphoma correlate with patient gender, bone marrow infiltration and clinical response. Burgstaller, S; Drach, J; Einberger, C; Fridrik, M; Gaiger, A; Greil, R; Heintel, D; Hopfinger, G; Jäger, U; Mannhalter, C; Oberaigner, W; Porpaczy, E; Putman, M; Raderer, M; Skrabs, C; Zeitlinger, M, 2012)	0.38
"The results of this pilot trial suggest that more differentiated dosing schedules based on gender and bone marrow infiltration should be explored for rituximab therapy for lymphoma."	( Rituximab serum concentrations during immuno-chemotherapy of follicular lymphoma correlate with patient gender, bone marrow infiltration and clinical response. Burgstaller, S; Drach, J; Einberger, C; Fridrik, M; Gaiger, A; Greil, R; Heintel, D; Hopfinger, G; Jäger, U; Mannhalter, C; Oberaigner, W; Porpaczy, E; Putman, M; Raderer, M; Skrabs, C; Zeitlinger, M, 2012)	0.38
"These results suggest that the combination of ixabepilone and mitoxantrone is both feasible and active in castration-resistant prostate cancer and requires dosing with pegfilgrastim."	( Ixabepilone, mitoxantrone, and prednisone for metastatic castration-resistant prostate cancer after docetaxel-based therapy: a phase 2 study of the Department Of Defense Prostate Cancer Clinical Trials Consortium. Beer, TM; Harzstark, AL; Liu, G; Pagliaro, LC; Rosenberg, JE; Ryan, CJ; Sharib, J; Small, EJ; Smith, DC; Weinberg, VK, 2011)	0.98
" Using TR-FRET, we screened the Sigma LOPAC library for MBD2-MBD inhibitors and identified four compounds that also validated in a dose-response series."	( Time-Resolved Fluorescence Resonance Energy Transfer Assay for Discovery of Small-Molecule Inhibitors of Methyl-CpG Binding Domain Protein 2. Giovinazzo, H; Nelson, WG; Walker, D; Wyhs, N; Yegnasubramanian, S, 2014)	0.4
" However, an effective combination with other drugs and a feasible dosage has not been identified."	( Clinical efficacy of mitoxantrone and Ara-C with or without etoposide salvage chemotherapy in adult patients with relapsed or refractory acute lymphoblastic leukemia: retrospective multicenter study of the Korean Adult ALL Working Party. Ahn, JS; Chung, JS; Jo, DY; Joo, YD; Jung, SH; Kim, DY; Kim, I; Lee, JJ; Lee, KH; Moon, JH; Park, S; Shin, HJ; Sohn, SK; Song, IC; Yang, DH, 2015)	0.74
" Multiple dosing of liposomal MTO strongly delayed tumor growth compared to free MTO and prolonged mouse survival, whereas among the liposomal MTO treatments, C8-GluCer-MTOL was most effective."	( Plasma membrane targeting by short chain sphingolipids inserted in liposomes improves anti-tumor activity of mitoxantrone in an orthotopic breast carcinoma xenograft model. Cordeiro Pedrosa, LR; Eggermont, AM; Koning, GA; Seynhaeve, AL; Soullié, T; Ten Hagen, TL; van Tellingen, O; Verheij, M, 2015)	0.63
" In addition, gemcitabine increased the elimination rate of the ABCG2 substrate, D-luciferin, and decreased D-luciferin accumulation in BxPC3 and Panc1 cells in a dose-response manner."	( Gemcitabine upregulates ABCG2/BCRP and modulates the intracellular pharmacokinetic profiles of bioluminescence in pancreatic cancer cells. Gu, M; Li, F; Liu, J; Sun, Y; Wei, Y; Xiong, Y; Zhu, L, 2016)	0.43
" In this study we assessed the dose-response characteristics as well as the feasibility and safety of mitoxantrone delivery to the brain and specifically to gliomas in a rodent model."	( Safety, feasibility, and optimization of intra-arterial mitoxantrone delivery to gliomas. Bigio, IJ; Bruce, JN; Cooke, J; Ellis, JA; Emala, CW; Joshi, S; Singh-Moon, RP; Wang, M, 2016)	0.9
" The affected tumors remained dormant long after dosing stopped, resulting in a prolonged progression-free survival and sustained immune surveillance of the host bearing desmoplastic melanoma."	( Nanocarrier-Mediated Chemo-Immunotherapy Arrested Cancer Progression and Induced Tumor Dormancy in Desmoplastic Melanoma. Chen, F; Hou, L; Huang, L; Liu, Q; Shen, L; Wang, D; Zhang, X, 2018)	0.48
" Ratios based on a continuous linear dose-response relationship were similar for daunorubicin (0."	( Derivation of Anthracycline and Anthraquinone Equivalence Ratios to Doxorubicin for Late-Onset Cardiotoxicity. Armstrong, GT; Aune, GJ; Chow, EJ; Feijen, EAM; Green, DM; Hudson, MM; Kremer, LCM; Leisenring, WM; Loonen, J; Ness, KK; Oeffinger, KC; Robison, LL; Stratton, KL; van Dalen, EC; van der Pal, HJH; Yasui, Y, 2019)	0.51
"Dual-targeted drug delivery is a new drug dosing strategy that is frequently used to enhance the therapeutic efficacy of anticancer drugs."	( New Folate-Modified Human Serum Albumin Conjugated to Cationic Lipid Carriers for Dual Targeting of Mitoxantrone against Breast Cancer. Azandaryani, AH; Kashanian, S; Mahdavian, E; Rafipour, R; Ridha, AA, 2020)	0.77

Role	Description
antineoplastic agent	A substance that inhibits or prevents the proliferation of neoplasms.
analgesic	An agent capable of relieving pain without the loss of consciousness or without producing anaesthesia. In addition, analgesic is a role played by a compound which is exhibited by a capability to cause a reduction of pain symptoms.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Class	Description
dihydroxyanthraquinone
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Chain A, TYROSYL-DNA PHOSPHODIESTERASE	Homo sapiens (human)	Potency	19.9526	0.0040	23.8416	100.0000	AID485290
Chain A, JmjC domain-containing histone demethylation protein 3A	Homo sapiens (human)	Potency	6.3096	0.6310	35.7641	100.0000	AID504339
Chain A, ATP-DEPENDENT DNA HELICASE Q1	Homo sapiens (human)	Potency	20.3865	0.1259	19.1169	125.8920	AID2549; AID2708
Chain A, Ferritin light chain	Equus caballus (horse)	Potency	11.2202	5.6234	17.2929	31.6228	AID485281
dopamine D1 receptor	Homo sapiens (human)	Potency	5.1735	0.0052	1.3022	8.1995	AID624455
glp-1 receptor, partial	Homo sapiens (human)	Potency	16.5468	0.0184	6.8060	14.1254	AID624172; AID624417
15-lipoxygenase, partial	Homo sapiens (human)	Potency	7.8758	0.0126	10.6917	88.5700	AID887
WRN	Homo sapiens (human)	Potency	4.9370	0.1683	31.2583	100.0000	AID651768; AID720497
ATAD5 protein, partial	Homo sapiens (human)	Potency	18.6192	0.0041	10.8903	31.5287	AID493106; AID493107
Fumarate hydratase	Homo sapiens (human)	Potency	0.6978	0.0030	8.7949	48.0869	AID1347053
USP1 protein, partial	Homo sapiens (human)	Potency	43.0132	0.0316	37.5844	354.8130	AID504865; AID743255
NFKB1 protein, partial	Homo sapiens (human)	Potency	1.9953	0.0282	7.0559	15.8489	AID895; AID928
GLS protein	Homo sapiens (human)	Potency	4.5858	0.3548	7.9355	39.8107	AID624146; AID624170
PPM1D protein	Homo sapiens (human)	Potency	0.9300	0.0052	9.4661	32.9993	AID1347411
TDP1 protein	Homo sapiens (human)	Potency	0.1081	0.0008	11.3822	44.6684	AID686978; AID686979
Thrombopoietin	Homo sapiens (human)	Potency	0.0251	0.0251	7.3048	31.6228	AID917; AID918
Smad3	Homo sapiens (human)	Potency	1.5849	0.0052	7.8098	29.0929	AID588855
apical membrane antigen 1, AMA1	Plasmodium falciparum 3D7	Potency	10.0000	0.7079	12.1943	39.8107	AID720542
DNA polymerase III, partial	Bacillus subtilis	Potency	1.5003	1.0621	14.1528	26.6795	AID485295
hypoxia-inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor)	Homo sapiens (human)	Potency	10.2663	0.0013	7.7625	44.6684	AID914; AID915
hypothetical protein, conserved	Trypanosoma brucei	Potency	39.8107	0.2239	11.2451	35.4813	AID624173
regulator of G-protein signaling 4	Homo sapiens (human)	Potency	11.9173	0.5318	15.4358	37.6858	AID504845
EWS/FLI fusion protein	Homo sapiens (human)	Potency	0.1063	0.0013	10.1577	42.8575	AID1259252; AID1259253; AID1259255
polyprotein	Zika virus	Potency	0.6978	0.0030	8.7949	48.0869	AID1347053
67.9K protein	Vaccinia virus	Potency	5.1581	0.0001	8.4406	100.0000	AID720579; AID720580
Parkin	Homo sapiens (human)	Potency	23.1093	0.8199	14.8306	44.6684	AID720573
arylsulfatase A	Homo sapiens (human)	Potency	23.9341	1.0691	13.9551	37.9330	AID720538
pyruvate kinase	Leishmania mexicana mexicana	Potency	15.8489	0.3981	13.7447	31.6228	AID945; AID959
IDH1	Homo sapiens (human)	Potency	20.5962	0.0052	10.8652	35.4813	AID686970
euchromatic histone-lysine N-methyltransferase 2	Homo sapiens (human)	Potency	6.2090	0.0355	20.9770	89.1251	AID504332
heat shock 70kDa protein 5 (glucose-regulated protein, 78kDa)	Homo sapiens (human)	Potency	2.3281	0.0165	25.3078	41.3999	AID504836; AID602332
Bloom syndrome protein isoform 1	Homo sapiens (human)	Potency	7.7417	0.5406	17.6392	96.1227	AID2528; AID720503
cytochrome P450 2D6 isoform 1	Homo sapiens (human)	Potency	39.8107	0.0020	7.5337	39.8107	AID891
NPC intracellular cholesterol transporter 1 precursor	Homo sapiens (human)	Potency	115.8210	0.0126	2.4518	25.0177	AID485313
cellular tumor antigen p53 isoform a	Homo sapiens (human)	Potency	7.6998	0.3162	12.4435	31.6228	AID902; AID924
atrial natriuretic peptide receptor 1 precursor	Homo sapiens (human)	Potency	23.9341	0.1346	10.3950	30.1313	AID1347049
vitamin D3 receptor isoform VDRA	Homo sapiens (human)	Potency	38.9519	0.3548	28.0659	89.1251	AID504847
chromobox protein homolog 1	Homo sapiens (human)	Potency	15.3712	0.0060	26.1688	89.1251	AID488953; AID540317
nuclear factor erythroid 2-related factor 2 isoform 2	Homo sapiens (human)	Potency	8.1995	0.0041	9.9848	25.9290	AID504444
huntingtin isoform 2	Homo sapiens (human)	Potency	10.0000	0.0006	18.4198	1,122.0200	AID1688
importin subunit beta-1 isoform 1	Homo sapiens (human)	Potency	31.6228	5.8048	36.1306	65.1308	AID540253
mitogen-activated protein kinase 1	Homo sapiens (human)	Potency	3.9811	0.0398	16.7842	39.8107	AID995
atrial natriuretic peptide receptor 2 precursor	Homo sapiens (human)	Potency	16.4816	0.0066	9.8094	18.4927	AID1347050
flap endonuclease 1	Homo sapiens (human)	Potency	2.5378	0.1337	25.4129	89.1251	AID488816; AID588795; AID720498
ubiquitin carboxyl-terminal hydrolase 2 isoform a	Homo sapiens (human)	Potency	14.6892	0.6561	9.4520	25.1189	AID463106
ras-related protein Rab-9A	Homo sapiens (human)	Potency	91.9997	0.0002	2.6215	31.4954	AID485297
serine/threonine-protein kinase mTOR isoform 1	Homo sapiens (human)	Potency	0.1469	0.0037	8.6189	23.2809	AID2668
tyrosine-protein kinase Yes	Homo sapiens (human)	Potency	34.4993	0.0000	5.0182	79.2586	AID686947
snurportin-1	Homo sapiens (human)	Potency	31.6228	5.8048	36.1306	65.1308	AID540253
histone-lysine N-methyltransferase 2A isoform 2 precursor	Homo sapiens (human)	Potency	12.5893	0.0103	23.8567	63.0957	AID2662
GTP-binding nuclear protein Ran isoform 1	Homo sapiens (human)	Potency	31.6228	5.8048	16.9962	25.9290	AID540253
DNA polymerase eta isoform 1	Homo sapiens (human)	Potency	11.0869	0.1000	28.9256	213.3130	AID588591; AID720502
DNA polymerase iota isoform a (long)	Homo sapiens (human)	Potency	7.1068	0.0501	27.0736	89.1251	AID588590; AID720496
DNA polymerase kappa isoform 1	Homo sapiens (human)	Potency	7.8754	0.0316	22.3146	100.0000	AID588579; AID720501
Vpr	Human immunodeficiency virus 1	Potency	11.2202	1.5849	19.6264	63.0957	AID651644
peripheral myelin protein 22	Rattus norvegicus (Norway rat)	Potency	0.3856	0.0056	12.3677	36.1254	AID624032; AID624044
survival motor neuron protein isoform d	Homo sapiens (human)	Potency	0.7943	0.1259	12.2344	35.4813	AID1458
cytochrome P450 3A4 isoform 1	Homo sapiens (human)	Potency	25.1189	0.0316	10.2792	39.8107	AID884; AID885
M-phase phosphoprotein 8	Homo sapiens (human)	Potency	6.7016	0.1778	24.7352	79.4328	AID488949
muscleblind-like protein 1 isoform 1	Homo sapiens (human)	Potency	5.3673	0.0041	9.9625	28.1838	AID493199; AID493205
histone acetyltransferase KAT2A isoform 1	Homo sapiens (human)	Potency	25.1189	0.2512	15.8432	39.8107	AID504327
muscarinic acetylcholine receptor M1	Rattus norvegicus (Norway rat)	Potency	11.3974	0.0010	6.0009	35.4813	AID943; AID944
lamin isoform A-delta10	Homo sapiens (human)	Potency	0.0708	0.8913	12.0676	28.1838	AID1487
pyruvate kinase PKM isoform b	Homo sapiens (human)	Potency	19.9526	2.5119	12.2628	25.1189	AID954; AID958
Gamma-aminobutyric acid receptor subunit pi	Rattus norvegicus (Norway rat)	Potency	25.1189	1.0000	12.2248	31.6228	AID885
Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)	Potency	7.8758	0.3162	12.7657	31.6228	AID881
Glycoprotein hormones alpha chain	Homo sapiens (human)	Potency	1.1220	4.4668	8.3448	10.0000	AID624291
Interferon beta	Homo sapiens (human)	Potency	0.9300	0.0033	9.1582	39.8107	AID1347411
Integrin beta-3	Homo sapiens (human)	Potency	6.4776	0.3162	11.4157	31.6228	AID924
Integrin alpha-IIb	Homo sapiens (human)	Potency	6.4776	0.3162	11.4157	31.6228	AID924
Gamma-aminobutyric acid receptor subunit beta-1	Rattus norvegicus (Norway rat)	Potency	25.1189	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit delta	Rattus norvegicus (Norway rat)	Potency	25.1189	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit gamma-2	Rattus norvegicus (Norway rat)	Potency	25.1189	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit alpha-5	Rattus norvegicus (Norway rat)	Potency	25.1189	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit alpha-3	Rattus norvegicus (Norway rat)	Potency	25.1189	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit gamma-1	Rattus norvegicus (Norway rat)	Potency	25.1189	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit alpha-2	Rattus norvegicus (Norway rat)	Potency	25.1189	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit alpha-4	Rattus norvegicus (Norway rat)	Potency	25.1189	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit gamma-3	Rattus norvegicus (Norway rat)	Potency	25.1189	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit alpha-6	Rattus norvegicus (Norway rat)	Potency	25.1189	1.0000	12.2248	31.6228	AID885
Histamine H2 receptor	Cavia porcellus (domestic guinea pig)	Potency	7.8758	0.0063	8.2350	39.8107	AID881
Gamma-aminobutyric acid receptor subunit alpha-1	Rattus norvegicus (Norway rat)	Potency	25.1189	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit beta-3	Rattus norvegicus (Norway rat)	Potency	25.1189	1.0000	12.2248	31.6228	AID885
Guanine nucleotide-binding protein G	Homo sapiens (human)	Potency	22.3872	1.9953	25.5327	50.1187	AID624288
Gamma-aminobutyric acid receptor subunit beta-2	Rattus norvegicus (Norway rat)	Potency	25.1189	1.0000	12.2248	31.6228	AID885
Inositol monophosphatase 1	Rattus norvegicus (Norway rat)	Potency	10.0000	1.0000	10.4756	28.1838	AID901
GABA theta subunit	Rattus norvegicus (Norway rat)	Potency	25.1189	1.0000	12.2248	31.6228	AID885
Ataxin-2	Homo sapiens (human)	Potency	0.3162	0.0119	12.2221	68.7989	AID588378
Gamma-aminobutyric acid receptor subunit epsilon	Rattus norvegicus (Norway rat)	Potency	25.1189	1.0000	12.2248	31.6228	AID885
Single-stranded DNA cytosine deaminase	Homo sapiens (human)	Potency	33.6698	28.1838	60.1453	89.1251	AID1347427; AID1347430
phosphoglycerate kinase	Trypanosoma brucei brucei TREU927	Potency	21.3313	0.0757	8.4742	29.0628	AID504547
2,3-bisphosphoglycerate-independent phosphoglycerate mutase	Leishmania major strain Friedlin	Potency	23.9341	7.5686	15.2306	21.3313	AID504548
ATP-dependent phosphofructokinase	Trypanosoma brucei brucei TREU927	Potency	4.7755	0.0601	10.7453	37.9330	AID485368
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Chain A, Probable serine/threonine-protein kinase pknB	Mycobacterium tuberculosis H37Rv	IC50 (µMol)	0.8000	0.8000	0.8000	0.8000	AID977608
nonstructural protein 1	Influenza A virus (A/California/07/2009(H1N1))	IC50 (µMol)	2.0490	0.2000	24.4540	100.0000	AID504329
rac GTPase-activating protein 1 isoform a	Homo sapiens (human)	IC50 (µMol)	14.4600	7.3900	57.8904	301.2400	AID624330
Solute carrier family 22 member 2	Homo sapiens (human)	IC50 (µMol)	73.3000	0.4000	3.1000	9.7000	AID721751
Solute carrier family 22 member 1	Homo sapiens (human)	IC50 (µMol)	43.9000	0.2100	5.5537	10.0000	AID721750
Voltage-dependent L-type calcium channel subunit alpha-1F	Homo sapiens (human)	IC50 (µMol)	22.5000	0.0003	2.6311	9.0000	AID1207752
5-hydroxytryptamine receptor 4	Cavia porcellus (domestic guinea pig)	IC50 (µMol)	3.5619	0.0001	1.0076	8.7800	AID625218
5-hydroxytryptamine receptor 4	Cavia porcellus (domestic guinea pig)	Ki	1.8657	0.0000	0.8871	10.0000	AID625218
Solute carrier family 22 member 3	Homo sapiens (human)	IC50 (µMol)	60.5000	0.0900	3.7277	9.5000	AID721749
Epidermal growth factor receptor	Homo sapiens (human)	IC50 (µMol)	5.3859	0.0000	0.5369	10.0000	AID625184
Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)	IC50 (µMol)	2.0352	0.0001	0.5453	10.0000	AID625186
Tyrosine-protein kinase Fyn	Homo sapiens (human)	IC50 (µMol)	1.2579	0.0002	1.6789	8.6800	AID625185
Aldo-keto reductase family 1 member B1	Rattus norvegicus (Norway rat)	IC50 (µMol)	4.9898	0.0004	1.8773	10.0000	AID625207
Aldo-keto reductase family 1 member B1	Rattus norvegicus (Norway rat)	Ki	4.9485	0.0032	2.2887	9.3160	AID625207
Muscarinic acetylcholine receptor M2	Homo sapiens (human)	IC50 (µMol)	0.2190	0.0000	1.2326	7.7930	AID625152
Muscarinic acetylcholine receptor M2	Homo sapiens (human)	Ki	0.0779	0.0000	0.6902	10.0000	AID625152
Muscarinic acetylcholine receptor M4	Homo sapiens (human)	IC50 (µMol)	0.6441	0.0000	1.1546	7.5858	AID625154
Muscarinic acetylcholine receptor M4	Homo sapiens (human)	Ki	0.0898	0.0000	0.7951	9.1201	AID625154
ATP-dependent translocase ABCB1	Homo sapiens (human)	IC50 (µMol)	1.5010	0.0002	2.3185	10.0000	AID1525935
Proto-oncogene tyrosine-protein kinase ROS	Homo sapiens (human)	IC50 (µMol)	2.9987	0.0001	0.3005	6.7000	AID1506771
Cytochrome P450 2D6	Homo sapiens (human)	IC50 (µMol)	76.3000	0.0000	2.0151	10.0000	AID240619
Muscarinic acetylcholine receptor M1	Homo sapiens (human)	IC50 (µMol)	0.7487	0.0000	1.4039	10.0000	AID625151
Muscarinic acetylcholine receptor M1	Homo sapiens (human)	Ki	0.1803	0.0000	0.5972	9.1201	AID625151
DNA topoisomerase 2-alpha	Homo sapiens (human)	IC50 (µMol)	5.3000	0.4800	4.3564	9.9400	AID381809
Polyunsaturated fatty acid lipoxygenase ALOX15	Oryctolagus cuniculus (rabbit)	IC50 (µMol)	1.7853	0.1100	3.2641	9.0330	AID625146
Angiotensin-converting enzyme	Oryctolagus cuniculus (rabbit)	IC50 (µMol)	3.5849	0.0000	1.6129	10.0000	AID625171
Angiotensin-converting enzyme	Oryctolagus cuniculus (rabbit)	Ki	2.9370	0.0004	2.0337	8.6606	AID625171
Casein kinase II subunit alpha'	Homo sapiens (human)	IC50 (µMol)	0.6600	0.0003	1.4320	10.0000	AID729381
Sodium-dependent noradrenaline transporter	Homo sapiens (human)	IC50 (µMol)	4.9898	0.0008	1.5416	20.0000	AID625207
Sodium-dependent noradrenaline transporter	Homo sapiens (human)	Ki	4.9485	0.0003	1.4656	10.0000	AID625207
5-hydroxytryptamine receptor 2C	Homo sapiens (human)	IC50 (µMol)	3.5619	0.0001	1.0302	9.0000	AID625218
5-hydroxytryptamine receptor 2C	Homo sapiens (human)	Ki	1.8657	0.0001	0.9549	10.0000	AID625218
Multidrug resistance-associated protein 1	Homo sapiens (human)	IC50 (µMol)	0.0081	0.0015	3.7110	9.6600	AID1525934; AID681514; AID681515; AID681516
Casein kinase II subunit beta	Homo sapiens (human)	IC50 (µMol)	0.6600	0.0003	1.4875	10.0000	AID729381
Casein kinase II subunit alpha	Homo sapiens (human)	IC50 (µMol)	0.6600	0.0005	1.3332	10.0000	AID729381
Voltage-dependent L-type calcium channel subunit alpha-1D	Homo sapiens (human)	IC50 (µMol)	22.5000	0.0003	2.5955	9.0000	AID1207752
Tyrosine-protein kinase BTK	Homo sapiens (human)	IC50 (µMol)	1.0000	0.0001	0.2557	7.6000	AID729382
Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)	IC50 (µMol)	3.5849	0.0009	1.9014	10.0000	AID625171
Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)	Ki	2.9370	0.0021	1.8407	10.0000	AID625171
TAR DNA-binding protein 43	Homo sapiens (human)	IC50 (µMol)	10.0000	10.0000	10.0000	10.0000	AID1666489
Voltage-dependent L-type calcium channel subunit alpha-1S	Homo sapiens (human)	IC50 (µMol)	22.5000	0.0003	2.6311	9.0000	AID1207752
Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)	IC50 (µMol)	22.5000	0.0003	2.2545	9.6000	AID1207752
Nuclear receptor subfamily 3 group C member 3	Bos taurus (cattle)	IC50 (µMol)	3.5849	0.1048	2.8398	8.3173	AID625171
Nuclear receptor subfamily 3 group C member 3	Bos taurus (cattle)	Ki	2.9370	0.0858	2.9542	8.6606	AID625171
Integrase	Human immunodeficiency virus 1	IC50 (µMol)	5.9000	0.0005	1.5443	10.0000	AID91425; AID91426
Multidrug and toxin extrusion protein 2	Homo sapiens (human)	IC50 (µMol)	0.6800	0.1600	3.9571	8.6000	AID721748; AID721752
Casein kinase II subunit alpha 3	Homo sapiens (human)	IC50 (µMol)	0.6600	0.0015	1.9664	10.0000	AID729381
Multidrug and toxin extrusion protein 1	Homo sapiens (human)	IC50 (µMol)	0.3733	0.0100	2.7656	10.0000	AID721746; AID721747; AID721754
P2Y purinoceptor 12	Homo sapiens (human)	Ki	10.0000	0.0020	2.8220	9.8300	AID375433
Solute carrier organic anion transporter family member 1B3	Homo sapiens (human)	IC50 (µMol)	3.3900	0.1047	2.7195	7.0795	AID1197747
Solute carrier organic anion transporter family member 1B3	Homo sapiens (human)	Ki	3.1000	0.0800	2.4688	9.8000	AID1197747
Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)	IC50 (µMol)	0.9038	0.0040	1.9666	10.0000	AID1525933
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
NEDD8-activating enzyme E1 regulatory subunit	Homo sapiens (human)	EC50 (µMol)	1.3000	0.0300	1.5767	3.4000	AID1349085
NEDD8-activating enzyme E1 catalytic subunit	Homo sapiens (human)	EC50 (µMol)	1.3000	0.0300	1.5767	3.4000	AID1349085
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
LANA	Human gammaherpesvirus 8	AC50	3.1955	0.0420	32.4569	312.0010	AID504726; AID504727
interferon gamma precursor	Homo sapiens (human)	AC50	0.1685	0.1280	15.1730	38.6100	AID1259418; AID1259420
histone-lysine N-methyltransferase NSD2 isoform 1	Homo sapiens (human)	AC50	2.3400	0.2930	7.3070	19.4400	AID1053173
protein AF-9 isoform a	Homo sapiens (human)	AC50	0.3740	0.0800	8.3802	17.9800	AID720495
dual specificity tyrosine-phosphorylation-regulated kinase 1A	Rattus norvegicus (Norway rat)	AC50	1.2480	0.0056	4.6932	26.6940	AID588345
DNA repair protein RAD52 homolog isoform a	Homo sapiens (human)	AC50	0.2440	0.1500	12.0662	35.2100	AID652116
DNA topoisomerase 2-alpha	Homo sapiens (human)	IC90 (µMol)	1.1000	1.1000	1.1000	1.1000	AID211122; AID57199
DNA topoisomerase 2-beta	Homo sapiens (human)	IC90 (µMol)	1.1000	1.1000	1.1000	1.1000	AID211122; AID57199
Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)	Kact	7.0000	1.0000	3.7500	7.0000	AID678804
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
activation of cysteine-type endopeptidase activity involved in apoptotic process	Solute carrier family 22 member 2	Homo sapiens (human)
positive regulation of gene expression	Solute carrier family 22 member 2	Homo sapiens (human)
organic cation transport	Solute carrier family 22 member 2	Homo sapiens (human)
monoatomic cation transport	Solute carrier family 22 member 2	Homo sapiens (human)
neurotransmitter transport	Solute carrier family 22 member 2	Homo sapiens (human)
serotonin transport	Solute carrier family 22 member 2	Homo sapiens (human)
body fluid secretion	Solute carrier family 22 member 2	Homo sapiens (human)
organic cation transport	Solute carrier family 22 member 2	Homo sapiens (human)
quaternary ammonium group transport	Solute carrier family 22 member 2	Homo sapiens (human)
prostaglandin transport	Solute carrier family 22 member 2	Homo sapiens (human)
amine transport	Solute carrier family 22 member 2	Homo sapiens (human)
putrescine transport	Solute carrier family 22 member 2	Homo sapiens (human)
spermidine transport	Solute carrier family 22 member 2	Homo sapiens (human)
acetylcholine transport	Solute carrier family 22 member 2	Homo sapiens (human)
choline transport	Solute carrier family 22 member 2	Homo sapiens (human)
dopamine transport	Solute carrier family 22 member 2	Homo sapiens (human)
norepinephrine transport	Solute carrier family 22 member 2	Homo sapiens (human)
xenobiotic transport	Solute carrier family 22 member 2	Homo sapiens (human)
epinephrine transport	Solute carrier family 22 member 2	Homo sapiens (human)
histamine transport	Solute carrier family 22 member 2	Homo sapiens (human)
serotonin uptake	Solute carrier family 22 member 2	Homo sapiens (human)
histamine uptake	Solute carrier family 22 member 2	Homo sapiens (human)
norepinephrine uptake	Solute carrier family 22 member 2	Homo sapiens (human)
thiamine transmembrane transport	Solute carrier family 22 member 2	Homo sapiens (human)
purine-containing compound transmembrane transport	Solute carrier family 22 member 2	Homo sapiens (human)
amino acid import across plasma membrane	Solute carrier family 22 member 2	Homo sapiens (human)
dopamine uptake	Solute carrier family 22 member 2	Homo sapiens (human)
L-arginine import across plasma membrane	Solute carrier family 22 member 2	Homo sapiens (human)
export across plasma membrane	Solute carrier family 22 member 2	Homo sapiens (human)
transport across blood-brain barrier	Solute carrier family 22 member 2	Homo sapiens (human)
L-alpha-amino acid transmembrane transport	Solute carrier family 22 member 2	Homo sapiens (human)
spermidine transmembrane transport	Solute carrier family 22 member 2	Homo sapiens (human)
L-arginine transmembrane transport	Solute carrier family 22 member 2	Homo sapiens (human)
cellular detoxification	Solute carrier family 22 member 2	Homo sapiens (human)
xenobiotic transport across blood-brain barrier	Solute carrier family 22 member 2	Homo sapiens (human)
xenobiotic metabolic process	Solute carrier family 22 member 1	Homo sapiens (human)
neurotransmitter transport	Solute carrier family 22 member 1	Homo sapiens (human)
serotonin transport	Solute carrier family 22 member 1	Homo sapiens (human)
establishment or maintenance of transmembrane electrochemical gradient	Solute carrier family 22 member 1	Homo sapiens (human)
organic cation transport	Solute carrier family 22 member 1	Homo sapiens (human)
quaternary ammonium group transport	Solute carrier family 22 member 1	Homo sapiens (human)
prostaglandin transport	Solute carrier family 22 member 1	Homo sapiens (human)
monoamine transport	Solute carrier family 22 member 1	Homo sapiens (human)
putrescine transport	Solute carrier family 22 member 1	Homo sapiens (human)
spermidine transport	Solute carrier family 22 member 1	Homo sapiens (human)
acetylcholine transport	Solute carrier family 22 member 1	Homo sapiens (human)
dopamine transport	Solute carrier family 22 member 1	Homo sapiens (human)
norepinephrine transport	Solute carrier family 22 member 1	Homo sapiens (human)
thiamine transport	Solute carrier family 22 member 1	Homo sapiens (human)
xenobiotic transport	Solute carrier family 22 member 1	Homo sapiens (human)
epinephrine transport	Solute carrier family 22 member 1	Homo sapiens (human)
serotonin uptake	Solute carrier family 22 member 1	Homo sapiens (human)
norepinephrine uptake	Solute carrier family 22 member 1	Homo sapiens (human)
thiamine transmembrane transport	Solute carrier family 22 member 1	Homo sapiens (human)
metanephric proximal tubule development	Solute carrier family 22 member 1	Homo sapiens (human)
purine-containing compound transmembrane transport	Solute carrier family 22 member 1	Homo sapiens (human)
dopamine uptake	Solute carrier family 22 member 1	Homo sapiens (human)
monoatomic cation transmembrane transport	Solute carrier family 22 member 1	Homo sapiens (human)
transport across blood-brain barrier	Solute carrier family 22 member 1	Homo sapiens (human)
(R)-carnitine transmembrane transport	Solute carrier family 22 member 1	Homo sapiens (human)
acyl carnitine transmembrane transport	Solute carrier family 22 member 1	Homo sapiens (human)
spermidine transmembrane transport	Solute carrier family 22 member 1	Homo sapiens (human)
cellular detoxification	Solute carrier family 22 member 1	Homo sapiens (human)
xenobiotic transport across blood-brain barrier	Solute carrier family 22 member 1	Homo sapiens (human)
lipid metabolic process	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
phospholipid metabolic process	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
apoptotic process	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
negative regulation of cell population proliferation	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
positive regulation of macrophage derived foam cell differentiation	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
arachidonic acid metabolic process	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
negative regulation of cell migration	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
prostate gland development	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
regulation of epithelial cell differentiation	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
positive regulation of chemokine production	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
positive regulation of peroxisome proliferator activated receptor signaling pathway	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
positive regulation of keratinocyte differentiation	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
negative regulation of cell cycle	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
negative regulation of growth	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
hepoxilin biosynthetic process	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
endocannabinoid signaling pathway	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
cannabinoid biosynthetic process	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
lipoxin A4 biosynthetic process	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
linoleic acid metabolic process	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
lipid oxidation	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
lipoxygenase pathway	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
visual perception	Voltage-dependent L-type calcium channel subunit alpha-1F	Homo sapiens (human)
detection of light stimulus involved in visual perception	Voltage-dependent L-type calcium channel subunit alpha-1F	Homo sapiens (human)
calcium ion import across plasma membrane	Voltage-dependent L-type calcium channel subunit alpha-1F	Homo sapiens (human)
histamine metabolic process	Solute carrier family 22 member 3	Homo sapiens (human)
organic cation transport	Solute carrier family 22 member 3	Homo sapiens (human)
quaternary ammonium group transport	Solute carrier family 22 member 3	Homo sapiens (human)
monoatomic ion transport	Solute carrier family 22 member 3	Homo sapiens (human)
neurotransmitter transport	Solute carrier family 22 member 3	Homo sapiens (human)
serotonin transport	Solute carrier family 22 member 3	Homo sapiens (human)
organic cation transport	Solute carrier family 22 member 3	Homo sapiens (human)
quaternary ammonium group transport	Solute carrier family 22 member 3	Homo sapiens (human)
organic anion transport	Solute carrier family 22 member 3	Homo sapiens (human)
monocarboxylic acid transport	Solute carrier family 22 member 3	Homo sapiens (human)
monoamine transport	Solute carrier family 22 member 3	Homo sapiens (human)
spermidine transport	Solute carrier family 22 member 3	Homo sapiens (human)
dopamine transport	Solute carrier family 22 member 3	Homo sapiens (human)
norepinephrine transport	Solute carrier family 22 member 3	Homo sapiens (human)
regulation of appetite	Solute carrier family 22 member 3	Homo sapiens (human)
xenobiotic transport	Solute carrier family 22 member 3	Homo sapiens (human)
epinephrine transport	Solute carrier family 22 member 3	Homo sapiens (human)
histamine transport	Solute carrier family 22 member 3	Homo sapiens (human)
serotonin uptake	Solute carrier family 22 member 3	Homo sapiens (human)
histamine uptake	Solute carrier family 22 member 3	Homo sapiens (human)
norepinephrine uptake	Solute carrier family 22 member 3	Homo sapiens (human)
epinephrine uptake	Solute carrier family 22 member 3	Homo sapiens (human)
purine-containing compound transmembrane transport	Solute carrier family 22 member 3	Homo sapiens (human)
dopamine uptake	Solute carrier family 22 member 3	Homo sapiens (human)
transport across blood-brain barrier	Solute carrier family 22 member 3	Homo sapiens (human)
spermidine transmembrane transport	Solute carrier family 22 member 3	Homo sapiens (human)
cellular detoxification	Solute carrier family 22 member 3	Homo sapiens (human)
cell surface receptor signaling pathway	Epidermal growth factor receptor	Homo sapiens (human)
epidermal growth factor receptor signaling pathway	Epidermal growth factor receptor	Homo sapiens (human)
positive regulation of cell population proliferation	Epidermal growth factor receptor	Homo sapiens (human)
MAPK cascade	Epidermal growth factor receptor	Homo sapiens (human)
ossification	Epidermal growth factor receptor	Homo sapiens (human)
embryonic placenta development	Epidermal growth factor receptor	Homo sapiens (human)
positive regulation of protein phosphorylation	Epidermal growth factor receptor	Homo sapiens (human)
hair follicle development	Epidermal growth factor receptor	Homo sapiens (human)
translation	Epidermal growth factor receptor	Homo sapiens (human)
signal transduction	Epidermal growth factor receptor	Homo sapiens (human)
epidermal growth factor receptor signaling pathway	Epidermal growth factor receptor	Homo sapiens (human)
activation of phospholipase C activity	Epidermal growth factor receptor	Homo sapiens (human)
salivary gland morphogenesis	Epidermal growth factor receptor	Homo sapiens (human)
midgut development	Epidermal growth factor receptor	Homo sapiens (human)
learning or memory	Epidermal growth factor receptor	Homo sapiens (human)
circadian rhythm	Epidermal growth factor receptor	Homo sapiens (human)
positive regulation of cell population proliferation	Epidermal growth factor receptor	Homo sapiens (human)
diterpenoid metabolic process	Epidermal growth factor receptor	Homo sapiens (human)
peptidyl-tyrosine phosphorylation	Epidermal growth factor receptor	Homo sapiens (human)
cerebral cortex cell migration	Epidermal growth factor receptor	Homo sapiens (human)
positive regulation of cell growth	Epidermal growth factor receptor	Homo sapiens (human)
lung development	Epidermal growth factor receptor	Homo sapiens (human)
positive regulation of cell migration	Epidermal growth factor receptor	Homo sapiens (human)
positive regulation of superoxide anion generation	Epidermal growth factor receptor	Homo sapiens (human)
positive regulation of peptidyl-serine phosphorylation	Epidermal growth factor receptor	Homo sapiens (human)
response to cobalamin	Epidermal growth factor receptor	Homo sapiens (human)
response to hydroxyisoflavone	Epidermal growth factor receptor	Homo sapiens (human)
cellular response to reactive oxygen species	Epidermal growth factor receptor	Homo sapiens (human)
peptidyl-tyrosine autophosphorylation	Epidermal growth factor receptor	Homo sapiens (human)
ERBB2-EGFR signaling pathway	Epidermal growth factor receptor	Homo sapiens (human)
negative regulation of epidermal growth factor receptor signaling pathway	Epidermal growth factor receptor	Homo sapiens (human)
negative regulation of protein catabolic process	Epidermal growth factor receptor	Homo sapiens (human)
vasodilation	Epidermal growth factor receptor	Homo sapiens (human)
positive regulation of phosphorylation	Epidermal growth factor receptor	Homo sapiens (human)
ovulation cycle	Epidermal growth factor receptor	Homo sapiens (human)
hydrogen peroxide metabolic process	Epidermal growth factor receptor	Homo sapiens (human)
negative regulation of apoptotic process	Epidermal growth factor receptor	Homo sapiens (human)
positive regulation of MAP kinase activity	Epidermal growth factor receptor	Homo sapiens (human)
tongue development	Epidermal growth factor receptor	Homo sapiens (human)
positive regulation of cyclin-dependent protein serine/threonine kinase activity	Epidermal growth factor receptor	Homo sapiens (human)
positive regulation of DNA repair	Epidermal growth factor receptor	Homo sapiens (human)
positive regulation of DNA replication	Epidermal growth factor receptor	Homo sapiens (human)
positive regulation of bone resorption	Epidermal growth factor receptor	Homo sapiens (human)
positive regulation of DNA-templated transcription	Epidermal growth factor receptor	Homo sapiens (human)
positive regulation of vasoconstriction	Epidermal growth factor receptor	Homo sapiens (human)
negative regulation of mitotic cell cycle	Epidermal growth factor receptor	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Epidermal growth factor receptor	Homo sapiens (human)
regulation of JNK cascade	Epidermal growth factor receptor	Homo sapiens (human)
symbiont entry into host cell	Epidermal growth factor receptor	Homo sapiens (human)
protein autophosphorylation	Epidermal growth factor receptor	Homo sapiens (human)
astrocyte activation	Epidermal growth factor receptor	Homo sapiens (human)
positive regulation of fibroblast proliferation	Epidermal growth factor receptor	Homo sapiens (human)
digestive tract morphogenesis	Epidermal growth factor receptor	Homo sapiens (human)
positive regulation of smooth muscle cell proliferation	Epidermal growth factor receptor	Homo sapiens (human)
neuron projection morphogenesis	Epidermal growth factor receptor	Homo sapiens (human)
epithelial cell proliferation	Epidermal growth factor receptor	Homo sapiens (human)
positive regulation of epithelial cell proliferation	Epidermal growth factor receptor	Homo sapiens (human)
regulation of peptidyl-tyrosine phosphorylation	Epidermal growth factor receptor	Homo sapiens (human)
protein insertion into membrane	Epidermal growth factor receptor	Homo sapiens (human)
response to calcium ion	Epidermal growth factor receptor	Homo sapiens (human)
regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction	Epidermal growth factor receptor	Homo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction	Epidermal growth factor receptor	Homo sapiens (human)
positive regulation of synaptic transmission, glutamatergic	Epidermal growth factor receptor	Homo sapiens (human)
positive regulation of glial cell proliferation	Epidermal growth factor receptor	Homo sapiens (human)
morphogenesis of an epithelial fold	Epidermal growth factor receptor	Homo sapiens (human)
eyelid development in camera-type eye	Epidermal growth factor receptor	Homo sapiens (human)
response to UV-A	Epidermal growth factor receptor	Homo sapiens (human)
positive regulation of mucus secretion	Epidermal growth factor receptor	Homo sapiens (human)
regulation of ERK1 and ERK2 cascade	Epidermal growth factor receptor	Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascade	Epidermal growth factor receptor	Homo sapiens (human)
cellular response to amino acid stimulus	Epidermal growth factor receptor	Homo sapiens (human)
cellular response to mechanical stimulus	Epidermal growth factor receptor	Homo sapiens (human)
cellular response to cadmium ion	Epidermal growth factor receptor	Homo sapiens (human)
cellular response to epidermal growth factor stimulus	Epidermal growth factor receptor	Homo sapiens (human)
cellular response to estradiol stimulus	Epidermal growth factor receptor	Homo sapiens (human)
cellular response to xenobiotic stimulus	Epidermal growth factor receptor	Homo sapiens (human)
cellular response to dexamethasone stimulus	Epidermal growth factor receptor	Homo sapiens (human)
positive regulation of canonical Wnt signaling pathway	Epidermal growth factor receptor	Homo sapiens (human)
liver regeneration	Epidermal growth factor receptor	Homo sapiens (human)
cell-cell adhesion	Epidermal growth factor receptor	Homo sapiens (human)
positive regulation of protein kinase C activity	Epidermal growth factor receptor	Homo sapiens (human)
positive regulation of G1/S transition of mitotic cell cycle	Epidermal growth factor receptor	Homo sapiens (human)
positive regulation of non-canonical NF-kappaB signal transduction	Epidermal growth factor receptor	Homo sapiens (human)
positive regulation of prolactin secretion	Epidermal growth factor receptor	Homo sapiens (human)
positive regulation of miRNA transcription	Epidermal growth factor receptor	Homo sapiens (human)
positive regulation of protein localization to plasma membrane	Epidermal growth factor receptor	Homo sapiens (human)
negative regulation of cardiocyte differentiation	Epidermal growth factor receptor	Homo sapiens (human)
neurogenesis	Epidermal growth factor receptor	Homo sapiens (human)
multicellular organism development	Epidermal growth factor receptor	Homo sapiens (human)
positive regulation of kinase activity	Epidermal growth factor receptor	Homo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathway	Epidermal growth factor receptor	Homo sapiens (human)
G protein-coupled receptor signaling pathway	Glycoprotein hormones alpha chain	Homo sapiens (human)
positive regulation of cell population proliferation	Glycoprotein hormones alpha chain	Homo sapiens (human)
hormone-mediated signaling pathway	Glycoprotein hormones alpha chain	Homo sapiens (human)
regulation of signaling receptor activity	Glycoprotein hormones alpha chain	Homo sapiens (human)
positive regulation of steroid biosynthetic process	Glycoprotein hormones alpha chain	Homo sapiens (human)
positive regulation of cell migration	Glycoprotein hormones alpha chain	Homo sapiens (human)
thyroid gland development	Glycoprotein hormones alpha chain	Homo sapiens (human)
luteinizing hormone secretion	Glycoprotein hormones alpha chain	Homo sapiens (human)
organ growth	Glycoprotein hormones alpha chain	Homo sapiens (human)
follicle-stimulating hormone signaling pathway	Glycoprotein hormones alpha chain	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Glycoprotein hormones alpha chain	Homo sapiens (human)
negative regulation of organ growth	Glycoprotein hormones alpha chain	Homo sapiens (human)
follicle-stimulating hormone secretion	Glycoprotein hormones alpha chain	Homo sapiens (human)
thyroid hormone generation	Glycoprotein hormones alpha chain	Homo sapiens (human)
cell surface receptor signaling pathway via JAK-STAT	Interferon beta	Homo sapiens (human)
response to exogenous dsRNA	Interferon beta	Homo sapiens (human)
B cell activation involved in immune response	Interferon beta	Homo sapiens (human)
cell surface receptor signaling pathway	Interferon beta	Homo sapiens (human)
cell surface receptor signaling pathway via JAK-STAT	Interferon beta	Homo sapiens (human)
response to virus	Interferon beta	Homo sapiens (human)
positive regulation of autophagy	Interferon beta	Homo sapiens (human)
cytokine-mediated signaling pathway	Interferon beta	Homo sapiens (human)
natural killer cell activation	Interferon beta	Homo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT protein	Interferon beta	Homo sapiens (human)
cellular response to interferon-beta	Interferon beta	Homo sapiens (human)
B cell proliferation	Interferon beta	Homo sapiens (human)
negative regulation of viral genome replication	Interferon beta	Homo sapiens (human)
innate immune response	Interferon beta	Homo sapiens (human)
positive regulation of innate immune response	Interferon beta	Homo sapiens (human)
regulation of MHC class I biosynthetic process	Interferon beta	Homo sapiens (human)
negative regulation of T cell differentiation	Interferon beta	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Interferon beta	Homo sapiens (human)
defense response to virus	Interferon beta	Homo sapiens (human)
type I interferon-mediated signaling pathway	Interferon beta	Homo sapiens (human)
neuron cellular homeostasis	Interferon beta	Homo sapiens (human)
cellular response to exogenous dsRNA	Interferon beta	Homo sapiens (human)
cellular response to virus	Interferon beta	Homo sapiens (human)
negative regulation of Lewy body formation	Interferon beta	Homo sapiens (human)
negative regulation of T-helper 2 cell cytokine production	Interferon beta	Homo sapiens (human)
positive regulation of apoptotic signaling pathway	Interferon beta	Homo sapiens (human)
response to exogenous dsRNA	Interferon beta	Homo sapiens (human)
B cell differentiation	Interferon beta	Homo sapiens (human)
natural killer cell activation involved in immune response	Interferon beta	Homo sapiens (human)
adaptive immune response	Interferon beta	Homo sapiens (human)
T cell activation involved in immune response	Interferon beta	Homo sapiens (human)
humoral immune response	Interferon beta	Homo sapiens (human)
cell surface receptor signaling pathway	Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)
positive regulation of protein phosphorylation	Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)
protein phosphorylation	Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)
signal transduction	Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)
enzyme-linked receptor protein signaling pathway	Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathway	Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)
heart development	Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)
neuromuscular junction development	Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)
motor neuron axon guidance	Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)
Schwann cell development	Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)
peptidyl-tyrosine phosphorylation	Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)
positive regulation of cell growth	Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)
regulation of microtubule-based process	Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)
immature T cell proliferation in thymus	Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)
negative regulation of immature T cell proliferation in thymus	Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)
positive regulation of Rho protein signal transduction	Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)
intracellular signal transduction	Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)
ERBB2-ERBB3 signaling pathway	Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)
ERBB2-EGFR signaling pathway	Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)
ERBB2-ERBB4 signaling pathway	Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)
wound healing	Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)
myelination	Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)
positive regulation of MAP kinase activity	Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)
phosphatidylinositol 3-kinase/protein kinase B signal transduction	Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)
positive regulation of translation	Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)
regulation of angiogenesis	Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)
positive regulation of cell adhesion	Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)
positive regulation of transcription by RNA polymerase I	Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)
oligodendrocyte differentiation	Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)
positive regulation of epithelial cell proliferation	Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)
regulation of ERK1 and ERK2 cascade	Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)
cellular response to growth factor stimulus	Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)
cellular response to epidermal growth factor stimulus	Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)
semaphorin-plexin signaling pathway	Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)
positive regulation of protein targeting to membrane	Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)
neurotransmitter receptor localization to postsynaptic specialization membrane	Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)
neurogenesis	Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)
positive regulation of MAPK cascade	Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)
negative regulation of apoptotic process	Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)
positive regulation of kinase activity	Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)
multicellular organism development	Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)
positive regulation of cell population proliferation	Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)
neuron differentiation	Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)
regulation of gene expression	Amyloid-beta precursor protein	Homo sapiens (human)
cognition	Amyloid-beta precursor protein	Homo sapiens (human)
G2/M transition of mitotic cell cycle	Amyloid-beta precursor protein	Homo sapiens (human)
microglial cell activation	Amyloid-beta precursor protein	Homo sapiens (human)
positive regulation of protein phosphorylation	Amyloid-beta precursor protein	Homo sapiens (human)
suckling behavior	Amyloid-beta precursor protein	Homo sapiens (human)
astrocyte activation involved in immune response	Amyloid-beta precursor protein	Homo sapiens (human)
regulation of translation	Amyloid-beta precursor protein	Homo sapiens (human)
protein phosphorylation	Amyloid-beta precursor protein	Homo sapiens (human)
intracellular copper ion homeostasis	Amyloid-beta precursor protein	Homo sapiens (human)
endocytosis	Amyloid-beta precursor protein	Homo sapiens (human)
response to oxidative stress	Amyloid-beta precursor protein	Homo sapiens (human)
cell adhesion	Amyloid-beta precursor protein	Homo sapiens (human)
regulation of epidermal growth factor-activated receptor activity	Amyloid-beta precursor protein	Homo sapiens (human)
Notch signaling pathway	Amyloid-beta precursor protein	Homo sapiens (human)
axonogenesis	Amyloid-beta precursor protein	Homo sapiens (human)
learning or memory	Amyloid-beta precursor protein	Homo sapiens (human)
learning	Amyloid-beta precursor protein	Homo sapiens (human)
mating behavior	Amyloid-beta precursor protein	Homo sapiens (human)
locomotory behavior	Amyloid-beta precursor protein	Homo sapiens (human)
axo-dendritic transport	Amyloid-beta precursor protein	Homo sapiens (human)
cholesterol metabolic process	Amyloid-beta precursor protein	Homo sapiens (human)
negative regulation of cell population proliferation	Amyloid-beta precursor protein	Homo sapiens (human)
adult locomotory behavior	Amyloid-beta precursor protein	Homo sapiens (human)
visual learning	Amyloid-beta precursor protein	Homo sapiens (human)
regulation of gene expression	Amyloid-beta precursor protein	Homo sapiens (human)
positive regulation of gene expression	Amyloid-beta precursor protein	Homo sapiens (human)
negative regulation of gene expression	Amyloid-beta precursor protein	Homo sapiens (human)
positive regulation of peptidyl-threonine phosphorylation	Amyloid-beta precursor protein	Homo sapiens (human)
positive regulation of G2/M transition of mitotic cell cycle	Amyloid-beta precursor protein	Homo sapiens (human)
microglia development	Amyloid-beta precursor protein	Homo sapiens (human)
axon midline choice point recognition	Amyloid-beta precursor protein	Homo sapiens (human)
neuron remodeling	Amyloid-beta precursor protein	Homo sapiens (human)
dendrite development	Amyloid-beta precursor protein	Homo sapiens (human)
regulation of Wnt signaling pathway	Amyloid-beta precursor protein	Homo sapiens (human)
extracellular matrix organization	Amyloid-beta precursor protein	Homo sapiens (human)
forebrain development	Amyloid-beta precursor protein	Homo sapiens (human)
neuron projection development	Amyloid-beta precursor protein	Homo sapiens (human)
positive regulation of chemokine production	Amyloid-beta precursor protein	Homo sapiens (human)
positive regulation of interleukin-1 beta production	Amyloid-beta precursor protein	Homo sapiens (human)
positive regulation of interleukin-6 production	Amyloid-beta precursor protein	Homo sapiens (human)
positive regulation of tumor necrosis factor production	Amyloid-beta precursor protein	Homo sapiens (human)
positive regulation of peptidyl-serine phosphorylation	Amyloid-beta precursor protein	Homo sapiens (human)
ionotropic glutamate receptor signaling pathway	Amyloid-beta precursor protein	Homo sapiens (human)
regulation of multicellular organism growth	Amyloid-beta precursor protein	Homo sapiens (human)
negative regulation of neuron differentiation	Amyloid-beta precursor protein	Homo sapiens (human)
positive regulation of glycolytic process	Amyloid-beta precursor protein	Homo sapiens (human)
positive regulation of mitotic cell cycle	Amyloid-beta precursor protein	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Amyloid-beta precursor protein	Homo sapiens (human)
positive regulation of JNK cascade	Amyloid-beta precursor protein	Homo sapiens (human)
astrocyte activation	Amyloid-beta precursor protein	Homo sapiens (human)
regulation of long-term neuronal synaptic plasticity	Amyloid-beta precursor protein	Homo sapiens (human)
collateral sprouting in absence of injury	Amyloid-beta precursor protein	Homo sapiens (human)
positive regulation of inflammatory response	Amyloid-beta precursor protein	Homo sapiens (human)
regulation of peptidyl-tyrosine phosphorylation	Amyloid-beta precursor protein	Homo sapiens (human)
regulation of synapse structure or activity	Amyloid-beta precursor protein	Homo sapiens (human)
synapse organization	Amyloid-beta precursor protein	Homo sapiens (human)
positive regulation of calcium-mediated signaling	Amyloid-beta precursor protein	Homo sapiens (human)
neuromuscular process controlling balance	Amyloid-beta precursor protein	Homo sapiens (human)
synaptic assembly at neuromuscular junction	Amyloid-beta precursor protein	Homo sapiens (human)
positive regulation of protein metabolic process	Amyloid-beta precursor protein	Homo sapiens (human)
neuron apoptotic process	Amyloid-beta precursor protein	Homo sapiens (human)
smooth endoplasmic reticulum calcium ion homeostasis	Amyloid-beta precursor protein	Homo sapiens (human)
neuron cellular homeostasis	Amyloid-beta precursor protein	Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascade	Amyloid-beta precursor protein	Homo sapiens (human)
response to interleukin-1	Amyloid-beta precursor protein	Homo sapiens (human)
modulation of excitatory postsynaptic potential	Amyloid-beta precursor protein	Homo sapiens (human)
NMDA selective glutamate receptor signaling pathway	Amyloid-beta precursor protein	Homo sapiens (human)
regulation of spontaneous synaptic transmission	Amyloid-beta precursor protein	Homo sapiens (human)
cytosolic mRNA polyadenylation	Amyloid-beta precursor protein	Homo sapiens (human)
negative regulation of long-term synaptic potentiation	Amyloid-beta precursor protein	Homo sapiens (human)
positive regulation of long-term synaptic potentiation	Amyloid-beta precursor protein	Homo sapiens (human)
positive regulation of non-canonical NF-kappaB signal transduction	Amyloid-beta precursor protein	Homo sapiens (human)
cellular response to amyloid-beta	Amyloid-beta precursor protein	Homo sapiens (human)
regulation of presynapse assembly	Amyloid-beta precursor protein	Homo sapiens (human)
positive regulation of amyloid fibril formation	Amyloid-beta precursor protein	Homo sapiens (human)
amyloid fibril formation	Amyloid-beta precursor protein	Homo sapiens (human)
neuron projection maintenance	Amyloid-beta precursor protein	Homo sapiens (human)
positive regulation of T cell migration	Amyloid-beta precursor protein	Homo sapiens (human)
central nervous system development	Amyloid-beta precursor protein	Homo sapiens (human)
negative regulation of low-density lipoprotein receptor activity	Integrin beta-3	Homo sapiens (human)
positive regulation of protein phosphorylation	Integrin beta-3	Homo sapiens (human)
positive regulation of endothelial cell proliferation	Integrin beta-3	Homo sapiens (human)
positive regulation of cell-matrix adhesion	Integrin beta-3	Homo sapiens (human)
cell-substrate junction assembly	Integrin beta-3	Homo sapiens (human)
cell adhesion	Integrin beta-3	Homo sapiens (human)
cell-matrix adhesion	Integrin beta-3	Homo sapiens (human)
integrin-mediated signaling pathway	Integrin beta-3	Homo sapiens (human)
embryo implantation	Integrin beta-3	Homo sapiens (human)
blood coagulation	Integrin beta-3	Homo sapiens (human)
positive regulation of endothelial cell migration	Integrin beta-3	Homo sapiens (human)
positive regulation of gene expression	Integrin beta-3	Homo sapiens (human)
negative regulation of macrophage derived foam cell differentiation	Integrin beta-3	Homo sapiens (human)
positive regulation of fibroblast migration	Integrin beta-3	Homo sapiens (human)
negative regulation of lipid storage	Integrin beta-3	Homo sapiens (human)
response to activity	Integrin beta-3	Homo sapiens (human)
smooth muscle cell migration	Integrin beta-3	Homo sapiens (human)
positive regulation of smooth muscle cell migration	Integrin beta-3	Homo sapiens (human)
platelet activation	Integrin beta-3	Homo sapiens (human)
positive regulation of vascular endothelial growth factor receptor signaling pathway	Integrin beta-3	Homo sapiens (human)
cell-substrate adhesion	Integrin beta-3	Homo sapiens (human)
activation of protein kinase activity	Integrin beta-3	Homo sapiens (human)
negative regulation of lipid transport	Integrin beta-3	Homo sapiens (human)
regulation of protein localization	Integrin beta-3	Homo sapiens (human)
regulation of actin cytoskeleton organization	Integrin beta-3	Homo sapiens (human)
cell adhesion mediated by integrin	Integrin beta-3	Homo sapiens (human)
positive regulation of cell adhesion mediated by integrin	Integrin beta-3	Homo sapiens (human)
positive regulation of osteoblast proliferation	Integrin beta-3	Homo sapiens (human)
heterotypic cell-cell adhesion	Integrin beta-3	Homo sapiens (human)
substrate adhesion-dependent cell spreading	Integrin beta-3	Homo sapiens (human)
tube development	Integrin beta-3	Homo sapiens (human)
wound healing, spreading of epidermal cells	Integrin beta-3	Homo sapiens (human)
cellular response to platelet-derived growth factor stimulus	Integrin beta-3	Homo sapiens (human)
apolipoprotein A-I-mediated signaling pathway	Integrin beta-3	Homo sapiens (human)
wound healing	Integrin beta-3	Homo sapiens (human)
apoptotic cell clearance	Integrin beta-3	Homo sapiens (human)
regulation of bone resorption	Integrin beta-3	Homo sapiens (human)
positive regulation of angiogenesis	Integrin beta-3	Homo sapiens (human)
positive regulation of bone resorption	Integrin beta-3	Homo sapiens (human)
symbiont entry into host cell	Integrin beta-3	Homo sapiens (human)
platelet-derived growth factor receptor signaling pathway	Integrin beta-3	Homo sapiens (human)
positive regulation of fibroblast proliferation	Integrin beta-3	Homo sapiens (human)
mesodermal cell differentiation	Integrin beta-3	Homo sapiens (human)
positive regulation of smooth muscle cell proliferation	Integrin beta-3	Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylation	Integrin beta-3	Homo sapiens (human)
negative regulation of lipoprotein metabolic process	Integrin beta-3	Homo sapiens (human)
negative chemotaxis	Integrin beta-3	Homo sapiens (human)
regulation of release of sequestered calcium ion into cytosol	Integrin beta-3	Homo sapiens (human)
regulation of serotonin uptake	Integrin beta-3	Homo sapiens (human)
angiogenesis involved in wound healing	Integrin beta-3	Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascade	Integrin beta-3	Homo sapiens (human)
platelet aggregation	Integrin beta-3	Homo sapiens (human)
cellular response to mechanical stimulus	Integrin beta-3	Homo sapiens (human)
cellular response to xenobiotic stimulus	Integrin beta-3	Homo sapiens (human)
positive regulation of glomerular mesangial cell proliferation	Integrin beta-3	Homo sapiens (human)
blood coagulation, fibrin clot formation	Integrin beta-3	Homo sapiens (human)
maintenance of postsynaptic specialization structure	Integrin beta-3	Homo sapiens (human)
regulation of postsynaptic neurotransmitter receptor internalization	Integrin beta-3	Homo sapiens (human)
regulation of postsynaptic neurotransmitter receptor diffusion trapping	Integrin beta-3	Homo sapiens (human)
positive regulation of substrate adhesion-dependent cell spreading	Integrin beta-3	Homo sapiens (human)
positive regulation of adenylate cyclase-inhibiting opioid receptor signaling pathway	Integrin beta-3	Homo sapiens (human)
regulation of trophoblast cell migration	Integrin beta-3	Homo sapiens (human)
regulation of extracellular matrix organization	Integrin beta-3	Homo sapiens (human)
cellular response to insulin-like growth factor stimulus	Integrin beta-3	Homo sapiens (human)
negative regulation of endothelial cell apoptotic process	Integrin beta-3	Homo sapiens (human)
positive regulation of T cell migration	Integrin beta-3	Homo sapiens (human)
cell migration	Integrin beta-3	Homo sapiens (human)
response to singlet oxygen	Tyrosine-protein kinase Fyn	Homo sapiens (human)
neuron migration	Tyrosine-protein kinase Fyn	Homo sapiens (human)
stimulatory C-type lectin receptor signaling pathway	Tyrosine-protein kinase Fyn	Homo sapiens (human)
adaptive immune response	Tyrosine-protein kinase Fyn	Homo sapiens (human)
negative regulation of inflammatory response to antigenic stimulus	Tyrosine-protein kinase Fyn	Homo sapiens (human)
heart process	Tyrosine-protein kinase Fyn	Homo sapiens (human)
protein phosphorylation	Tyrosine-protein kinase Fyn	Homo sapiens (human)
calcium ion transport	Tyrosine-protein kinase Fyn	Homo sapiens (human)
G protein-coupled glutamate receptor signaling pathway	Tyrosine-protein kinase Fyn	Homo sapiens (human)
axon guidance	Tyrosine-protein kinase Fyn	Homo sapiens (human)
learning	Tyrosine-protein kinase Fyn	Homo sapiens (human)
feeding behavior	Tyrosine-protein kinase Fyn	Homo sapiens (human)
regulation of cell shape	Tyrosine-protein kinase Fyn	Homo sapiens (human)
gene expression	Tyrosine-protein kinase Fyn	Homo sapiens (human)
negative regulation of gene expression	Tyrosine-protein kinase Fyn	Homo sapiens (human)
negative regulation of hydrogen peroxide biosynthetic process	Tyrosine-protein kinase Fyn	Homo sapiens (human)
positive regulation of neuron projection development	Tyrosine-protein kinase Fyn	Homo sapiens (human)
protein ubiquitination	Tyrosine-protein kinase Fyn	Homo sapiens (human)
peptidyl-tyrosine phosphorylation	Tyrosine-protein kinase Fyn	Homo sapiens (human)
protein catabolic process	Tyrosine-protein kinase Fyn	Homo sapiens (human)
forebrain development	Tyrosine-protein kinase Fyn	Homo sapiens (human)
T cell costimulation	Tyrosine-protein kinase Fyn	Homo sapiens (human)
negative regulation of protein ubiquitination	Tyrosine-protein kinase Fyn	Homo sapiens (human)
intracellular signal transduction	Tyrosine-protein kinase Fyn	Homo sapiens (human)
cellular response to platelet-derived growth factor stimulus	Tyrosine-protein kinase Fyn	Homo sapiens (human)
Fc-gamma receptor signaling pathway involved in phagocytosis	Tyrosine-protein kinase Fyn	Homo sapiens (human)
negative regulation of protein catabolic process	Tyrosine-protein kinase Fyn	Homo sapiens (human)
positive regulation of tyrosine phosphorylation of STAT protein	Tyrosine-protein kinase Fyn	Homo sapiens (human)
response to ethanol	Tyrosine-protein kinase Fyn	Homo sapiens (human)
vascular endothelial growth factor receptor signaling pathway	Tyrosine-protein kinase Fyn	Homo sapiens (human)
ephrin receptor signaling pathway	Tyrosine-protein kinase Fyn	Homo sapiens (human)
dendrite morphogenesis	Tyrosine-protein kinase Fyn	Homo sapiens (human)
regulation of peptidyl-tyrosine phosphorylation	Tyrosine-protein kinase Fyn	Homo sapiens (human)
activated T cell proliferation	Tyrosine-protein kinase Fyn	Homo sapiens (human)
modulation of chemical synaptic transmission	Tyrosine-protein kinase Fyn	Homo sapiens (human)
T cell receptor signaling pathway	Tyrosine-protein kinase Fyn	Homo sapiens (human)
leukocyte migration	Tyrosine-protein kinase Fyn	Homo sapiens (human)
detection of mechanical stimulus involved in sensory perception of pain	Tyrosine-protein kinase Fyn	Homo sapiens (human)
cellular response to hydrogen peroxide	Tyrosine-protein kinase Fyn	Homo sapiens (human)
cellular response to transforming growth factor beta stimulus	Tyrosine-protein kinase Fyn	Homo sapiens (human)
positive regulation of protein targeting to membrane	Tyrosine-protein kinase Fyn	Homo sapiens (human)
dendritic spine maintenance	Tyrosine-protein kinase Fyn	Homo sapiens (human)
positive regulation of protein localization to nucleus	Tyrosine-protein kinase Fyn	Homo sapiens (human)
regulation of glutamate receptor signaling pathway	Tyrosine-protein kinase Fyn	Homo sapiens (human)
negative regulation of oxidative stress-induced intrinsic apoptotic signaling pathway	Tyrosine-protein kinase Fyn	Homo sapiens (human)
negative regulation of dendritic spine maintenance	Tyrosine-protein kinase Fyn	Homo sapiens (human)
response to amyloid-beta	Tyrosine-protein kinase Fyn	Homo sapiens (human)
cellular response to amyloid-beta	Tyrosine-protein kinase Fyn	Homo sapiens (human)
cellular response to L-glutamate	Tyrosine-protein kinase Fyn	Homo sapiens (human)
cellular response to glycine	Tyrosine-protein kinase Fyn	Homo sapiens (human)
positive regulation of protein localization to membrane	Tyrosine-protein kinase Fyn	Homo sapiens (human)
regulation of calcium ion import across plasma membrane	Tyrosine-protein kinase Fyn	Homo sapiens (human)
positive regulation of cysteine-type endopeptidase activity	Tyrosine-protein kinase Fyn	Homo sapiens (human)
innate immune response	Tyrosine-protein kinase Fyn	Homo sapiens (human)
cell differentiation	Tyrosine-protein kinase Fyn	Homo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathway	Tyrosine-protein kinase Fyn	Homo sapiens (human)
G protein-coupled receptor signaling pathway	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathway	Muscarinic acetylcholine receptor M2	Homo sapiens (human)

Process	via Protein(s)	Taxonomy
amine transmembrane transporter activity	Solute carrier family 22 member 2	Homo sapiens (human)
acetylcholine transmembrane transporter activity	Solute carrier family 22 member 2	Homo sapiens (human)
neurotransmitter transmembrane transporter activity	Solute carrier family 22 member 2	Homo sapiens (human)
monoamine transmembrane transporter activity	Solute carrier family 22 member 2	Homo sapiens (human)
organic anion transmembrane transporter activity	Solute carrier family 22 member 2	Homo sapiens (human)
organic cation transmembrane transporter activity	Solute carrier family 22 member 2	Homo sapiens (human)
prostaglandin transmembrane transporter activity	Solute carrier family 22 member 2	Homo sapiens (human)
L-amino acid transmembrane transporter activity	Solute carrier family 22 member 2	Homo sapiens (human)
pyrimidine nucleoside transmembrane transporter activity	Solute carrier family 22 member 2	Homo sapiens (human)
choline transmembrane transporter activity	Solute carrier family 22 member 2	Homo sapiens (human)
thiamine transmembrane transporter activity	Solute carrier family 22 member 2	Homo sapiens (human)
putrescine transmembrane transporter activity	Solute carrier family 22 member 2	Homo sapiens (human)
efflux transmembrane transporter activity	Solute carrier family 22 member 2	Homo sapiens (human)
spermidine transmembrane transporter activity	Solute carrier family 22 member 2	Homo sapiens (human)
quaternary ammonium group transmembrane transporter activity	Solute carrier family 22 member 2	Homo sapiens (human)
toxin transmembrane transporter activity	Solute carrier family 22 member 2	Homo sapiens (human)
xenobiotic transmembrane transporter activity	Solute carrier family 22 member 2	Homo sapiens (human)
L-arginine transmembrane transporter activity	Solute carrier family 22 member 2	Homo sapiens (human)
acetylcholine transmembrane transporter activity	Solute carrier family 22 member 1	Homo sapiens (human)
neurotransmitter transmembrane transporter activity	Solute carrier family 22 member 1	Homo sapiens (human)
dopamine:sodium symporter activity	Solute carrier family 22 member 1	Homo sapiens (human)
norepinephrine:sodium symporter activity	Solute carrier family 22 member 1	Homo sapiens (human)
protein binding	Solute carrier family 22 member 1	Homo sapiens (human)
monoamine transmembrane transporter activity	Solute carrier family 22 member 1	Homo sapiens (human)
secondary active organic cation transmembrane transporter activity	Solute carrier family 22 member 1	Homo sapiens (human)
organic anion transmembrane transporter activity	Solute carrier family 22 member 1	Homo sapiens (human)
organic cation transmembrane transporter activity	Solute carrier family 22 member 1	Homo sapiens (human)
prostaglandin transmembrane transporter activity	Solute carrier family 22 member 1	Homo sapiens (human)
pyrimidine nucleoside transmembrane transporter activity	Solute carrier family 22 member 1	Homo sapiens (human)
thiamine transmembrane transporter activity	Solute carrier family 22 member 1	Homo sapiens (human)
putrescine transmembrane transporter activity	Solute carrier family 22 member 1	Homo sapiens (human)
spermidine transmembrane transporter activity	Solute carrier family 22 member 1	Homo sapiens (human)
quaternary ammonium group transmembrane transporter activity	Solute carrier family 22 member 1	Homo sapiens (human)
toxin transmembrane transporter activity	Solute carrier family 22 member 1	Homo sapiens (human)
identical protein binding	Solute carrier family 22 member 1	Homo sapiens (human)
xenobiotic transmembrane transporter activity	Solute carrier family 22 member 1	Homo sapiens (human)
(R)-carnitine transmembrane transporter activity	Solute carrier family 22 member 1	Homo sapiens (human)
iron ion binding	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
calcium ion binding	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
protein binding	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
lipid binding	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
linoleate 13S-lipoxygenase activity	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
arachidonate 8(S)-lipoxygenase activity	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
arachidonate 15-lipoxygenase activity	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
linoleate 9S-lipoxygenase activity	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
voltage-gated calcium channel activity	Voltage-dependent L-type calcium channel subunit alpha-1F	Homo sapiens (human)
metal ion binding	Voltage-dependent L-type calcium channel subunit alpha-1F	Homo sapiens (human)
high voltage-gated calcium channel activity	Voltage-dependent L-type calcium channel subunit alpha-1F	Homo sapiens (human)
neurotransmitter transmembrane transporter activity	Solute carrier family 22 member 3	Homo sapiens (human)
protein binding	Solute carrier family 22 member 3	Homo sapiens (human)
monoamine transmembrane transporter activity	Solute carrier family 22 member 3	Homo sapiens (human)
organic anion transmembrane transporter activity	Solute carrier family 22 member 3	Homo sapiens (human)
organic cation transmembrane transporter activity	Solute carrier family 22 member 3	Homo sapiens (human)
spermidine transmembrane transporter activity	Solute carrier family 22 member 3	Homo sapiens (human)
quaternary ammonium group transmembrane transporter activity	Solute carrier family 22 member 3	Homo sapiens (human)
toxin transmembrane transporter activity	Solute carrier family 22 member 3	Homo sapiens (human)
epidermal growth factor receptor activity	Epidermal growth factor receptor	Homo sapiens (human)
virus receptor activity	Epidermal growth factor receptor	Homo sapiens (human)
chromatin binding	Epidermal growth factor receptor	Homo sapiens (human)
double-stranded DNA binding	Epidermal growth factor receptor	Homo sapiens (human)
MAP kinase kinase kinase activity	Epidermal growth factor receptor	Homo sapiens (human)
protein tyrosine kinase activity	Epidermal growth factor receptor	Homo sapiens (human)
transmembrane receptor protein tyrosine kinase activity	Epidermal growth factor receptor	Homo sapiens (human)
transmembrane signaling receptor activity	Epidermal growth factor receptor	Homo sapiens (human)
epidermal growth factor receptor activity	Epidermal growth factor receptor	Homo sapiens (human)
integrin binding	Epidermal growth factor receptor	Homo sapiens (human)
protein binding	Epidermal growth factor receptor	Homo sapiens (human)
calmodulin binding	Epidermal growth factor receptor	Homo sapiens (human)
ATP binding	Epidermal growth factor receptor	Homo sapiens (human)
enzyme binding	Epidermal growth factor receptor	Homo sapiens (human)
kinase binding	Epidermal growth factor receptor	Homo sapiens (human)
protein kinase binding	Epidermal growth factor receptor	Homo sapiens (human)
protein phosphatase binding	Epidermal growth factor receptor	Homo sapiens (human)
protein tyrosine kinase activator activity	Epidermal growth factor receptor	Homo sapiens (human)
transmembrane receptor protein tyrosine kinase activator activity	Epidermal growth factor receptor	Homo sapiens (human)
ubiquitin protein ligase binding	Epidermal growth factor receptor	Homo sapiens (human)
identical protein binding	Epidermal growth factor receptor	Homo sapiens (human)
cadherin binding	Epidermal growth factor receptor	Homo sapiens (human)
actin filament binding	Epidermal growth factor receptor	Homo sapiens (human)
ATPase binding	Epidermal growth factor receptor	Homo sapiens (human)
epidermal growth factor binding	Epidermal growth factor receptor	Homo sapiens (human)
hormone activity	Glycoprotein hormones alpha chain	Homo sapiens (human)
protein binding	Glycoprotein hormones alpha chain	Homo sapiens (human)
follicle-stimulating hormone activity	Glycoprotein hormones alpha chain	Homo sapiens (human)
cytokine activity	Interferon beta	Homo sapiens (human)
cytokine receptor binding	Interferon beta	Homo sapiens (human)
type I interferon receptor binding	Interferon beta	Homo sapiens (human)
protein binding	Interferon beta	Homo sapiens (human)
chloramphenicol O-acetyltransferase activity	Interferon beta	Homo sapiens (human)
growth factor binding	Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)
RNA polymerase I core binding	Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)
protein tyrosine kinase activity	Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)
transmembrane receptor protein tyrosine kinase activity	Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)
transmembrane signaling receptor activity	Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)
signaling receptor binding	Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)
protein binding	Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)
ATP binding	Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)
coreceptor activity	Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)
receptor tyrosine kinase binding	Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)
identical protein binding	Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)
ErbB-3 class receptor binding	Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)
protein heterodimerization activity	Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA binding	Amyloid-beta precursor protein	Homo sapiens (human)
DNA binding	Amyloid-beta precursor protein	Homo sapiens (human)
serine-type endopeptidase inhibitor activity	Amyloid-beta precursor protein	Homo sapiens (human)
signaling receptor binding	Amyloid-beta precursor protein	Homo sapiens (human)
protein binding	Amyloid-beta precursor protein	Homo sapiens (human)
heparin binding	Amyloid-beta precursor protein	Homo sapiens (human)
enzyme binding	Amyloid-beta precursor protein	Homo sapiens (human)
identical protein binding	Amyloid-beta precursor protein	Homo sapiens (human)
transition metal ion binding	Amyloid-beta precursor protein	Homo sapiens (human)
receptor ligand activity	Amyloid-beta precursor protein	Homo sapiens (human)
PTB domain binding	Amyloid-beta precursor protein	Homo sapiens (human)
protein serine/threonine kinase binding	Amyloid-beta precursor protein	Homo sapiens (human)
signaling receptor activator activity	Amyloid-beta precursor protein	Homo sapiens (human)
fibroblast growth factor binding	Integrin beta-3	Homo sapiens (human)
C-X3-C chemokine binding	Integrin beta-3	Homo sapiens (human)
insulin-like growth factor I binding	Integrin beta-3	Homo sapiens (human)
neuregulin binding	Integrin beta-3	Homo sapiens (human)
virus receptor activity	Integrin beta-3	Homo sapiens (human)
fibronectin binding	Integrin beta-3	Homo sapiens (human)
protease binding	Integrin beta-3	Homo sapiens (human)
protein disulfide isomerase activity	Integrin beta-3	Homo sapiens (human)
protein kinase C binding	Integrin beta-3	Homo sapiens (human)
platelet-derived growth factor receptor binding	Integrin beta-3	Homo sapiens (human)
integrin binding	Integrin beta-3	Homo sapiens (human)
protein binding	Integrin beta-3	Homo sapiens (human)
coreceptor activity	Integrin beta-3	Homo sapiens (human)
enzyme binding	Integrin beta-3	Homo sapiens (human)
identical protein binding	Integrin beta-3	Homo sapiens (human)
vascular endothelial growth factor receptor 2 binding	Integrin beta-3	Homo sapiens (human)
metal ion binding	Integrin beta-3	Homo sapiens (human)
cell adhesion molecule binding	Integrin beta-3	Homo sapiens (human)
extracellular matrix binding	Integrin beta-3	Homo sapiens (human)
fibrinogen binding	Integrin beta-3	Homo sapiens (human)
protein tyrosine kinase activity	Tyrosine-protein kinase Fyn	Homo sapiens (human)
non-membrane spanning protein tyrosine kinase activity	Tyrosine-protein kinase Fyn	Homo sapiens (human)
protein binding	Tyrosine-protein kinase Fyn	Homo sapiens (human)
ATP binding	Tyrosine-protein kinase Fyn	Homo sapiens (human)
phospholipase activator activity	Tyrosine-protein kinase Fyn	Homo sapiens (human)
enzyme binding	Tyrosine-protein kinase Fyn	Homo sapiens (human)
type 5 metabotropic glutamate receptor binding	Tyrosine-protein kinase Fyn	Homo sapiens (human)
identical protein binding	Tyrosine-protein kinase Fyn	Homo sapiens (human)
alpha-tubulin binding	Tyrosine-protein kinase Fyn	Homo sapiens (human)
phospholipase binding	Tyrosine-protein kinase Fyn	Homo sapiens (human)
transmembrane transporter binding	Tyrosine-protein kinase Fyn	Homo sapiens (human)
metal ion binding	Tyrosine-protein kinase Fyn	Homo sapiens (human)
ephrin receptor binding	Tyrosine-protein kinase Fyn	Homo sapiens (human)
tau protein binding	Tyrosine-protein kinase Fyn	Homo sapiens (human)
tau-protein kinase activity	Tyrosine-protein kinase Fyn	Homo sapiens (human)
growth factor receptor binding	Tyrosine-protein kinase Fyn	Homo sapiens (human)
scaffold protein binding	Tyrosine-protein kinase Fyn	Homo sapiens (human)
disordered domain specific binding	Tyrosine-protein kinase Fyn	Homo sapiens (human)
signaling receptor binding	Tyrosine-protein kinase Fyn	Homo sapiens (human)
G protein-coupled acetylcholine receptor activity	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
arrestin family protein binding	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
G protein-coupled serotonin receptor activity	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
G protein-coupled serotonin receptor activity	Muscarinic acetylcholine receptor M4	Homo sapiens (human)
G protein-coupled acetylcholine receptor activity	Muscarinic acetylcholine receptor M4	Homo sapiens (human)
protein binding	ATP-dependent translocase ABCB1	Homo sapiens (human)
ATP binding	ATP-dependent translocase ABCB1	Homo sapiens (human)
ABC-type xenobiotic transporter activity	ATP-dependent translocase ABCB1	Homo sapiens (human)
efflux transmembrane transporter activity	ATP-dependent translocase ABCB1	Homo sapiens (human)
ATP hydrolysis activity	ATP-dependent translocase ABCB1	Homo sapiens (human)
transmembrane transporter activity	ATP-dependent translocase ABCB1	Homo sapiens (human)
ubiquitin protein ligase binding	ATP-dependent translocase ABCB1	Homo sapiens (human)
ATPase-coupled transmembrane transporter activity	ATP-dependent translocase ABCB1	Homo sapiens (human)
xenobiotic transmembrane transporter activity	ATP-dependent translocase ABCB1	Homo sapiens (human)
carboxylic acid transmembrane transporter activity	ATP-dependent translocase ABCB1	Homo sapiens (human)
phosphatidylcholine floppase activity	ATP-dependent translocase ABCB1	Homo sapiens (human)
phosphatidylethanolamine flippase activity	ATP-dependent translocase ABCB1	Homo sapiens (human)
ceramide floppase activity	ATP-dependent translocase ABCB1	Homo sapiens (human)
floppase activity	ATP-dependent translocase ABCB1	Homo sapiens (human)
protein binding	Integrin alpha-IIb	Homo sapiens (human)
identical protein binding	Integrin alpha-IIb	Homo sapiens (human)
metal ion binding	Integrin alpha-IIb	Homo sapiens (human)
extracellular matrix binding	Integrin alpha-IIb	Homo sapiens (human)
molecular adaptor activity	Integrin alpha-IIb	Homo sapiens (human)
fibrinogen binding	Integrin alpha-IIb	Homo sapiens (human)
integrin binding	Integrin alpha-IIb	Homo sapiens (human)
protein tyrosine kinase activity	Proto-oncogene tyrosine-protein kinase ROS	Homo sapiens (human)
protein binding	Proto-oncogene tyrosine-protein kinase ROS	Homo sapiens (human)
ATP binding	Proto-oncogene tyrosine-protein kinase ROS	Homo sapiens (human)
protein phosphatase binding	Proto-oncogene tyrosine-protein kinase ROS	Homo sapiens (human)
transmembrane receptor protein tyrosine kinase activity	Proto-oncogene tyrosine-protein kinase ROS	Homo sapiens (human)
monooxygenase activity	Cytochrome P450 2D6	Homo sapiens (human)
iron ion binding	Cytochrome P450 2D6	Homo sapiens (human)
oxidoreductase activity	Cytochrome P450 2D6	Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen	Cytochrome P450 2D6	Homo sapiens (human)
heme binding	Cytochrome P450 2D6	Homo sapiens (human)
anandamide 8,9 epoxidase activity	Cytochrome P450 2D6	Homo sapiens (human)
anandamide 11,12 epoxidase activity	Cytochrome P450 2D6	Homo sapiens (human)
anandamide 14,15 epoxidase activity	Cytochrome P450 2D6	Homo sapiens (human)
phosphatidylinositol phospholipase C activity	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
protein binding	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
G protein-coupled acetylcholine receptor activity	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
G protein-coupled serotonin receptor activity	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
magnesium ion binding	DNA topoisomerase 2-alpha	Homo sapiens (human)
DNA binding	DNA topoisomerase 2-alpha	Homo sapiens (human)
chromatin binding	DNA topoisomerase 2-alpha	Homo sapiens (human)
RNA binding	DNA topoisomerase 2-alpha	Homo sapiens (human)
DNA topoisomerase type II (double strand cut, ATP-hydrolyzing) activity	DNA topoisomerase 2-alpha	Homo sapiens (human)
protein kinase C binding	DNA topoisomerase 2-alpha	Homo sapiens (human)
protein binding	DNA topoisomerase 2-alpha	Homo sapiens (human)
ATP binding	DNA topoisomerase 2-alpha	Homo sapiens (human)
ATP-dependent activity, acting on DNA	DNA topoisomerase 2-alpha	Homo sapiens (human)
DNA binding, bending	DNA topoisomerase 2-alpha	Homo sapiens (human)
protein homodimerization activity	DNA topoisomerase 2-alpha	Homo sapiens (human)
ubiquitin binding	DNA topoisomerase 2-alpha	Homo sapiens (human)
protein heterodimerization activity	DNA topoisomerase 2-alpha	Homo sapiens (human)
protein serine/threonine kinase activity	Casein kinase II subunit alpha'	Homo sapiens (human)
protein binding	Casein kinase II subunit alpha'	Homo sapiens (human)
ATP binding	Casein kinase II subunit alpha'	Homo sapiens (human)
protein serine kinase activity	Casein kinase II subunit alpha'	Homo sapiens (human)
actin binding	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
neurotransmitter transmembrane transporter activity	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
neurotransmitter:sodium symporter activity	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
dopamine:sodium symporter activity	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
norepinephrine:sodium symporter activity	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
protein binding	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
monoamine transmembrane transporter activity	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
alpha-tubulin binding	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
metal ion binding	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
beta-tubulin binding	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
Gq/11-coupled serotonin receptor activity	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
G protein-coupled serotonin receptor activity	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
protein binding	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
identical protein binding	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
serotonin binding	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine binding	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
neurotransmitter receptor activity	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
ATP binding	Multidrug resistance-associated protein 1	Homo sapiens (human)
ABC-type vitamin B12 transporter activity	Multidrug resistance-associated protein 1	Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activity	Multidrug resistance-associated protein 1	Homo sapiens (human)
efflux transmembrane transporter activity	Multidrug resistance-associated protein 1	Homo sapiens (human)
ATP hydrolysis activity	Multidrug resistance-associated protein 1	Homo sapiens (human)
ATPase-coupled lipid transmembrane transporter activity	Multidrug resistance-associated protein 1	Homo sapiens (human)
glutathione transmembrane transporter activity	Multidrug resistance-associated protein 1	Homo sapiens (human)
ATPase-coupled transmembrane transporter activity	Multidrug resistance-associated protein 1	Homo sapiens (human)
xenobiotic transmembrane transporter activity	Multidrug resistance-associated protein 1	Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activity	Multidrug resistance-associated protein 1	Homo sapiens (human)
sphingolipid transporter activity	Multidrug resistance-associated protein 1	Homo sapiens (human)
carboxylic acid transmembrane transporter activity	Multidrug resistance-associated protein 1	Homo sapiens (human)
ABC-type transporter activity	Multidrug resistance-associated protein 1	Homo sapiens (human)
ABC-type xenobiotic transporter activity	Multidrug resistance-associated protein 1	Homo sapiens (human)
G protein activity	Guanine nucleotide-binding protein G	Homo sapiens (human)
adenylate cyclase activator activity	Guanine nucleotide-binding protein G	Homo sapiens (human)
protein serine/threonine kinase activity	Casein kinase II subunit beta	Homo sapiens (human)
chromatin binding	Casein kinase II subunit beta	Homo sapiens (human)
protein serine/threonine kinase activity	Casein kinase II subunit beta	Homo sapiens (human)
signaling receptor binding	Casein kinase II subunit beta	Homo sapiens (human)
protein binding	Casein kinase II subunit beta	Homo sapiens (human)
protein kinase regulator activity	Casein kinase II subunit beta	Homo sapiens (human)
protein domain specific binding	Casein kinase II subunit beta	Homo sapiens (human)
protein-macromolecule adaptor activity	Casein kinase II subunit beta	Homo sapiens (human)
identical protein binding	Casein kinase II subunit beta	Homo sapiens (human)
metal ion binding	Casein kinase II subunit beta	Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor binding	Casein kinase II subunit beta	Homo sapiens (human)
protein serine/threonine kinase activity	Casein kinase II subunit alpha	Homo sapiens (human)
protein binding	Casein kinase II subunit alpha	Homo sapiens (human)
ATP binding	Casein kinase II subunit alpha	Homo sapiens (human)
kinase activity	Casein kinase II subunit alpha	Homo sapiens (human)
identical protein binding	Casein kinase II subunit alpha	Homo sapiens (human)
Hsp90 protein binding	Casein kinase II subunit alpha	Homo sapiens (human)
protein serine kinase activity	Casein kinase II subunit alpha	Homo sapiens (human)
high voltage-gated calcium channel activity	Voltage-dependent L-type calcium channel subunit alpha-1D	Homo sapiens (human)
voltage-gated calcium channel activity	Voltage-dependent L-type calcium channel subunit alpha-1D	Homo sapiens (human)
calcium channel activity	Voltage-dependent L-type calcium channel subunit alpha-1D	Homo sapiens (human)
protein binding	Voltage-dependent L-type calcium channel subunit alpha-1D	Homo sapiens (human)
ankyrin binding	Voltage-dependent L-type calcium channel subunit alpha-1D	Homo sapiens (human)
metal ion binding	Voltage-dependent L-type calcium channel subunit alpha-1D	Homo sapiens (human)
alpha-actinin binding	Voltage-dependent L-type calcium channel subunit alpha-1D	Homo sapiens (human)
voltage-gated calcium channel activity involved in cardiac muscle cell action potential	Voltage-dependent L-type calcium channel subunit alpha-1D	Homo sapiens (human)
voltage-gated calcium channel activity involved SA node cell action potential	Voltage-dependent L-type calcium channel subunit alpha-1D	Homo sapiens (human)
DNA binding	DNA topoisomerase 2-beta	Homo sapiens (human)
chromatin binding	DNA topoisomerase 2-beta	Homo sapiens (human)
DNA topoisomerase type II (double strand cut, ATP-hydrolyzing) activity	DNA topoisomerase 2-beta	Homo sapiens (human)
protein binding	DNA topoisomerase 2-beta	Homo sapiens (human)
ATP binding	DNA topoisomerase 2-beta	Homo sapiens (human)
ribonucleoprotein complex binding	DNA topoisomerase 2-beta	Homo sapiens (human)
metal ion binding	DNA topoisomerase 2-beta	Homo sapiens (human)
protein tyrosine kinase activity	Tyrosine-protein kinase BTK	Homo sapiens (human)
non-membrane spanning protein tyrosine kinase activity	Tyrosine-protein kinase BTK	Homo sapiens (human)
protein binding	Tyrosine-protein kinase BTK	Homo sapiens (human)
ATP binding	Tyrosine-protein kinase BTK	Homo sapiens (human)
phosphatidylinositol-3,4,5-trisphosphate binding	Tyrosine-protein kinase BTK	Homo sapiens (human)
phospholipase activator activity	Tyrosine-protein kinase BTK	Homo sapiens (human)
identical protein binding	Tyrosine-protein kinase BTK	Homo sapiens (human)
phospholipase binding	Tyrosine-protein kinase BTK	Homo sapiens (human)
metal ion binding	Tyrosine-protein kinase BTK	Homo sapiens (human)
transcription cis-regulatory region binding	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
inward rectifier potassium channel activity	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
voltage-gated potassium channel activity	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
delayed rectifier potassium channel activity	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
protein binding	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
ubiquitin protein ligase binding	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
identical protein binding	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
protein homodimerization activity	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
C3HC4-type RING finger domain binding	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
voltage-gated potassium channel activity involved in cardiac muscle cell action potential repolarization	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
scaffold protein binding	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarization	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA binding	TAR DNA-binding protein 43	Homo sapiens (human)
DNA binding	TAR DNA-binding protein 43	Homo sapiens (human)
double-stranded DNA binding	TAR DNA-binding protein 43	Homo sapiens (human)
RNA binding	TAR DNA-binding protein 43	Homo sapiens (human)
mRNA 3'-UTR binding	TAR DNA-binding protein 43	Homo sapiens (human)
protein binding	TAR DNA-binding protein 43	Homo sapiens (human)
lipid binding	TAR DNA-binding protein 43	Homo sapiens (human)
identical protein binding	TAR DNA-binding protein 43	Homo sapiens (human)
pre-mRNA intronic binding	TAR DNA-binding protein 43	Homo sapiens (human)
molecular condensate scaffold activity	TAR DNA-binding protein 43	Homo sapiens (human)
NEDD8 activating enzyme activity	NEDD8-activating enzyme E1 regulatory subunit	Homo sapiens (human)
protein binding	NEDD8-activating enzyme E1 regulatory subunit	Homo sapiens (human)
ubiquitin protein ligase binding	NEDD8-activating enzyme E1 regulatory subunit	Homo sapiens (human)
protein heterodimerization activity	NEDD8-activating enzyme E1 regulatory subunit	Homo sapiens (human)
ubiquitin activating enzyme activity	NEDD8-activating enzyme E1 regulatory subunit	Homo sapiens (human)
voltage-gated calcium channel activity	Voltage-dependent L-type calcium channel subunit alpha-1S	Homo sapiens (human)
protein binding	Voltage-dependent L-type calcium channel subunit alpha-1S	Homo sapiens (human)
calmodulin binding	Voltage-dependent L-type calcium channel subunit alpha-1S	Homo sapiens (human)
high voltage-gated calcium channel activity	Voltage-dependent L-type calcium channel subunit alpha-1S	Homo sapiens (human)
small molecule binding	Voltage-dependent L-type calcium channel subunit alpha-1S	Homo sapiens (human)
metal ion binding	Voltage-dependent L-type calcium channel subunit alpha-1S	Homo sapiens (human)
molecular function activator activity	Voltage-dependent L-type calcium channel subunit alpha-1S	Homo sapiens (human)
high voltage-gated calcium channel activity	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
voltage-gated calcium channel activity involved in cardiac muscle cell action potential	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
voltage-gated calcium channel activity	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
protein binding	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
calmodulin binding	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
high voltage-gated calcium channel activity	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
metal ion binding	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
alpha-actinin binding	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
voltage-gated calcium channel activity involved in cardiac muscle cell action potential	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
voltage-gated calcium channel activity involved in AV node cell action potential	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
organic cation transmembrane transporter activity	Multidrug and toxin extrusion protein 2	Homo sapiens (human)
antiporter activity	Multidrug and toxin extrusion protein 2	Homo sapiens (human)
transmembrane transporter activity	Multidrug and toxin extrusion protein 2	Homo sapiens (human)
xenobiotic transmembrane transporter activity	Multidrug and toxin extrusion protein 2	Homo sapiens (human)
polyspecific organic cation:proton antiporter activity	Multidrug and toxin extrusion protein 2	Homo sapiens (human)
protein serine/threonine kinase activity	Casein kinase II subunit alpha 3	Homo sapiens (human)
protein binding	Casein kinase II subunit alpha 3	Homo sapiens (human)
ATP binding	Casein kinase II subunit alpha 3	Homo sapiens (human)
protein serine kinase activity	Casein kinase II subunit alpha 3	Homo sapiens (human)
NEDD8 activating enzyme activity	NEDD8-activating enzyme E1 catalytic subunit	Homo sapiens (human)
protein binding	NEDD8-activating enzyme E1 catalytic subunit	Homo sapiens (human)
ATP binding	NEDD8-activating enzyme E1 catalytic subunit	Homo sapiens (human)
NEDD8 activating enzyme activity	NEDD8-activating enzyme E1 catalytic subunit	Homo sapiens (human)
NEDD8 transferase activity	NEDD8-activating enzyme E1 catalytic subunit	Homo sapiens (human)
identical protein binding	NEDD8-activating enzyme E1 catalytic subunit	Homo sapiens (human)
protein heterodimerization activity	NEDD8-activating enzyme E1 catalytic subunit	Homo sapiens (human)
protein binding	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
organic cation transmembrane transporter activity	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
L-amino acid transmembrane transporter activity	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
thiamine transmembrane transporter activity	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
antiporter activity	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
putrescine transmembrane transporter activity	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
transmembrane transporter activity	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
xenobiotic transmembrane transporter activity	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
L-arginine transmembrane transporter activity	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
polyspecific organic cation:proton antiporter activity	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
RNA binding	Ataxin-2	Homo sapiens (human)
epidermal growth factor receptor binding	Ataxin-2	Homo sapiens (human)
protein binding	Ataxin-2	Homo sapiens (human)
mRNA binding	Ataxin-2	Homo sapiens (human)
cytidine deaminase activity	Single-stranded DNA cytosine deaminase	Homo sapiens (human)
protein binding	Single-stranded DNA cytosine deaminase	Homo sapiens (human)
zinc ion binding	Single-stranded DNA cytosine deaminase	Homo sapiens (human)
ubiquitin protein ligase binding	Single-stranded DNA cytosine deaminase	Homo sapiens (human)
identical protein binding	Single-stranded DNA cytosine deaminase	Homo sapiens (human)
RNA binding	Single-stranded DNA cytosine deaminase	Homo sapiens (human)
G protein-coupled adenosine receptor activity	P2Y purinoceptor 12	Homo sapiens (human)
G protein-coupled ADP receptor activity	P2Y purinoceptor 12	Homo sapiens (human)
guanyl-nucleotide exchange factor activity	P2Y purinoceptor 12	Homo sapiens (human)
G protein-coupled purinergic nucleotide receptor activity	P2Y purinoceptor 12	Homo sapiens (human)
serine-type endopeptidase inhibitor activity	Solute carrier organic anion transporter family member 1B3	Homo sapiens (human)
organic anion transmembrane transporter activity	Solute carrier organic anion transporter family member 1B3	Homo sapiens (human)
bile acid transmembrane transporter activity	Solute carrier organic anion transporter family member 1B3	Homo sapiens (human)
sodium-independent organic anion transmembrane transporter activity	Solute carrier organic anion transporter family member 1B3	Homo sapiens (human)
protein binding	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
ATP binding	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
organic anion transmembrane transporter activity	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
ABC-type xenobiotic transporter activity	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
urate transmembrane transporter activity	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
biotin transmembrane transporter activity	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
efflux transmembrane transporter activity	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
ATP hydrolysis activity	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
riboflavin transmembrane transporter activity	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
ATPase-coupled transmembrane transporter activity	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
identical protein binding	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
protein homodimerization activity	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
xenobiotic transmembrane transporter activity	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
sphingolipid transporter activity	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
plasma membrane	Solute carrier family 22 member 2	Homo sapiens (human)
basal plasma membrane	Solute carrier family 22 member 2	Homo sapiens (human)
membrane	Solute carrier family 22 member 2	Homo sapiens (human)
basolateral plasma membrane	Solute carrier family 22 member 2	Homo sapiens (human)
apical plasma membrane	Solute carrier family 22 member 2	Homo sapiens (human)
extracellular exosome	Solute carrier family 22 member 2	Homo sapiens (human)
presynapse	Solute carrier family 22 member 2	Homo sapiens (human)
plasma membrane	Solute carrier family 22 member 1	Homo sapiens (human)
basal plasma membrane	Solute carrier family 22 member 1	Homo sapiens (human)
membrane	Solute carrier family 22 member 1	Homo sapiens (human)
basolateral plasma membrane	Solute carrier family 22 member 1	Homo sapiens (human)
apical plasma membrane	Solute carrier family 22 member 1	Homo sapiens (human)
lateral plasma membrane	Solute carrier family 22 member 1	Homo sapiens (human)
presynapse	Solute carrier family 22 member 1	Homo sapiens (human)
nucleus	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
cytosol	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
cytoskeleton	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
plasma membrane	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
adherens junction	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
focal adhesion	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
membrane	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
extracellular exosome	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
photoreceptor outer segment	Voltage-dependent L-type calcium channel subunit alpha-1F	Homo sapiens (human)
membrane	Voltage-dependent L-type calcium channel subunit alpha-1F	Homo sapiens (human)
perikaryon	Voltage-dependent L-type calcium channel subunit alpha-1F	Homo sapiens (human)
voltage-gated calcium channel complex	Voltage-dependent L-type calcium channel subunit alpha-1F	Homo sapiens (human)
nuclear outer membrane	Solute carrier family 22 member 3	Homo sapiens (human)
plasma membrane	Solute carrier family 22 member 3	Homo sapiens (human)
endomembrane system	Solute carrier family 22 member 3	Homo sapiens (human)
membrane	Solute carrier family 22 member 3	Homo sapiens (human)
basolateral plasma membrane	Solute carrier family 22 member 3	Homo sapiens (human)
apical plasma membrane	Solute carrier family 22 member 3	Homo sapiens (human)
mitochondrial membrane	Solute carrier family 22 member 3	Homo sapiens (human)
neuronal cell body	Solute carrier family 22 member 3	Homo sapiens (human)
presynapse	Solute carrier family 22 member 3	Homo sapiens (human)
endosome	Epidermal growth factor receptor	Homo sapiens (human)
plasma membrane	Epidermal growth factor receptor	Homo sapiens (human)
ruffle membrane	Epidermal growth factor receptor	Homo sapiens (human)
Golgi membrane	Epidermal growth factor receptor	Homo sapiens (human)
extracellular space	Epidermal growth factor receptor	Homo sapiens (human)
nucleus	Epidermal growth factor receptor	Homo sapiens (human)
cytoplasm	Epidermal growth factor receptor	Homo sapiens (human)
endosome	Epidermal growth factor receptor	Homo sapiens (human)
endoplasmic reticulum membrane	Epidermal growth factor receptor	Homo sapiens (human)
plasma membrane	Epidermal growth factor receptor	Homo sapiens (human)
focal adhesion	Epidermal growth factor receptor	Homo sapiens (human)
cell surface	Epidermal growth factor receptor	Homo sapiens (human)
endosome membrane	Epidermal growth factor receptor	Homo sapiens (human)
membrane	Epidermal growth factor receptor	Homo sapiens (human)
basolateral plasma membrane	Epidermal growth factor receptor	Homo sapiens (human)
apical plasma membrane	Epidermal growth factor receptor	Homo sapiens (human)
cell junction	Epidermal growth factor receptor	Homo sapiens (human)
clathrin-coated endocytic vesicle membrane	Epidermal growth factor receptor	Homo sapiens (human)
early endosome membrane	Epidermal growth factor receptor	Homo sapiens (human)
nuclear membrane	Epidermal growth factor receptor	Homo sapiens (human)
membrane raft	Epidermal growth factor receptor	Homo sapiens (human)
perinuclear region of cytoplasm	Epidermal growth factor receptor	Homo sapiens (human)
multivesicular body, internal vesicle lumen	Epidermal growth factor receptor	Homo sapiens (human)
intracellular vesicle	Epidermal growth factor receptor	Homo sapiens (human)
protein-containing complex	Epidermal growth factor receptor	Homo sapiens (human)
receptor complex	Epidermal growth factor receptor	Homo sapiens (human)
Shc-EGFR complex	Epidermal growth factor receptor	Homo sapiens (human)
basal plasma membrane	Epidermal growth factor receptor	Homo sapiens (human)
extracellular region	Glycoprotein hormones alpha chain	Homo sapiens (human)
extracellular space	Glycoprotein hormones alpha chain	Homo sapiens (human)
Golgi lumen	Glycoprotein hormones alpha chain	Homo sapiens (human)
follicle-stimulating hormone complex	Glycoprotein hormones alpha chain	Homo sapiens (human)
pituitary gonadotropin complex	Glycoprotein hormones alpha chain	Homo sapiens (human)
extracellular space	Glycoprotein hormones alpha chain	Homo sapiens (human)
extracellular space	Interferon beta	Homo sapiens (human)
extracellular region	Interferon beta	Homo sapiens (human)
semaphorin receptor complex	Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)
nucleus	Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)
nucleoplasm	Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)
early endosome	Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)
cytosol	Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)
plasma membrane	Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)
endosome membrane	Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)
membrane	Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)
basolateral plasma membrane	Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)
apical plasma membrane	Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)
neuromuscular junction	Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)
ruffle membrane	Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)
presynaptic membrane	Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)
myelin sheath	Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)
perinuclear region of cytoplasm	Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)
ERBB3:ERBB2 complex	Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)
receptor complex	Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)
plasma membrane	Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)
basal plasma membrane	Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)
extracellular space	Amyloid-beta precursor protein	Homo sapiens (human)
dendrite	Amyloid-beta precursor protein	Homo sapiens (human)
extracellular region	Amyloid-beta precursor protein	Homo sapiens (human)
extracellular space	Amyloid-beta precursor protein	Homo sapiens (human)
nuclear envelope lumen	Amyloid-beta precursor protein	Homo sapiens (human)
cytoplasm	Amyloid-beta precursor protein	Homo sapiens (human)
mitochondrial inner membrane	Amyloid-beta precursor protein	Homo sapiens (human)
endosome	Amyloid-beta precursor protein	Homo sapiens (human)
early endosome	Amyloid-beta precursor protein	Homo sapiens (human)
endoplasmic reticulum	Amyloid-beta precursor protein	Homo sapiens (human)
endoplasmic reticulum lumen	Amyloid-beta precursor protein	Homo sapiens (human)
smooth endoplasmic reticulum	Amyloid-beta precursor protein	Homo sapiens (human)
Golgi apparatus	Amyloid-beta precursor protein	Homo sapiens (human)
Golgi lumen	Amyloid-beta precursor protein	Homo sapiens (human)
Golgi-associated vesicle	Amyloid-beta precursor protein	Homo sapiens (human)
cytosol	Amyloid-beta precursor protein	Homo sapiens (human)
plasma membrane	Amyloid-beta precursor protein	Homo sapiens (human)
clathrin-coated pit	Amyloid-beta precursor protein	Homo sapiens (human)
cell-cell junction	Amyloid-beta precursor protein	Homo sapiens (human)
synaptic vesicle	Amyloid-beta precursor protein	Homo sapiens (human)
cell surface	Amyloid-beta precursor protein	Homo sapiens (human)
membrane	Amyloid-beta precursor protein	Homo sapiens (human)
COPII-coated ER to Golgi transport vesicle	Amyloid-beta precursor protein	Homo sapiens (human)
axon	Amyloid-beta precursor protein	Homo sapiens (human)
growth cone	Amyloid-beta precursor protein	Homo sapiens (human)
platelet alpha granule lumen	Amyloid-beta precursor protein	Homo sapiens (human)
neuromuscular junction	Amyloid-beta precursor protein	Homo sapiens (human)
endosome lumen	Amyloid-beta precursor protein	Homo sapiens (human)
trans-Golgi network membrane	Amyloid-beta precursor protein	Homo sapiens (human)
ciliary rootlet	Amyloid-beta precursor protein	Homo sapiens (human)
dendritic spine	Amyloid-beta precursor protein	Homo sapiens (human)
dendritic shaft	Amyloid-beta precursor protein	Homo sapiens (human)
perikaryon	Amyloid-beta precursor protein	Homo sapiens (human)
membrane raft	Amyloid-beta precursor protein	Homo sapiens (human)
apical part of cell	Amyloid-beta precursor protein	Homo sapiens (human)
synapse	Amyloid-beta precursor protein	Homo sapiens (human)
perinuclear region of cytoplasm	Amyloid-beta precursor protein	Homo sapiens (human)
presynaptic active zone	Amyloid-beta precursor protein	Homo sapiens (human)
spindle midzone	Amyloid-beta precursor protein	Homo sapiens (human)
recycling endosome	Amyloid-beta precursor protein	Homo sapiens (human)
extracellular exosome	Amyloid-beta precursor protein	Homo sapiens (human)
receptor complex	Amyloid-beta precursor protein	Homo sapiens (human)
early endosome	Amyloid-beta precursor protein	Homo sapiens (human)
membrane raft	Amyloid-beta precursor protein	Homo sapiens (human)
cell surface	Amyloid-beta precursor protein	Homo sapiens (human)
Golgi apparatus	Amyloid-beta precursor protein	Homo sapiens (human)
plasma membrane	Amyloid-beta precursor protein	Homo sapiens (human)
glutamatergic synapse	Integrin beta-3	Homo sapiens (human)
nucleus	Integrin beta-3	Homo sapiens (human)
nucleoplasm	Integrin beta-3	Homo sapiens (human)
plasma membrane	Integrin beta-3	Homo sapiens (human)
cell-cell junction	Integrin beta-3	Homo sapiens (human)
focal adhesion	Integrin beta-3	Homo sapiens (human)
external side of plasma membrane	Integrin beta-3	Homo sapiens (human)
cell surface	Integrin beta-3	Homo sapiens (human)
apical plasma membrane	Integrin beta-3	Homo sapiens (human)
platelet alpha granule membrane	Integrin beta-3	Homo sapiens (human)
lamellipodium membrane	Integrin beta-3	Homo sapiens (human)
filopodium membrane	Integrin beta-3	Homo sapiens (human)
microvillus membrane	Integrin beta-3	Homo sapiens (human)
ruffle membrane	Integrin beta-3	Homo sapiens (human)
integrin alphav-beta3 complex	Integrin beta-3	Homo sapiens (human)
melanosome	Integrin beta-3	Homo sapiens (human)
synapse	Integrin beta-3	Homo sapiens (human)
postsynaptic membrane	Integrin beta-3	Homo sapiens (human)
extracellular exosome	Integrin beta-3	Homo sapiens (human)
integrin alphaIIb-beta3 complex	Integrin beta-3	Homo sapiens (human)
glycinergic synapse	Integrin beta-3	Homo sapiens (human)
integrin complex	Integrin beta-3	Homo sapiens (human)
protein-containing complex	Integrin beta-3	Homo sapiens (human)
alphav-beta3 integrin-PKCalpha complex	Integrin beta-3	Homo sapiens (human)
alphav-beta3 integrin-IGF-1-IGF1R complex	Integrin beta-3	Homo sapiens (human)
alphav-beta3 integrin-HMGB1 complex	Integrin beta-3	Homo sapiens (human)
receptor complex	Integrin beta-3	Homo sapiens (human)
alphav-beta3 integrin-vitronectin complex	Integrin beta-3	Homo sapiens (human)
alpha9-beta1 integrin-ADAM8 complex	Integrin beta-3	Homo sapiens (human)
focal adhesion	Integrin beta-3	Homo sapiens (human)
cell surface	Integrin beta-3	Homo sapiens (human)
synapse	Integrin beta-3	Homo sapiens (human)
membrane raft	Tyrosine-protein kinase Fyn	Homo sapiens (human)
dendrite	Tyrosine-protein kinase Fyn	Homo sapiens (human)
nucleus	Tyrosine-protein kinase Fyn	Homo sapiens (human)
mitochondrion	Tyrosine-protein kinase Fyn	Homo sapiens (human)
endosome	Tyrosine-protein kinase Fyn	Homo sapiens (human)
cytosol	Tyrosine-protein kinase Fyn	Homo sapiens (human)
actin filament	Tyrosine-protein kinase Fyn	Homo sapiens (human)
plasma membrane	Tyrosine-protein kinase Fyn	Homo sapiens (human)
postsynaptic density	Tyrosine-protein kinase Fyn	Homo sapiens (human)
dendrite	Tyrosine-protein kinase Fyn	Homo sapiens (human)
perikaryon	Tyrosine-protein kinase Fyn	Homo sapiens (human)
cell body	Tyrosine-protein kinase Fyn	Homo sapiens (human)
membrane raft	Tyrosine-protein kinase Fyn	Homo sapiens (human)
perinuclear region of cytoplasm	Tyrosine-protein kinase Fyn	Homo sapiens (human)
perinuclear endoplasmic reticulum	Tyrosine-protein kinase Fyn	Homo sapiens (human)
glial cell projection	Tyrosine-protein kinase Fyn	Homo sapiens (human)
Schaffer collateral - CA1 synapse	Tyrosine-protein kinase Fyn	Homo sapiens (human)
plasma membrane	Tyrosine-protein kinase Fyn	Homo sapiens (human)
plasma membrane	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
membrane	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
clathrin-coated endocytic vesicle membrane	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
asymmetric synapse	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
symmetric synapse	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
presynaptic membrane	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
neuronal cell body	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
axon terminus	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
postsynaptic membrane	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
glutamatergic synapse	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
cholinergic synapse	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
plasma membrane	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
synapse	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
dendrite	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
plasma membrane	Muscarinic acetylcholine receptor M4	Homo sapiens (human)
postsynaptic membrane	Muscarinic acetylcholine receptor M4	Homo sapiens (human)
dendrite	Muscarinic acetylcholine receptor M4	Homo sapiens (human)
plasma membrane	Muscarinic acetylcholine receptor M4	Homo sapiens (human)
synapse	Muscarinic acetylcholine receptor M4	Homo sapiens (human)
cytoplasm	ATP-dependent translocase ABCB1	Homo sapiens (human)
plasma membrane	ATP-dependent translocase ABCB1	Homo sapiens (human)
cell surface	ATP-dependent translocase ABCB1	Homo sapiens (human)
membrane	ATP-dependent translocase ABCB1	Homo sapiens (human)
apical plasma membrane	ATP-dependent translocase ABCB1	Homo sapiens (human)
extracellular exosome	ATP-dependent translocase ABCB1	Homo sapiens (human)
external side of apical plasma membrane	ATP-dependent translocase ABCB1	Homo sapiens (human)
plasma membrane	ATP-dependent translocase ABCB1	Homo sapiens (human)
plasma membrane	Integrin alpha-IIb	Homo sapiens (human)
focal adhesion	Integrin alpha-IIb	Homo sapiens (human)
cell surface	Integrin alpha-IIb	Homo sapiens (human)
platelet alpha granule membrane	Integrin alpha-IIb	Homo sapiens (human)
extracellular exosome	Integrin alpha-IIb	Homo sapiens (human)
integrin alphaIIb-beta3 complex	Integrin alpha-IIb	Homo sapiens (human)
blood microparticle	Integrin alpha-IIb	Homo sapiens (human)
integrin complex	Integrin alpha-IIb	Homo sapiens (human)
external side of plasma membrane	Integrin alpha-IIb	Homo sapiens (human)
membrane	Proto-oncogene tyrosine-protein kinase ROS	Homo sapiens (human)
receptor complex	Proto-oncogene tyrosine-protein kinase ROS	Homo sapiens (human)
plasma membrane	Proto-oncogene tyrosine-protein kinase ROS	Homo sapiens (human)
mitochondrion	Cytochrome P450 2D6	Homo sapiens (human)
endoplasmic reticulum	Cytochrome P450 2D6	Homo sapiens (human)
endoplasmic reticulum membrane	Cytochrome P450 2D6	Homo sapiens (human)
cytoplasm	Cytochrome P450 2D6	Homo sapiens (human)
intracellular membrane-bounded organelle	Cytochrome P450 2D6	Homo sapiens (human)
plasma membrane	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
membrane	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
presynaptic membrane	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
axon terminus	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
Schaffer collateral - CA1 synapse	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
postsynaptic density membrane	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
glutamatergic synapse	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
cholinergic synapse	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
synapse	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
dendrite	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
plasma membrane	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
nucleolus	DNA topoisomerase 2-alpha	Homo sapiens (human)
nuclear chromosome	DNA topoisomerase 2-alpha	Homo sapiens (human)
centriole	DNA topoisomerase 2-alpha	Homo sapiens (human)
chromosome, centromeric region	DNA topoisomerase 2-alpha	Homo sapiens (human)
condensed chromosome	DNA topoisomerase 2-alpha	Homo sapiens (human)
male germ cell nucleus	DNA topoisomerase 2-alpha	Homo sapiens (human)
nucleus	DNA topoisomerase 2-alpha	Homo sapiens (human)
nucleoplasm	DNA topoisomerase 2-alpha	Homo sapiens (human)
nucleolus	DNA topoisomerase 2-alpha	Homo sapiens (human)
cytoplasm	DNA topoisomerase 2-alpha	Homo sapiens (human)
DNA topoisomerase type II (double strand cut, ATP-hydrolyzing) complex	DNA topoisomerase 2-alpha	Homo sapiens (human)
protein-containing complex	DNA topoisomerase 2-alpha	Homo sapiens (human)
ribonucleoprotein complex	DNA topoisomerase 2-alpha	Homo sapiens (human)
nucleus	DNA topoisomerase 2-alpha	Homo sapiens (human)
plasma membrane	Gamma-aminobutyric acid receptor subunit gamma-2	Rattus norvegicus (Norway rat)
PcG protein complex	Casein kinase II subunit alpha'	Homo sapiens (human)
acrosomal vesicle	Casein kinase II subunit alpha'	Homo sapiens (human)
nucleus	Casein kinase II subunit alpha'	Homo sapiens (human)
nucleoplasm	Casein kinase II subunit alpha'	Homo sapiens (human)
cytosol	Casein kinase II subunit alpha'	Homo sapiens (human)
protein kinase CK2 complex	Casein kinase II subunit alpha'	Homo sapiens (human)
chromatin	Casein kinase II subunit alpha'	Homo sapiens (human)
cytosol	Casein kinase II subunit alpha'	Homo sapiens (human)
nucleus	Casein kinase II subunit alpha'	Homo sapiens (human)
plasma membrane	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
cell surface	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
membrane	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
neuronal cell body membrane	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
presynaptic membrane	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
plasma membrane	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
axon	Sodium-dependent noradrenaline transporter	Homo sapiens (human)
plasma membrane	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
synapse	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
G protein-coupled serotonin receptor complex	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
plasma membrane	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
dendrite	5-hydroxytryptamine receptor 2C	Homo sapiens (human)
plasma membrane	Multidrug resistance-associated protein 1	Homo sapiens (human)
basal plasma membrane	Multidrug resistance-associated protein 1	Homo sapiens (human)
membrane	Multidrug resistance-associated protein 1	Homo sapiens (human)
basolateral plasma membrane	Multidrug resistance-associated protein 1	Homo sapiens (human)
apical plasma membrane	Multidrug resistance-associated protein 1	Homo sapiens (human)
lateral plasma membrane	Multidrug resistance-associated protein 1	Homo sapiens (human)
extracellular exosome	Multidrug resistance-associated protein 1	Homo sapiens (human)
basolateral plasma membrane	Multidrug resistance-associated protein 1	Homo sapiens (human)
plasma membrane	Gamma-aminobutyric acid receptor subunit alpha-1	Rattus norvegicus (Norway rat)
plasma membrane	Guanine nucleotide-binding protein G	Homo sapiens (human)
plasma membrane	Gamma-aminobutyric acid receptor subunit beta-2	Rattus norvegicus (Norway rat)
plasma membrane	Casein kinase II subunit beta	Homo sapiens (human)
PcG protein complex	Casein kinase II subunit beta	Homo sapiens (human)
PML body	Casein kinase II subunit beta	Homo sapiens (human)
extracellular region	Casein kinase II subunit beta	Homo sapiens (human)
nucleus	Casein kinase II subunit beta	Homo sapiens (human)
nucleoplasm	Casein kinase II subunit beta	Homo sapiens (human)
cytoplasm	Casein kinase II subunit beta	Homo sapiens (human)
cytosol	Casein kinase II subunit beta	Homo sapiens (human)
protein kinase CK2 complex	Casein kinase II subunit beta	Homo sapiens (human)
secretory granule lumen	Casein kinase II subunit beta	Homo sapiens (human)
extracellular exosome	Casein kinase II subunit beta	Homo sapiens (human)
ficolin-1-rich granule lumen	Casein kinase II subunit beta	Homo sapiens (human)
chromatin	Casein kinase II subunit beta	Homo sapiens (human)
cytoplasm	Casein kinase II subunit beta	Homo sapiens (human)
PcG protein complex	Casein kinase II subunit alpha	Homo sapiens (human)
PML body	Casein kinase II subunit alpha	Homo sapiens (human)
nucleus	Casein kinase II subunit alpha	Homo sapiens (human)
nucleoplasm	Casein kinase II subunit alpha	Homo sapiens (human)
cytosol	Casein kinase II subunit alpha	Homo sapiens (human)
plasma membrane	Casein kinase II subunit alpha	Homo sapiens (human)
protein kinase CK2 complex	Casein kinase II subunit alpha	Homo sapiens (human)
Sin3-type complex	Casein kinase II subunit alpha	Homo sapiens (human)
cytosol	Casein kinase II subunit alpha	Homo sapiens (human)
nucleus	Casein kinase II subunit alpha	Homo sapiens (human)
plasma membrane	Voltage-dependent L-type calcium channel subunit alpha-1D	Homo sapiens (human)
Z disc	Voltage-dependent L-type calcium channel subunit alpha-1D	Homo sapiens (human)
voltage-gated calcium channel complex	Voltage-dependent L-type calcium channel subunit alpha-1D	Homo sapiens (human)
L-type voltage-gated calcium channel complex	Voltage-dependent L-type calcium channel subunit alpha-1D	Homo sapiens (human)
nucleolus	DNA topoisomerase 2-beta	Homo sapiens (human)
heterochromatin	DNA topoisomerase 2-beta	Homo sapiens (human)
nucleus	DNA topoisomerase 2-beta	Homo sapiens (human)
nucleoplasm	DNA topoisomerase 2-beta	Homo sapiens (human)
nucleolus	DNA topoisomerase 2-beta	Homo sapiens (human)
cytosol	DNA topoisomerase 2-beta	Homo sapiens (human)
ribonucleoprotein complex	DNA topoisomerase 2-beta	Homo sapiens (human)
nucleus	DNA topoisomerase 2-beta	Homo sapiens (human)
nucleus	Tyrosine-protein kinase BTK	Homo sapiens (human)
cytoplasm	Tyrosine-protein kinase BTK	Homo sapiens (human)
cytosol	Tyrosine-protein kinase BTK	Homo sapiens (human)
plasma membrane	Tyrosine-protein kinase BTK	Homo sapiens (human)
cytoplasmic vesicle	Tyrosine-protein kinase BTK	Homo sapiens (human)
membrane raft	Tyrosine-protein kinase BTK	Homo sapiens (human)
perinuclear region of cytoplasm	Tyrosine-protein kinase BTK	Homo sapiens (human)
plasma membrane	Tyrosine-protein kinase BTK	Homo sapiens (human)
plasma membrane	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
cell surface	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
perinuclear region of cytoplasm	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
voltage-gated potassium channel complex	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
inward rectifier potassium channel complex	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
plasma membrane	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
intracellular non-membrane-bounded organelle	TAR DNA-binding protein 43	Homo sapiens (human)
nucleus	TAR DNA-binding protein 43	Homo sapiens (human)
nucleoplasm	TAR DNA-binding protein 43	Homo sapiens (human)
perichromatin fibrils	TAR DNA-binding protein 43	Homo sapiens (human)
mitochondrion	TAR DNA-binding protein 43	Homo sapiens (human)
cytoplasmic stress granule	TAR DNA-binding protein 43	Homo sapiens (human)
nuclear speck	TAR DNA-binding protein 43	Homo sapiens (human)
interchromatin granule	TAR DNA-binding protein 43	Homo sapiens (human)
nucleoplasm	TAR DNA-binding protein 43	Homo sapiens (human)
chromatin	TAR DNA-binding protein 43	Homo sapiens (human)
cytosol	NEDD8-activating enzyme E1 regulatory subunit	Homo sapiens (human)
plasma membrane	NEDD8-activating enzyme E1 regulatory subunit	Homo sapiens (human)
protein-containing complex	NEDD8-activating enzyme E1 regulatory subunit	Homo sapiens (human)
cytoplasm	NEDD8-activating enzyme E1 regulatory subunit	Homo sapiens (human)
nucleus	NEDD8-activating enzyme E1 regulatory subunit	Homo sapiens (human)
cytoplasm	Voltage-dependent L-type calcium channel subunit alpha-1S	Homo sapiens (human)
plasma membrane	Voltage-dependent L-type calcium channel subunit alpha-1S	Homo sapiens (human)
sarcoplasmic reticulum	Voltage-dependent L-type calcium channel subunit alpha-1S	Homo sapiens (human)
T-tubule	Voltage-dependent L-type calcium channel subunit alpha-1S	Homo sapiens (human)
I band	Voltage-dependent L-type calcium channel subunit alpha-1S	Homo sapiens (human)
L-type voltage-gated calcium channel complex	Voltage-dependent L-type calcium channel subunit alpha-1S	Homo sapiens (human)
voltage-gated calcium channel complex	Voltage-dependent L-type calcium channel subunit alpha-1S	Homo sapiens (human)
cytoplasm	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
plasma membrane	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
postsynaptic density	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
membrane	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
Z disc	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
dendrite	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
perikaryon	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
postsynaptic density membrane	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
L-type voltage-gated calcium channel complex	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
voltage-gated calcium channel complex	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
plasma membrane	Multidrug and toxin extrusion protein 2	Homo sapiens (human)
apical plasma membrane	Multidrug and toxin extrusion protein 2	Homo sapiens (human)
membrane	Multidrug and toxin extrusion protein 2	Homo sapiens (human)
nucleoplasm	Casein kinase II subunit alpha 3	Homo sapiens (human)
nucleus	Casein kinase II subunit alpha 3	Homo sapiens (human)
cytosol	Casein kinase II subunit alpha 3	Homo sapiens (human)
protein kinase CK2 complex	Casein kinase II subunit alpha 3	Homo sapiens (human)
nucleus	NEDD8-activating enzyme E1 catalytic subunit	Homo sapiens (human)
cytosol	NEDD8-activating enzyme E1 catalytic subunit	Homo sapiens (human)
protein-containing complex	NEDD8-activating enzyme E1 catalytic subunit	Homo sapiens (human)
cytoplasm	NEDD8-activating enzyme E1 catalytic subunit	Homo sapiens (human)
nucleus	NEDD8-activating enzyme E1 catalytic subunit	Homo sapiens (human)
plasma membrane	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
basolateral plasma membrane	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
apical plasma membrane	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
membrane	Multidrug and toxin extrusion protein 1	Homo sapiens (human)
cytoplasm	Ataxin-2	Homo sapiens (human)
Golgi apparatus	Ataxin-2	Homo sapiens (human)
trans-Golgi network	Ataxin-2	Homo sapiens (human)
cytosol	Ataxin-2	Homo sapiens (human)
cytoplasmic stress granule	Ataxin-2	Homo sapiens (human)
membrane	Ataxin-2	Homo sapiens (human)
perinuclear region of cytoplasm	Ataxin-2	Homo sapiens (human)
ribonucleoprotein complex	Ataxin-2	Homo sapiens (human)
cytoplasmic stress granule	Ataxin-2	Homo sapiens (human)
nucleus	Single-stranded DNA cytosine deaminase	Homo sapiens (human)
cytoplasm	Single-stranded DNA cytosine deaminase	Homo sapiens (human)
cytosol	Single-stranded DNA cytosine deaminase	Homo sapiens (human)
protein-containing complex	Single-stranded DNA cytosine deaminase	Homo sapiens (human)
nucleus	Single-stranded DNA cytosine deaminase	Homo sapiens (human)
cytoplasm	Single-stranded DNA cytosine deaminase	Homo sapiens (human)
P-body	Single-stranded DNA cytosine deaminase	Homo sapiens (human)
plasma membrane	P2Y purinoceptor 12	Homo sapiens (human)
cell surface	P2Y purinoceptor 12	Homo sapiens (human)
membrane	P2Y purinoceptor 12	Homo sapiens (human)
cell projection membrane	P2Y purinoceptor 12	Homo sapiens (human)
cell body membrane	P2Y purinoceptor 12	Homo sapiens (human)
plasma membrane	Solute carrier organic anion transporter family member 1B3	Homo sapiens (human)
basal plasma membrane	Solute carrier organic anion transporter family member 1B3	Homo sapiens (human)
basolateral plasma membrane	Solute carrier organic anion transporter family member 1B3	Homo sapiens (human)
nucleoplasm	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
plasma membrane	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
apical plasma membrane	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
brush border membrane	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
mitochondrial membrane	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
membrane raft	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
external side of apical plasma membrane	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
plasma membrane	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (933)

Assay ID	Title	Year	Journal	Article
AID504812	Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504836	Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation	2002	The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16	Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID1347057	CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation	2019	PloS one, , Volume: 14, Issue:7	Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347058	CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation	2019	PloS one, , Volume: 14, Issue:7	Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID588349	qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID1347410	qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library	2019	Cellular signalling, 08, Volume: 60	A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID1347083	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347045	Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line	2019	Science translational medicine, 07-10, Volume: 11, Issue:500	Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347059	CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation	2019	PloS one, , Volume: 14, Issue:7	Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347151	Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347050	Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay	2019	Science translational medicine, 07-10, Volume: 11, Issue:500	Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347082	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID588378	qHTS for Inhibitors of ATXN expression: Validation
AID1508630	Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay	2021	Cell reports, 04-27, Volume: 35, Issue:4	A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347405	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347049	Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen	2019	Science translational medicine, 07-10, Volume: 11, Issue:500	Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID504810	Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347086	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347128	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for OHS-50 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347112	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-12 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347113	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for LAN-5 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347121	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for control Hh wild type fibroblast cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845	Primary qHTS for Inhibitors of ATXN expression
AID1347115	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB-EBc1 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008	Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening	2020	SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1	Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347125	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh18 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347109	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB1643 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347137	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Orthogonal 3D viability screen for Daoy cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347114	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for DAOY cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347122	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for U-2 OS cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347126	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh30 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347111	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-MC cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347118	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for TC32 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347123	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh41 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346987	P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347105	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347138	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Orthogonal 3D caspase screen for TC32 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347127	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Saos-2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID686947	qHTS for small molecule inhibitors of Yes1 kinase: Primary Screen	2013	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 23, Issue:15	Identification of potent Yes1 kinase inhibitors using a library screening approach.
AID1347116	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SJ-GBM2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347139	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Orthogonal 3D viability screen for TC32 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347141	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Orthogonal 3D viability screen for RD cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346986	P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347140	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Orthogonal 3D viability screen for MG 63 (6-TG R) cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347117	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-37 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347136	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Orthogonal 3D viability screen for SJ-GBM2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347129	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-SH cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347110	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for A673 cells)	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347135	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Orthogonal 3D viability screen for SK-N-SH cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154	Primary screen GU AMC qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347119	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for MG 63 (6-TG R) cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347124	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for RD cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID504749	qHTS profiling for inhibitors of Plasmodium falciparum proliferation	2011	Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043	Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID45645	Survivors of CDF1 mice on day 4 after 1st injection of compound at 1.5 mg/kg in six mice; 6/6	1989	Journal of medicinal chemistry, Aug, Volume: 32, Issue:8	Synthesis of unsymmetrically substituted 1,4-bis[(aminoalkyl)amino]anthracene-9,10-diones as potential antileukemic agents.
AID354543	Cytotoxicity against rat C6 cells assessed as cell release at 50 ug/mL to 2.5 mg/mL after 5 hrs by MTT assay in absence of db-cAMP	1996	Journal of natural products, Dec, Volume: 59, Issue:12	Cell-based screen for identification of inhibitors of tubulin polymerization.
AID99359	Tested for inhibitory activity against murine cell line L12110, a strain sensitive to doxorubicin using MTT assay.	2000	Journal of medicinal chemistry, Aug-10, Volume: 43, Issue:16	Analogues of amonafide and azonafide with novel ring systems.
AID8289	In vitro cytotoxic activity against human lung A549 cell line ( standard deviation in parenthesis)	2002	Journal of medicinal chemistry, Jun-06, Volume: 45, Issue:12	Design, synthesis, and antiproliferative activity of some new pyrazole-fused amino derivatives of the pyranoxanthenone, pyranothioxanthenone, and pyranoacridone ring systems: a new class of cytotoxic agents.
AID1349098	Inhibition of NAE in human Caco2 cells assessed as increase in p27 protein levels at 0.1 to 10 uM after 16 hrs by Western blot analysis	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	Structure-based identification of a NEDD8-activating enzyme inhibitor via drug repurposing.
AID1550885	Induction of immunogenic cell death in mouse H22 cells assessed as increase in extracellular ATP level at 2 uM measured after 5 hrs by chemiluminescence-based assay	2019	European journal of medicinal chemistry, Jun-01, Volume: 171	Naphthyl quinoxaline thymidine conjugate is a potent anticancer agent post UVA activation and elicits marked inhibition of tumor growth through vaccination.
AID248060	Cytotoxicity against human HCT116 cancer cell line was determined after 144 hr	2004	Journal of medicinal chemistry, Oct-07, Volume: 47, Issue:21	Rational design, synthesis, and biological evaluation of bis(pyrimido[5,6,1-de]acridines) and bis(pyrazolo[3,4,5-kl]acridine-5-carboxamides) as new anticancer agents.
AID624623	Apparent permeability (Papp) from basolateral to apical side determined in MDR1-MDCKII cells	2001	The Journal of pharmacology and experimental therapeutics, Nov, Volume: 299, Issue:2	Rational use of in vitro P-glycoprotein assays in drug discovery.
AID154065	Inhibition of P388 leukemia cells in mice, measured as percent treated to the control values with the number of 30 day survivors	1987	Journal of medicinal chemistry, Jan, Volume: 30, Issue:1	Anthrapyrazole anticancer agents. Synthesis and structure-activity relationships against murine leukemias.
AID466798	Growth inhibition of human A549 cells by MTT assay	2010	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 20, Issue:5	Triterpene compounds isolated from Acer mandshuricum and their anti-inflammatory activity.
AID1883025	Antitumor activity against mouse 4T1 cells implanted in Balb/c mouse assessed as nuclei disappearance at 50 mg/kg administered intratumorally every four days for 14 days in the presence of liquid cyanoacrylate	2022	European journal of medicinal chemistry, Jul-05, Volume: 237	Design, synthesis, and evaluation of a novel series of mono-indolylbenzoquinones derivatives for the potential treatment of breast cancer.
AID51931	Tested for the cytotoxicity against the repair deficient xrs-6 chinese hamster ovary cell line	1994	Journal of medicinal chemistry, Oct-28, Volume: 37, Issue:22	Inhibition of topoisomerase II catalytic activity by pyridoacridine alkaloids from a Cystodytes sp. ascidian: a mechanism for the apparent intercalator-induced inhibition of topoisomerase II.
AID683854	Antiproliferative activity against human LoVo cells after 72 hrs by SRB assay	2012	Bioorganic & medicinal chemistry letters, Oct-01, Volume: 22, Issue:19	New derivatives of 11-methyl-6-[2-(dimethylamino)ethyl]-6H-indolo[2,3-b]quinoline as cytotoxic DNA topoisomerase II inhibitors.
AID354542	Inhibition of tubulin polymerization in rat C6 cells at 50 ug/mL to 2.5 mg/mL after 4 hrs	1996	Journal of natural products, Dec, Volume: 59, Issue:12	Cell-based screen for identification of inhibitors of tubulin polymerization.
AID524790	Antiplasmodial activity against Plasmodium falciparum 3D7 after 72 hrs by SYBR green assay	2009	Nature chemical biology, Oct, Volume: 5, Issue:10	Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID45657	Survivors of CDF1 mice on day 4 after 1st injection of compound at 6 mg/kg in six mice; 6/6	1989	Journal of medicinal chemistry, Aug, Volume: 32, Issue:8	Synthesis of unsymmetrically substituted 1,4-bis[(aminoalkyl)amino]anthracene-9,10-diones as potential antileukemic agents.
AID1525941	Resistance factor, ratio of IC50 for human LCC6MDR cells overexpressing P-gp to IC50 for human LCC6 cells	2019	Journal of medicinal chemistry, 09-26, Volume: 62, Issue:18	Triazole Bridged Flavonoid Dimers as Potent, Nontoxic, and Highly Selective Breast Cancer Resistance Protein (BCRP/ABCG2) Inhibitors.
AID270856	Resistant factor, IC50 for MES-SA/Dx5/ IC50 for MES-SA cells by MTT assay after 72 hrs	2006	Bioorganic & medicinal chemistry letters, Sep-15, Volume: 16, Issue:18	Synthesis and antiproliferative activity of substituted benzopyranoisoindoles: a new class of cytotoxic compounds.
AID681572	TP_TRANSPORTER: drug resistance in BCRP-expressing MEF3.8 cells	2003	Cancer research, Mar-15, Volume: 63, Issue:6	Mouse breast cancer resistance protein (Bcrp1/Abcg2) mediates etoposide resistance and transport, but etoposide oral availability is limited primarily by P-glycoprotein.
AID84475	Inhibitory concentration of compound against proliferation of colon carcinoma HT-29 cell line	2002	Bioorganic & medicinal chemistry letters, Jun-03, Volume: 12, Issue:11	Design and synthesis of some new pyranoxanthenone aminoderivatives with cytotoxic activity.
AID562245	Antimycobacterial activity against Mycobacterium smegmatis grown in nitrogen -limited broth medium assessed as growth inhibition in mid-logarithmic phase by GFP-based fluorescence assay	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Modifying culture conditions in chemical library screening identifies alternative inhibitors of mycobacteria.
AID272514	Antiproliferative activity against adriamycin resistant P388 cells in presence of 5 uM 1,13-bis[4'-((5,7-dihydroxy)-4H-chromen-4-on-2-yl)phenyl]-1,4,7,10,13-pentaoxatridecane by ELISA	2006	Journal of medicinal chemistry, Nov-16, Volume: 49, Issue:23	Flavonoid dimers as bivalent modulators for P-glycoprotein-based multidrug resistance: synthetic apigenin homodimers linked with defined-length poly(ethylene glycol) spacers increase drug retention and enhance chemosensitivity in resistant cancer cells.
AID55499	Concentration required to give 50% fluorescence quenching of bound ethidium for [ethidium]: [(poly dG-dC)]2 DNA in ratio of 0.1:1 at pH 5	1997	Journal of medicinal chemistry, Nov-07, Volume: 40, Issue:23	1-[(omega-aminoalkyl)amino]-4-[N-(omega-aminoalkyl)carbamoyl]-9-oxo-9, 10-dihydroacridines as intercalating cytotoxic agents: synthesis, DNA binding, and biological evaluation.
AID524793	Antiplasmodial activity against Plasmodium falciparum Dd2 after 72 hrs by SYBR green assay	2009	Nature chemical biology, Oct, Volume: 5, Issue:10	Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID134572	In vitro cytotoxicity against L1210 leukemia cell line	1993	Journal of medicinal chemistry, Jul-23, Volume: 36, Issue:15	Synthesis and antitumor properties of an anthraquinone bisubstituted by the copper chelating peptide Gly-Gly-L-His.
AID1130156	Antineoplastic activity against mouse Colon 26 cells allografted in CDF1 mouse assessed as survival at 1.08 mg/kg qd for 9 days	1979	Journal of medicinal chemistry, May, Volume: 22, Issue:5	Structural modification study of bis(substituted aminoalkylamino)anthraquinones. An evaluation of the relationship of the [2-[(2-hydroxyethyl)amino]ethyl]amino side chain with antineoplastic activity.
AID202628	Mean percentage reduction in tumor weight at 0.75 mg/kg (cumulative dose 525 mg/Kg) introduced (in vivo) ip; Significant	1988	Journal of medicinal chemistry, Apr, Volume: 31, Issue:4	Synthesis, molecular modeling, DNA binding, and antitumor properties of some substituted amidoanthraquinones.
AID1130157	Antineoplastic activity against mouse Colon 26 cells allografted in CDF1 mouse at 1.08 mg/kg qd for 9 days relative to control	1979	Journal of medicinal chemistry, May, Volume: 22, Issue:5	Structural modification study of bis(substituted aminoalkylamino)anthraquinones. An evaluation of the relationship of the [2-[(2-hydroxyethyl)amino]ethyl]amino side chain with antineoplastic activity.
AID1349095	Inhibition of NAE in human Caco2 cells harboring p53-luc plasmid assessed as increase in p53 transcriptional activity after 16 hrs by luciferase reporter gene assay	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	Structure-based identification of a NEDD8-activating enzyme inhibitor via drug repurposing.
AID132862	In vitro for its inhibitory activity against murine L1210 leukemia	1988	Journal of medicinal chemistry, Aug, Volume: 31, Issue:8	Benzothiopyranoindazoles, a new class of chromophore modified anthracenedione anticancer agents. Synthesis and activity against murine leukemias.
AID625287	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID219914	Cytotoxicity against CHO cell line xrs6	1995	Journal of medicinal chemistry, Oct-27, Volume: 38, Issue:22	Topoisomerase II-mediated DNA cleavage by adocia- and xestoquinones from the Philippine sponge Xestospongia sp.
AID624628	Drug-stimulated Pgp ATPase activity ratio determined in MDR1-Sf9 cell membranes with test compound at a concentration of 20uM	2001	The Journal of pharmacology and experimental therapeutics, Nov, Volume: 299, Issue:2	Rational use of in vitro P-glycoprotein assays in drug discovery.
AID102333	In vitro cytotoxicity on human colon adenocarcinoma resistant to doxorubicin (LoVo/Dx ) tumor cell line.	1998	Journal of medicinal chemistry, Dec-31, Volume: 41, Issue:27	Synthesis and antitumor evaluation of 2,5-disubstituted-indazolo[4, 3-gh]isoquinolin-6(2H)-ones (9-aza-anthrapyrazoles).
AID429650	Cytotoxicity against human HL60 cells by MTT assay	2009	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 19, Issue:16	C29 sterols with a cyclopropane ring at C-25 and 26 from the Vietnamese marine sponge Ianthella sp. and their anticancer properties.
AID39742	Optimal dose per injection in mg/kg required to inhibit growth of murine B-16 melanoma in vivo	1987	Journal of medicinal chemistry, Jan, Volume: 30, Issue:1	Anthrapyrazole anticancer agents. Synthesis and structure-activity relationships against murine leukemias.
AID1221982	Fraction absorbed in human	2011	Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2	Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID1883021	Toxicity in Balb/c mouse implanted with mouse 4T1 cells assessed as liver lesions at 50 mg/kg administered intratumorally every four days for 14 days in the presence of liquid cyanoacrylate by H&E staining based histopathological analysis	2022	European journal of medicinal chemistry, Jul-05, Volume: 237	Design, synthesis, and evaluation of a novel series of mono-indolylbenzoquinones derivatives for the potential treatment of breast cancer.
AID103420	Tested for inhibitory activity against human tumor cell line MCF7, a strain resistant to mitoxantrone of breast carcinoma using sulforhodamine B assay.	2000	Journal of medicinal chemistry, Aug-10, Volume: 43, Issue:16	Analogues of amonafide and azonafide with novel ring systems.
AID1506786	Induction of apoptosis in human HCC78 cells assessed as necrotic cells level at 10 nM incubated fro 48 hrs by Annexin-V FITC and propidium iodide staining based flow cytometry (Rvb = 0.06%)	2017	MedChemComm, Mar-01, Volume: 8, Issue:3	Identification of mitoxantrone as a new inhibitor of ROS1 fusion protein in non-small cell lung cancer cells.
AID272515	Antiproliferative activity against adriamycin resistant P388 cells in presence of 5 uM verapamil by ELISA	2006	Journal of medicinal chemistry, Nov-16, Volume: 49, Issue:23	Flavonoid dimers as bivalent modulators for P-glycoprotein-based multidrug resistance: synthetic apigenin homodimers linked with defined-length poly(ethylene glycol) spacers increase drug retention and enhance chemosensitivity in resistant cancer cells.
AID223628	Tested for inhibitory activity against human tumor cell line OVCAR-3, a resistant ovarian carcinoma using sulforhodamine B assay.	2000	Journal of medicinal chemistry, Aug-10, Volume: 43, Issue:16	Analogues of amonafide and azonafide with novel ring systems.
AID595061	Cytotoxicity against human HCT116 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay	2011	Bioorganic & medicinal chemistry letters, May-15, Volume: 21, Issue:10	Design, synthesis and antiproliferative activity of novel aminosubstituted benzothiopyranoisoindoles.
AID1079943	Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID1349093	Inhibition of NAE in human Caco2 cells assessed as increase in p53 protein levels at 1 to 10 uM after 16 hrs by Western blot analysis	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	Structure-based identification of a NEDD8-activating enzyme inhibitor via drug repurposing.
AID647963	Cytotoxicity against human H1299 cells assessed as cell growth at 10 uM after 48 hrs by MTT assay	2012	European journal of medicinal chemistry, Apr, Volume: 50	Design, synthesis and evaluation of telomerase inhibitory, hTERT repressing, and anti-proliferation activities of symmetrical 1,8-disubstituted amidoanthraquinones.
AID83792	Percent inhibition at G2/M phase of cell cycle at a dose of 25 ng/mL after 72 hours of induction in HT-29 cell line	1999	Journal of medicinal chemistry, Sep-09, Volume: 42, Issue:18	8,11-dihydroxy-6-[(aminoalkyl)amino]-7H-benzo[e]perimidin-7-ones with activity in multidrug-resistant cell lines: synthesis and antitumor evaluation.
AID588217	FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase	2004	Current drug discovery technologies, Dec, Volume: 1, Issue:4	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1349084	Inhibition of NAE-mediated Ubcl2-NEDD8 conjugation in human Caco2 cells at 10 uM after 16 hrs by Western blot analysis	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	Structure-based identification of a NEDD8-activating enzyme inhibitor via drug repurposing.
AID107941	Compound was evaluated in vivo for the antitumor activity at a dose of 1.25 mg/kg & 3.75 mg/kg against mammary adenocarcinoma 16C to assess tumor growth delay (T-C).	1984	Journal of medicinal chemistry, Mar, Volume: 27, Issue:3	5-[(Aminoalkyl)amino]-substituted anthra[1,9-cd]pyrazol-6(2H)-ones as novel anticancer agents. Synthesis and biological evaluation.
AID1506772	Cytotoxicity in human HCC78 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	2017	MedChemComm, Mar-01, Volume: 8, Issue:3	Identification of mitoxantrone as a new inhibitor of ROS1 fusion protein in non-small cell lung cancer cells.
AID81486	Relative cytotoxicity against Human promyelocytic Leukemia(HL-60) cells; Value is in range, activity expressed as IC50	1999	Journal of medicinal chemistry, Jun-17, Volume: 42, Issue:12	Design and synthesis of modified quinolones as antitumoral acridones.
AID1883016	Antitumor activity against mouse 4T1 cells implanted in Balb/c mouse assessed as tumor growth inhibition by measuring T/C ratio at 50 mg/kg administered intratumorally every four days for 14 days in the presence of liquid cyanoacrylate	2022	European journal of medicinal chemistry, Jul-05, Volume: 237	Design, synthesis, and evaluation of a novel series of mono-indolylbenzoquinones derivatives for the potential treatment of breast cancer.
AID363203	Antitumor activity against human NCI60 cells after 48 hrs by SRB assay	2008	Bioorganic & medicinal chemistry, Sep-01, Volume: 16, Issue:17	Design, synthesis, and antitumor activity of new bis-aminomethylnaphthalenes.
AID591077	Resistance index, ratio IC50 for human HL60/MX2 cells to IC50 for human HL60 cells	2011	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 21, Issue:8	Synthesis, cytotoxicity and topoisomerase inhibition properties of multifarious aminoalkylated indeno[1,2-c]isoquinolin-5,11-diones.
AID562244	Antimycobacterial activity against Mycobacterium smegmatis grown in carbon-limited broth medium assessed as growth inhibition in mid-logarithmic phase by GFP-based fluorescence assay	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Modifying culture conditions in chemical library screening identifies alternative inhibitors of mycobacteria.
AID1130148	Antineoplastic activity against mouse B16 cells allografted in BDF1 mouse assessed as survival at 2 mg/kg qd for 9 days	1979	Journal of medicinal chemistry, May, Volume: 22, Issue:5	Structural modification study of bis(substituted aminoalkylamino)anthraquinones. An evaluation of the relationship of the [2-[(2-hydroxyethyl)amino]ethyl]amino side chain with antineoplastic activity.
AID1903849	Antitumor immunity against human U2OS cells assessed as inhibition of RNA synthesis at 3 uM pretreated for 2.5 hrs by bright field microscopic analysis	2022	Journal of medicinal chemistry, 03-24, Volume: 65, Issue:6	Biological Investigation of a Water-Soluble Isoginkgetin-Phosphate Analogue, Targeting the Spliceosome with
AID729377	Effect on total BAD level in human MV411 cells at 10 to 100 nM after 12 hrs by Western blotting analysis	2013	Journal of medicinal chemistry, Mar-28, Volume: 56, Issue:6	A new target for an old drug: identifying mitoxantrone as a nanomolar inhibitor of PIM1 kinase via kinome-wide selectivity modeling.
AID536040	Cytotoxicity against human HL60/MX2 cells after 72 hrs	2010	Bioorganic & medicinal chemistry, Nov-15, Volume: 18, Issue:22	Indeno[1,2-c]isoquinolin-5,11-diones conjugated to amino acids: Synthesis, cytotoxicity, DNA interaction, and topoisomerase II inhibition properties.
AID45643	Survivors of CDF1 mice on day 4 after 1st injection of compound at 0.75 mg/kg in six mice; 6/6	1989	Journal of medicinal chemistry, Aug, Volume: 32, Issue:8	Synthesis of unsymmetrically substituted 1,4-bis[(aminoalkyl)amino]anthracene-9,10-diones as potential antileukemic agents.
AID1430730	Antitumor activity against mouse 4T1.2 cells implanted in Balb/c mouse assessed as mouse survival time at 3 mg/kg, iv encapsulated within cucurbit[8]uril administered twice weekly for 2 weeks measured up to 33 days	2017	ACS medicinal chemistry letters, May-11, Volume: 8, Issue:5	Encapsulation of Mitoxantrone within Cucurbit[8]uril Decreases Toxicity and Enhances Survival in a Mouse Model of Cancer.
AID1349102	Induction of apoptosis in human Caco2 cells assessed as viable cells at 1 uM after 16 hrs by Annexin V-FITC/propidium iodide staining-based flow cytometric analysis (Rvb = 98.4%)	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	Structure-based identification of a NEDD8-activating enzyme inhibitor via drug repurposing.
AID84105	In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line HT-29/Mx	1999	Journal of medicinal chemistry, Sep-09, Volume: 42, Issue:18	8,11-dihydroxy-6-[(aminoalkyl)amino]-7H-benzo[e]perimidin-7-ones with activity in multidrug-resistant cell lines: synthesis and antitumor evaluation.
AID1381971	Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay	2018	European journal of medicinal chemistry, Feb-25, Volume: 146	The lead optimization of the polyamine conjugate of flavonoid with a naphthalene motif: Synthesis and biological evaluation.
AID1268088	Binding affinity to calf thymus double stranded DNA by spectrophotometric titration method	2015	Journal of medicinal chemistry, Dec-24, Volume: 58, Issue:24	Synthesis and Characterization of 4,11-Diaminoanthra[2,3-b]furan-5,10-diones: Tumor Cell Apoptosis through tNOX-Modulated NAD(+)/NADH Ratio and SIRT1.
AID1079934	Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID721746	Inhibition of human MATE1-mediated [14]-metformin uptake expressed in polarized MDCK2 cells after 5 mins by liquid scintillation counting analysis	2013	Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3	Discovery of potent, selective multidrug and toxin extrusion transporter 1 (MATE1, SLC47A1) inhibitors through prescription drug profiling and computational modeling.
AID425653	Renal clearance in human	2009	Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15	Physicochemical determinants of human renal clearance.
AID32544	Inhibitory activity against AUC375 cell line	1996	Journal of medicinal chemistry, Apr-12, Volume: 39, Issue:8	6- and 7-substituted 2-[2'-(dimethylamino)ethyl]-1,2-dihydro-3H-dibenz[de,h] isoquinoline-1,3-diones: synthesis, nucleophilic displacements, antitumor activity, and quantitative structure-activity relationships.
AID307326	Growth inhibition of topoisomerase 2 mutated mitoxantrone-resistant MX2 cells by Alamar blue assay	2007	Bioorganic & medicinal chemistry, Jun-15, Volume: 15, Issue:12	Synthesis and topoisomerase poisoning activity of A-ring and E-ring substituted luotonin A derivatives.
AID102201	In vitro cytotoxic activity against human colon adenocarcinoma (LoVo) cells	2000	Bioorganic & medicinal chemistry letters, Feb-07, Volume: 10, Issue:3	Synthesis and antitumor activities of 5-methyl-1- and 2-[[2-dimethylaminoethyl]amino]-aza-thiopyranoindazoles.
AID1682834	Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	2021	Bioorganic & medicinal chemistry, 01-01, Volume: 29	Structure-activity relationship of novel acridone derivatives as antiproliferative agents.
AID1132472	Antitumor activity against mouse P388 cells allografted in BDF1 mouse assessed as increase in survival time at 0.12 mg/kg administered 24 hrs post challenge relative to control	1978	Journal of medicinal chemistry, Mar, Volume: 21, Issue:3	Antineoplastic agents. Structure-activity relationship study of bis(substituted aminoalkylamino)anthraquinones.
AID537735	Binding affinity to Candida albicans CaMdr1p expressed in yeast AD1-8u	2010	European journal of medicinal chemistry, Nov, Volume: 45, Issue:11	Analysis of physico-chemical properties of substrates of ABC and MFS multidrug transporters of pathogenic Candida albicans.
AID1132507	Toxicity in mouse P388 cells allografted BDF1 mouse assessed as body weight difference at 2 mg/kg administered 24 hrs post challenge relative to control	1978	Journal of medicinal chemistry, Mar, Volume: 21, Issue:3	Antineoplastic agents. Structure-activity relationship study of bis(substituted aminoalkylamino)anthraquinones.
AID1132492	Antitumor activity against mouse P388 cells allografted in BDF1 mouse assessed as mouse survival at 0.06 mg/kg administered 24 hrs post challenge relative to control	1978	Journal of medicinal chemistry, Mar, Volume: 21, Issue:3	Antineoplastic agents. Structure-activity relationship study of bis(substituted aminoalkylamino)anthraquinones.
AID567091	Drug absorption in human assessed as human intestinal absorption rate	2011	European journal of medicinal chemistry, Jan, Volume: 46, Issue:1	Prediction of drug intestinal absorption by new linear and non-linear QSPR.
AID436881	Inhibition of VIM2 in imipenem-resistant Escherichia coli BL21(DE3) assessed as potentiation of imipenem-induced bactericidal activity at 50 uM after 18 hrs by twofold serial broth dilution method	2009	Bioorganic & medicinal chemistry, Jul-15, Volume: 17, Issue:14	Inhibitors of VIM-2 by screening pharmacologically active and click-chemistry compound libraries.
AID1506771	Inhibition of ROS1 (unknown origin) using poly (Glu,Tyr)4:1 substrate and ATP incubated for 60 mins by ELISA	2017	MedChemComm, Mar-01, Volume: 8, Issue:3	Identification of mitoxantrone as a new inhibitor of ROS1 fusion protein in non-small cell lung cancer cells.
AID1233373	Antiproliferative activity against human MES-SA cells after 72 hrs by MTT assay	2015	Bioorganic & medicinal chemistry letters, Jul-01, Volume: 25, Issue:13	Synthesis and antiproliferative activity of some novel benzo-fused imidazo[1,8]naphthyridinones.
AID232811	Toxicity ratio determined by the quotient of IC50 values in the myocytes divided by the average value in the three tumor lines.	1996	Journal of medicinal chemistry, Apr-12, Volume: 39, Issue:8	6- and 7-substituted 2-[2'-(dimethylamino)ethyl]-1,2-dihydro-3H-dibenz[de,h] isoquinoline-1,3-diones: synthesis, nucleophilic displacements, antitumor activity, and quantitative structure-activity relationships.
AID27139	Apparent equilibrium constant for DNA binding (C-T)	2003	Journal of medicinal chemistry, Jul-03, Volume: 46, Issue:14	Design, synthesis, and biological properties of new bis(acridine-4-carboxamides) as anticancer agents.
AID437514	Displacement of fluorescent pyrene-neomycin conjugate from tau stem-loop RNA	2009	Journal of medicinal chemistry, Nov-12, Volume: 52, Issue:21	Mitoxantrone analogues as ligands for a stem-loop structure of tau pre-mRNA.
AID729384	Inhibition of BTK (unknown origin) using [gamma33P]ATP assessed as residual activity at 1 uM after 120 mins by radiometric assay	2013	Journal of medicinal chemistry, Mar-28, Volume: 56, Issue:6	A new target for an old drug: identifying mitoxantrone as a nanomolar inhibitor of PIM1 kinase via kinome-wide selectivity modeling.
AID320432	Binding affinity to calf thymus DNA assessed as thermal denaturation temperature at 10 uM	2008	Bioorganic & medicinal chemistry, Jan-15, Volume: 16, Issue:2	Synthesis, DNA binding, and cytotoxicity of 1,4-bis(2-amino-ethylamino)anthraquinone-amino acid conjugates.
AID1130153	Antineoplastic activity against mouse B16 cells allografted in BDF1 mouse at 0.5 mg/kg qd for 9 days relative to control	1979	Journal of medicinal chemistry, May, Volume: 22, Issue:5	Structural modification study of bis(substituted aminoalkylamino)anthraquinones. An evaluation of the relationship of the [2-[(2-hydroxyethyl)amino]ethyl]amino side chain with antineoplastic activity.
AID380013	Cytotoxicity against human HCT cells after 48 hrs by MTT assay	2000	Journal of natural products, May, Volume: 63, Issue:5	New 7,20:14,20-diepoxy ent-kauranoids from Isodon xerophilus.
AID84119	Effect of compound as percent survival at dose of 1000 ng/mL on HT-29/Mx cell line after 72 hours	1999	Journal of medicinal chemistry, Sep-09, Volume: 42, Issue:18	8,11-dihydroxy-6-[(aminoalkyl)amino]-7H-benzo[e]perimidin-7-ones with activity in multidrug-resistant cell lines: synthesis and antitumor evaluation.
AID681516	TP_TRANSPORTER: cell accumulation in MCF7/MRP1-10 cells	2006	Molecular pharmacology, Apr, Volume: 69, Issue:4	Multidrug resistance protein 1 (MRP1, ABCC1) mediates resistance to mitoxantrone via glutathione-dependent drug efflux.
AID431399	Cytotoxicity against human HL60/MX2 cells after 48 hrs by cell titer-blue assay	2009	Journal of medicinal chemistry, Oct-08, Volume: 52, Issue:19	Structure-activity relationship and molecular mechanisms of ethyl 2-amino-4-(2-ethoxy-2-oxoethyl)-6-phenyl-4h-chromene-3-carboxylate (sha 14-1) and its analogues.
AID588219	FDA HLAED, gamma-glutamyl transferase (GGT) increase	2004	Current drug discovery technologies, Dec, Volume: 1, Issue:4	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID154579	Percent ratio of the medium survival time for P388 murine leukemia in CDF1 mice at 6 mg/kg	1989	Journal of medicinal chemistry, Aug, Volume: 32, Issue:8	Synthesis of unsymmetrically substituted 1,4-bis[(aminoalkyl)amino]anthracene-9,10-diones as potential antileukemic agents.
AID46133	Inhibitory concentration against ethidium:calf thymus DNA (1.26:1) binding at pH 5	1997	Journal of medicinal chemistry, Nov-07, Volume: 40, Issue:23	1-[(omega-aminoalkyl)amino]-4-[N-(omega-aminoalkyl)carbamoyl]-9-oxo-9, 10-dihydroacridines as intercalating cytotoxic agents: synthesis, DNA binding, and biological evaluation.
AID588215	FDA HLAED, alkaline phosphatase increase	2004	Current drug discovery technologies, Dec, Volume: 1, Issue:4	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID154575	Percent ratio of the medium survival time for P388 murine leukemia in CDF1 mice at 3 mg/kg	1989	Journal of medicinal chemistry, Aug, Volume: 32, Issue:8	Synthesis of unsymmetrically substituted 1,4-bis[(aminoalkyl)amino]anthracene-9,10-diones as potential antileukemic agents.
AID1506322	Growth inhibition of human umbilical cord cells	2018	Journal of medicinal chemistry, Aug-09, Volume: 61, Issue:15	Exploring the Structure-Activity Relationship and Mechanism of a Chromene Scaffold (CXL Series) for Its Selective Antiproliferative Activity toward Multidrug-Resistant Cancer Cells.
AID1209592	Dissociation constant, pKa of the basic compound by capillary electrophoresis-mass spectrometry analysis	2011	Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3	Measurement of unbound drug exposure in brain: modeling of pH partitioning explains diverging results between the brain slice and brain homogenate methods.
AID592673	Cytotoxicity against human HL60 cells by MTT assay	2011	Bioorganic & medicinal chemistry, Apr-15, Volume: 19, Issue:8	Cytotoxic and anti-inflammatory cembranoids from the Vietnamese soft coral Lobophytum laevigatum.
AID106292	Tested against MXF7 breast carcinoma (doxorubicin resistant) cell line in the sulforhodamine B assay.	1996	Journal of medicinal chemistry, Apr-12, Volume: 39, Issue:8	6- and 7-substituted 2-[2'-(dimethylamino)ethyl]-1,2-dihydro-3H-dibenz[de,h] isoquinoline-1,3-diones: synthesis, nucleophilic displacements, antitumor activity, and quantitative structure-activity relationships.
AID404304	Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control	2008	Journal of medicinal chemistry, Jun-12, Volume: 51, Issue:11	Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).
AID625290	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID8424	In vitro inhibition of tumor cell growth in the human myeloma 8226/ADR system.	1992	Journal of medicinal chemistry, Nov-13, Volume: 35, Issue:23	Novel non-cross resistant diaminoanthraquinones as potential chemotherapeutic agents.
AID687163	Ratio of IC50 for doxorubicin-resistant human HL60 cells to IC50 for human HL60 cells	2012	Journal of medicinal chemistry, Jun-14, Volume: 55, Issue:11	Structure-activity relationship (SAR) study of ethyl 2-amino-6-(3,5-dimethoxyphenyl)-4-(2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate (CXL017) and the potential of the lead against multidrug resistance in cancer treatment.
AID272493	Antiproliferative activity against adriamycin resistant P388 cells by ELISA	2006	Journal of medicinal chemistry, Nov-16, Volume: 49, Issue:23	Flavonoid dimers as bivalent modulators for P-glycoprotein-based multidrug resistance: synthetic apigenin homodimers linked with defined-length poly(ethylene glycol) spacers increase drug retention and enhance chemosensitivity in resistant cancer cells.
AID114263	In vivo antitumor activity against subcutaneous Colon 38 tumors in mice determined as delay in growth after 3.9 mg/kg/day dose given as 3 times in a day for 4 days	2003	Journal of medicinal chemistry, Mar-13, Volume: 46, Issue:6	Synthesis and cytotoxic activity of carboxamide derivatives of benzo[b][1,6]naphthyridines.
AID320438	Cytotoxicity against DNA topoisomerase-2 deficient human HL60/MX2 cells by MTT assay	2008	Bioorganic & medicinal chemistry, Jan-15, Volume: 16, Issue:2	Synthesis, DNA binding, and cytotoxicity of 1,4-bis(2-amino-ethylamino)anthraquinone-amino acid conjugates.
AID307328	Ratio of GI50 for mitoxantrone-resistant human MX2 cells to GI50 for human HL60 cells	2007	Bioorganic & medicinal chemistry, Jun-15, Volume: 15, Issue:12	Synthesis and topoisomerase poisoning activity of A-ring and E-ring substituted luotonin A derivatives.
AID380012	Cytotoxicity against human HL60 cells after 48 hrs by MTT assay	2000	Journal of natural products, May, Volume: 63, Issue:5	New 7,20:14,20-diepoxy ent-kauranoids from Isodon xerophilus.
AID214778	Anti-tumor activity against human UACC375 melanoma cell lines by using MTT assay	1995	Journal of medicinal chemistry, Mar-17, Volume: 38, Issue:6	Amino-substituted 2-[2'-(dimethylamino)ethyl]-1,2-dihydro-3H- dibenz[de,h]isoquinoline-1,3-diones. Synthesis, antitumor activity, and quantitative structure--activity relationship.
AID84288	In vitro cytotoxic potency against HT-29 (human colon adenocarcinoma) cell line.	2002	Journal of medicinal chemistry, Jan-31, Volume: 45, Issue:3	2,6-Di(omega-aminoalkyl)-2,5,6,7-tetrahydropyrazolo[3,4,5-mn]pyrimido[5,6,1-de]acridine-5,7-diones: novel, potent, cytotoxic, and DNA-binding agents.
AID562242	Antimycobacterial activity against Mycobacterium smegmatis grown in nitrogen -limited broth medium assessed as growth inhibition in mid-logarithmic phase by spectrophotometry	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Modifying culture conditions in chemical library screening identifies alternative inhibitors of mycobacteria.
AID154568	Percent ratio of the medium survival time for P388 murine leukemia in CDF1 mice at 1.5 mg/kg	1989	Journal of medicinal chemistry, Aug, Volume: 32, Issue:8	Synthesis of unsymmetrically substituted 1,4-bis[(aminoalkyl)amino]anthracene-9,10-diones as potential antileukemic agents.
AID1439469	Cytotoxicity against mouse NIH/3T3 cells assessed as reduction in cell viability after 24 hrs by MTT assay	2017	European journal of medicinal chemistry, Mar-31, Volume: 129	Allylic isothiouronium salts: The discovery of a novel class of thiourea analogues with antitumor activity.
AID54993	Compound was evaluated for the increase in melting temperature (delta Tm) for calf Thymus DNA on interaction with Ligand at DNAp to ligand ratio 10:1	1992	Journal of medicinal chemistry, Apr-17, Volume: 35, Issue:8	Anthracene-9,10-diones as potential anticancer agents. Synthesis, DNA-binding, and biological studies on a series of 2,6-disubstituted derivatives.
AID320435	Cytotoxicity against human SF268 cells at 4 ug/ml after 48 hrs by SRB assay	2008	Bioorganic & medicinal chemistry, Jan-15, Volume: 16, Issue:2	Synthesis, DNA binding, and cytotoxicity of 1,4-bis(2-amino-ethylamino)anthraquinone-amino acid conjugates.
AID253344	Cytotoxicity against human MKN45 cancer cell line was determined after 1 hr	2004	Journal of medicinal chemistry, Oct-07, Volume: 47, Issue:21	Rational design, synthesis, and biological evaluation of bis(pyrimido[5,6,1-de]acridines) and bis(pyrazolo[3,4,5-kl]acridine-5-carboxamides) as new anticancer agents.
AID592676	Cytotoxicity against human MCF7 cells by MTT assay	2011	Bioorganic & medicinal chemistry, Apr-15, Volume: 19, Issue:8	Cytotoxic and anti-inflammatory cembranoids from the Vietnamese soft coral Lobophytum laevigatum.
AID1221962	Efflux ratio of permeability from apical to basolateral side over basolateral to apical side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 1 uM of P-gp inhibitor LY335979	2011	Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2	Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID1711987	Antimetastatic activity against mouse H22 cells implanted in Kunming mouse assessed as number of metastatic focus at 0.4 mg/kg, iv administered for 7 consecutive days starting from day 11 post inoculation and measured after 18 days (Rvb = 5.73 +/- 14.6 No	2016	European journal of medicinal chemistry, Oct-04, Volume: 121	Synthesis and biological properties of polyamine modified flavonoids as hepatocellular carcinoma inhibitors.
AID1349104	Induction of apoptosis in human Caco2 cells assessed as late apoptotic cells at 1 uM after 16 hrs by Annexin V-FITC/propidium iodide staining-based flow cytometric analysis (Rvb = 0.072%)	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	Structure-based identification of a NEDD8-activating enzyme inhibitor via drug repurposing.
AID625291	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID156652	In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line PC3	1999	Journal of medicinal chemistry, Sep-09, Volume: 42, Issue:18	8,11-dihydroxy-6-[(aminoalkyl)amino]-7H-benzo[e]perimidin-7-ones with activity in multidrug-resistant cell lines: synthesis and antitumor evaluation.
AID129072	Antileukemic activity towards P388 Murine Leukemia at a dose of 0.1 mg/kg, expressed as body weight change	1999	Journal of medicinal chemistry, Sep-09, Volume: 42, Issue:18	8,11-dihydroxy-6-[(aminoalkyl)amino]-7H-benzo[e]perimidin-7-ones with activity in multidrug-resistant cell lines: synthesis and antitumor evaluation.
AID98537	Compound was tested in vitro for cytotoxicity against L1210 murine cell line (48 hr exposure to compound)	1999	Journal of medicinal chemistry, Sep-09, Volume: 42, Issue:18	8,11-dihydroxy-6-[(aminoalkyl)amino]-7H-benzo[e]perimidin-7-ones with activity in multidrug-resistant cell lines: synthesis and antitumor evaluation.
AID1079945	Animal toxicity known. [column 'TOXIC' in source]
AID102325	In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line LoVo/Dx(RI)	1999	Journal of medicinal chemistry, Sep-09, Volume: 42, Issue:18	8,11-dihydroxy-6-[(aminoalkyl)amino]-7H-benzo[e]perimidin-7-ones with activity in multidrug-resistant cell lines: synthesis and antitumor evaluation.
AID681514	TP_TRANSPORTER: cell accumulation in MCF7/MRP1-M6 cells	2006	Molecular pharmacology, Apr, Volume: 69, Issue:4	Multidrug resistance protein 1 (MRP1, ABCC1) mediates resistance to mitoxantrone via glutathione-dependent drug efflux.
AID8690	Activity against A549 cancer cell line.	1996	Journal of medicinal chemistry, Dec-06, Volume: 39, Issue:25	2-[2'-(Dimethylamino)ethyl]-1,2-dihydro- 3H-dibenz[de,h]isoquinoline-1,3-diones with substituents at positions 4, 8, 9, 10, and 11. Synthesis, antitumor activity, and quantitative structure-activity relationships.
AID201222	Bacterial mutagenicity was measured against Salmonella Typhimurium TA1538 at dose range of 0-5 ug/plate	1998	Journal of medicinal chemistry, Sep-10, Volume: 41, Issue:19	Anthracene-9,10-diones as potential anticancer agents: bacterial mutation studies of amido-substituted derivatives reveal an unexpected lack of mutagenicity.
AID624629	Inhibition of Pgp expressed in MDR1-MDCKII cells measured by calcein-AM assay	2001	The Journal of pharmacology and experimental therapeutics, Nov, Volume: 299, Issue:2	Rational use of in vitro P-glycoprotein assays in drug discovery.
AID588218	FDA HLAED, lactate dehydrogenase (LDH) increase	2004	Current drug discovery technologies, Dec, Volume: 1, Issue:4	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID83602	In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line HT-29	1999	Journal of medicinal chemistry, Sep-09, Volume: 42, Issue:18	8,11-dihydroxy-6-[(aminoalkyl)amino]-7H-benzo[e]perimidin-7-ones with activity in multidrug-resistant cell lines: synthesis and antitumor evaluation.
AID681062	TP_TRANSPORTER: Northern blot from primary hepatocytes	1996	Biochemical pharmacology, Nov-08, Volume: 52, Issue:9	Multidrug resistance gene expression in rodents and rodent hepatocytes treated with mitoxantrone.
AID699539	Inhibition of human liver OATP1B1 expressed in HEK293 Flp-In cells assessed as reduction in E17-betaG uptake at 20 uM by scintillation counting	2012	Journal of medicinal chemistry, May-24, Volume: 55, Issue:10	Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
AID72412	Cytotoxic potency required to inhibit G-361 cell growth by 50%	1997	Journal of medicinal chemistry, Nov-07, Volume: 40, Issue:23	1-[(omega-aminoalkyl)amino]-4-[N-(omega-aminoalkyl)carbamoyl]-9-oxo-9, 10-dihydroacridines as intercalating cytotoxic agents: synthesis, DNA binding, and biological evaluation.
AID436893	Bacteriostatic activity against imipenem-non resistant Escherichia coli BL21(DE3) at 2.1 ug/mL after 24 hrs by broth microdilution method	2009	Bioorganic & medicinal chemistry, Jul-15, Volume: 17, Issue:14	Inhibitors of VIM-2 by screening pharmacologically active and click-chemistry compound libraries.
AID1349096	Inhibition of NAE in human Caco2 cells assessed as increase in beta-catenin protein levels after 16 hrs by Western blot analysis	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	Structure-based identification of a NEDD8-activating enzyme inhibitor via drug repurposing.
AID47499	Cytotoxic potency required to inhibit CH1 cell growth by 50%	1997	Journal of medicinal chemistry, Nov-07, Volume: 40, Issue:23	1-[(omega-aminoalkyl)amino]-4-[N-(omega-aminoalkyl)carbamoyl]-9-oxo-9, 10-dihydroacridines as intercalating cytotoxic agents: synthesis, DNA binding, and biological evaluation.
AID1271102	Cytotoxicity against rat C6 cells after 24 hrs by MTT assay	2016	European journal of medicinal chemistry, Jan-01, Volume: 107	Synthesis and evaluation of bis-thiazole derivatives as new anticancer agents.
AID1506785	Induction of apoptosis in human HCC78 cells assessed as late apoptotic cells level at 10 nM incubated fro 48 hrs by Annexin-V FITC and propidium iodide staining based flow cytometry (Rvb = 13.8%)	2017	MedChemComm, Mar-01, Volume: 8, Issue:3	Identification of mitoxantrone as a new inhibitor of ROS1 fusion protein in non-small cell lung cancer cells.
AID647961	Inhibition of human TERT expression in H1299 cells at 100 uM after 24 hrs by secreted alkaline phosphatase reporter gene assay relative to control	2012	European journal of medicinal chemistry, Apr, Volume: 50	Design, synthesis and evaluation of telomerase inhibitory, hTERT repressing, and anti-proliferation activities of symmetrical 1,8-disubstituted amidoanthraquinones.
AID98910	Inhibitory activity against resistant murine leukemia L1210 cell lines.	1996	Journal of medicinal chemistry, Apr-12, Volume: 39, Issue:8	6- and 7-substituted 2-[2'-(dimethylamino)ethyl]-1,2-dihydro-3H-dibenz[de,h] isoquinoline-1,3-diones: synthesis, nucleophilic displacements, antitumor activity, and quantitative structure-activity relationships.
AID1271104	Cytotoxicity against mouse NIH/3T3 cells after 24 hrs by MTT assay	2016	European journal of medicinal chemistry, Jan-01, Volume: 107	Synthesis and evaluation of bis-thiazole derivatives as new anticancer agents.
AID1550895	Antitumor activity against mouse H22 cells allografted in immunocompetent Balb/c mouse assessed as inhibition of tumour formation at 2 uM incubated with cells for 5 hrs prior to 20 mins 2 mW/cm2 UVA irradiation post compound washout followed by vaccinatio	2019	European journal of medicinal chemistry, Jun-01, Volume: 171	Naphthyl quinoxaline thymidine conjugate is a potent anticancer agent post UVA activation and elicits marked inhibition of tumor growth through vaccination.
AID1130617	Antitumor activity against mouse P388 cells allografted in mouse assessed as increase of median life span at 6.2 mg/kg, ip on day 1, 5 and 9 measured up to 60 days relative to control	1979	Journal of medicinal chemistry, Sep, Volume: 22, Issue:9	Antitumor agents. 1. 1,4-Bis[(aminoalkyl)amino]-9,10-anthracenediones.
AID216451	Activity against sensitive cell line of WiDr human colon tumor	1995	Journal of medicinal chemistry, Mar-17, Volume: 38, Issue:6	Amino-substituted 2-[2'-(dimethylamino)ethyl]-1,2-dihydro-3H- dibenz[de,h]isoquinoline-1,3-diones. Synthesis, antitumor activity, and quantitative structure--activity relationship.
AID1130149	Antineoplastic activity against mouse B16 cells allografted in BDF1 mouse at 2 mg/kg qd for 9 days relative to control	1979	Journal of medicinal chemistry, May, Volume: 22, Issue:5	Structural modification study of bis(substituted aminoalkylamino)anthraquinones. An evaluation of the relationship of the [2-[(2-hydroxyethyl)amino]ethyl]amino side chain with antineoplastic activity.
AID103088	In vitro inhibition of tumor cell growth in the human mammary carcinoma MCF-7/ADR system.	1992	Journal of medicinal chemistry, Nov-13, Volume: 35, Issue:23	Novel non-cross resistant diaminoanthraquinones as potential chemotherapeutic agents.
AID216595	Activity against human colon carcinoma sensitive WiDr cell line.	1996	Journal of medicinal chemistry, Dec-06, Volume: 39, Issue:25	2-[2'-(Dimethylamino)ethyl]-1,2-dihydro- 3H-dibenz[de,h]isoquinoline-1,3-diones with substituents at positions 4, 8, 9, 10, and 11. Synthesis, antitumor activity, and quantitative structure-activity relationships.
AID243266	Thermal denaturation of calf thymus DNA at 37 degree C	2004	Bioorganic & medicinal chemistry letters, Oct-04, Volume: 14, Issue:19	Pyrrolo[2,1-c][1,4]benzodiazepine-anthraquinone conjugates. Synthesis, DNA binding and cytotoxicity.
AID1883020	Toxicity in Balb/c mouse implanted with mouse 4T1 cells assessed as heart lesions at 50 mg/kg administered intratumorally every four days for 14 days in the presence of liquid cyanoacrylate by H&E staining based histopathological analysis	2022	European journal of medicinal chemistry, Jul-05, Volume: 237	Design, synthesis, and evaluation of a novel series of mono-indolylbenzoquinones derivatives for the potential treatment of breast cancer.
AID721742	Ratio of Cmax unbound to IC50 for human MATE1-mediated [14]-metformin uptake expressed in polarized MDCK2 cells	2013	Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3	Discovery of potent, selective multidrug and toxin extrusion transporter 1 (MATE1, SLC47A1) inhibitors through prescription drug profiling and computational modeling.
AID1132511	Toxicity in mouse P388 cells allografted BDF1 mouse assessed as body weight difference at 0.12 mg/kg administered 24 hrs post challenge relative to control	1978	Journal of medicinal chemistry, Mar, Volume: 21, Issue:3	Antineoplastic agents. Structure-activity relationship study of bis(substituted aminoalkylamino)anthraquinones.
AID1130159	Antineoplastic activity against mouse Colon 26 cells allografted in CDF1 mouse at 0.69 mg/kg qd for 9 days relative to control	1979	Journal of medicinal chemistry, May, Volume: 22, Issue:5	Structural modification study of bis(substituted aminoalkylamino)anthraquinones. An evaluation of the relationship of the [2-[(2-hydroxyethyl)amino]ethyl]amino side chain with antineoplastic activity.
AID381805	Binding affinity to calf thymus DNA assessed as change in thermal stability at 2 uM in tris-HCl buffer at pH 7.5 by thermal denaturation assay	2008	Bioorganic & medicinal chemistry, Apr-01, Volume: 16, Issue:7	The structure-based design, synthesis and biological evaluation of DNA-binding bisintercalating bisanthrapyrazole anticancer compounds.
AID540213	Half life in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID216450	Activity against resistant cell line of WiDr human colon tumor	1995	Journal of medicinal chemistry, Mar-17, Volume: 38, Issue:6	Amino-substituted 2-[2'-(dimethylamino)ethyl]-1,2-dihydro-3H- dibenz[de,h]isoquinoline-1,3-diones. Synthesis, antitumor activity, and quantitative structure--activity relationship.
AID1209590	Drug uptake in Sprague-Dawley rat brain slices at 100 nM after 5 hrs in presence of 20 uM of MK-571	2011	Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3	Measurement of unbound drug exposure in brain: modeling of pH partitioning explains diverging results between the brain slice and brain homogenate methods.
AID46325	Thermal denaturation of calf-thymus DNA was evaluated	1993	Journal of medicinal chemistry, Jul-23, Volume: 36, Issue:15	Synthesis and antitumor properties of an anthraquinone bisubstituted by the copper chelating peptide Gly-Gly-L-His.
AID1079932	Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID47668	Concentration required to inhibit CH1-cell growth by 50%	1998	Journal of medicinal chemistry, Aug-13, Volume: 41, Issue:17	1,4- and 2,6-disubstituted amidoanthracene-9,10-dione derivatives as inhibitors of human telomerase.
AID136070	Antileukemic activity towards P388 Murine Leukemia at a dose of 0.2 mg/kg	1999	Journal of medicinal chemistry, Sep-09, Volume: 42, Issue:18	8,11-dihydroxy-6-[(aminoalkyl)amino]-7H-benzo[e]perimidin-7-ones with activity in multidrug-resistant cell lines: synthesis and antitumor evaluation.
AID248039	Cytotoxicity against human H460M cancer cell line was determined after 144 hr	2004	Journal of medicinal chemistry, Oct-07, Volume: 47, Issue:21	Rational design, synthesis, and biological evaluation of bis(pyrimido[5,6,1-de]acridines) and bis(pyrazolo[3,4,5-kl]acridine-5-carboxamides) as new anticancer agents.
AID540210	Clearance in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID318700	Antiproliferative activity against human MDA-MB-231 cells	2008	Bioorganic & medicinal chemistry, Mar-15, Volume: 16, Issue:6	Design, synthesis and cell growth inhibitory activity of a series of novel aminosubstituted xantheno[1,2-d]imidazoles in breast cancer cells.
AID588975	Substrates of transporters of clinical importance in the absorption and disposition of drugs, BCRP	2010	Nature reviews. Drug discovery, Mar, Volume: 9, Issue:3	Membrane transporters in drug development.
AID1130174	Antineoplastic activity against mouse P388 cells allografted in CDF1 mouse assessed as survival at 1 mg/kg qd for 9 days	1979	Journal of medicinal chemistry, May, Volume: 22, Issue:5	Structural modification study of bis(substituted aminoalkylamino)anthraquinones. An evaluation of the relationship of the [2-[(2-hydroxyethyl)amino]ethyl]amino side chain with antineoplastic activity.
AID1132470	Antitumor activity against mouse P388 cells allografted in BDF1 mouse assessed as increase in survival time at 0.5 mg/kg administered 24 hrs post challenge relative to control	1978	Journal of medicinal chemistry, Mar, Volume: 21, Issue:3	Antineoplastic agents. Structure-activity relationship study of bis(substituted aminoalkylamino)anthraquinones.
AID102330	Inhibitory activity against human colon adenocarcinoma cell line LoVo/Dx.	1995	Journal of medicinal chemistry, Feb-03, Volume: 38, Issue:3	Chromophore-modified antitumor anthracenediones: synthesis, DNA binding, and cytotoxic activity of 1,4-bis[(aminoalkyl)amino]benzo[g]-phthalazine-5,10-diones.
AID320433	Cytotoxicity against human MCF7 cells at 4 ug/ml after 48 hrs by SRB assay	2008	Bioorganic & medicinal chemistry, Jan-15, Volume: 16, Issue:2	Synthesis, DNA binding, and cytotoxicity of 1,4-bis(2-amino-ethylamino)anthraquinone-amino acid conjugates.
AID1079942	Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID624622	Apparent permeability (Papp) from apical to basolateral side determined in MDR1-MDCKII cells	2001	The Journal of pharmacology and experimental therapeutics, Nov, Volume: 299, Issue:2	Rational use of in vitro P-glycoprotein assays in drug discovery.
AID1130163	Antineoplastic activity against mouse L1210 cells allografted in CDF1 mouse at 18 mg/kg qd for 9 days relative to control	1979	Journal of medicinal chemistry, May, Volume: 22, Issue:5	Structural modification study of bis(substituted aminoalkylamino)anthraquinones. An evaluation of the relationship of the [2-[(2-hydroxyethyl)amino]ethyl]amino side chain with antineoplastic activity.
AID1130171	Antineoplastic activity against mouse L1210 cells allografted in CDF1 mouse at 1 mg/kg qd for 9 days relative to control	1979	Journal of medicinal chemistry, May, Volume: 22, Issue:5	Structural modification study of bis(substituted aminoalkylamino)anthraquinones. An evaluation of the relationship of the [2-[(2-hydroxyethyl)amino]ethyl]amino side chain with antineoplastic activity.
AID364460	Cytotoxicity against human HeLa cells expressing telomerase after 96 hrs by MTT assay	2008	Journal of medicinal chemistry, Sep-25, Volume: 51, Issue:18	Aminoacyl-anthraquinone conjugates as telomerase inhibitors: synthesis, biophysical and biological evaluation.
AID320441	Cytotoxicity against human NCI-H460 cells after 48 hrs by SRB assay	2008	Bioorganic & medicinal chemistry, Jan-15, Volume: 16, Issue:2	Synthesis, DNA binding, and cytotoxicity of 1,4-bis(2-amino-ethylamino)anthraquinone-amino acid conjugates.
AID320440	Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay	2008	Bioorganic & medicinal chemistry, Jan-15, Volume: 16, Issue:2	Synthesis, DNA binding, and cytotoxicity of 1,4-bis(2-amino-ethylamino)anthraquinone-amino acid conjugates.
AID121351	Therapeutic effect against P388 leukemia in mice on days 1, 5 and 9 after administration of 1.6 mg/kg dose expressed as median survival time of treated and control mice (in vivo)	1993	Journal of medicinal chemistry, Jul-23, Volume: 36, Issue:15	Synthesis and antitumor properties of an anthraquinone bisubstituted by the copper chelating peptide Gly-Gly-L-His.
AID1271101	Cytotoxicity against human A549 cells after 24 hrs by MTT assay	2016	European journal of medicinal chemistry, Jan-01, Volume: 107	Synthesis and evaluation of bis-thiazole derivatives as new anticancer agents.
AID84437	Cytotoxic potency required to inhibit HT-29 cell growth by 50% after cell drug contact for 144 hrs	1997	Journal of medicinal chemistry, Nov-07, Volume: 40, Issue:23	1-[(omega-aminoalkyl)amino]-4-[N-(omega-aminoalkyl)carbamoyl]-9-oxo-9, 10-dihydroacridines as intercalating cytotoxic agents: synthesis, DNA binding, and biological evaluation.
AID1079933	Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID270853	Antiproliferative activity against HT29 cells by MTT assay after 72 hrs	2006	Bioorganic & medicinal chemistry letters, Sep-15, Volume: 16, Issue:18	Synthesis and antiproliferative activity of substituted benzopyranoisoindoles: a new class of cytotoxic compounds.
AID1550902	Antitumor activity against mouse H22 cells allografted in immunocompetent Balb/c mouse assessed as decrease in lump formation in vaccination site at 2 uM incubated with cells for 5 hrs prior to 20 mins 2 mW/cm2 UVA irradiation post compound washout follow	2019	European journal of medicinal chemistry, Jun-01, Volume: 171	Naphthyl quinoxaline thymidine conjugate is a potent anticancer agent post UVA activation and elicits marked inhibition of tumor growth through vaccination.
AID1233375	Ratio of IC50 for human MES-SA/Dx5 cells to IC50 for human MES-SA cells	2015	Bioorganic & medicinal chemistry letters, Jul-01, Volume: 25, Issue:13	Synthesis and antiproliferative activity of some novel benzo-fused imidazo[1,8]naphthyridinones.
AID1197747	Inhibition of human OATP1B3-mediated [3H]CCK-8 after 5 mins by Dixon plot method	2015	European journal of medicinal chemistry, Mar-06, Volume: 92	Interaction of human organic anion transporter polypeptides 1B1 and 1B3 with antineoplastic compounds.
AID1130178	Antineoplastic activity against mouse P388 cells allografted in CDF1 mouse assessed as survival at 0.25 mg/kg qd for 9 days	1979	Journal of medicinal chemistry, May, Volume: 22, Issue:5	Structural modification study of bis(substituted aminoalkylamino)anthraquinones. An evaluation of the relationship of the [2-[(2-hydroxyethyl)amino]ethyl]amino side chain with antineoplastic activity.
AID154372	Optimal dose per injection in mg/kg required to inhibit growth of P388 leukemia cells in mice	1987	Journal of medicinal chemistry, Jan, Volume: 30, Issue:1	Anthrapyrazole anticancer agents. Synthesis and structure-activity relationships against murine leukemias.
AID1079938	Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID1474167	Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status	2016	Drug discovery today, Apr, Volume: 21, Issue:4	DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID477017	Displacement of ethidium bromide from calf thymus DNA assessed as decrease of fluorescence of bound ethidium bromide by fluorometric assay	2010	European journal of medicinal chemistry, Apr, Volume: 45, Issue:4	Synthesis, cytotoxicity and DNA-binding of novel bisnaphthalimidopropyl derivatives in breast cancer MDA-MB-231 cells.
AID381807	Growth inhibition of etoposide-resistant human K/VP.5 cells after 72 hrs by MTS method	2008	Bioorganic & medicinal chemistry, Apr-01, Volume: 16, Issue:7	The structure-based design, synthesis and biological evaluation of DNA-binding bisintercalating bisanthrapyrazole anticancer compounds.
AID1130170	Antineoplastic activity against mouse L1210 cells allografted in CDF1 mouse assessed as survival at 1 mg/kg qd for 9 days	1979	Journal of medicinal chemistry, May, Volume: 22, Issue:5	Structural modification study of bis(substituted aminoalkylamino)anthraquinones. An evaluation of the relationship of the [2-[(2-hydroxyethyl)amino]ethyl]amino side chain with antineoplastic activity.
AID98563	Cytotoxic potency required to inhibit L1210 cell growth by 50% after cell drug contact for 48 hrs	1997	Journal of medicinal chemistry, Nov-07, Volume: 40, Issue:23	1-[(omega-aminoalkyl)amino]-4-[N-(omega-aminoalkyl)carbamoyl]-9-oxo-9, 10-dihydroacridines as intercalating cytotoxic agents: synthesis, DNA binding, and biological evaluation.
AID436885	Bactericidal activity against imipenem-non resistant Escherichia coli BL21(DE3) at 2.1 ug/mL after 24 hrs by broth microdilution method	2009	Bioorganic & medicinal chemistry, Jul-15, Volume: 17, Issue:14	Inhibitors of VIM-2 by screening pharmacologically active and click-chemistry compound libraries.
AID1550871	Cytotoxicity against human Bel7402 cells assessed as reduction in cell viability preincubated for 5 hrs followed by compound washout and measured after 48 hrs by CCK8 assay	2019	European journal of medicinal chemistry, Jun-01, Volume: 171	Naphthyl quinoxaline thymidine conjugate is a potent anticancer agent post UVA activation and elicits marked inhibition of tumor growth through vaccination.
AID687167	Ratio of IC50 for human CCRF-CEM/VM-1-5 cells IC50 for human CCRF-CEM cells	2012	Journal of medicinal chemistry, Jun-14, Volume: 55, Issue:11	Structure-activity relationship (SAR) study of ethyl 2-amino-6-(3,5-dimethoxyphenyl)-4-(2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate (CXL017) and the potential of the lead against multidrug resistance in cancer treatment.
AID1209591	Drug uptake in Sprague-Dawley rat brain slices at 100 nM after 5 hrs in presence of 10 uM of fumitremorgin-C and 20 uM of MK-571	2011	Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3	Measurement of unbound drug exposure in brain: modeling of pH partitioning explains diverging results between the brain slice and brain homogenate methods.
AID232808	The quotient of the IC50 in the myocytes divided by the mean IC50 in the three cell lines	1996	Journal of medicinal chemistry, Dec-06, Volume: 39, Issue:25	2-[2'-(Dimethylamino)ethyl]-1,2-dihydro- 3H-dibenz[de,h]isoquinoline-1,3-diones with substituents at positions 4, 8, 9, 10, and 11. Synthesis, antitumor activity, and quantitative structure-activity relationships.
AID134227	The compound was tested for antitumor activity against P388 murine leukemia by measuring maximum tolerated dose	1994	Journal of medicinal chemistry, Mar-18, Volume: 37, Issue:6	6,9-Bis[(aminoalkyl)amino]benzo[g]isoquinoline-5,10-diones. A novel class of chromophore-modified antitumor anthracene-9,10-diones: synthesis and antitumor evaluations.
AID1506773	Cytotoxicity in human CCD-19Lu cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	2017	MedChemComm, Mar-01, Volume: 8, Issue:3	Identification of mitoxantrone as a new inhibitor of ROS1 fusion protein in non-small cell lung cancer cells.
AID1209582	Unbound volume of distribution in Sprague-Dawley rat brain slices at 100 nM after 5 hrs	2011	Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3	Measurement of unbound drug exposure in brain: modeling of pH partitioning explains diverging results between the brain slice and brain homogenate methods.
AID436883	Inhibition of VIM2 in imipenem-resistant Escherichia coli BL21(DE3) assessed as potentiation of imipenem-induced bactericidal activity at 2.1 ug/mL after 18 hrs by checkerboard microdilution method	2009	Bioorganic & medicinal chemistry, Jul-15, Volume: 17, Issue:14	Inhibitors of VIM-2 by screening pharmacologically active and click-chemistry compound libraries.
AID1506798	Inhibition of ROS1 in human HCC78 cells assessed as reduction in ERK phosphorylation incubated for 48 hrs by Western blot method	2017	MedChemComm, Mar-01, Volume: 8, Issue:3	Identification of mitoxantrone as a new inhibitor of ROS1 fusion protein in non-small cell lung cancer cells.
AID272491	Antiproliferative activity against multidrug resistant MDA435/LCC6 cells by ELISA	2006	Journal of medicinal chemistry, Nov-16, Volume: 49, Issue:23	Flavonoid dimers as bivalent modulators for P-glycoprotein-based multidrug resistance: synthetic apigenin homodimers linked with defined-length poly(ethylene glycol) spacers increase drug retention and enhance chemosensitivity in resistant cancer cells.
AID733190	Antiproliferative activity against human RKOp27 cells after 48 hrs	2013	Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6	Synthesis and biological evaluation of new cytotoxic indazolo[4,3-gh]isoquinolinone derivatives.
AID1525935	Inhibition of MDR in human LCC6MDR cells assessed as reduction in cell viability after 5 days by MTS/PMS assay	2019	Journal of medicinal chemistry, 09-26, Volume: 62, Issue:18	Triazole Bridged Flavonoid Dimers as Potent, Nontoxic, and Highly Selective Breast Cancer Resistance Protein (BCRP/ABCG2) Inhibitors.
AID588212	Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents	2010	Chemical research in toxicology, Jan, Volume: 23, Issue:1	Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID524794	Antiplasmodial activity against Plasmodium falciparum GB4 after 72 hrs by SYBR green assay	2009	Nature chemical biology, Oct, Volume: 5, Issue:10	Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID436895	Inhibition of VIM2 in imipenem-resistant Escherichia coli BL21(DE3) assessed as potentiation of imipenem-induced bactericidal activity at 8.4 ug/mL after 18 hrs by checkerboard microdilution method	2009	Bioorganic & medicinal chemistry, Jul-15, Volume: 17, Issue:14	Inhibitors of VIM-2 by screening pharmacologically active and click-chemistry compound libraries.
AID540211	Fraction unbound in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1506790	Induction of apoptosis in human HCC78 cells assessed as necrotic cells level at 20 nM incubated fro 48 hrs by Annexin-V FITC and propidium iodide staining based flow cytometry (Rvb = 0.06%)	2017	MedChemComm, Mar-01, Volume: 8, Issue:3	Identification of mitoxantrone as a new inhibitor of ROS1 fusion protein in non-small cell lung cancer cells.
AID588214	FDA HLAED, liver enzyme composite activity	2004	Current drug discovery technologies, Dec, Volume: 1, Issue:4	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID681494	TP_TRANSPORTER: Northern blot in vivo Wistar rat	1996	Biochemical pharmacology, Nov-08, Volume: 52, Issue:9	Multidrug resistance gene expression in rodents and rodent hepatocytes treated with mitoxantrone.
AID721748	Inhibition of human MATE2K-mediated ASP+ uptake expressed in HEK293 cells up to 500 uM after 1.5 mins by fluorescence assay	2013	Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3	Discovery of potent, selective multidrug and toxin extrusion transporter 1 (MATE1, SLC47A1) inhibitors through prescription drug profiling and computational modeling.
AID1132512	Toxicity in mouse P388 cells allografted BDF1 mouse assessed as body weight difference at 0.06 mg/kg administered 24 hrs post challenge relative to control	1978	Journal of medicinal chemistry, Mar, Volume: 21, Issue:3	Antineoplastic agents. Structure-activity relationship study of bis(substituted aminoalkylamino)anthraquinones.
AID1130169	Antineoplastic activity against mouse L1210 cells allografted in CDF1 mouse at 2 mg/kg qd for 9 days relative to control	1979	Journal of medicinal chemistry, May, Volume: 22, Issue:5	Structural modification study of bis(substituted aminoalkylamino)anthraquinones. An evaluation of the relationship of the [2-[(2-hydroxyethyl)amino]ethyl]amino side chain with antineoplastic activity.
AID334268	Cytotoxicity against human K562 cells after 48 hrs by MTT assay	2002	Journal of natural products, May, Volume: 65, Issue:5	Abietane diterpenoids from Coleus xanthanthus.
AID624606	Specific activity of expressed human recombinant UGT1A1	2000	Annual review of pharmacology and toxicology, , Volume: 40	Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID721750	Inhibition of human OCT1-mediated ASP+ uptake expressed in HEK293 cells after 3 mins by fluorescence assay	2013	Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3	Discovery of potent, selective multidrug and toxin extrusion transporter 1 (MATE1, SLC47A1) inhibitors through prescription drug profiling and computational modeling.
AID248010	Cytotoxicity against human PC3 cancer cell line was determined after 144 hr	2004	Journal of medicinal chemistry, Oct-07, Volume: 47, Issue:21	Rational design, synthesis, and biological evaluation of bis(pyrimido[5,6,1-de]acridines) and bis(pyrazolo[3,4,5-kl]acridine-5-carboxamides) as new anticancer agents.
AID1349086	Inhibition of NAE (unknown origin) assessed as decrease in NAE-mediated Ubc12-NEDD8 conjugation levels preincubated for 10 mins followed by ATP and Mg2+ addition measured after 60 mins by Western blot analysis	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	Structure-based identification of a NEDD8-activating enzyme inhibitor via drug repurposing.
AID679173	TP_TRANSPORTER: drug resistance in BCRP-expressing K562 cells	2003	Molecular cancer therapeutics, Jan, Volume: 2, Issue:1	Reversal of breast cancer resistance protein-mediated drug resistance by estrogen antagonists and agonists.
AID83791	Percent inhibition at G2/M phase of cell cycle at a dose of 100n g/mL after 72 hours of induction in HT-29 cell line	1999	Journal of medicinal chemistry, Sep-09, Volume: 42, Issue:18	8,11-dihydroxy-6-[(aminoalkyl)amino]-7H-benzo[e]perimidin-7-ones with activity in multidrug-resistant cell lines: synthesis and antitumor evaluation.
AID1586108	Antiproliferative activity against human A549 cells after 72 hrs by sulforhodamine B assay	2018	Journal of natural products, 12-28, Volume: 81, Issue:12	A Pair of Enantiomeric Bis- seco-abietane Diterpenoids from Cryptomeria fortunei.
AID1711939	Antiproliferative activity against human SMMC-7221 cells assessed as inhibition of cell proliferation at 1 uM measured after 48 hrs by MTT assay relative to control	2016	European journal of medicinal chemistry, Oct-04, Volume: 121	Synthesis and biological properties of polyamine modified flavonoids as hepatocellular carcinoma inhibitors.
AID625281	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1711940	Antiproliferative activity against human SMMC-7221 cells assessed as inhibition of cell proliferation at 5 uM measured after 48 hrs by MTT assay relative to control	2016	European journal of medicinal chemistry, Oct-04, Volume: 121	Synthesis and biological properties of polyamine modified flavonoids as hepatocellular carcinoma inhibitors.
AID1349110	Induction of apoptosis in human Caco2 cells assessed as viable cells at 10 uM after 16 hrs by Annexin V-FITC/propidium iodide staining-based flow cytometric analysis (Rvb = 98.4%)	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	Structure-based identification of a NEDD8-activating enzyme inhibitor via drug repurposing.
AID562240	Antimycobacterial activity against Mycobacterium smegmatis grown in Luria-Bertani broth medium assessed as growth inhibition in mid-logarithmic phase by spectrophotometry	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Modifying culture conditions in chemical library screening identifies alternative inhibitors of mycobacteria.
AID524792	Antiplasmodial activity against Plasmodium falciparum D10 after 72 hrs by SYBR green assay	2009	Nature chemical biology, Oct, Volume: 5, Issue:10	Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID85757	In vitro cytotoxic activity against human colon HT-29 cell line ( standard deviation in parenthesis)	2002	Journal of medicinal chemistry, Jun-06, Volume: 45, Issue:12	Design, synthesis, and antiproliferative activity of some new pyrazole-fused amino derivatives of the pyranoxanthenone, pyranothioxanthenone, and pyranoacridone ring systems: a new class of cytotoxic agents.
AID103419	Tested for inhibitory activity against human tumor cell line D40, a strain resistant to doxorubicin of breast carcinoma using sulforhodamine B assay.	2000	Journal of medicinal chemistry, Aug-10, Volume: 43, Issue:16	Analogues of amonafide and azonafide with novel ring systems.
AID106296	Antitumor activity against human mammary carcinoma mitoxantrone-resistant MXF7 breast cell line.	1996	Journal of medicinal chemistry, Dec-06, Volume: 39, Issue:25	2-[2'-(Dimethylamino)ethyl]-1,2-dihydro- 3H-dibenz[de,h]isoquinoline-1,3-diones with substituents at positions 4, 8, 9, 10, and 11. Synthesis, antitumor activity, and quantitative structure-activity relationships.
AID591076	Cytotoxicity against human HL60/MX2 cells	2011	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 21, Issue:8	Synthesis, cytotoxicity and topoisomerase inhibition properties of multifarious aminoalkylated indeno[1,2-c]isoquinolin-5,11-diones.
AID153899	In vivo antitumor activity against P388 leukemia cells at a dose of 0.75 mg/kg as a single injection and 1.5 mg/kg as a total	1984	Journal of medicinal chemistry, Mar, Volume: 27, Issue:3	5-[(Aminoalkyl)amino]-substituted anthra[1,9-cd]pyrazol-6(2H)-ones as novel anticancer agents. Synthesis and biological evaluation.
AID1903854	Antitumor immunity against human U2OS cells expressing CALR-GFP fusion protein assessed as accumulation CALR-GFP fusion protein at 3 uM measured upto 24 hrs by live cell microscopic analysis	2022	Journal of medicinal chemistry, 03-24, Volume: 65, Issue:6	Biological Investigation of a Water-Soluble Isoginkgetin-Phosphate Analogue, Targeting the Spliceosome with
AID87741	Effective concentration required to inhibit by 50% the growth of HeLa S3 cells	1988	Journal of medicinal chemistry, Oct, Volume: 31, Issue:10	Synthesis and antineoplastic evaluation of 1,4-bis(aminoalkanamido)-9,10-anthracenediones.
AID540209	Volume of distribution at steady state in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1396805	Antiproliferative activity against human HL60 cells after 72 hrs by SRB assay	2018	Bioorganic & medicinal chemistry letters, 08-15, Volume: 28, Issue:15	Phosphorus-containing isothiocyanate-derived mercapturic acids as a useful alternative for parental isothiocyanates in experimental oncology.
AID404700	Cytotoxicity against mitoxantrone-resistant human HL60/MX2 cells after 72 hrs	2008	Journal of medicinal chemistry, Jun-26, Volume: 51, Issue:12	Synthesis, cytotoxicity, DNA interaction, and topoisomerase II inhibition properties of novel indeno[2,1-c]quinolin-7-one and indeno[1,2-c]isoquinolin-5,11-dione derivatives.
AID404701	Resistant index, ratio of IC50 for mitoxantrone-resistant human HL60/MX2 cells to IC50 for mitoxantrone-sensitive human HL60 cells	2008	Journal of medicinal chemistry, Jun-26, Volume: 51, Issue:12	Synthesis, cytotoxicity, DNA interaction, and topoisomerase II inhibition properties of novel indeno[2,1-c]quinolin-7-one and indeno[1,2-c]isoquinolin-5,11-dione derivatives.
AID320437	Cytotoxicity against human HL60 cells after 48 hrs by MTT assay	2008	Bioorganic & medicinal chemistry, Jan-15, Volume: 16, Issue:2	Synthesis, DNA binding, and cytotoxicity of 1,4-bis(2-amino-ethylamino)anthraquinone-amino acid conjugates.
AID272512	Relative fold, IC50 in absence to presence of 1,13-bis[4'-((5,7-dihydroxy)-4H-chromen-4-on-2-yl)phenyl]-1,4,7,10,13-pentaoxatridecane in multidrug resistant MDA435/LCC6 cells	2006	Journal of medicinal chemistry, Nov-16, Volume: 49, Issue:23	Flavonoid dimers as bivalent modulators for P-glycoprotein-based multidrug resistance: synthetic apigenin homodimers linked with defined-length poly(ethylene glycol) spacers increase drug retention and enhance chemosensitivity in resistant cancer cells.
AID1079946	Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID1711981	Toxicity in Kunming mouse implanted with mouse H22 cells assessed as change in mouse body weight at 0.4 mg/kg, iv administered for 7 consecutive days starting from day 8 post inoculation and measured after 16 days (Rvb = 21 %)	2016	European journal of medicinal chemistry, Oct-04, Volume: 121	Synthesis and biological properties of polyamine modified flavonoids as hepatocellular carcinoma inhibitors.
AID477016	Binding affinity to calf thymus DNA assessed as temperature required to cause 50% of DNA denatured at 10 uM by thermal denaturation assay	2010	European journal of medicinal chemistry, Apr, Volume: 45, Issue:4	Synthesis, cytotoxicity and DNA-binding of novel bisnaphthalimidopropyl derivatives in breast cancer MDA-MB-231 cells.
AID135061	In vivo antileukemic activity towards P388 Murine Leukemia at a dose of 0.8 mg/kg, expressed as long time survivors tested in 6 animals	1999	Journal of medicinal chemistry, Sep-09, Volume: 42, Issue:18	8,11-dihydroxy-6-[(aminoalkyl)amino]-7H-benzo[e]perimidin-7-ones with activity in multidrug-resistant cell lines: synthesis and antitumor evaluation.
AID537734	Antifungal activity against yeast AD1-8u expressing Candida albicans CaMdr1p by agar disk diffusion assay	2010	European journal of medicinal chemistry, Nov, Volume: 45, Issue:11	Analysis of physico-chemical properties of substrates of ABC and MFS multidrug transporters of pathogenic Candida albicans.
AID1711982	Toxicity in iv dosed Kunming mouse assessed as maximum tolerated dose	2016	European journal of medicinal chemistry, Oct-04, Volume: 121	Synthesis and biological properties of polyamine modified flavonoids as hepatocellular carcinoma inhibitors.
AID202844	Concentration required to inhibit SKOV-3-cell growth by 50%	1998	Journal of medicinal chemistry, Aug-13, Volume: 41, Issue:17	1,4- and 2,6-disubstituted amidoanthracene-9,10-dione derivatives as inhibitors of human telomerase.
AID230412	It is the ratio of IC50 for LOVO tumor cell line to that of LOVO/DOXO cell line.	1991	Journal of medicinal chemistry, Aug, Volume: 34, Issue:8	Synthesis and antitumor evaluations of symmetrically and unsymmetrically substituted 1,4-bis[(aminoalkyl)amino]anthracene-9,10-diones and 1,4-bis[(aminoalkyl)amino]-5,8-dihydroxyanthracene-9,10-diones.
AID436892	Bacteriostatic activity against imipenem-resistant Escherichia coli BL21(DE3) expressing VIM2 gene at 2.1 ug/mL after 24 hrs by broth microdilution method	2009	Bioorganic & medicinal chemistry, Jul-15, Volume: 17, Issue:14	Inhibitors of VIM-2 by screening pharmacologically active and click-chemistry compound libraries.
AID729382	Inhibition of BTK (unknown origin)	2013	Journal of medicinal chemistry, Mar-28, Volume: 56, Issue:6	A new target for an old drug: identifying mitoxantrone as a nanomolar inhibitor of PIM1 kinase via kinome-wide selectivity modeling.
AID1132508	Toxicity in mouse P388 cells allografted BDF1 mouse assessed as body weight difference at 1 mg/kg administered 24 hrs post challenge relative to control	1978	Journal of medicinal chemistry, Mar, Volume: 21, Issue:3	Antineoplastic agents. Structure-activity relationship study of bis(substituted aminoalkylamino)anthraquinones.
AID216575	Tested against WiDr colon (sensitive) in the sulforhodamine B assay.	1996	Journal of medicinal chemistry, Apr-12, Volume: 39, Issue:8	6- and 7-substituted 2-[2'-(dimethylamino)ethyl]-1,2-dihydro-3H-dibenz[de,h] isoquinoline-1,3-diones: synthesis, nucleophilic displacements, antitumor activity, and quantitative structure-activity relationships.
AID562243	Antimycobacterial activity against Mycobacterium smegmatis grown in Luria-Bertani broth medium assessed as growth inhibition in mid-logarithmic phase by GFP-based fluorescence assay	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Modifying culture conditions in chemical library screening identifies alternative inhibitors of mycobacteria.
AID1130183	Antineoplastic activity against mouse P388 cells allografted in CDF1 mouse at 0.06 mg/kg qd for 9 days relative to control	1979	Journal of medicinal chemistry, May, Volume: 22, Issue:5	Structural modification study of bis(substituted aminoalkylamino)anthraquinones. An evaluation of the relationship of the [2-[(2-hydroxyethyl)amino]ethyl]amino side chain with antineoplastic activity.
AID729385	Inhibition of AKT1 (unknown origin) using [gamma33P]ATP assessed as residual activity at 1 uM after 120 mins by radiometric assay	2013	Journal of medicinal chemistry, Mar-28, Volume: 56, Issue:6	A new target for an old drug: identifying mitoxantrone as a nanomolar inhibitor of PIM1 kinase via kinome-wide selectivity modeling.
AID1070863	Cytotoxicity against human H1299 cells assessed as cell viability at 10 uM after 48 hrs by MTT assay	2013	European journal of medicinal chemistry, Nov, Volume: 69	Structure-based design, synthesis and biological evaluation of novel anthra[1,2-d]imidazole-6,11-dione homologues as potential antitumor agents.
AID733196	Antiproliferative activity against human SF268 cells after 48 hrs	2013	Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6	Synthesis and biological evaluation of new cytotoxic indazolo[4,3-gh]isoquinolinone derivatives.
AID216596	Activity against human colon carcinoma multi drug resistant (MDR)-WiDr cell line.	1996	Journal of medicinal chemistry, Dec-06, Volume: 39, Issue:25	2-[2'-(Dimethylamino)ethyl]-1,2-dihydro- 3H-dibenz[de,h]isoquinoline-1,3-diones with substituents at positions 4, 8, 9, 10, and 11. Synthesis, antitumor activity, and quantitative structure-activity relationships.
AID1152333	Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay	2014	Bioorganic & medicinal chemistry, Jun-15, Volume: 22, Issue:12	Novel aromatic-polyamine conjugates as cholinesterase inhibitors with notable selectivity toward butyrylcholinesterase.
AID624626	Ratio of apparent permeability from basolateral to apical side over apical to basolateral side determined in MDR1-MDCKII cells	2001	The Journal of pharmacology and experimental therapeutics, Nov, Volume: 299, Issue:2	Rational use of in vitro P-glycoprotein assays in drug discovery.
AID99088	Tested in vitro for inhibitory activity against L1210 murine leukemia	1994	Journal of medicinal chemistry, Mar-18, Volume: 37, Issue:6	6,9-Bis[(aminoalkyl)amino]benzo[g]isoquinoline-5,10-diones. A novel class of chromophore-modified antitumor anthracene-9,10-diones: synthesis and antitumor evaluations.
AID10003	Concentration required to inhibit A2780-cell growth by 50%	1998	Journal of medicinal chemistry, Aug-13, Volume: 41, Issue:17	1,4- and 2,6-disubstituted amidoanthracene-9,10-dione derivatives as inhibitors of human telomerase.
AID425652	Total body clearance in human	2009	Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15	Physicochemical determinants of human renal clearance.
AID222140	Inhibition of cellular growth was evaluated in vitro against human colon carcinoma LOVO.	1991	Journal of medicinal chemistry, Aug, Volume: 34, Issue:8	Synthesis and antitumor evaluations of symmetrically and unsymmetrically substituted 1,4-bis[(aminoalkyl)amino]anthracene-9,10-diones and 1,4-bis[(aminoalkyl)amino]-5,8-dihydroxyanthracene-9,10-diones.
AID1883024	Toxicity in Balb/c mouse implanted with mouse 4T1 cells assessed as kidney lesions at 50 mg/kg administered intratumorally every four days for 14 days in the presence of liquid cyanoacrylate by H&E staining based histopathological analysis	2022	European journal of medicinal chemistry, Jul-05, Volume: 237	Design, synthesis, and evaluation of a novel series of mono-indolylbenzoquinones derivatives for the potential treatment of breast cancer.
AID1130160	Antineoplastic activity against mouse Colon 26 cells allografted in CDF1 mouse assessed as survival at 0.39 mg/kg qd for 9 days	1979	Journal of medicinal chemistry, May, Volume: 22, Issue:5	Structural modification study of bis(substituted aminoalkylamino)anthraquinones. An evaluation of the relationship of the [2-[(2-hydroxyethyl)amino]ethyl]amino side chain with antineoplastic activity.
AID106430	Antitumor activity against human mammary carcinoma doxorubicin-resistant MXF7 breast cell line.	1996	Journal of medicinal chemistry, Dec-06, Volume: 39, Issue:25	2-[2'-(Dimethylamino)ethyl]-1,2-dihydro- 3H-dibenz[de,h]isoquinoline-1,3-diones with substituents at positions 4, 8, 9, 10, and 11. Synthesis, antitumor activity, and quantitative structure-activity relationships.
AID253346	Cytotoxicity against human HCT116 cancer cell line was determined after 1 hr	2004	Journal of medicinal chemistry, Oct-07, Volume: 47, Issue:21	Rational design, synthesis, and biological evaluation of bis(pyrimido[5,6,1-de]acridines) and bis(pyrazolo[3,4,5-kl]acridine-5-carboxamides) as new anticancer agents.
AID1525937	Antiproliferative activity against human 2008 cells assessed as reduction in cell viability after 5 days by MTS/PMS assay	2019	Journal of medicinal chemistry, 09-26, Volume: 62, Issue:18	Triazole Bridged Flavonoid Dimers as Potent, Nontoxic, and Highly Selective Breast Cancer Resistance Protein (BCRP/ABCG2) Inhibitors.
AID84124	Effect of compound as percent survival at dose of 3000 ng/mL on HT-29/Mx cell line after 72 hours	1999	Journal of medicinal chemistry, Sep-09, Volume: 42, Issue:18	8,11-dihydroxy-6-[(aminoalkyl)amino]-7H-benzo[e]perimidin-7-ones with activity in multidrug-resistant cell lines: synthesis and antitumor evaluation.
AID1079931	Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID1712013	Toxicity in Kunming mouse implanted with mouse H22 cells assessed as mouse mortality at 0.4 mg/kg, iv administered for 7 consecutive days starting from day 8 post inoculation and measured after 16 days	2016	European journal of medicinal chemistry, Oct-04, Volume: 121	Synthesis and biological properties of polyamine modified flavonoids as hepatocellular carcinoma inhibitors.
AID83926	Effect of compound as percent survival at dose of 100n g/mL on HT-29 cell line after 72 hours	1999	Journal of medicinal chemistry, Sep-09, Volume: 42, Issue:18	8,11-dihydroxy-6-[(aminoalkyl)amino]-7H-benzo[e]perimidin-7-ones with activity in multidrug-resistant cell lines: synthesis and antitumor evaluation.
AID54113	Increase in Melting temperature (delta Tm) for Micrococcus lysodeikticus DNA on interaction against ligand (mole ratio of 10:1)	1992	Journal of medicinal chemistry, Apr-17, Volume: 35, Issue:8	Anthracene-9,10-diones as potential anticancer agents. Synthesis, DNA-binding, and biological studies on a series of 2,6-disubstituted derivatives.
AID99358	Tested for inhibitory activity against murine cell line L12110, a strain resistant to doxorubicin using MTT assay.	2000	Journal of medicinal chemistry, Aug-10, Volume: 43, Issue:16	Analogues of amonafide and azonafide with novel ring systems.
AID602039	Cytotoxicity against human A549 cells after 24 hrs by MTT assay	2011	Bioorganic & medicinal chemistry letters, May-15, Volume: 21, Issue:10	Cytotoxic and PPARs transcriptional activities of sterols from the Vietnamese soft coral Lobophytum laevigatum.
AID364461	Cytotoxicity against human 293T cells expressing telomerase after 96 hrs by MTT assay	2008	Journal of medicinal chemistry, Sep-25, Volume: 51, Issue:18	Aminoacyl-anthraquinone conjugates as telomerase inhibitors: synthesis, biophysical and biological evaluation.
AID136071	Antileukemic activity towards P388 Murine Leukemia at a dose of 0.4 mg/kg	1999	Journal of medicinal chemistry, Sep-09, Volume: 42, Issue:18	8,11-dihydroxy-6-[(aminoalkyl)amino]-7H-benzo[e]perimidin-7-ones with activity in multidrug-resistant cell lines: synthesis and antitumor evaluation.
AID1130154	Antineoplastic activity against mouse B16 cells allografted in BDF1 mouse assessed as survival at 0.25 mg/kg qd for 9 days	1979	Journal of medicinal chemistry, May, Volume: 22, Issue:5	Structural modification study of bis(substituted aminoalkylamino)anthraquinones. An evaluation of the relationship of the [2-[(2-hydroxyethyl)amino]ethyl]amino side chain with antineoplastic activity.
AID1132468	Antitumor activity against mouse P388 cells allografted in BDF1 mouse assessed as increase in survival time at 2 mg/kg administered 24 hrs post challenge relative to control	1978	Journal of medicinal chemistry, Mar, Volume: 21, Issue:3	Antineoplastic agents. Structure-activity relationship study of bis(substituted aminoalkylamino)anthraquinones.
AID116824	Percent increase in life span when given at a dose in P388 leukemia cells of mice	1996	Journal of medicinal chemistry, Dec-06, Volume: 39, Issue:25	2-[2'-(Dimethylamino)ethyl]-1,2-dihydro- 3H-dibenz[de,h]isoquinoline-1,3-diones with substituents at positions 4, 8, 9, 10, and 11. Synthesis, antitumor activity, and quantitative structure-activity relationships.
AID153498	In vivo antineoplastic activity was determined in BDF1 mice implanted with P388 leukemia and activity is expressed as T/C at 1 mg/kg	1987	Journal of medicinal chemistry, Sep, Volume: 30, Issue:9	Structural modification study of mitoxantrone (DHAQ). Chloro-substituted mono- and bis[(aminoalkyl)amino]anthraquinones.
AID202642	Mean percentage reduction in tumor weight on S180 tumor cell at 0.75 mg/kg (cumulative dose 16 mg/Kg) introduced ip (in vivo)	1988	Journal of medicinal chemistry, Apr, Volume: 31, Issue:4	Synthesis, molecular modeling, DNA binding, and antitumor properties of some substituted amidoanthraquinones.
AID683860	Antiproliferative activity against human HL60 cells after 72 hrs by SRB assay	2012	Bioorganic & medicinal chemistry letters, Oct-01, Volume: 22, Issue:19	New derivatives of 11-methyl-6-[2-(dimethylamino)ethyl]-6H-indolo[2,3-b]quinoline as cytotoxic DNA topoisomerase II inhibitors.
AID1130150	Antineoplastic activity against mouse B16 cells allografted in BDF1 mouse assessed as survival at 1 mg/kg qd for 9 days	1979	Journal of medicinal chemistry, May, Volume: 22, Issue:5	Structural modification study of bis(substituted aminoalkylamino)anthraquinones. An evaluation of the relationship of the [2-[(2-hydroxyethyl)amino]ethyl]amino side chain with antineoplastic activity.
AID1132519	Antitumor activity against mouse B16 cells allografted in BDF1 mouse assessed as increase in survival time at 1 mg/kg administered 24 hrs post challenge relative to control	1978	Journal of medicinal chemistry, Mar, Volume: 21, Issue:3	Antineoplastic agents. Structure-activity relationship study of bis(substituted aminoalkylamino)anthraquinones.
AID681132	TP_TRANSPORTER: ATP hydrolysis in MDR1-expressing Sf9 cells	2001	The Journal of pharmacology and experimental therapeutics, Nov, Volume: 299, Issue:2	Rational use of in vitro P-glycoprotein assays in drug discovery.
AID127620	The compound was evaluated in vivo for the optimal dose for activity against murine B-16 melanoma	1988	Journal of medicinal chemistry, Aug, Volume: 31, Issue:8	Benzothiopyranoindazoles, a new class of chromophore modified anthracenedione anticancer agents. Synthesis and activity against murine leukemias.
AID436879	Antibacterial activity against imipenem-resistant Escherichia coli BL21(DE3) expressing VIM2 gene after 18 hrs by twofold serial broth dilution method	2009	Bioorganic & medicinal chemistry, Jul-15, Volume: 17, Issue:14	Inhibitors of VIM-2 by screening pharmacologically active and click-chemistry compound libraries.
AID45652	Survivors of CDF1 mice on day 4 after 1st injection of compound at 3 mg/kg in six mice; 6/6	1989	Journal of medicinal chemistry, Aug, Volume: 32, Issue:8	Synthesis of unsymmetrically substituted 1,4-bis[(aminoalkyl)amino]anthracene-9,10-diones as potential antileukemic agents.
AID89435	In vitro inhibitory activity against MCF-7 mammary cell line	1993	Journal of medicinal chemistry, Jul-23, Volume: 36, Issue:15	Synthesis and antitumor properties of an anthraquinone bisubstituted by the copper chelating peptide Gly-Gly-L-His.
AID153496	In vivo antineoplastic activity was determined in BDF1 mice implanted with P388 leukemia and activity is expressed as T/C at 0.25 mg/kg	1987	Journal of medicinal chemistry, Sep, Volume: 30, Issue:9	Structural modification study of mitoxantrone (DHAQ). Chloro-substituted mono- and bis[(aminoalkyl)amino]anthraquinones.
AID67112	Percent colony reduction in cell growth in EBV-positive nasopharyngeal cell lines after administration of 0.1 ug/mL dose	1983	Journal of medicinal chemistry, Dec, Volume: 26, Issue:12	Bis(bioreductive) alkylating agents: synthesis and biological activity in a nude mouse human carcinoma model.
AID211122	Effect of dose dependent inhibition of TOPO II-catalyzed kDNA decatenation in vitro	1994	Journal of medicinal chemistry, Oct-28, Volume: 37, Issue:22	Inhibition of topoisomerase II catalytic activity by pyridoacridine alkaloids from a Cystodytes sp. ascidian: a mechanism for the apparent intercalator-induced inhibition of topoisomerase II.
AID681563	TP_TRANSPORTER: Cytotoxicity in MT-4 and MT-4/DOX500 cells	2003	Molecular pharmacology, Jan, Volume: 63, Issue:1	Breast cancer resistance protein (BCRP/ABCG2) induces cellular resistance to HIV-1 nucleoside reverse transcriptase inhibitors.
AID436878	Antibacterial activity against imipenem-non resistant Escherichia coli BL21(DE3) after 18 hrs by twofold serial broth dilution method	2009	Bioorganic & medicinal chemistry, Jul-15, Volume: 17, Issue:14	Inhibitors of VIM-2 by screening pharmacologically active and click-chemistry compound libraries.
AID54626	Apparent equilibrium constant for binding to calf thymus DNA by competitive displacement fluorometric assay	2001	Journal of medicinal chemistry, Sep-27, Volume: 44, Issue:20	Synthesis, antitumor cytotoxicity, and DNA-binding of novel N-5,2-di(omega-aminoalkyl)-2,6-dihydropyrazolo[3,4,5-kl]acridine-5-carboxamides.
AID1130182	Antineoplastic activity against mouse P388 cells allografted in CDF1 mouse assessed as survival at 0.06 mg/kg qd for 9 days	1979	Journal of medicinal chemistry, May, Volume: 22, Issue:5	Structural modification study of bis(substituted aminoalkylamino)anthraquinones. An evaluation of the relationship of the [2-[(2-hydroxyethyl)amino]ethyl]amino side chain with antineoplastic activity.
AID1381975	Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay	2018	European journal of medicinal chemistry, Feb-25, Volume: 146	The lead optimization of the polyamine conjugate of flavonoid with a naphthalene motif: Synthesis and biological evaluation.
AID1525938	Antiproliferative activity against human LCC6 cells assessed as reduction in cell viability after 5 days by MTS/PMS assay	2019	Journal of medicinal chemistry, 09-26, Volume: 62, Issue:18	Triazole Bridged Flavonoid Dimers as Potent, Nontoxic, and Highly Selective Breast Cancer Resistance Protein (BCRP/ABCG2) Inhibitors.
AID9611	Inhibitory activity against human tumor cell line A0375 melanoma.	1995	Journal of medicinal chemistry, Feb-03, Volume: 38, Issue:3	Chromophore-modified antitumor anthracenediones: synthesis, DNA binding, and cytotoxic activity of 1,4-bis[(aminoalkyl)amino]benzo[g]-phthalazine-5,10-diones.
AID1233371	Antiproliferative activity against human Ishikawa cells after 72 hrs by MTT assay	2015	Bioorganic & medicinal chemistry letters, Jul-01, Volume: 25, Issue:13	Synthesis and antiproliferative activity of some novel benzo-fused imidazo[1,8]naphthyridinones.
AID625280	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID135278	Net log value for P388 leukemia cell kill in mice was determined	1988	Journal of medicinal chemistry, Aug, Volume: 31, Issue:8	Benzothiopyranoindazoles, a new class of chromophore modified anthracenedione anticancer agents. Synthesis and activity against murine leukemias.
AID255441	Resistant factor as ability to overcome multidrug resistance of MES-SA/Dx5 cells compared to MES-SA cells	2005	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 15, Issue:22	Design, synthesis, and antiproliferative activity of some novel aminosubstituted xanthenones, able to overcome multidrug resistance toward MES-SA/Dx5 cells.
AID1130152	Antineoplastic activity against mouse B16 cells allografted in BDF1 mouse assessed as survival at 0.5 mg/kg qd for 9 days	1979	Journal of medicinal chemistry, May, Volume: 22, Issue:5	Structural modification study of bis(substituted aminoalkylamino)anthraquinones. An evaluation of the relationship of the [2-[(2-hydroxyethyl)amino]ethyl]amino side chain with antineoplastic activity.
AID43704	Cytotoxicity in human leukemic CCRF-CEM cells.	2003	Journal of medicinal chemistry, Dec-18, Volume: 46, Issue:26	Bisintercalating threading diacridines: relationships between DNA binding, cytotoxicity, and cell cycle arrest.
AID594148	Antiproliferative activity against human SKOV3 cells after 48 hrs by XTT assay	2011	Bioorganic & medicinal chemistry letters, May-15, Volume: 21, Issue:10	Synthesis and antiproliferative activity of new cytotoxic azanaphthoquinone pyrrolo-annelated derivatives: Part II.
AID1903856	Antitumor immunity against human U2OS cells expressing HMGBI-GFP fusion protein assessed as accumulation HMGBI-GFP fusion protein at 3 uM measured upto 24 hrs by live cell microscopic analysis	2022	Journal of medicinal chemistry, 03-24, Volume: 65, Issue:6	Biological Investigation of a Water-Soluble Isoginkgetin-Phosphate Analogue, Targeting the Spliceosome with
AID687165	Ratio of IC50 for human K562/HHT300 cells to IC50 for human K562 cells	2012	Journal of medicinal chemistry, Jun-14, Volume: 55, Issue:11	Structure-activity relationship (SAR) study of ethyl 2-amino-6-(3,5-dimethoxyphenyl)-4-(2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate (CXL017) and the potential of the lead against multidrug resistance in cancer treatment.
AID536041	Resistance index, ratio of IC50 for human HL60/MX2 cells to IC50 for human HL60 cells	2010	Bioorganic & medicinal chemistry, Nov-15, Volume: 18, Issue:22	Indeno[1,2-c]isoquinolin-5,11-diones conjugated to amino acids: Synthesis, cytotoxicity, DNA interaction, and topoisomerase II inhibition properties.
AID26757	DNA binding dissociation constant as KD; No data	1984	Journal of medicinal chemistry, Apr, Volume: 27, Issue:4	Interactions of antitumor drugs with natural DNA: 1H NMR study of binding mode and kinetics.
AID253343	Cytotoxicity against human H460M cancer cell line was determined after 1 hr	2004	Journal of medicinal chemistry, Oct-07, Volume: 47, Issue:21	Rational design, synthesis, and biological evaluation of bis(pyrimido[5,6,1-de]acridines) and bis(pyrazolo[3,4,5-kl]acridine-5-carboxamides) as new anticancer agents.
AID431400	Ratio of GI50 for human HL60/MX2 cells to GI50 for human HL60 cells	2009	Journal of medicinal chemistry, Oct-08, Volume: 52, Issue:19	Structure-activity relationship and molecular mechanisms of ethyl 2-amino-4-(2-ethoxy-2-oxoethyl)-6-phenyl-4h-chromene-3-carboxylate (sha 14-1) and its analogues.
AID683858	Antiproliferative activity against human MESSA/DX5 cells after 72 hrs by SRB assay	2012	Bioorganic & medicinal chemistry letters, Oct-01, Volume: 22, Issue:19	New derivatives of 11-methyl-6-[2-(dimethylamino)ethyl]-6H-indolo[2,3-b]quinoline as cytotoxic DNA topoisomerase II inhibitors.
AID538479	Cytotoxicity against human HL60 cells by MTT assay	2010	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 20, Issue:23	Oleanane-type triterpenoids from Panax stipuleanatus and their anticancer activities.
AID106294	Tested against MXF7 breast carcinoma (sensitive) cell line in the sulforhodamine B assay.	1996	Journal of medicinal chemistry, Apr-12, Volume: 39, Issue:8	6- and 7-substituted 2-[2'-(dimethylamino)ethyl]-1,2-dihydro-3H-dibenz[de,h] isoquinoline-1,3-diones: synthesis, nucleophilic displacements, antitumor activity, and quantitative structure-activity relationships.
AID170463	Cardiotoxicity by a neonatal rat heart myocyte assay	1996	Journal of medicinal chemistry, Apr-12, Volume: 39, Issue:8	6- and 7-substituted 2-[2'-(dimethylamino)ethyl]-1,2-dihydro-3H-dibenz[de,h] isoquinoline-1,3-diones: synthesis, nucleophilic displacements, antitumor activity, and quantitative structure-activity relationships.
AID83759	Inhibitory activity against human tumor cell line HT-29.	1995	Journal of medicinal chemistry, Feb-03, Volume: 38, Issue:3	Chromophore-modified antitumor anthracenediones: synthesis, DNA binding, and cytotoxic activity of 1,4-bis[(aminoalkyl)amino]benzo[g]-phthalazine-5,10-diones.
AID721754	Inhibition of human MATE1-mediated ASP+ uptake expressed in HEK293 cells after 1.5 mins by fluorescence assay	2013	Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3	Discovery of potent, selective multidrug and toxin extrusion transporter 1 (MATE1, SLC47A1) inhibitors through prescription drug profiling and computational modeling.
AID95160	Compound was tested in vitro for cytotoxicity against MDR cell line K562R (72 hr exposure to compound)	1999	Journal of medicinal chemistry, Sep-09, Volume: 42, Issue:18	8,11-dihydroxy-6-[(aminoalkyl)amino]-7H-benzo[e]perimidin-7-ones with activity in multidrug-resistant cell lines: synthesis and antitumor evaluation.
AID540212	Mean residence time in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID83793	Percent inhibition at S phase of cell cycle at a dose of 100n g/mL after 72 hours of induction in HT-29 cell line	1999	Journal of medicinal chemistry, Sep-09, Volume: 42, Issue:18	8,11-dihydroxy-6-[(aminoalkyl)amino]-7H-benzo[e]perimidin-7-ones with activity in multidrug-resistant cell lines: synthesis and antitumor evaluation.
AID647964	Cytotoxicity against human H1299 cells assessed as cell growth at 100 uM after 48 hrs by MTT assay	2012	European journal of medicinal chemistry, Apr, Volume: 50	Design, synthesis and evaluation of telomerase inhibitory, hTERT repressing, and anti-proliferation activities of symmetrical 1,8-disubstituted amidoanthraquinones.
AID592674	Cytotoxicity against human A549 cells by MTT assay	2011	Bioorganic & medicinal chemistry, Apr-15, Volume: 19, Issue:8	Cytotoxic and anti-inflammatory cembranoids from the Vietnamese soft coral Lobophytum laevigatum.
AID1132509	Toxicity in mouse P388 cells allografted BDF1 mouse assessed as body weight difference at 0.5 mg/kg administered 24 hrs post challenge relative to control	1978	Journal of medicinal chemistry, Mar, Volume: 21, Issue:3	Antineoplastic agents. Structure-activity relationship study of bis(substituted aminoalkylamino)anthraquinones.
AID1550896	Antitumor activity against mouse H22 cells allografted in immunocompetent Balb/c mouse assessed as decrease in lump formation at challenge site at 2 uM incubated with cells for 5 hrs followed by compound washout prior to vaccination and subsequent H22 cel	2019	European journal of medicinal chemistry, Jun-01, Volume: 171	Naphthyl quinoxaline thymidine conjugate is a potent anticancer agent post UVA activation and elicits marked inhibition of tumor growth through vaccination.
AID678963	TP_TRANSPORTER: uptake in BCRP-expressing oocyte cells	2003	Molecular pharmacology, Dec, Volume: 64, Issue:6	Functional characterization of human breast cancer resistance protein (BCRP, ABCG2) expressed in the oocytes of Xenopus laevis.
AID1349085	Inhibition of NAE-mediated Ubcl2-NEDD8 conjugation in human Caco2 cells after 16 hrs by Western blot analysis	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	Structure-based identification of a NEDD8-activating enzyme inhibitor via drug repurposing.
AID84123	Effect of compound as percent survival at dose of 250 ng/mL on HT-29/Mx cell line after 72 hours	1999	Journal of medicinal chemistry, Sep-09, Volume: 42, Issue:18	8,11-dihydroxy-6-[(aminoalkyl)amino]-7H-benzo[e]perimidin-7-ones with activity in multidrug-resistant cell lines: synthesis and antitumor evaluation.
AID1882975	Antitumor activity against mouse 4T1 cells implanted in Balb/c mouse assessed as apoptotic rate of dissected tumor cell at 50 mg/kg administered intratumorally every four days for 14 days in the presence of liquid cyanoacrylate by flow cytometric analysis	2022	European journal of medicinal chemistry, Jul-05, Volume: 237	Design, synthesis, and evaluation of a novel series of mono-indolylbenzoquinones derivatives for the potential treatment of breast cancer.
AID1519982	Inhibition of Nedd8-cullin1 adduct formation in human A549 cells assessed as decrease in cullin1 neddylation at 75 uM measured after 6 hrs by Western blot analysis	2020	European journal of medicinal chemistry, Jan-01, Volume: 185	Discovery of candesartan cilexetic as a novel neddylation inhibitor for suppressing tumor growth.
AID381806	Growth inhibition of human K562 cells after 72 hrs by MTS method	2008	Bioorganic & medicinal chemistry, Apr-01, Volume: 16, Issue:7	The structure-based design, synthesis and biological evaluation of DNA-binding bisintercalating bisanthrapyrazole anticancer compounds.
AID733197	Antiproliferative activity against human SKOV3 cells after 48 hrs	2013	Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6	Synthesis and biological evaluation of new cytotoxic indazolo[4,3-gh]isoquinolinone derivatives.
AID98865	Percentage increase in lifespan of mice in L1210 leukemia cells (in vivo) at 0.4 mg/kg (cumulative dose 6.8 mg/Kg) with ip day 1,5&9 (once daily)	1988	Journal of medicinal chemistry, Apr, Volume: 31, Issue:4	Synthesis, molecular modeling, DNA binding, and antitumor properties of some substituted amidoanthraquinones.
AID100154	Number of tumor free survivors of mice was measured (in vivo) at a 0.75 mg/kg dose (cumulative dose 225 mg/kg)	1988	Journal of medicinal chemistry, Apr, Volume: 31, Issue:4	Synthesis, molecular modeling, DNA binding, and antitumor properties of some substituted amidoanthraquinones.
AID202783	Percentage of tumor free survivors of mice at 0.75 mg/kg (cumulative dose 525 mg/Kg) introduced (in vivo) ip; value given as 0/10	1988	Journal of medicinal chemistry, Apr, Volume: 31, Issue:4	Synthesis, molecular modeling, DNA binding, and antitumor properties of some substituted amidoanthraquinones.
AID1430726	Toxicity in Balb/c mouse assessed as body weight loss at 3 mg/kg, iv encapsulated within cucurbit[8]uril administered twice weekly for 2 weeks	2017	ACS medicinal chemistry letters, May-11, Volume: 8, Issue:5	Encapsulation of Mitoxantrone within Cucurbit[8]uril Decreases Toxicity and Enhances Survival in a Mouse Model of Cancer.
AID221330	Tested for inhibitory activity against human tumor cell line A549 (a non small, drug resistant cell line that does not produce P-glycoprotein) of lung carcinoma using sulforhodamine B assay.	2000	Journal of medicinal chemistry, Aug-10, Volume: 43, Issue:16	Analogues of amonafide and azonafide with novel ring systems.
AID102203	In vitro cytotoxicity on human colon adenocarcinoma (LoVo ) tumor cell line.	1998	Journal of medicinal chemistry, Dec-31, Volume: 41, Issue:27	Synthesis and antitumor evaluation of 2,5-disubstituted-indazolo[4, 3-gh]isoquinolin-6(2H)-ones (9-aza-anthrapyrazoles).
AID212547	Inhibition of Taq polymerase at 50 uM (Total inhibition)	1998	Journal of medicinal chemistry, Aug-13, Volume: 41, Issue:17	1,4- and 2,6-disubstituted amidoanthracene-9,10-dione derivatives as inhibitors of human telomerase.
AID729386	Inhibition of CHK2 (unknown origin) using [gamma33P]ATP assessed as residual activity at 1 uM after 120 mins by radiometric assay	2013	Journal of medicinal chemistry, Mar-28, Volume: 56, Issue:6	A new target for an old drug: identifying mitoxantrone as a nanomolar inhibitor of PIM1 kinase via kinome-wide selectivity modeling.
AID145445	Inhibitory activity against OVCAR-3 cell line	1996	Journal of medicinal chemistry, Apr-12, Volume: 39, Issue:8	6- and 7-substituted 2-[2'-(dimethylamino)ethyl]-1,2-dihydro-3H-dibenz[de,h] isoquinoline-1,3-diones: synthesis, nucleophilic displacements, antitumor activity, and quantitative structure-activity relationships.
AID594152	Antiproliferative activity against human RKOp27IND cells after 48 hrs by XTT assay	2011	Bioorganic & medicinal chemistry letters, May-15, Volume: 21, Issue:10	Synthesis and antiproliferative activity of new cytotoxic azanaphthoquinone pyrrolo-annelated derivatives: Part II.
AID83927	Effect of compound as percent survival at dose of 25 ng/mL on HT-29 cell line after 72 hours	1999	Journal of medicinal chemistry, Sep-09, Volume: 42, Issue:18	8,11-dihydroxy-6-[(aminoalkyl)amino]-7H-benzo[e]perimidin-7-ones with activity in multidrug-resistant cell lines: synthesis and antitumor evaluation.
AID681121	TP_TRANSPORTER: inhibition of Calcein-AM efflux in MDR1-expressing MDCKII cells	2001	The Journal of pharmacology and experimental therapeutics, Nov, Volume: 299, Issue:2	Rational use of in vitro P-glycoprotein assays in drug discovery.
AID136072	Antileukemic activity towards P388 Murine Leukemia at a dose of 0.8 mg/kg	1999	Journal of medicinal chemistry, Sep-09, Volume: 42, Issue:18	8,11-dihydroxy-6-[(aminoalkyl)amino]-7H-benzo[e]perimidin-7-ones with activity in multidrug-resistant cell lines: synthesis and antitumor evaluation.
AID230916	Ratio of antilog(mean log IC90 in bone marrow sample) and antolog(mean log IC90) in HL-60)	1999	Journal of medicinal chemistry, Jun-17, Volume: 42, Issue:12	Design and synthesis of modified quinolones as antitumoral acridones.
AID380014	Cytotoxicity against human MKN28 cells after 48 hrs by MTT assay	2000	Journal of natural products, May, Volume: 63, Issue:5	New 7,20:14,20-diepoxy ent-kauranoids from Isodon xerophilus.
AID625282	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID215072	An average for IC50 values in the two solid tumor cell lines.	1996	Journal of medicinal chemistry, Apr-12, Volume: 39, Issue:8	6- and 7-substituted 2-[2'-(dimethylamino)ethyl]-1,2-dihydro-3H-dibenz[de,h] isoquinoline-1,3-diones: synthesis, nucleophilic displacements, antitumor activity, and quantitative structure-activity relationships.
AID721743	Ratio of Cmax unbound to IC50 for human MATE1-mediated [14]-metformin uptake expressed in HEK293 cells	2013	Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3	Discovery of potent, selective multidrug and toxin extrusion transporter 1 (MATE1, SLC47A1) inhibitors through prescription drug profiling and computational modeling.
AID524791	Antiplasmodial activity against Plasmodium falciparum 7G8 after 72 hrs by SYBR green assay	2009	Nature chemical biology, Oct, Volume: 5, Issue:10	Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID588216	FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase	2004	Current drug discovery technologies, Dec, Volume: 1, Issue:4	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID625289	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID153497	In vivo antineoplastic activity was determined in BDF1 mice implanted with P388 leukemia and activity is expressed as T/C at 0.5 mg/kg	1987	Journal of medicinal chemistry, Sep, Volume: 30, Issue:9	Structural modification study of mitoxantrone (DHAQ). Chloro-substituted mono- and bis[(aminoalkyl)amino]anthraquinones.
AID102184	Inhibitory activity against human colon adenocarcinoma cell line LoVo.	1995	Journal of medicinal chemistry, Feb-03, Volume: 38, Issue:3	Chromophore-modified antitumor anthracenediones: synthesis, DNA binding, and cytotoxic activity of 1,4-bis[(aminoalkyl)amino]benzo[g]-phthalazine-5,10-diones.
AID320436	Cytotoxicity against human PC3 cells after 48 hrs by SRB assay	2008	Bioorganic & medicinal chemistry, Jan-15, Volume: 16, Issue:2	Synthesis, DNA binding, and cytotoxicity of 1,4-bis(2-amino-ethylamino)anthraquinone-amino acid conjugates.
AID106293	Tested against MXF7 breast carcinoma (mitoxantrone resistant)cell line in the sulforhodamine B assay.	1996	Journal of medicinal chemistry, Apr-12, Volume: 39, Issue:8	6- and 7-substituted 2-[2'-(dimethylamino)ethyl]-1,2-dihydro-3H-dibenz[de,h] isoquinoline-1,3-diones: synthesis, nucleophilic displacements, antitumor activity, and quantitative structure-activity relationships.
AID110796	Number of mice(with Colon 38 tumors) cured after treatment of 3.9 mg/kg/day dose given as 3 times in a day for 4 days out of 5 mice	2003	Journal of medicinal chemistry, Mar-13, Volume: 46, Issue:6	Synthesis and cytotoxic activity of carboxamide derivatives of benzo[b][1,6]naphthyridines.
AID1430725	Toxicity in Balb/c mouse assessed as body weight loss at 2 mg/kg, iv administered twice weekly for 2 weeks relative to control	2017	ACS medicinal chemistry letters, May-11, Volume: 8, Issue:5	Encapsulation of Mitoxantrone within Cucurbit[8]uril Decreases Toxicity and Enhances Survival in a Mouse Model of Cancer.
AID594147	Antiproliferative activity against human KB/HeLa cells after 48 hrs by XTT assay	2011	Bioorganic & medicinal chemistry letters, May-15, Volume: 21, Issue:10	Synthesis and antiproliferative activity of new cytotoxic azanaphthoquinone pyrrolo-annelated derivatives: Part II.
AID236912	Permeability Coefficient in 2/4/A1 cell model	2005	Journal of medicinal chemistry, Jan-27, Volume: 48, Issue:2	Exploring the role of different drug transport routes in permeability screening.
AID1550889	Induction of immunogenic cell death in mouse H22 cells assessed as increase in extracellular HMGB1 level at 2 uM incubated for 5 hrs by ELISA	2019	European journal of medicinal chemistry, Jun-01, Volume: 171	Naphthyl quinoxaline thymidine conjugate is a potent anticancer agent post UVA activation and elicits marked inhibition of tumor growth through vaccination.
AID1506782	Induction of apoptosis in human HCC78 cells assessed as necrotic cells level at 5 nM incubated fro 48 hrs by Annexin-V FITC and propidium iodide staining based flow cytometry (Rvb = 0.06%)	2017	MedChemComm, Mar-01, Volume: 8, Issue:3	Identification of mitoxantrone as a new inhibitor of ROS1 fusion protein in non-small cell lung cancer cells.
AID1381973	Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay	2018	European journal of medicinal chemistry, Feb-25, Volume: 146	The lead optimization of the polyamine conjugate of flavonoid with a naphthalene motif: Synthesis and biological evaluation.
AID127618	In vivo for the optimal dose for activity against P388 leukemia per injection	1988	Journal of medicinal chemistry, Aug, Volume: 31, Issue:8	Benzothiopyranoindazoles, a new class of chromophore modified anthracenedione anticancer agents. Synthesis and activity against murine leukemias.
AID54632	Binding affinity towards calf thymus DNA	1999	Journal of medicinal chemistry, Jul-15, Volume: 42, Issue:14	2,3-Dihydro-1H,7H-pyrimido[5,6,1-de]acridine-1,3,7-trione derivatives, a class of cytotoxic agents active on multidrug-resistant cell lines: synthesis, biological evaluation, and structure-activity relationships.
AID1883023	Toxicity in Balb/c mouse implanted with mouse 4T1 cells assessed as lung lesions at 50 mg/kg administered intratumorally every four days for 14 days in the presence of liquid cyanoacrylate by H&E staining based histopathological analysis	2022	European journal of medicinal chemistry, Jul-05, Volume: 237	Design, synthesis, and evaluation of a novel series of mono-indolylbenzoquinones derivatives for the potential treatment of breast cancer.
AID729381	Inhibition of human recombinant casein kinase 2 using [gamma-32P] ATP	2013	Journal of medicinal chemistry, Mar-28, Volume: 56, Issue:6	A new target for an old drug: identifying mitoxantrone as a nanomolar inhibitor of PIM1 kinase via kinome-wide selectivity modeling.
AID729388	Inhibition of CK2alpha2 (unknown origin) using [gamma33P]ATP assessed as residual activity at 1 uM after 120 mins by radiometric assay	2013	Journal of medicinal chemistry, Mar-28, Volume: 56, Issue:6	A new target for an old drug: identifying mitoxantrone as a nanomolar inhibitor of PIM1 kinase via kinome-wide selectivity modeling.
AID211285	Inhibition of commercially obtained pure Drosophila Topoisomerase II in catalytic DNA unwinding.	1995	Journal of medicinal chemistry, Oct-27, Volume: 38, Issue:22	Topoisomerase II-mediated DNA cleavage by adocia- and xestoquinones from the Philippine sponge Xestospongia sp.
AID595064	Resistant factor, ratio of IC50 for doxorubicin-resistant human MES-SA/Dx5 cells to IC50 for doxorubicin-sensitive human MES-SA cells	2011	Bioorganic & medicinal chemistry letters, May-15, Volume: 21, Issue:10	Design, synthesis and antiproliferative activity of novel aminosubstituted benzothiopyranoisoindoles.
AID1525939	Resistance factor, ratio of IC50 for human HEK293/R2 cells overexpressing BCRP to IC50 for human HEK293 cells	2019	Journal of medicinal chemistry, 09-26, Volume: 62, Issue:18	Triazole Bridged Flavonoid Dimers as Potent, Nontoxic, and Highly Selective Breast Cancer Resistance Protein (BCRP/ABCG2) Inhibitors.
AID200624	Cytotoxicity against human SCLC cells resistant to cisplatin (SCLC/CDDP)	1993	Journal of medicinal chemistry, Dec-10, Volume: 36, Issue:25	Design of antineoplastic agents on the basis of the "2-phenylnaphthalene-type" structural pattern. 2. Synthesis and biological activity studies of benzo]b]naphtho[2,3-d]furan-6,11-dione derivatives.
AID270855	Antiproliferative activity against doxorubicin-resistant MES-SA/Dx5 cells by MTT assay after 72 hrs	2006	Bioorganic & medicinal chemistry letters, Sep-15, Volume: 16, Issue:18	Synthesis and antiproliferative activity of substituted benzopyranoisoindoles: a new class of cytotoxic compounds.
AID1381974	Antiproliferative activity against human K562 cells after 48 hrs by MTT assay	2018	European journal of medicinal chemistry, Feb-25, Volume: 146	The lead optimization of the polyamine conjugate of flavonoid with a naphthalene motif: Synthesis and biological evaluation.
AID1079939	Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID253340	Cytotoxicity against human PC3 cancer cell line was determined after 1 hr	2004	Journal of medicinal chemistry, Oct-07, Volume: 47, Issue:21	Rational design, synthesis, and biological evaluation of bis(pyrimido[5,6,1-de]acridines) and bis(pyrazolo[3,4,5-kl]acridine-5-carboxamides) as new anticancer agents.
AID227751	Concentration required to reduce ethidium bromide fluorescence to 50% of control in presence of calf thymus DNA; ND is Not Determined.	1994	Journal of medicinal chemistry, Oct-28, Volume: 37, Issue:22	Inhibition of topoisomerase II catalytic activity by pyridoacridine alkaloids from a Cystodytes sp. ascidian: a mechanism for the apparent intercalator-induced inhibition of topoisomerase II.
AID201633	The IC50 value was measured on human breast cancer cell line SK-BR-3.	1995	Journal of medicinal chemistry, Mar-17, Volume: 38, Issue:6	Synthesis and biological activity of thiazolylindolequinones, analogues of the natural product BE 10988.
AID98403	Tested in vitro against murine L1210 leukemia.	1987	Journal of medicinal chemistry, Jan, Volume: 30, Issue:1	Anthrapyrazole anticancer agents. Synthesis and structure-activity relationships against murine leukemias.
AID1550875	Cytotoxicity against human A375 cells assessed as reduction in cell viability preincubated for 5 hrs followed by compound washout and measured after 48 hrs by CCK8 assay	2019	European journal of medicinal chemistry, Jun-01, Volume: 171	Naphthyl quinoxaline thymidine conjugate is a potent anticancer agent post UVA activation and elicits marked inhibition of tumor growth through vaccination.
AID771325	Cytotoxicity against human NCI-H460 cells after 48 hrs by resazurin dye assay	2013	Bioorganic & medicinal chemistry letters, Oct-01, Volume: 23, Issue:19	Synthesis and antiproliferative activity of new cytotoxic tri- and tetraazabenzo[3,2-a]fluorene-5,6-dione derivatives.
AID524796	Antiplasmodial activity against Plasmodium falciparum W2 after 72 hrs by SYBR green assay	2009	Nature chemical biology, Oct, Volume: 5, Issue:10	Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID232016	Resistance index is the ratio of IC50 of resistant cell line/IC50 of sensitive cell line	1994	Journal of medicinal chemistry, Mar-18, Volume: 37, Issue:6	6,9-Bis[(aminoalkyl)amino]benzo[g]isoquinoline-5,10-diones. A novel class of chromophore-modified antitumor anthracene-9,10-diones: synthesis and antitumor evaluations.
AID1132488	Antitumor activity against mouse P388 cells allografted in BDF1 mouse assessed as mouse survival at 2 mg/kg administered 24 hrs post challenge relative to control	1978	Journal of medicinal chemistry, Mar, Volume: 21, Issue:3	Antineoplastic agents. Structure-activity relationship study of bis(substituted aminoalkylamino)anthraquinones.
AID625286	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID255803	In vitro cytotoxicity against murine leukemia cell line L1210	2005	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 15, Issue:22	Design, synthesis, and antiproliferative activity of some novel aminosubstituted xanthenones, able to overcome multidrug resistance toward MES-SA/Dx5 cells.
AID232812	Toxicity ratio of quotient of the IC50 in myocytes divided by the average IC50 for three tumor cell lines	1995	Journal of medicinal chemistry, Mar-17, Volume: 38, Issue:6	Amino-substituted 2-[2'-(dimethylamino)ethyl]-1,2-dihydro-3H- dibenz[de,h]isoquinoline-1,3-diones. Synthesis, antitumor activity, and quantitative structure--activity relationship.
AID1079937	Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID46135	Inhibitory concentration against ethidium:Calf thymus DNA (1.26:1) binding at pH 7	1997	Journal of medicinal chemistry, Nov-07, Volume: 40, Issue:23	1-[(omega-aminoalkyl)amino]-4-[N-(omega-aminoalkyl)carbamoyl]-9-oxo-9, 10-dihydroacridines as intercalating cytotoxic agents: synthesis, DNA binding, and biological evaluation.
AID680987	TP_TRANSPORTER: inhibition of MTX update by Mitoxantrone at a concentration of 50uM in membrane vesicles from BCRP-expressing MCF7 cells	2003	Cancer research, Sep-01, Volume: 63, Issue:17	Wild-type breast cancer resistance protein (BCRP/ABCG2) is a methotrexate polyglutamate transporter.
AID1197745	Inhibition of human OATP1B3-mediated [3H]CCK-8 at 100 uM after 5 mins relative to control	2015	European journal of medicinal chemistry, Mar-06, Volume: 92	Interaction of human organic anion transporter polypeptides 1B1 and 1B3 with antineoplastic compounds.
AID255789	In vitro cytotoxicity against uterine sarcoma MES-SA cells	2005	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 15, Issue:22	Design, synthesis, and antiproliferative activity of some novel aminosubstituted xanthenones, able to overcome multidrug resistance toward MES-SA/Dx5 cells.
AID102168	In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line LoVo	1999	Journal of medicinal chemistry, Sep-09, Volume: 42, Issue:18	8,11-dihydroxy-6-[(aminoalkyl)amino]-7H-benzo[e]perimidin-7-ones with activity in multidrug-resistant cell lines: synthesis and antitumor evaluation.
AID272492	Antiproliferative activity against MDA435/LCC6 cells by ELISA	2006	Journal of medicinal chemistry, Nov-16, Volume: 49, Issue:23	Flavonoid dimers as bivalent modulators for P-glycoprotein-based multidrug resistance: synthetic apigenin homodimers linked with defined-length poly(ethylene glycol) spacers increase drug retention and enhance chemosensitivity in resistant cancer cells.
AID95161	Compound was tested in vitro for cytotoxicity against MDR cell line K562R (RI) (72 hr exposure to compound)	1999	Journal of medicinal chemistry, Sep-09, Volume: 42, Issue:18	8,11-dihydroxy-6-[(aminoalkyl)amino]-7H-benzo[e]perimidin-7-ones with activity in multidrug-resistant cell lines: synthesis and antitumor evaluation.
AID100158	Number of tumor free survivors of mice was measured in L1210 leukemia cells (in vivo) at 0.4 mg/kg (cumulative dose 6.8 mg/Kg) with ip day 1,5&9 (once daily)	1988	Journal of medicinal chemistry, Apr, Volume: 31, Issue:4	Synthesis, molecular modeling, DNA binding, and antitumor properties of some substituted amidoanthraquinones.
AID230914	Ratio of antilog(mean log IC50 in bone marrow sample) and antolog(mean log IC50) in HL-60)	1999	Journal of medicinal chemistry, Jun-17, Volume: 42, Issue:12	Design and synthesis of modified quinolones as antitumoral acridones.
AID1550873	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability preincubated for 5 hrs followed by compound washout and measured after 48 hrs by CCK8 assay	2019	European journal of medicinal chemistry, Jun-01, Volume: 171	Naphthyl quinoxaline thymidine conjugate is a potent anticancer agent post UVA activation and elicits marked inhibition of tumor growth through vaccination.
AID681515	TP_TRANSPORTER: cell accumulation in MCF7/MRP1-M24 cells	2006	Molecular pharmacology, Apr, Volume: 69, Issue:4	Multidrug resistance protein 1 (MRP1, ABCC1) mediates resistance to mitoxantrone via glutathione-dependent drug efflux.
AID220579	Binding affinity towards [poly(dA-dT)]2	1999	Journal of medicinal chemistry, Jul-15, Volume: 42, Issue:14	2,3-Dihydro-1H,7H-pyrimido[5,6,1-de]acridine-1,3,7-trione derivatives, a class of cytotoxic agents active on multidrug-resistant cell lines: synthesis, biological evaluation, and structure-activity relationships.
AID102033	In vitro cytotoxic activity against human colon adenocarcinoma resistant to doxorubicin (LoVo Dx) cells.	2000	Bioorganic & medicinal chemistry letters, Feb-07, Volume: 10, Issue:3	Synthesis and antitumor activities of 5-methyl-1- and 2-[[2-dimethylaminoethyl]amino]-aza-thiopyranoindazoles.
AID1349101	Inhibition of NAE in human Caco2 cells assessed as increase in phosphorylated NF-kappaB protein levels at 0.1 to 10 uM after 16 hrs by Western blot analysis	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	Structure-based identification of a NEDD8-activating enzyme inhibitor via drug repurposing.
AID602041	Cytotoxicity against human HL60 cells after 24 hrs by MTT assay	2011	Bioorganic & medicinal chemistry letters, May-15, Volume: 21, Issue:10	Cytotoxic and PPARs transcriptional activities of sterols from the Vietnamese soft coral Lobophytum laevigatum.
AID1525940	Resistance factor, ratio of IC50 for human 2008/MRP1 cells overexpressing MRP1 to IC50 for human 2008 cells	2019	Journal of medicinal chemistry, 09-26, Volume: 62, Issue:18	Triazole Bridged Flavonoid Dimers as Potent, Nontoxic, and Highly Selective Breast Cancer Resistance Protein (BCRP/ABCG2) Inhibitors.
AID1130161	Antineoplastic activity against mouse Colon 26 cells allografted in CDF1 mouse at 0.39 mg/kg qd for 9 days relative to control	1979	Journal of medicinal chemistry, May, Volume: 22, Issue:5	Structural modification study of bis(substituted aminoalkylamino)anthraquinones. An evaluation of the relationship of the [2-[(2-hydroxyethyl)amino]ethyl]amino side chain with antineoplastic activity.
AID1209583	Unbound drug partitioning coefficient, Kp of the compound assessed as ratio of unbound concentration in Sprague-Dawley rat brain to unbound concentration in plasma	2011	Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3	Measurement of unbound drug exposure in brain: modeling of pH partitioning explains diverging results between the brain slice and brain homogenate methods.
AID687168	Ratio of IC50 for human CCRF-CEM/VLB100 cells IC50 for human CCRF-CEM cells	2012	Journal of medicinal chemistry, Jun-14, Volume: 55, Issue:11	Structure-activity relationship (SAR) study of ethyl 2-amino-6-(3,5-dimethoxyphenyl)-4-(2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate (CXL017) and the potential of the lead against multidrug resistance in cancer treatment.
AID1506789	Induction of apoptosis in human HCC78 cells assessed as late apoptotic cells level at 20 nM incubated fro 48 hrs by Annexin-V FITC and propidium iodide staining based flow cytometry (Rvb = 13.8%)	2017	MedChemComm, Mar-01, Volume: 8, Issue:3	Identification of mitoxantrone as a new inhibitor of ROS1 fusion protein in non-small cell lung cancer cells.
AID699540	Inhibition of human liver OATP1B3 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E17-betaG uptake at 20 uM incubated for 5 mins by scintillation counting	2012	Journal of medicinal chemistry, May-24, Volume: 55, Issue:10	Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
AID1167196	Intrinsic cytotoxicity against HEK293 cells assessed as reduction in cell viability after 72 hrs by MTT assay	2015	Journal of medicinal chemistry, Jan-08, Volume: 58, Issue:1	Converting potent indeno[1,2-b]indole inhibitors of protein kinase CK2 into selective inhibitors of the breast cancer resistance protein ABCG2.
AID1474537	Cytotoxicity against human HL60 cells after 72 hrs by sulforhodamine B assay	2017	European journal of medicinal chemistry, May-26, Volume: 132	Novel phosphonate analogs of sulforaphane: Synthesis, in vitro and in vivo anticancer activity.
AID594149	Antiproliferative activity against human SF268 cells after 48 hrs by XTT assay	2011	Bioorganic & medicinal chemistry letters, May-15, Volume: 21, Issue:10	Synthesis and antiproliferative activity of new cytotoxic azanaphthoquinone pyrrolo-annelated derivatives: Part II.
AID98386	Antitumor activity against murine leukemia L1210 cell line.	1996	Journal of medicinal chemistry, Dec-06, Volume: 39, Issue:25	2-[2'-(Dimethylamino)ethyl]-1,2-dihydro- 3H-dibenz[de,h]isoquinoline-1,3-diones with substituents at positions 4, 8, 9, 10, and 11. Synthesis, antitumor activity, and quantitative structure-activity relationships.
AID1070861	Inhibition of human tert transcriptional activity assessed as SEAP activity at 1 uM after 24 hrs by SEAP reporter assay	2013	European journal of medicinal chemistry, Nov, Volume: 69	Structure-based design, synthesis and biological evaluation of novel anthra[1,2-d]imidazole-6,11-dione homologues as potential antitumor agents.
AID436872	Inhibition of IMP1 using nitrocefin as substrate at 56 uM after 15 mins by microtiter plate assay	2009	Bioorganic & medicinal chemistry, Jul-15, Volume: 17, Issue:14	Inhibitors of VIM-2 by screening pharmacologically active and click-chemistry compound libraries.
AID1221961	Apparent permeability from basolateral to apical side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 1 uM of P-gp inhibitor LY335979	2011	Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2	Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID1711948	Cytotoxicity against human QSG7701 cells assessed as inhibition of cell proliferation at 5 uM measured after 48 hrs by MTT assay relative to control	2016	European journal of medicinal chemistry, Oct-04, Volume: 121	Synthesis and biological properties of polyamine modified flavonoids as hepatocellular carcinoma inhibitors.
AID1053262	Agonist activity at human recombinant dopamine D2 long receptor expressed in CHOK1 cells coexpressing mitochondrial apoaequorin at 100 uM by luminometric analysis relative to quinpirol	2013	Journal of medicinal chemistry, Nov-14, Volume: 56, Issue:21	Experimental confirmation of new drug-target interactions predicted by Drug Profile Matching.
AID8485	Tested against A549 lung carcinoma in the sulforhodamine B assay.	1996	Journal of medicinal chemistry, Apr-12, Volume: 39, Issue:8	6- and 7-substituted 2-[2'-(dimethylamino)ethyl]-1,2-dihydro-3H-dibenz[de,h] isoquinoline-1,3-diones: synthesis, nucleophilic displacements, antitumor activity, and quantitative structure-activity relationships.
AID1271103	Cytotoxicity against rat 5RP7 cells after 24 hrs by MTT assay	2016	European journal of medicinal chemistry, Jan-01, Volume: 107	Synthesis and evaluation of bis-thiazole derivatives as new anticancer agents.
AID1711943	Antiproliferative activity against human HepG2 cells assessed as inhibition of cell proliferation at 1 uM measured after 48 hrs by MTT assay relative to control	2016	European journal of medicinal chemistry, Oct-04, Volume: 121	Synthesis and biological properties of polyamine modified flavonoids as hepatocellular carcinoma inhibitors.
AID437515	Binding affinity to tau stem-loop RNA assessed as inhibition of RNA stem-loop unfolding	2009	Journal of medicinal chemistry, Nov-12, Volume: 52, Issue:21	Mitoxantrone analogues as ligands for a stem-loop structure of tau pre-mRNA.
AID84114	Percent inhibition at S phase of cell cycle at a dose of 1000 ng/mL after 72 hours of induction in HT-29/Mx cell line	1999	Journal of medicinal chemistry, Sep-09, Volume: 42, Issue:18	8,11-dihydroxy-6-[(aminoalkyl)amino]-7H-benzo[e]perimidin-7-ones with activity in multidrug-resistant cell lines: synthesis and antitumor evaluation.
AID1506779	Induction of apoptosis in human HCC78 cells assessed as viable cells level at 5 nM incubated fro 48 hrs by Annexin-V FITC and propidium iodide staining based flow cytometry (Rvb = 80.8%)	2017	MedChemComm, Mar-01, Volume: 8, Issue:3	Identification of mitoxantrone as a new inhibitor of ROS1 fusion protein in non-small cell lung cancer cells.
AID202961	Cytotoxic potency required to inhibit SKOV-3 cell growth 50%	1997	Journal of medicinal chemistry, Nov-07, Volume: 40, Issue:23	1-[(omega-aminoalkyl)amino]-4-[N-(omega-aminoalkyl)carbamoyl]-9-oxo-9, 10-dihydroacridines as intercalating cytotoxic agents: synthesis, DNA binding, and biological evaluation.
AID1349097	Inhibition of NAE in human Caco2 cells assessed as increase in c-myc protein levels after 16 hrs by Western blot analysis	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	Structure-based identification of a NEDD8-activating enzyme inhibitor via drug repurposing.
AID54438	In vitro inhibition of calf thymus DNA/ethidium bromide complex formation.	2002	Journal of medicinal chemistry, Jun-06, Volume: 45, Issue:12	Design, synthesis, and antiproliferative activity of some new pyrazole-fused amino derivatives of the pyranoxanthenone, pyranothioxanthenone, and pyranoacridone ring systems: a new class of cytotoxic agents.
AID1439468	Cytotoxicity against mouse L1210 cells assessed as reduction in cell viability after 24 hrs by MTT assay	2017	European journal of medicinal chemistry, Mar-31, Volume: 129	Allylic isothiouronium salts: The discovery of a novel class of thiourea analogues with antitumor activity.
AID687166	Ratio of IC50 for human CCRF-CEM/C2 cells IC50 for human CCRF-CEM cells	2012	Journal of medicinal chemistry, Jun-14, Volume: 55, Issue:11	Structure-activity relationship (SAR) study of ethyl 2-amino-6-(3,5-dimethoxyphenyl)-4-(2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate (CXL017) and the potential of the lead against multidrug resistance in cancer treatment.
AID1520331	Cytotoxicity against human A549 cells after 48 hrs by MTT assay	2019	European journal of medicinal chemistry, Mar-15, Volume: 166	All that glitters is not gold: Panning cytotoxic natural products and derivatives with a fused tricyclic backbone by the estimation of their leadlikeness for cancer treatment.
AID97252	Compound was tested against L1210 leukemia at % increase in life span (ILS) in mice at 1.6 mg/kg dosage.	1996	Journal of medicinal chemistry, Apr-12, Volume: 39, Issue:8	6- and 7-substituted 2-[2'-(dimethylamino)ethyl]-1,2-dihydro-3H-dibenz[de,h] isoquinoline-1,3-diones: synthesis, nucleophilic displacements, antitumor activity, and quantitative structure-activity relationships.
AID733194	Antiproliferative activity against human NCI-H460 cells after 48 hrs	2013	Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6	Synthesis and biological evaluation of new cytotoxic indazolo[4,3-gh]isoquinolinone derivatives.
AID1506783	Induction of apoptosis in human HCC78 cells assessed as viable cells level at 10 nM incubated fro 48 hrs by Annexin-V FITC and propidium iodide staining based flow cytometry (Rvb = 80.8%)	2017	MedChemComm, Mar-01, Volume: 8, Issue:3	Identification of mitoxantrone as a new inhibitor of ROS1 fusion protein in non-small cell lung cancer cells.
AID236914	Permeability Coefficient in hexadecane membranes model	2005	Journal of medicinal chemistry, Jan-27, Volume: 48, Issue:2	Exploring the role of different drug transport routes in permeability screening.
AID681522	TP_TRANSPORTER: ATP- and GSH-dependent transport in MCF7/MRP1-10 cells	2006	Molecular pharmacology, Apr, Volume: 69, Issue:4	Multidrug resistance protein 1 (MRP1, ABCC1) mediates resistance to mitoxantrone via glutathione-dependent drug efflux.
AID683857	Antiproliferative activity against human MESSA cells after 72 hrs by SRB assay	2012	Bioorganic & medicinal chemistry letters, Oct-01, Volume: 22, Issue:19	New derivatives of 11-methyl-6-[2-(dimethylamino)ethyl]-6H-indolo[2,3-b]quinoline as cytotoxic DNA topoisomerase II inhibitors.
AID1221964	Transporter substrate index ratio of permeability from basolateral to apical side in human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 1 uM of P-gp inhibitor LY335979	2011	Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2	Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID625288	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID230379	Resistance index measured as the ratio of IC50 of LoVo/Dx cell line to that of LoVo cell line.	1998	Journal of medicinal chemistry, Dec-31, Volume: 41, Issue:27	Synthesis and antitumor evaluation of 2,5-disubstituted-indazolo[4, 3-gh]isoquinolin-6(2H)-ones (9-aza-anthrapyrazoles).
AID562241	Antimycobacterial activity against Mycobacterium smegmatis grown in carbon-limited broth medium assessed as growth inhibition in mid-logarithmic phase by spectrophotometry	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Modifying culture conditions in chemical library screening identifies alternative inhibitors of mycobacteria.
AID1207752	Inhibition of Cav1.2 current measured using QPatch automatic path clamp system in CHO cells expressing Cav1.2, beta-2 and alpha-2/delta-1 subunits	2013	Scientific reports, , Volume: 3	MICE models: superior to the HERG model in predicting Torsade de Pointes.
AID381809	Inhibition of human topoisomerase 2alpha decantation activity	2008	Bioorganic & medicinal chemistry, Apr-01, Volume: 16, Issue:7	The structure-based design, synthesis and biological evaluation of DNA-binding bisintercalating bisanthrapyrazole anticancer compounds.
AID107945	In vivo antitumor activity at a single dose of 12.5 mg/kg & 37.5 mg/kg total against mammary adenocarcinoma 16C	1984	Journal of medicinal chemistry, Mar, Volume: 27, Issue:3	5-[(Aminoalkyl)amino]-substituted anthra[1,9-cd]pyrazol-6(2H)-ones as novel anticancer agents. Synthesis and biological evaluation.
AID137725	Percentage ratio of treated animals to cured animals against murine B-16 melanoma (day 60 surv)	1988	Journal of medicinal chemistry, Aug, Volume: 31, Issue:8	Benzothiopyranoindazoles, a new class of chromophore modified anthracenedione anticancer agents. Synthesis and activity against murine leukemias.
AID1130168	Antineoplastic activity against mouse L1210 cells allografted in CDF1 mouse assessed as survival at 2 mg/kg qd for 9 days	1979	Journal of medicinal chemistry, May, Volume: 22, Issue:5	Structural modification study of bis(substituted aminoalkylamino)anthraquinones. An evaluation of the relationship of the [2-[(2-hydroxyethyl)amino]ethyl]amino side chain with antineoplastic activity.
AID375434	Displacement of [3H]PSB0413 from human platelet P2Y12 receptor at 10 uM	2009	Journal of medicinal chemistry, Jun-25, Volume: 52, Issue:12	High-affinity, non-nucleotide-derived competitive antagonists of platelet P2Y12 receptors.
AID429711	Cytotoxicity against human U937 cells by MTT assay	2009	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 19, Issue:16	C29 sterols with a cyclopropane ring at C-25 and 26 from the Vietnamese marine sponge Ianthella sp. and their anticancer properties.
AID721749	Inhibition of human OCT3-mediated ASP+ uptake expressed in HEK293 cells after 3 mins by fluorescence assay	2013	Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3	Discovery of potent, selective multidrug and toxin extrusion transporter 1 (MATE1, SLC47A1) inhibitors through prescription drug profiling and computational modeling.
AID429709	Cytotoxicity against human MCF7 cells by MTT assay	2009	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 19, Issue:16	C29 sterols with a cyclopropane ring at C-25 and 26 from the Vietnamese marine sponge Ianthella sp. and their anticancer properties.
AID1130167	Antineoplastic activity against mouse L1210 cells allografted in CDF1 mouse at 4 mg/kg qd for 9 days relative to control	1979	Journal of medicinal chemistry, May, Volume: 22, Issue:5	Structural modification study of bis(substituted aminoalkylamino)anthraquinones. An evaluation of the relationship of the [2-[(2-hydroxyethyl)amino]ethyl]amino side chain with antineoplastic activity.
AID537733	Binding affinity to Candida albicans CaCdr1p expressed in yeast AD1-8u	2010	European journal of medicinal chemistry, Nov, Volume: 45, Issue:11	Analysis of physico-chemical properties of substrates of ABC and MFS multidrug transporters of pathogenic Candida albicans.
AID588977	Substrates of transporters of clinical importance in the absorption and disposition of drugs, MRP2	2010	Nature reviews. Drug discovery, Mar, Volume: 9, Issue:3	Membrane transporters in drug development.
AID729375	Effect on total PIM1 level in human MV411 cells at 10 to 100 nM after 12 hrs by Western blotting analysis	2013	Journal of medicinal chemistry, Mar-28, Volume: 56, Issue:6	A new target for an old drug: identifying mitoxantrone as a nanomolar inhibitor of PIM1 kinase via kinome-wide selectivity modeling.
AID137724	Percentage ratio of treated animals to cured animals against P388 leukemia (day 30 surv)	1988	Journal of medicinal chemistry, Aug, Volume: 31, Issue:8	Benzothiopyranoindazoles, a new class of chromophore modified anthracenedione anticancer agents. Synthesis and activity against murine leukemias.
AID625292	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID242838	Concentration required to displace ethidium from CT-DNA was determined from fluorescence binding studies	2004	Journal of medicinal chemistry, Oct-07, Volume: 47, Issue:21	Rational design, synthesis, and biological evaluation of bis(pyrimido[5,6,1-de]acridines) and bis(pyrazolo[3,4,5-kl]acridine-5-carboxamides) as new anticancer agents.
AID236269	Fraction absorbed in human intestine after oral administration compound was measured; NA=Not available	2005	Journal of medicinal chemistry, Jan-27, Volume: 48, Issue:2	Exploring the role of different drug transport routes in permeability screening.
AID429710	Cytotoxicity against human SKOV3 cells by MTT assay	2009	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 19, Issue:16	C29 sterols with a cyclopropane ring at C-25 and 26 from the Vietnamese marine sponge Ianthella sp. and their anticancer properties.
AID248040	Cytotoxicity against human MKN45 cancer cell line was determined after 144 hr	2004	Journal of medicinal chemistry, Oct-07, Volume: 47, Issue:21	Rational design, synthesis, and biological evaluation of bis(pyrimido[5,6,1-de]acridines) and bis(pyrazolo[3,4,5-kl]acridine-5-carboxamides) as new anticancer agents.
AID135719	The compound was tested for antitumor activity against P388 murine leukemia by measuring median survival time of treated mice/median survival time of control x 100	1994	Journal of medicinal chemistry, Mar-18, Volume: 37, Issue:6	6,9-Bis[(aminoalkyl)amino]benzo[g]isoquinoline-5,10-diones. A novel class of chromophore-modified antitumor anthracene-9,10-diones: synthesis and antitumor evaluations.
AID524795	Antiplasmodial activity against Plasmodium falciparum HB3 after 72 hrs by SYBR green assay	2009	Nature chemical biology, Oct, Volume: 5, Issue:10	Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID588213	Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents	2010	Chemical research in toxicology, Jan, Volume: 23, Issue:1	Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID272510	Antiproliferative activity against multidrug resistant MDA435/LCC6 cells in presence of 5 uM 1,13-bis[4'-((5,7-dihydroxy)-4H-chromen-4-on-2-yl)phenyl]-1,4,7,10,13-pentaoxatridecane by ELISA	2006	Journal of medicinal chemistry, Nov-16, Volume: 49, Issue:23	Flavonoid dimers as bivalent modulators for P-glycoprotein-based multidrug resistance: synthetic apigenin homodimers linked with defined-length poly(ethylene glycol) spacers increase drug retention and enhance chemosensitivity in resistant cancer cells.
AID466796	Growth inhibition of human HL60 cells by MTT assay	2010	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 20, Issue:5	Triterpene compounds isolated from Acer mandshuricum and their anti-inflammatory activity.
AID322369	Inhibition of human BCRP mediated mitoxantrone accumulation in wild type MCF7 cells at 5 uM by flow cytometry	2008	Bioorganic & medicinal chemistry, Jan-01, Volume: 16, Issue:1	Functionalized chalcones as selective inhibitors of P-glycoprotein and breast cancer resistance protein.
AID1129361	Unbound fraction in HEK293 cell homogenate at 0.1 uM by equilibrium dialysis based UPLC-MS/MS analysis	2014	Journal of medicinal chemistry, Apr-10, Volume: 57, Issue:7	A high-throughput cell-based method to predict the unbound drug fraction in the brain.
AID1525934	Inhibition of MRP1 in human 2008/MRP1 cells assessed as reduction in cell viability after 5 days by MTS/PMS assay	2019	Journal of medicinal chemistry, 09-26, Volume: 62, Issue:18	Triazole Bridged Flavonoid Dimers as Potent, Nontoxic, and Highly Selective Breast Cancer Resistance Protein (BCRP/ABCG2) Inhibitors.
AID681085	TP_TRANSPORTER: transport in etoposide-selected MCF7 cells	2006	Molecular pharmacology, Apr, Volume: 69, Issue:4	Multidrug resistance protein 1 (MRP1, ABCC1) mediates resistance to mitoxantrone via glutathione-dependent drug efflux.
AID201223	Bacterial mutagenicity was measured against Salmonella Typhimurium TA97a at dose range of 0-400 ug/plate	1998	Journal of medicinal chemistry, Sep-10, Volume: 41, Issue:19	Anthracene-9,10-diones as potential anticancer agents: bacterial mutation studies of amido-substituted derivatives reveal an unexpected lack of mutagenicity.
AID153494	In vivo antineoplastic activity was determined in BDF1 mice implanted with P388 leukemia and activity is expressed as T/C at 0.06 mg/kg	1987	Journal of medicinal chemistry, Sep, Volume: 30, Issue:9	Structural modification study of mitoxantrone (DHAQ). Chloro-substituted mono- and bis[(aminoalkyl)amino]anthraquinones.
AID153505	In vivo antineoplastic activity was determined in BDF1 mice implanted with P388 leukemia and activity is expressed as T/C at 2 mg/kg	1987	Journal of medicinal chemistry, Sep, Volume: 30, Issue:9	Structural modification study of mitoxantrone (DHAQ). Chloro-substituted mono- and bis[(aminoalkyl)amino]anthraquinones.
AID588211	Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans	2010	Chemical research in toxicology, Jan, Volume: 23, Issue:1	Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID721752	Inhibition of human MATE2K-mediated ASP+ uptake expressed in HEK293 cells after 1.5 mins by fluorescence assay	2013	Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3	Discovery of potent, selective multidrug and toxin extrusion transporter 1 (MATE1, SLC47A1) inhibitors through prescription drug profiling and computational modeling.
AID627483	Inhibition of ATP-dependent ABCG2 pump assessed as ratio of compound IC50 for HEK/ABCG2-482-R2 cells to IC50 for HEK293/pcDNA3.1 cells after 72 hrs by MTT assay	2011	Bioorganic & medicinal chemistry letters, Nov-01, Volume: 21, Issue:21	Inhibition of c-Kit, VEGFR-2 (KDR), and ABCG2 by analogues of OSI-930.
AID226658	An average for IC50 values in the two solid tumor cell lines and sensitive L1210 leukemia cell line.	1996	Journal of medicinal chemistry, Apr-12, Volume: 39, Issue:8	6- and 7-substituted 2-[2'-(dimethylamino)ethyl]-1,2-dihydro-3H-dibenz[de,h] isoquinoline-1,3-diones: synthesis, nucleophilic displacements, antitumor activity, and quantitative structure-activity relationships.
AID1221958	Efflux ratio of permeability from apical to basolateral side over basolateral to apical side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis	2011	Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2	Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID280856	Antiproliferative activity against human MDA-MB-231 cells by WST-1 method after 72 hrs	2007	Journal of medicinal chemistry, Apr-05, Volume: 50, Issue:7	Design, synthesis, and evaluation of the antiproliferative activity of a series of novel fused xanthenone aminoderivatives in human breast cancer cells.
AID103421	Tested for inhibitory activity against human tumor cell line MCF7, a strain sensitive to doxorubicin of breast carcinoma using sulforhodamine B assay.	2000	Journal of medicinal chemistry, Aug-10, Volume: 43, Issue:16	Analogues of amonafide and azonafide with novel ring systems.
AID102188	Tested in vitro for cytotoxic activity against Human colon Adenocarcinoma sensitive cell line (LoVo)	1994	Journal of medicinal chemistry, Mar-18, Volume: 37, Issue:6	6,9-Bis[(aminoalkyl)amino]benzo[g]isoquinoline-5,10-diones. A novel class of chromophore-modified antitumor anthracene-9,10-diones: synthesis and antitumor evaluations.
AID8247	In vitro inhibition of tumor cell growth in the human myeloma 8226 system.	1992	Journal of medicinal chemistry, Nov-13, Volume: 35, Issue:23	Novel non-cross resistant diaminoanthraquinones as potential chemotherapeutic agents.
AID216434	Tested for inhibitory activity against a multi drug resistant (MDR) strain of human colon carcinoma WiDr using sulforhodamine B assay (it is MRP positive but non-P-glycoprotein).	2000	Journal of medicinal chemistry, Aug-10, Volume: 43, Issue:16	Analogues of amonafide and azonafide with novel ring systems.
AID1349100	Inhibition of NAE in human Caco2 cells assessed as decrease in Bcl2 protein levels at 0.1 to 10 uM after 16 hrs by Western blot analysis	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	Structure-based identification of a NEDD8-activating enzyme inhibitor via drug repurposing.
AID81308	Compound was tested in vitro for cytotoxicity against HL60 human leukemia cell line (72 hr exposure to compound)	1999	Journal of medicinal chemistry, Sep-09, Volume: 42, Issue:18	8,11-dihydroxy-6-[(aminoalkyl)amino]-7H-benzo[e]perimidin-7-ones with activity in multidrug-resistant cell lines: synthesis and antitumor evaluation.
AID595063	Cytotoxicity against human MES-SA/Dx5 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay	2011	Bioorganic & medicinal chemistry letters, May-15, Volume: 21, Issue:10	Design, synthesis and antiproliferative activity of novel aminosubstituted benzothiopyranoisoindoles.
AID200620	Cytotoxicity against human small-cell lung cancer (SCLC)	1993	Journal of medicinal chemistry, Dec-10, Volume: 36, Issue:25	Design of antineoplastic agents on the basis of the "2-phenylnaphthalene-type" structural pattern. 2. Synthesis and biological activity studies of benzo]b]naphtho[2,3-d]furan-6,11-dione derivatives.
AID98355	Inhibitory concentration of compound against proliferation of murine leukemia L1210 cell line	2002	Bioorganic & medicinal chemistry letters, Jun-03, Volume: 12, Issue:11	Design and synthesis of some new pyranoxanthenone aminoderivatives with cytotoxic activity.
AID1079935	Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID1129639	Cytotoxicity against HEK293 cells overexpressing ABCG2 after 72 hrs by MTT assay	2014	Journal of medicinal chemistry, Apr-10, Volume: 57, Issue:7	Symmetric bis-chalcones as a new type of breast cancer resistance protein inhibitors with a mechanism different from that of chromones.
AID253341	Cytotoxicity against human LoVo cancer cell line was determined after 1 hr	2004	Journal of medicinal chemistry, Oct-07, Volume: 47, Issue:21	Rational design, synthesis, and biological evaluation of bis(pyrimido[5,6,1-de]acridines) and bis(pyrazolo[3,4,5-kl]acridine-5-carboxamides) as new anticancer agents.
AID135709	Tested for antitumor activity against P388 murine leukemia	1994	Journal of medicinal chemistry, Mar-18, Volume: 37, Issue:6	6,9-Bis[(aminoalkyl)amino]benzo[g]isoquinoline-5,10-diones. A novel class of chromophore-modified antitumor anthracene-9,10-diones: synthesis and antitumor evaluations.
AID1079940	Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID1349116	Inhibition of SAE-mediated Ubc9-SUMO conjugation in human Caco2 cells up to 10 uM preincubated for 10 mins followed by ATP and Mg2+ addition measured after 60 mins by Western blot analysis	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	Structure-based identification of a NEDD8-activating enzyme inhibitor via drug repurposing.
AID1130165	Antineoplastic activity against mouse L1210 cells allografted in CDF1 mouse at 10.8 mg/kg qd for 9 days relative to control	1979	Journal of medicinal chemistry, May, Volume: 22, Issue:5	Structural modification study of bis(substituted aminoalkylamino)anthraquinones. An evaluation of the relationship of the [2-[(2-hydroxyethyl)amino]ethyl]amino side chain with antineoplastic activity.
AID729387	Inhibition of PIM1 (unknown origin) using [gamma33P]ATP assessed as residual activity at 1 uM after 120 mins by radiometric assayATP	2013	Journal of medicinal chemistry, Mar-28, Volume: 56, Issue:6	A new target for an old drug: identifying mitoxantrone as a nanomolar inhibitor of PIM1 kinase via kinome-wide selectivity modeling.
AID67127	EBV-positive nasopharyngeal colony count obtained from the examination of uniform plate surface areas after a dose of 0.1 ug/mL	1983	Journal of medicinal chemistry, Dec, Volume: 26, Issue:12	Bis(bioreductive) alkylating agents: synthesis and biological activity in a nude mouse human carcinoma model.
AID624609	Specific activity of expressed human recombinant UGT1A6	2000	Annual review of pharmacology and toxicology, , Volume: 40	Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID154566	Percent ratio of the medium survival time for P388 murine leukemia in CDF1 mice at 0.75 mg/kg	1989	Journal of medicinal chemistry, Aug, Volume: 32, Issue:8	Synthesis of unsymmetrically substituted 1,4-bis[(aminoalkyl)amino]anthracene-9,10-diones as potential antileukemic agents.
AID216573	Tested against WiDr colon carcinoma (resistant) in the sulforhodamine B assay.	1996	Journal of medicinal chemistry, Apr-12, Volume: 39, Issue:8	6- and 7-substituted 2-[2'-(dimethylamino)ethyl]-1,2-dihydro-3H-dibenz[de,h] isoquinoline-1,3-diones: synthesis, nucleophilic displacements, antitumor activity, and quantitative structure-activity relationships.
AID98384	Antitumor activity against sensitive L1210 murine leukemia cell lines.	1996	Journal of medicinal chemistry, Dec-06, Volume: 39, Issue:25	2-[2'-(Dimethylamino)ethyl]-1,2-dihydro- 3H-dibenz[de,h]isoquinoline-1,3-diones with substituents at positions 4, 8, 9, 10, and 11. Synthesis, antitumor activity, and quantitative structure-activity relationships.
AID101065	In vitro extracellular concentration required to reduce cell population to 50% against L1210 leukemia cells	1992	Journal of medicinal chemistry, Apr-17, Volume: 35, Issue:8	Anthracene-9,10-diones as potential anticancer agents. Synthesis, DNA-binding, and biological studies on a series of 2,6-disubstituted derivatives.
AID102597	In vitro inhibition of tumor cell growth in the human mammary tumor MCF-7 system	1992	Journal of medicinal chemistry, Nov-13, Volume: 35, Issue:23	Novel non-cross resistant diaminoanthraquinones as potential chemotherapeutic agents.
AID1129642	Cytotoxicity against HEK293 cells after 72 hrs by MTT assay	2014	Journal of medicinal chemistry, Apr-10, Volume: 57, Issue:7	Symmetric bis-chalcones as a new type of breast cancer resistance protein inhibitors with a mechanism different from that of chromones.
AID1130623	Antitumor activity against mouse B16 cells allografted in BDF1 mouse assessed as increase of median life span at 3.1 mg/kg, ip on day 1 to 9 measured up to 80 days relative to control	1979	Journal of medicinal chemistry, Sep, Volume: 22, Issue:9	Antitumor agents. 1. 1,4-Bis[(aminoalkyl)amino]-9,10-anthracenediones.
AID196905	Cardiotoxicity was measured by using Neonatal rat heart myocyte assay	1995	Journal of medicinal chemistry, Mar-17, Volume: 38, Issue:6	Amino-substituted 2-[2'-(dimethylamino)ethyl]-1,2-dihydro-3H- dibenz[de,h]isoquinoline-1,3-diones. Synthesis, antitumor activity, and quantitative structure--activity relationship.
AID272516	Relative fold, IC50 in absence to presence of 1,13-bis[4'-((5,7-dihydroxy)-4H-chromen-4-on-2-yl)phenyl]-1,4,7,10,13-pentaoxatridecane in multidrug resistant P388 cells	2006	Journal of medicinal chemistry, Nov-16, Volume: 49, Issue:23	Flavonoid dimers as bivalent modulators for P-glycoprotein-based multidrug resistance: synthetic apigenin homodimers linked with defined-length poly(ethylene glycol) spacers increase drug retention and enhance chemosensitivity in resistant cancer cells.
AID1562300	Antimycobacterial activity against Mycobacterium smegmatis atR10 assessed as decrease in drug resistance development at 10 nmol/disc after 2 to 3 days by paper disc method	2019	European journal of medicinal chemistry, Sep-15, Volume: 178	Synthesis and antimycobacterial activity of imidazo[1,2-b][1,2,4,5]tetrazines.
AID729379	Inhibition of PIM1-mediated BAD phosphorylation in human MV411 cells after 12 hrs by Western blotting analysis	2013	Journal of medicinal chemistry, Mar-28, Volume: 56, Issue:6	A new target for an old drug: identifying mitoxantrone as a nanomolar inhibitor of PIM1 kinase via kinome-wide selectivity modeling.
AID1197743	Inhibition of human OATP1B1-mediated [3H]estrone 3-sulfate at 100 uM after 5 mins relative to control	2015	European journal of medicinal chemistry, Mar-06, Volume: 92	Interaction of human organic anion transporter polypeptides 1B1 and 1B3 with antineoplastic compounds.
AID466797	Growth inhibition of human SKOV3 cells by MTT assay	2010	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 20, Issue:5	Triterpene compounds isolated from Acer mandshuricum and their anti-inflammatory activity.
AID1550877	Dark toxicity against mouse H22 cells assessed as reduction in cell viability preincubated for 5 hrs followed by compound washout and measured after 48 hrs by CCK8 assay	2019	European journal of medicinal chemistry, Jun-01, Volume: 171	Naphthyl quinoxaline thymidine conjugate is a potent anticancer agent post UVA activation and elicits marked inhibition of tumor growth through vaccination.
AID436862	Inhibition of VIM2 using nitrocefin as substrate after 15 mins by microtiter plate assay	2009	Bioorganic & medicinal chemistry, Jul-15, Volume: 17, Issue:14	Inhibitors of VIM-2 by screening pharmacologically active and click-chemistry compound libraries.
AID1506797	Inhibition of ROS1 in human HCC78 cells assessed as reduction in AKT phosphorylation incubated for 48 hrs by Western blot method	2017	MedChemComm, Mar-01, Volume: 8, Issue:3	Identification of mitoxantrone as a new inhibitor of ROS1 fusion protein in non-small cell lung cancer cells.
AID1402046	Induction of apoptosis in human Jurkat T cells assessed as downregulation of Bcl2 expression at 10 uM after 48 hrs by Western blot analysis	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	Design, synthesis and evaluation of an anthraquinone derivative conjugated to myelin basic protein immunodominant (MBP
AID1430728	Antitumor activity against mouse 4T1.2 cells implanted in Balb/c mouse assessed as tumor growth inhibition at 2 mg/kg, iv administered twice weekly for 2 weeks	2017	ACS medicinal chemistry letters, May-11, Volume: 8, Issue:5	Encapsulation of Mitoxantrone within Cucurbit[8]uril Decreases Toxicity and Enhances Survival in a Mouse Model of Cancer.
AID1851422	Antiproliferative activity against human HeLa cells assessed as inhibition of cell growth	2022	Bioorganic & medicinal chemistry letters, 10-01, Volume: 73	Synthesis and antitumor activity of a series of novel N-aryl-5-(2,2,2-trifluoroethoxy)-1,5-dihydro-2H-pyrrol-2-ones derivatives.
AID466799	Growth inhibition of human HT-29 cells by MTT assay	2010	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 20, Issue:5	Triterpene compounds isolated from Acer mandshuricum and their anti-inflammatory activity.
AID1130179	Antineoplastic activity against mouse P388 cells allografted in CDF1 mouse at 0.25 mg/kg qd for 9 days relative to control	1979	Journal of medicinal chemistry, May, Volume: 22, Issue:5	Structural modification study of bis(substituted aminoalkylamino)anthraquinones. An evaluation of the relationship of the [2-[(2-hydroxyethyl)amino]ethyl]amino side chain with antineoplastic activity.
AID1132471	Antitumor activity against mouse P388 cells allografted in BDF1 mouse assessed as increase in survival time at 0.25 mg/kg administered 24 hrs post challenge relative to control	1978	Journal of medicinal chemistry, Mar, Volume: 21, Issue:3	Antineoplastic agents. Structure-activity relationship study of bis(substituted aminoalkylamino)anthraquinones.
AID240619	Inhibitory concentration against cytochrome P450 2D6	2004	Journal of medicinal chemistry, Oct-21, Volume: 47, Issue:22	Validation of model of cytochrome P450 2D6: an in silico tool for predicting metabolism and inhibition.
AID54994	Compound was evaluated for the increase in melting temperature (delta Tm) for calf Thymus DNA on interaction with Ligand at DNAp to ligand ratio 20:1	1992	Journal of medicinal chemistry, Apr-17, Volume: 35, Issue:8	Anthracene-9,10-diones as potential anticancer agents. Synthesis, DNA-binding, and biological studies on a series of 2,6-disubstituted derivatives.
AID687159	Cytotoxicity against human CCRF-CEM cells assessed as cell viability after 48 hrs by celltiter-blue assay	2012	Journal of medicinal chemistry, Jun-14, Volume: 55, Issue:11	Structure-activity relationship (SAR) study of ethyl 2-amino-6-(3,5-dimethoxyphenyl)-4-(2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate (CXL017) and the potential of the lead against multidrug resistance in cancer treatment.
AID1070860	Inhibition of human tert transcriptional activity assessed as SEAP activity at 10 uM after 24 hrs by SEAP reporter assay	2013	European journal of medicinal chemistry, Nov, Volume: 69	Structure-based design, synthesis and biological evaluation of novel anthra[1,2-d]imidazole-6,11-dione homologues as potential antitumor agents.
AID683855	Antiproliferative activity against human LoVo/DX cells after 72 hrs by SRB assay	2012	Bioorganic & medicinal chemistry letters, Oct-01, Volume: 22, Issue:19	New derivatives of 11-methyl-6-[2-(dimethylamino)ethyl]-6H-indolo[2,3-b]quinoline as cytotoxic DNA topoisomerase II inhibitors.
AID1079948	Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID537736	Antifungal activity against yeast AD1-8u expressing Candida albicans CaCdr1p by agar disk diffusion assay	2010	European journal of medicinal chemistry, Nov, Volume: 45, Issue:11	Analysis of physico-chemical properties of substrates of ABC and MFS multidrug transporters of pathogenic Candida albicans.
AID255777	In vitro cytotoxicity variant MES-SA/Dx5 multidrug resistant cells	2005	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 15, Issue:22	Design, synthesis, and antiproliferative activity of some novel aminosubstituted xanthenones, able to overcome multidrug resistance toward MES-SA/Dx5 cells.
AID1550905	Induction of immunogenic cell death in mouse H22 cells assessed as increase in intracellular calreticulin level at 2 uM measured after 5 hrs by flow cytometric analysis	2019	European journal of medicinal chemistry, Jun-01, Volume: 171	Naphthyl quinoxaline thymidine conjugate is a potent anticancer agent post UVA activation and elicits marked inhibition of tumor growth through vaccination.
AID1233368	Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay	2015	Bioorganic & medicinal chemistry letters, Jul-01, Volume: 25, Issue:13	Synthesis and antiproliferative activity of some novel benzo-fused imidazo[1,8]naphthyridinones.
AID39730	Tested for activity against murine B-16 melanoma in mice and percent treated to the control values with the number of 60 day survivors	1987	Journal of medicinal chemistry, Jan, Volume: 30, Issue:1	Anthrapyrazole anticancer agents. Synthesis and structure-activity relationships against murine leukemias.
AID1396804	Antiproliferative activity against human HL60/MX2 cells after 72 hrs by SRB assay	2018	Bioorganic & medicinal chemistry letters, 08-15, Volume: 28, Issue:15	Phosphorus-containing isothiocyanate-derived mercapturic acids as a useful alternative for parental isothiocyanates in experimental oncology.
AID1349094	Inhibition of NAE in human Caco2 cells assessed as increase in p53 protein levels by measuring p53 degradation at 10 uM preincubated for 16 hrs followed by cycloheximide addition measured up to 60 mins by Western blot analysis relative to control	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	Structure-based identification of a NEDD8-activating enzyme inhibitor via drug repurposing.
AID1130162	Antineoplastic activity against mouse L1210 cells allografted in CDF1 mouse assessed as survival at 18 mg/kg qd for 9 days	1979	Journal of medicinal chemistry, May, Volume: 22, Issue:5	Structural modification study of bis(substituted aminoalkylamino)anthraquinones. An evaluation of the relationship of the [2-[(2-hydroxyethyl)amino]ethyl]amino side chain with antineoplastic activity.
AID255826	In vitro cytotoxicity against colorectal adenocarcinoma HT-29 cells	2005	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 15, Issue:22	Design, synthesis, and antiproliferative activity of some novel aminosubstituted xanthenones, able to overcome multidrug resistance toward MES-SA/Dx5 cells.
AID1132469	Antitumor activity against mouse P388 cells allografted in BDF1 mouse assessed as increase in survival time at 1 mg/kg administered 24 hrs post challenge relative to control	1978	Journal of medicinal chemistry, Mar, Volume: 21, Issue:3	Antineoplastic agents. Structure-activity relationship study of bis(substituted aminoalkylamino)anthraquinones.
AID1883022	Toxicity in Balb/c mouse implanted with mouse 4T1 cells assessed as spleen lesions at 50 mg/kg administered intratumorally every four days for 14 days in the presence of liquid cyanoacrylate by H&E staining based histopathological analysis	2022	European journal of medicinal chemistry, Jul-05, Volume: 237	Design, synthesis, and evaluation of a novel series of mono-indolylbenzoquinones derivatives for the potential treatment of breast cancer.
AID1883019	Antitumor activity against mouse 4T1 cells implanted in Balb/c mouse assessed as tumor growth inhibition at 50 mg/kg administered intratumorally every four days for 14 days in the presence of liquid cyanoacrylate relative to control	2022	European journal of medicinal chemistry, Jul-05, Volume: 237	Design, synthesis, and evaluation of a novel series of mono-indolylbenzoquinones derivatives for the potential treatment of breast cancer.
AID307325	Growth inhibition of human HL60 cells by Almar blue assay	2007	Bioorganic & medicinal chemistry, Jun-15, Volume: 15, Issue:12	Synthesis and topoisomerase poisoning activity of A-ring and E-ring substituted luotonin A derivatives.
AID98871	Percentage increase in lifespan of mice was measured (in vivo) at 0.75 mg/kg dose	1988	Journal of medicinal chemistry, Apr, Volume: 31, Issue:4	Synthesis, molecular modeling, DNA binding, and antitumor properties of some substituted amidoanthraquinones.
AID84111	Percent inhibition at G2/M phase of cell cycle at a dose of 100n g/mL after 72 hours of induction in HT-29/Mx cell line	1999	Journal of medicinal chemistry, Sep-09, Volume: 42, Issue:18	8,11-dihydroxy-6-[(aminoalkyl)amino]-7H-benzo[e]perimidin-7-ones with activity in multidrug-resistant cell lines: synthesis and antitumor evaluation.
AID152915	In vivo antitumor activity was measured on systemic P388 murine leukemia cells. Optimal dose at 3 mg/kg/day	1998	Journal of medicinal chemistry, Dec-31, Volume: 41, Issue:27	Synthesis and antitumor evaluation of 2,5-disubstituted-indazolo[4, 3-gh]isoquinolin-6(2H)-ones (9-aza-anthrapyrazoles).
AID436876	Inhibition of Enterobacter cloacae AmpC using nitrocefin as substrate after 15 mins by microtiter plate assay	2009	Bioorganic & medicinal chemistry, Jul-15, Volume: 17, Issue:14	Inhibitors of VIM-2 by screening pharmacologically active and click-chemistry compound libraries.
AID201224	Bacterial mutagenicity was measured against Salmonella Typhimurium TA98 at dose range of 0-10 ug/plate	1998	Journal of medicinal chemistry, Sep-10, Volume: 41, Issue:19	Anthracene-9,10-diones as potential anticancer agents: bacterial mutation studies of amido-substituted derivatives reveal an unexpected lack of mutagenicity.
AID771326	Cytotoxicity against human SKOV3 cells after 48 hrs by resazurin dye assay	2013	Bioorganic & medicinal chemistry letters, Oct-01, Volume: 23, Issue:19	Synthesis and antiproliferative activity of new cytotoxic tri- and tetraazabenzo[3,2-a]fluorene-5,6-dione derivatives.
AID538480	Cytotoxicity against human HCT116 cells by MTT assay	2010	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 20, Issue:23	Oleanane-type triterpenoids from Panax stipuleanatus and their anticancer activities.
AID1506323	Growth inhibition of human bone marrow cells	2018	Journal of medicinal chemistry, Aug-09, Volume: 61, Issue:15	Exploring the Structure-Activity Relationship and Mechanism of a Chromene Scaffold (CXL Series) for Its Selective Antiproliferative Activity toward Multidrug-Resistant Cancer Cells.
AID1132510	Toxicity in mouse P388 cells allografted BDF1 mouse assessed as body weight difference at 0.25 mg/kg administered 24 hrs post challenge relative to control	1978	Journal of medicinal chemistry, Mar, Volume: 21, Issue:3	Antineoplastic agents. Structure-activity relationship study of bis(substituted aminoalkylamino)anthraquinones.
AID220580	Binding affinity towards [poly(dG-dC)]2	1999	Journal of medicinal chemistry, Jul-15, Volume: 42, Issue:14	2,3-Dihydro-1H,7H-pyrimido[5,6,1-de]acridine-1,3,7-trione derivatives, a class of cytotoxic agents active on multidrug-resistant cell lines: synthesis, biological evaluation, and structure-activity relationships.
AID1349091	Inhibition of NAE in human Caco2 cells assessed as increase in p53 protein levels at 0.1 to 10 uM after 16 hrs by Western blot analysis	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	Structure-based identification of a NEDD8-activating enzyme inhibitor via drug repurposing.
AID129075	Antileukemic activity towards P388 Murine Leukemia at a dose of 0.8 mg/kg, expressed as body weight change	1999	Journal of medicinal chemistry, Sep-09, Volume: 42, Issue:18	8,11-dihydroxy-6-[(aminoalkyl)amino]-7H-benzo[e]perimidin-7-ones with activity in multidrug-resistant cell lines: synthesis and antitumor evaluation.
AID1132490	Antitumor activity against mouse P388 cells allografted in BDF1 mouse assessed as mouse survival at 0.25 mg/kg administered 24 hrs post challenge relative to control	1978	Journal of medicinal chemistry, Mar, Volume: 21, Issue:3	Antineoplastic agents. Structure-activity relationship study of bis(substituted aminoalkylamino)anthraquinones.
AID436867	Inhibition of VIM2 using nitrocefin as substrate by rapid dilution method	2009	Bioorganic & medicinal chemistry, Jul-15, Volume: 17, Issue:14	Inhibitors of VIM-2 by screening pharmacologically active and click-chemistry compound libraries.
AID613827	Ratio of IC50 for vinblastine100-resistant human CCRF-CEM cells to IC50 for human CCRF-CEM cells	2011	Journal of medicinal chemistry, Aug-25, Volume: 54, Issue:16	Structure-activity relationship and molecular mechanisms of ethyl 2-amino-6-(3,5-dimethoxyphenyl)-4-(2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate (CXL017) and its analogues.
AID100159	Number of tumor free survivors of mice was measured in L1210 leukemia cells (in vivo) at 3 mg/kg (cumulative dose 9 mg/kg) with ip day 1-9 (twice daily); value give as 7/10	1988	Journal of medicinal chemistry, Apr, Volume: 31, Issue:4	Synthesis, molecular modeling, DNA binding, and antitumor properties of some substituted amidoanthraquinones.
AID687157	Cytotoxicity against human HL60 cells assessed as cell viability after 48 hrs by celltiter-blue assay	2012	Journal of medicinal chemistry, Jun-14, Volume: 55, Issue:11	Structure-activity relationship (SAR) study of ethyl 2-amino-6-(3,5-dimethoxyphenyl)-4-(2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate (CXL017) and the potential of the lead against multidrug resistance in cancer treatment.
AID1130166	Antineoplastic activity against mouse L1210 cells allografted in CDF1 mouse assessed as survival at 4 mg/kg qd for 9 days	1979	Journal of medicinal chemistry, May, Volume: 22, Issue:5	Structural modification study of bis(substituted aminoalkylamino)anthraquinones. An evaluation of the relationship of the [2-[(2-hydroxyethyl)amino]ethyl]amino side chain with antineoplastic activity.
AID272494	Antiproliferative activity against P388 cells by ELISA	2006	Journal of medicinal chemistry, Nov-16, Volume: 49, Issue:23	Flavonoid dimers as bivalent modulators for P-glycoprotein-based multidrug resistance: synthetic apigenin homodimers linked with defined-length poly(ethylene glycol) spacers increase drug retention and enhance chemosensitivity in resistant cancer cells.
AID1506784	Induction of apoptosis in human HCC78 cells assessed as early apoptotic cells level at 10 nM incubated fro 48 hrs by Annexin-V FITC and propidium iodide staining based flow cytometry (Rvb = 6.33%)	2017	MedChemComm, Mar-01, Volume: 8, Issue:3	Identification of mitoxantrone as a new inhibitor of ROS1 fusion protein in non-small cell lung cancer cells.
AID681447	TP_TRANSPORTER: cell accumulation in KOT52 and D320 cells	1999	Cancer research, Sep-01, Volume: 59, Issue:17	The mouse Bcrp1/Mxr/Abcp gene: amplification and overexpression in cell lines selected for resistance to topotecan, mitoxantrone, or doxorubicin.
AID91425	Inhibition of HIV-1 integrase, under 1 uM for the 3''-preprocessing	2000	Journal of medicinal chemistry, Jun-01, Volume: 43, Issue:11	Developing a dynamic pharmacophore model for HIV-1 integrase.
AID1289283	Cytotoxicity against human HaCaT cells by Cell titre-blue assay	2016	Journal of natural products, Jan-22, Volume: 79, Issue:1	Cylindrofridins A-C, Linear Cylindrocyclophane-Related Alkylresorcinols from the Cyanobacterium Cylindrospermum stagnale.
AID85749	Concentration required to inhibit cell growth by 50% in vitro against Human colon adenocarcinoma cell line	2001	Journal of medicinal chemistry, Sep-27, Volume: 44, Issue:20	Synthesis, antitumor cytotoxicity, and DNA-binding of novel N-5,2-di(omega-aminoalkyl)-2,6-dihydropyrazolo[3,4,5-kl]acridine-5-carboxamides.
AID647960	Inhibition of human TERT expression in H1299 cells at 10 uM after 24 hrs by secreted alkaline phosphatase reporter gene assay relative to control	2012	European journal of medicinal chemistry, Apr, Volume: 50	Design, synthesis and evaluation of telomerase inhibitory, hTERT repressing, and anti-proliferation activities of symmetrical 1,8-disubstituted amidoanthraquinones.
AID25619	Estimated pKa value of the compound	1992	Journal of medicinal chemistry, Apr-17, Volume: 35, Issue:8	Anthracene-9,10-diones as potential anticancer agents. Synthesis, DNA-binding, and biological studies on a series of 2,6-disubstituted derivatives.
AID613825	Ratio of IC50 for daunorubicin-resistant human HL60 cells to IC50 for human HL60 cells	2011	Journal of medicinal chemistry, Aug-25, Volume: 54, Issue:16	Structure-activity relationship and molecular mechanisms of ethyl 2-amino-6-(3,5-dimethoxyphenyl)-4-(2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate (CXL017) and its analogues.
AID140016	The compound was tested for antitumor activity against P388 murine leukemia at 2 (mg/kg/day) dose; 0/82 -no. of toxic deaths/no. of mice	1994	Journal of medicinal chemistry, Mar-18, Volume: 37, Issue:6	6,9-Bis[(aminoalkyl)amino]benzo[g]isoquinoline-5,10-diones. A novel class of chromophore-modified antitumor anthracene-9,10-diones: synthesis and antitumor evaluations.
AID1851421	Antiproliferative activity against human A549 cells assessed as inhibition of cell growth	2022	Bioorganic & medicinal chemistry letters, 10-01, Volume: 73	Synthesis and antitumor activity of a series of novel N-aryl-5-(2,2,2-trifluoroethoxy)-1,5-dihydro-2H-pyrrol-2-ones derivatives.
AID771327	Cytotoxicity against human KB/HeLa cells after 48 hrs by resazurin dye assay	2013	Bioorganic & medicinal chemistry letters, Oct-01, Volume: 23, Issue:19	Synthesis and antiproliferative activity of new cytotoxic tri- and tetraazabenzo[3,2-a]fluorene-5,6-dione derivatives.
AID98310	Dose level for 50% inhibition of L1210 cell growth was measured after 24 h.	1988	Journal of medicinal chemistry, Apr, Volume: 31, Issue:4	Synthesis, molecular modeling, DNA binding, and antitumor properties of some substituted amidoanthraquinones.
AID140020	The compound was tested for antitumor activity against P388 murine leukemia at 4 (mg/kg/day) dose; 43/48 -no. of toxic deaths/no. of mice	1994	Journal of medicinal chemistry, Mar-18, Volume: 37, Issue:6	6,9-Bis[(aminoalkyl)amino]benzo[g]isoquinoline-5,10-diones. A novel class of chromophore-modified antitumor anthracene-9,10-diones: synthesis and antitumor evaluations.
AID436864	Inhibition of IMP1 using nitrocefin as substrate after 15 mins by microtiter plate assay	2009	Bioorganic & medicinal chemistry, Jul-15, Volume: 17, Issue:14	Inhibitors of VIM-2 by screening pharmacologically active and click-chemistry compound libraries.
AID1474538	Cytotoxicity against human HL60/MX2 cells after 72 hrs by sulforhodamine B assay	2017	European journal of medicinal chemistry, May-26, Volume: 132	Novel phosphonate analogs of sulforaphane: Synthesis, in vitro and in vivo anticancer activity.
AID96751	Effect of dosing on L1210 leukemia in vivo measured as mean at 0.75 mg/kg	1988	Journal of medicinal chemistry, Apr, Volume: 31, Issue:4	Synthesis, molecular modeling, DNA binding, and antitumor properties of some substituted amidoanthraquinones.
AID55292	CT-DNA binding required to produce a 50% drop in fluorescence of DNA-bound ethidium.	2002	Journal of medicinal chemistry, Jan-31, Volume: 45, Issue:3	2,6-Di(omega-aminoalkyl)-2,5,6,7-tetrahydropyrazolo[3,4,5-mn]pyrimido[5,6,1-de]acridine-5,7-diones: novel, potent, cytotoxic, and DNA-binding agents.
AID98911	Inhibitory activity against sensitive L1210 cell lines	1996	Journal of medicinal chemistry, Apr-12, Volume: 39, Issue:8	6- and 7-substituted 2-[2'-(dimethylamino)ethyl]-1,2-dihydro-3H-dibenz[de,h] isoquinoline-1,3-diones: synthesis, nucleophilic displacements, antitumor activity, and quantitative structure-activity relationships.
AID153495	In vivo antineoplastic activity was determined in BDF1 mice implanted with P388 leukemia and activity is expressed as T/C at 0.12 mg/kg	1987	Journal of medicinal chemistry, Sep, Volume: 30, Issue:9	Structural modification study of mitoxantrone (DHAQ). Chloro-substituted mono- and bis[(aminoalkyl)amino]anthraquinones.
AID380011	Cytotoxicity against human K562 cells after 48 hrs by MTT assay	2000	Journal of natural products, May, Volume: 63, Issue:5	New 7,20:14,20-diepoxy ent-kauranoids from Isodon xerophilus.
AID98203	Anti-tumor activity against murine L1210 sensitive cell line by using MTT assay	1995	Journal of medicinal chemistry, Mar-17, Volume: 38, Issue:6	Amino-substituted 2-[2'-(dimethylamino)ethyl]-1,2-dihydro-3H- dibenz[de,h]isoquinoline-1,3-diones. Synthesis, antitumor activity, and quantitative structure--activity relationship.
AID681063	TP_TRANSPORTER: Northern blot in vivo Wistar rat	1996	Biochemical pharmacology, Nov-08, Volume: 52, Issue:9	Multidrug resistance gene expression in rodents and rodent hepatocytes treated with mitoxantrone.
AID1053260	Antagonist activity at human recombinant dopamine D2 long receptor expressed in CHOK1 cells coexpressing mitochondrial apoaequorin assessed as inhibition of agonist-induced effect at 50 uM after 15 mins by luminometric analysis relative to haloperidol	2013	Journal of medicinal chemistry, Nov-14, Volume: 56, Issue:21	Experimental confirmation of new drug-target interactions predicted by Drug Profile Matching.
AID594150	Antiproliferative activity against human NCI-H460 cells after 48 hrs by XTT assay	2011	Bioorganic & medicinal chemistry letters, May-15, Volume: 21, Issue:10	Synthesis and antiproliferative activity of new cytotoxic azanaphthoquinone pyrrolo-annelated derivatives: Part II.
AID409954	Inhibition of mouse brain MAOA	2008	Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21	Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID487000	Binding affinity to calf thymus DNA assessed as ratio of final absorbance area to the absorbance at 100 uM after 24 hrs by UV spectrophotometer analysis relative to control	2010	Bioorganic & medicinal chemistry, Jun-15, Volume: 18, Issue:12	Study of benzo[a]phenazine 7,12-dioxide as selective hypoxic cytotoxin-scaffold. Identification of aerobic-antitumoral activity through DNA fragmentation.
AID107214	Tested for inhibitory activity against human tumor cell line UA375 of melanoma using sulforhodamine B assay.	2000	Journal of medicinal chemistry, Aug-10, Volume: 43, Issue:16	Analogues of amonafide and azonafide with novel ring systems.
AID729380	Inhibition of PIM1-mediated BAD phosphorylation in human K562 cells after 12 hrs by Western blotting analysis	2013	Journal of medicinal chemistry, Mar-28, Volume: 56, Issue:6	A new target for an old drug: identifying mitoxantrone as a nanomolar inhibitor of PIM1 kinase via kinome-wide selectivity modeling.
AID699541	Inhibition of human liver OATP2B1 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E3S uptake at 20 uM incubated for 5 mins by scintillation counting	2012	Journal of medicinal chemistry, May-24, Volume: 55, Issue:10	Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
AID54998	Increase in Melting temperature (delta Tm) for Calf thymus DNA on interaction against ligand (mole ratio of 10:1)	1992	Journal of medicinal chemistry, Apr-17, Volume: 35, Issue:8	Anthracene-9,10-diones as potential anticancer agents. Synthesis, DNA-binding, and biological studies on a series of 2,6-disubstituted derivatives.
AID613826	Ratio of IC50 for homoharringtonine300-resistant human K562 cells to IC50 for human K562 cells	2011	Journal of medicinal chemistry, Aug-25, Volume: 54, Issue:16	Structure-activity relationship and molecular mechanisms of ethyl 2-amino-6-(3,5-dimethoxyphenyl)-4-(2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate (CXL017) and its analogues.
AID1557151	Cytotoxicity against human NCI-H460 cells assessed as inhibition of cell viability incubated for 2 hrs by MTT assay	2019	European journal of medicinal chemistry, Oct-01, Volume: 179	Benzoyl indoles with metabolic stability as reversal agents for ABCG2-mediated multidrug resistance.
AID682127	TP_TRANSPORTER: Northern blot in vivo NMRI mouse	1996	Biochemical pharmacology, Nov-08, Volume: 52, Issue:9	Multidrug resistance gene expression in rodents and rodent hepatocytes treated with mitoxantrone.
AID1711944	Antiproliferative activity against human HepG2 cells assessed as inhibition of cell proliferation at 5 uM measured after 48 hrs by MTT assay relative to control	2016	European journal of medicinal chemistry, Oct-04, Volume: 121	Synthesis and biological properties of polyamine modified flavonoids as hepatocellular carcinoma inhibitors.
AID591075	Cytotoxicity against human HL60 cells	2011	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 21, Issue:8	Synthesis, cytotoxicity and topoisomerase inhibition properties of multifarious aminoalkylated indeno[1,2-c]isoquinolin-5,11-diones.
AID429649	Cytotoxicity against human A549 cells by MTT assay	2009	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 19, Issue:16	C29 sterols with a cyclopropane ring at C-25 and 26 from the Vietnamese marine sponge Ianthella sp. and their anticancer properties.
AID721751	Inhibition of human OCT2-mediated ASP+ uptake expressed in HEK293 cells after 3 mins by fluorescence assay	2013	Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3	Discovery of potent, selective multidrug and toxin extrusion transporter 1 (MATE1, SLC47A1) inhibitors through prescription drug profiling and computational modeling.
AID436868	Inhibition of VIM2 using nitrocefin as substrate at 44 uM after 15 mins by microtiter plate assay	2009	Bioorganic & medicinal chemistry, Jul-15, Volume: 17, Issue:14	Inhibitors of VIM-2 by screening pharmacologically active and click-chemistry compound libraries.
AID80704	Tested for the cytotoxicity to inhibit replication assay against the human colon tumor cell line HCT116; ND is Not Determined	1994	Journal of medicinal chemistry, Oct-28, Volume: 37, Issue:22	Inhibition of topoisomerase II catalytic activity by pyridoacridine alkaloids from a Cystodytes sp. ascidian: a mechanism for the apparent intercalator-induced inhibition of topoisomerase II.
AID222141	Inhibition of cellular growth was evaluated in vitro against human colon carcinoma subline resistant to DOXO (LOVO/DOXO).	1991	Journal of medicinal chemistry, Aug, Volume: 34, Issue:8	Synthesis and antitumor evaluations of symmetrically and unsymmetrically substituted 1,4-bis[(aminoalkyl)amino]anthracene-9,10-diones and 1,4-bis[(aminoalkyl)amino]-5,8-dihydroxyanthracene-9,10-diones.
AID247764	In vitro cytotoxicity against mouse leukemia L1210 cell lines	2004	Bioorganic & medicinal chemistry letters, Oct-04, Volume: 14, Issue:19	Pyrrolo[2,1-c][1,4]benzodiazepine-anthraquinone conjugates. Synthesis, DNA binding and cytotoxicity.
AID1562301	Antimycobacterial activity against Mycobacterium smegmatis atR17 assessed as decrease in drug resistance at 10 nmol/disc after 2 to 3 days by paper disc method	2019	European journal of medicinal chemistry, Sep-15, Volume: 178	Synthesis and antimycobacterial activity of imidazo[1,2-b][1,2,4,5]tetrazines.
AID625285	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID436865	Inhibition of VIM2 using CCF2 as substrate after 15 mins by FRET assay	2009	Bioorganic & medicinal chemistry, Jul-15, Volume: 17, Issue:14	Inhibitors of VIM-2 by screening pharmacologically active and click-chemistry compound libraries.
AID375433	Displacement of [3H]PSB0413 from human platelet P2Y12 receptor	2009	Journal of medicinal chemistry, Jun-25, Volume: 52, Issue:12	High-affinity, non-nucleotide-derived competitive antagonists of platelet P2Y12 receptors.
AID436896	Inhibition of VIM2 in imipenem-resistant Escherichia coli BL21(DE3) assessed as potentiation of imipenem-induced bactericidal activity at 4.2 ug/mL after 18 hrs by checkerboard microdilution method	2009	Bioorganic & medicinal chemistry, Jul-15, Volume: 17, Issue:14	Inhibitors of VIM-2 by screening pharmacologically active and click-chemistry compound libraries.
AID236913	Permeability Coefficient in Caco-2 cell culture model	2005	Journal of medicinal chemistry, Jan-27, Volume: 48, Issue:2	Exploring the role of different drug transport routes in permeability screening.
AID1079936	Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID7501	In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780/DX(RI)	1999	Journal of medicinal chemistry, Sep-09, Volume: 42, Issue:18	8,11-dihydroxy-6-[(aminoalkyl)amino]-7H-benzo[e]perimidin-7-ones with activity in multidrug-resistant cell lines: synthesis and antitumor evaluation.
AID1132491	Antitumor activity against mouse P388 cells allografted in BDF1 mouse assessed as mouse survival at 0.12 mg/kg administered 24 hrs post challenge relative to control	1978	Journal of medicinal chemistry, Mar, Volume: 21, Issue:3	Antineoplastic agents. Structure-activity relationship study of bis(substituted aminoalkylamino)anthraquinones.
AID1221956	Apparent permeability from apical to basolateral side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis	2011	Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2	Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID1506781	Induction of apoptosis in human HCC78 cells assessed as late apoptotic cells level at 5 nM incubated fro 48 hrs by Annexin-V FITC and propidium iodide staining based flow cytometry (Rvb = 13.8%)	2017	MedChemComm, Mar-01, Volume: 8, Issue:3	Identification of mitoxantrone as a new inhibitor of ROS1 fusion protein in non-small cell lung cancer cells.
AID55500	Concentration required to give 50% fluorescence quenching of bound ethidium for [ethidium]: [poly(dA-dT)]2 DNA in ratio of 0.1:1 at pH 5	1997	Journal of medicinal chemistry, Nov-07, Volume: 40, Issue:23	1-[(omega-aminoalkyl)amino]-4-[N-(omega-aminoalkyl)carbamoyl]-9-oxo-9, 10-dihydroacridines as intercalating cytotoxic agents: synthesis, DNA binding, and biological evaluation.
AID1547889	Inhibition of MTH1 in human U2OS cells assessed as activation of p53 at 2.25 uM incubated for 4 and 24 hrs by Peggy sue Western blot assay	2020	ACS medicinal chemistry letters, Mar-12, Volume: 11, Issue:3	Discovery of Potent and Selective MTH1 Inhibitors for Oncology: Enabling Rapid Target (In)Validation.
AID1586107	Antiproliferative activity against human HL60 cells after 72 hrs by CCK8 assay	2018	Journal of natural products, 12-28, Volume: 81, Issue:12	A Pair of Enantiomeric Bis- seco-abietane Diterpenoids from Cryptomeria fortunei.
AID106431	Antitumor activity against human mammary carcinoma sensitive MXF7 breast cell line.	1996	Journal of medicinal chemistry, Dec-06, Volume: 39, Issue:25	2-[2'-(Dimethylamino)ethyl]-1,2-dihydro- 3H-dibenz[de,h]isoquinoline-1,3-diones with substituents at positions 4, 8, 9, 10, and 11. Synthesis, antitumor activity, and quantitative structure-activity relationships.
AID1506795	Inhibition of ROS1 phosphorylation in human HCC78 cells incubated for 48 hrs by Western blot method	2017	MedChemComm, Mar-01, Volume: 8, Issue:3	Identification of mitoxantrone as a new inhibitor of ROS1 fusion protein in non-small cell lung cancer cells.
AID1519983	Inhibition of Nedd8-cullin1 adduct formation in human A549 cells assessed as decrease in cullin1 neddylation at 50 uM measured after 6 hrs by Western blot analysis	2020	European journal of medicinal chemistry, Jan-01, Volume: 185	Discovery of candesartan cilexetic as a novel neddylation inhibitor for suppressing tumor growth.
AID1209589	Drug uptake in Sprague-Dawley rat brain slices at 100 nM after 5 hrs in presence of 10 uM of fumitremorgin-C	2011	Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3	Measurement of unbound drug exposure in brain: modeling of pH partitioning explains diverging results between the brain slice and brain homogenate methods.
AID1130180	Antineoplastic activity against mouse P388 cells allografted in CDF1 mouse assessed as survival at 0.12 mg/kg qd for 9 days	1979	Journal of medicinal chemistry, May, Volume: 22, Issue:5	Structural modification study of bis(substituted aminoalkylamino)anthraquinones. An evaluation of the relationship of the [2-[(2-hydroxyethyl)amino]ethyl]amino side chain with antineoplastic activity.
AID45639	Survivors of CDF1 mice on day 4 after 1st injection of compound 12 at mg/kg in six mice; 6/6	1989	Journal of medicinal chemistry, Aug, Volume: 32, Issue:8	Synthesis of unsymmetrically substituted 1,4-bis[(aminoalkyl)amino]anthracene-9,10-diones as potential antileukemic agents.
AID1130177	Antineoplastic activity against mouse P388 cells allografted in CDF1 mouse at 0.5 mg/kg qd for 9 days relative to control	1979	Journal of medicinal chemistry, May, Volume: 22, Issue:5	Structural modification study of bis(substituted aminoalkylamino)anthraquinones. An evaluation of the relationship of the [2-[(2-hydroxyethyl)amino]ethyl]amino side chain with antineoplastic activity.
AID1349115	Cytotoxicity against NAE-knockdown human Caco2 cells after 72 hrs by MTT assay	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	Structure-based identification of a NEDD8-activating enzyme inhibitor via drug repurposing.
AID1349109	Induction of apoptosis in human Caco2 cells assessed as necrotic cells at 5 uM after 16 hrs by Annexin V-FITC/propidium iodide staining-based flow cytometric analysis (Rvb = 0.12%)	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	Structure-based identification of a NEDD8-activating enzyme inhibitor via drug repurposing.
AID436877	Inhibition of Enterobacter cloacae AmpC using nitrocefin as substrate at 25 uM after 15 mins by microtiter plate assay	2009	Bioorganic & medicinal chemistry, Jul-15, Volume: 17, Issue:14	Inhibitors of VIM-2 by screening pharmacologically active and click-chemistry compound libraries.
AID1132473	Antitumor activity against mouse P388 cells allografted in BDF1 mouse assessed as increase in survival time at 0.06 mg/kg administered 24 hrs post challenge relative to control	1978	Journal of medicinal chemistry, Mar, Volume: 21, Issue:3	Antineoplastic agents. Structure-activity relationship study of bis(substituted aminoalkylamino)anthraquinones.
AID477295	Octanol-water partition coefficient, log P of the compound	2010	European journal of medicinal chemistry, Apr, Volume: 45, Issue:4	QSPR modeling of octanol/water partition coefficient of antineoplastic agents by balance of correlations.
AID83790	Percent inhibition at G1 phase of cell cycle at a dose of 25 ng/mL after 72 hours of induction in HT-29 cell line	1999	Journal of medicinal chemistry, Sep-09, Volume: 42, Issue:18	8,11-dihydroxy-6-[(aminoalkyl)amino]-7H-benzo[e]perimidin-7-ones with activity in multidrug-resistant cell lines: synthesis and antitumor evaluation.
AID1656533	Stabilization of dsBE12 oligonucleotide (unknown origin) assessed as drug-DNA adduct formation at 5 to 50 uM incubated for 4 hrs in presence of formaldehyde using [gamma-32P]ATP by phosphorimaging analysis relative to control	2020	Bioorganic & medicinal chemistry, 02-01, Volume: 28, Issue:3	Formaldehyde-activated WEHI-150 induces DNA interstrand crosslinks with unique structural features.
AID270854	Antiproliferative activity against MES-SA cells by MTT assay after 72 hrs	2006	Bioorganic & medicinal chemistry letters, Sep-15, Volume: 16, Issue:18	Synthesis and antiproliferative activity of substituted benzopyranoisoindoles: a new class of cytotoxic compounds.
AID1130175	Antineoplastic activity against mouse P388 cells allografted in CDF1 mouse at 1 mg/kg qd for 9 days relative to control	1979	Journal of medicinal chemistry, May, Volume: 22, Issue:5	Structural modification study of bis(substituted aminoalkylamino)anthraquinones. An evaluation of the relationship of the [2-[(2-hydroxyethyl)amino]ethyl]amino side chain with antineoplastic activity.
AID431398	Cytotoxicity against human HL60 cells after 48 hrs by cell titer-blue assay	2009	Journal of medicinal chemistry, Oct-08, Volume: 52, Issue:19	Structure-activity relationship and molecular mechanisms of ethyl 2-amino-4-(2-ethoxy-2-oxoethyl)-6-phenyl-4h-chromene-3-carboxylate (sha 14-1) and its analogues.
AID54441	In vitro calf thymus DNA binding affinity by ethidium bromide displacement	2002	Bioorganic & medicinal chemistry letters, Jun-03, Volume: 12, Issue:11	Design and synthesis of some new pyranoxanthenone aminoderivatives with cytotoxic activity.
AID624612	Specific activity of expressed human recombinant UGT1A9	2000	Annual review of pharmacology and toxicology, , Volume: 40	Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID681130	TP_TRANSPORTER: transepithelial transport (basal to apical) in MDR1-expressing MDCKII cells	2001	The Journal of pharmacology and experimental therapeutics, Nov, Volume: 299, Issue:2	Rational use of in vitro P-glycoprotein assays in drug discovery.
AID1079949	Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID521220	Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay	2007	Nature chemical biology, May, Volume: 3, Issue:5	Chemical genetics reveals a complex functional ground state of neural stem cells.
AID1430723	Growth inhibition of mouse 4T1.2 cells up to 20000 nM after 48 hrs by MTT assay	2017	ACS medicinal chemistry letters, May-11, Volume: 8, Issue:5	Encapsulation of Mitoxantrone within Cucurbit[8]uril Decreases Toxicity and Enhances Survival in a Mouse Model of Cancer.
AID687158	Cytotoxicity against human K562 cells assessed as cell viability after 48 hrs by celltiter-blue assay	2012	Journal of medicinal chemistry, Jun-14, Volume: 55, Issue:11	Structure-activity relationship (SAR) study of ethyl 2-amino-6-(3,5-dimethoxyphenyl)-4-(2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate (CXL017) and the potential of the lead against multidrug resistance in cancer treatment.
AID54104	Increase in Melting temperature (delta Tm) for Clostridium perfringens DNA on interaction against ligand (mole ratio of 10:1)	1992	Journal of medicinal chemistry, Apr-17, Volume: 35, Issue:8	Anthracene-9,10-diones as potential anticancer agents. Synthesis, DNA-binding, and biological studies on a series of 2,6-disubstituted derivatives.
AID102335	Resistance index is IC50 ratio of LoVo/Dx to LoVo	1999	Journal of medicinal chemistry, Jul-15, Volume: 42, Issue:14	2,3-Dihydro-1H,7H-pyrimido[5,6,1-de]acridine-1,3,7-trione derivatives, a class of cytotoxic agents active on multidrug-resistant cell lines: synthesis, biological evaluation, and structure-activity relationships.
AID729389	Inhibition of Mycobacterium tuberculosis protein kinase B	2013	Journal of medicinal chemistry, Mar-28, Volume: 56, Issue:6	A new target for an old drug: identifying mitoxantrone as a nanomolar inhibitor of PIM1 kinase via kinome-wide selectivity modeling.
AID107942	Compound was evaluated in vivo for the antitumor activity at a dose of 2.5 mg/kg & 7.5 mg/kg against mammary adenocarcinoma 16C to assess tumor growth delay (T-C)	1984	Journal of medicinal chemistry, Mar, Volume: 27, Issue:3	5-[(Aminoalkyl)amino]-substituted anthra[1,9-cd]pyrazol-6(2H)-ones as novel anticancer agents. Synthesis and biological evaluation.
AID320434	Cytotoxicity against human NCI-H460 cells at 4 ug/ml after 48 hrs by SRB assay	2008	Bioorganic & medicinal chemistry, Jan-15, Volume: 16, Issue:2	Synthesis, DNA binding, and cytotoxicity of 1,4-bis(2-amino-ethylamino)anthraquinone-amino acid conjugates.
AID230386	Resistance index as the ratio of IC50 value against LoVo/Dx to that of LoVo cell lines.	1995	Journal of medicinal chemistry, Feb-03, Volume: 38, Issue:3	Chromophore-modified antitumor anthracenediones: synthesis, DNA binding, and cytotoxic activity of 1,4-bis[(aminoalkyl)amino]benzo[g]-phthalazine-5,10-diones.
AID681446	TP_TRANSPORTER: cell accumulation in MEF3.8, M32 and T6400 cells	1999	Cancer research, Sep-01, Volume: 59, Issue:17	The mouse Bcrp1/Mxr/Abcp gene: amplification and overexpression in cell lines selected for resistance to topotecan, mitoxantrone, or doxorubicin.
AID84106	Percent inhibition at G1 phase of cell cycle at a dose of 1000 ng/mL after 72 hours of induction in HT-29 cell line	1999	Journal of medicinal chemistry, Sep-09, Volume: 42, Issue:18	8,11-dihydroxy-6-[(aminoalkyl)amino]-7H-benzo[e]perimidin-7-ones with activity in multidrug-resistant cell lines: synthesis and antitumor evaluation.
AID84110	Percent inhibition at G1 phase of cell cycle at a dose of 250 ng/mL after 72 hours of induction in HT-29/Mx cell line	1999	Journal of medicinal chemistry, Sep-09, Volume: 42, Issue:18	8,11-dihydroxy-6-[(aminoalkyl)amino]-7H-benzo[e]perimidin-7-ones with activity in multidrug-resistant cell lines: synthesis and antitumor evaluation.
AID83618	In vitro cytotoxicity was tested against human colon adenocarcinoma HT-29 cell line	1999	Journal of medicinal chemistry, Jul-15, Volume: 42, Issue:14	2,3-Dihydro-1H,7H-pyrimido[5,6,1-de]acridine-1,3,7-trione derivatives, a class of cytotoxic agents active on multidrug-resistant cell lines: synthesis, biological evaluation, and structure-activity relationships.
AID436884	Bactericidal activity against imipenem-resistant Escherichia coli BL21(DE3) expressing VIM2 gene at 2.1 ug/mL after 24 hrs by broth microdilution method	2009	Bioorganic & medicinal chemistry, Jul-15, Volume: 17, Issue:14	Inhibitors of VIM-2 by screening pharmacologically active and click-chemistry compound libraries.
AID107946	In vivo antitumor activity at a single dose of 6.5 mg/kg & 18.8 mg/kg total against mammary adenocarcinoma 16C	1984	Journal of medicinal chemistry, Mar, Volume: 27, Issue:3	5-[(Aminoalkyl)amino]-substituted anthra[1,9-cd]pyrazol-6(2H)-ones as novel anticancer agents. Synthesis and biological evaluation.
AID145432	Anti-tumor activity against human OVCAR-3 ovarian cancer cell lines by using MTT assay	1995	Journal of medicinal chemistry, Mar-17, Volume: 38, Issue:6	Amino-substituted 2-[2'-(dimethylamino)ethyl]-1,2-dihydro-3H- dibenz[de,h]isoquinoline-1,3-diones. Synthesis, antitumor activity, and quantitative structure--activity relationship.
AID232336	Ratio of BR1 IC50 to xrs-6 IC50	1995	Journal of medicinal chemistry, Oct-27, Volume: 38, Issue:22	Topoisomerase II-mediated DNA cleavage by adocia- and xestoquinones from the Philippine sponge Xestospongia sp.
AID232294	Differential cytotoxicity was determined from the ratio between BR1(IC50) and xrs-6 (IC50)	1994	Journal of medicinal chemistry, Oct-28, Volume: 37, Issue:22	Inhibition of topoisomerase II catalytic activity by pyridoacridine alkaloids from a Cystodytes sp. ascidian: a mechanism for the apparent intercalator-induced inhibition of topoisomerase II.
AID1233372	Antiproliferative activity against human Daudi cells after 72 hrs by MTT assay	2015	Bioorganic & medicinal chemistry letters, Jul-01, Volume: 25, Issue:13	Synthesis and antiproliferative activity of some novel benzo-fused imidazo[1,8]naphthyridinones.
AID1666489	Inhibition of TDP-43 (unknown origin) binding to RNA	2020	Bioorganic & medicinal chemistry letters, 02-15, Volume: 30, Issue:4	Emerging small-molecule therapeutic approaches for amyotrophic lateral sclerosis and frontotemporal dementia.
AID135058	In vivo antileukemic activity towards P388 Murine Leukemia at a dose of 0.1 mg/kg, expressed as long time survivors tested in 12 animals	1999	Journal of medicinal chemistry, Sep-09, Volume: 42, Issue:18	8,11-dihydroxy-6-[(aminoalkyl)amino]-7H-benzo[e]perimidin-7-ones with activity in multidrug-resistant cell lines: synthesis and antitumor evaluation.
AID1682835	Antiproliferative activity against human K562 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	2021	Bioorganic & medicinal chemistry, 01-01, Volume: 29	Structure-activity relationship of novel acridone derivatives as antiproliferative agents.
AID136069	Antileukemic activity towards P388 Murine Leukemia at a dose of 0.1 mg/kg	1999	Journal of medicinal chemistry, Sep-09, Volume: 42, Issue:18	8,11-dihydroxy-6-[(aminoalkyl)amino]-7H-benzo[e]perimidin-7-ones with activity in multidrug-resistant cell lines: synthesis and antitumor evaluation.
AID91426	Tested for inhibition of HIV-1 integrase, under 1 uM for the strand transfer	2000	Journal of medicinal chemistry, Jun-01, Volume: 43, Issue:11	Developing a dynamic pharmacophore model for HIV-1 integrase.
AID625279	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1349117	Inhibition of UAE1-mediated Ubc10-ubiquitin conjugation in human Caco2 cells up to 10 uM preincubated for 10 mins followed by ATP and Mg2+ addition measured after 60 mins by Western blot analysis	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	Structure-based identification of a NEDD8-activating enzyme inhibitor via drug repurposing.
AID429651	Cytotoxicity against human HT-29 cells by MTT assay	2009	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 19, Issue:16	C29 sterols with a cyclopropane ring at C-25 and 26 from the Vietnamese marine sponge Ianthella sp. and their anticancer properties.
AID90440	In vitro cytotoxic activity against human colon adenocarcinoma (HT-29).	2003	Journal of medicinal chemistry, Jul-03, Volume: 46, Issue:14	Design, synthesis, and biological properties of new bis(acridine-4-carboxamides) as anticancer agents.
AID687162	Ratio of IC50 for daunorubicin-resistant human HL60 cells to IC50 for human HL60 cells	2012	Journal of medicinal chemistry, Jun-14, Volume: 55, Issue:11	Structure-activity relationship (SAR) study of ethyl 2-amino-6-(3,5-dimethoxyphenyl)-4-(2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate (CXL017) and the potential of the lead against multidrug resistance in cancer treatment.
AID1430724	Growth inhibition of mouse 4T1.2 cells up to 20000 nM encapsulated within cucurbit[8]uril after 48 hrs by MTT assay	2017	ACS medicinal chemistry letters, May-11, Volume: 8, Issue:5	Encapsulation of Mitoxantrone within Cucurbit[8]uril Decreases Toxicity and Enhances Survival in a Mouse Model of Cancer.
AID1381972	Antiproliferative activity against human HT-29 cells after 48 hrs by MTT assay	2018	European journal of medicinal chemistry, Feb-25, Volume: 146	The lead optimization of the polyamine conjugate of flavonoid with a naphthalene motif: Synthesis and biological evaluation.
AID130603	In vitro inhibitory activity against L1210 leukemia cell line	1993	Journal of medicinal chemistry, Jul-23, Volume: 36, Issue:15	Synthesis and antitumor properties of an anthraquinone bisubstituted by the copper chelating peptide Gly-Gly-L-His.
AID1506788	Induction of apoptosis in human HCC78 cells assessed as early apoptotic cells level at 20 nM incubated fro 48 hrs by Annexin-V FITC and propidium iodide staining based flow cytometry (Rvb = 6.33%)	2017	MedChemComm, Mar-01, Volume: 8, Issue:3	Identification of mitoxantrone as a new inhibitor of ROS1 fusion protein in non-small cell lung cancer cells.
AID536039	Cytotoxicity against human HL60 cells after 72 hrs	2010	Bioorganic & medicinal chemistry, Nov-15, Volume: 18, Issue:22	Indeno[1,2-c]isoquinolin-5,11-diones conjugated to amino acids: Synthesis, cytotoxicity, DNA interaction, and topoisomerase II inhibition properties.
AID1209581	Fraction unbound in Sprague-Dawley rat brain homogenates at 5 uM by equilibrium dialysis analysis	2011	Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3	Measurement of unbound drug exposure in brain: modeling of pH partitioning explains diverging results between the brain slice and brain homogenate methods.
AID1130181	Antineoplastic activity against mouse P388 cells allografted in CDF1 mouse at 0.12 mg/kg qd for 9 days relative to control	1979	Journal of medicinal chemistry, May, Volume: 22, Issue:5	Structural modification study of bis(substituted aminoalkylamino)anthraquinones. An evaluation of the relationship of the [2-[(2-hydroxyethyl)amino]ethyl]amino side chain with antineoplastic activity.
AID395134	Binding affinity to poly(dA).poly(dT) DNA assessed as change in melting temperature	2008	European journal of medicinal chemistry, Nov, Volume: 43, Issue:11	Ligand binding to nucleic acids and proteins: Does selectivity increase with strength?
AID1506787	Induction of apoptosis in human HCC78 cells assessed as viable cells level at 20 nM incubated fro 48 hrs by Annexin-V FITC and propidium iodide staining based flow cytometry (Rvb = 80.8%)	2017	MedChemComm, Mar-01, Volume: 8, Issue:3	Identification of mitoxantrone as a new inhibitor of ROS1 fusion protein in non-small cell lung cancer cells.
AID129073	Antileukemic activity towards P388 Murine Leukemia at a dose of 0.2 mg/kg, expressed as body weight change	1999	Journal of medicinal chemistry, Sep-09, Volume: 42, Issue:18	8,11-dihydroxy-6-[(aminoalkyl)amino]-7H-benzo[e]perimidin-7-ones with activity in multidrug-resistant cell lines: synthesis and antitumor evaluation.
AID235123	Resistance index was determined by ratio of cytotoxicities of human colon adenocarcinoma (LoVo) cells to human colon adenocarcinoma resistant to doxorubicin (LoVo Dx) cells.	2000	Bioorganic & medicinal chemistry letters, Feb-07, Volume: 10, Issue:3	Synthesis and antitumor activities of 5-methyl-1- and 2-[[2-dimethylaminoethyl]amino]-aza-thiopyranoindazoles.
AID150676	Relative cytotoxicity against Human bone marrow samples; Value is in range, activity expressed as IC50	1999	Journal of medicinal chemistry, Jun-17, Volume: 42, Issue:12	Design and synthesis of modified quinolones as antitumoral acridones.
AID1233369	Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay	2015	Bioorganic & medicinal chemistry letters, Jul-01, Volume: 25, Issue:13	Synthesis and antiproliferative activity of some novel benzo-fused imidazo[1,8]naphthyridinones.
AID354538	Cytotoxicity against rat C6 cells at 50 ug/mL to 2.5 mg/mL after 3 days treated 4 hrs before db-cAMP challenge by MTT assay	1996	Journal of natural products, Dec, Volume: 59, Issue:12	Cell-based screen for identification of inhibitors of tubulin polymerization.
AID1349092	Upregulation of p53 protein levels in NAE knockdown human Caco2 cells at 10 uM after 16 hrs by Western blot analysis	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	Structure-based identification of a NEDD8-activating enzyme inhibitor via drug repurposing.
AID729376	Inhibition of PIM1-mediated BAD phosphorylation in human K562 cells at 0.1 to 30 uM after 12 hrs by Western blotting analysis	2013	Journal of medicinal chemistry, Mar-28, Volume: 56, Issue:6	A new target for an old drug: identifying mitoxantrone as a nanomolar inhibitor of PIM1 kinase via kinome-wide selectivity modeling.
AID729378	Inhibition of PIM1-mediated BAD phosphorylation in human MV411 cells at 100 nM after 12 hrs by Western blotting analysis	2013	Journal of medicinal chemistry, Mar-28, Volume: 56, Issue:6	A new target for an old drug: identifying mitoxantrone as a nanomolar inhibitor of PIM1 kinase via kinome-wide selectivity modeling.
AID1349108	Induction of apoptosis in human Caco2 cells assessed as late apoptotic cells at 5 uM after 16 hrs by Annexin V-FITC/propidium iodide staining-based flow cytometric analysis (Rvb = 0.072%)	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	Structure-based identification of a NEDD8-activating enzyme inhibitor via drug repurposing.
AID1557152	Cytotoxicity against human NCI-H460/MX20 cells assessed as inhibition of cell viability incubated for 2 hrs by MTT assay	2019	European journal of medicinal chemistry, Oct-01, Volume: 179	Benzoyl indoles with metabolic stability as reversal agents for ABCG2-mediated multidrug resistance.
AID1349112	Induction of apoptosis in human Caco2 cells assessed as late apoptotic cells at 10 uM after 16 hrs by Annexin V-FITC/propidium iodide staining-based flow cytometric analysis (Rvb = 0.072%)	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	Structure-based identification of a NEDD8-activating enzyme inhibitor via drug repurposing.
AID232611	Ratio of IC50 against V79 cells in the presence of air to that of nitrogen.	1995	Journal of medicinal chemistry, Mar-17, Volume: 38, Issue:6	Synthesis and biological activity of thiazolylindolequinones, analogues of the natural product BE 10988.
AID602040	Cytotoxicity against human HCT116 cells after 24 hrs by MTT assay	2011	Bioorganic & medicinal chemistry letters, May-15, Volume: 21, Issue:10	Cytotoxic and PPARs transcriptional activities of sterols from the Vietnamese soft coral Lobophytum laevigatum.
AID679172	TP_TRANSPORTER: drug resistance in BCRP-expressing LLC-PK1 cells	2003	Molecular pharmacology, Sep, Volume: 64, Issue:3	Breast cancer resistance protein exports sulfated estrogens but not free estrogens.
AID135059	In vivo antileukemic activity towards P388 Murine Leukemia at a dose of 0.2 mg/kg, expressed as long time survivors tested in 6 animals	1999	Journal of medicinal chemistry, Sep-09, Volume: 42, Issue:18	8,11-dihydroxy-6-[(aminoalkyl)amino]-7H-benzo[e]perimidin-7-ones with activity in multidrug-resistant cell lines: synthesis and antitumor evaluation.
AID1711947	Cytotoxicity against human QSG7701 cells assessed as inhibition of cell proliferation at 1 uM measured after 48 hrs by MTT assay relative to control	2016	European journal of medicinal chemistry, Oct-04, Volume: 121	Synthesis and biological properties of polyamine modified flavonoids as hepatocellular carcinoma inhibitors.
AID1130173	Antineoplastic activity against mouse P388 cells allografted in CDF1 mouse at 2 mg/kg qd for 9 days relative to control	1979	Journal of medicinal chemistry, May, Volume: 22, Issue:5	Structural modification study of bis(substituted aminoalkylamino)anthraquinones. An evaluation of the relationship of the [2-[(2-hydroxyethyl)amino]ethyl]amino side chain with antineoplastic activity.
AID150691	Relative cytotoxicity against Human bone marrow samples; Value is in range, activity expressed as IC90	1999	Journal of medicinal chemistry, Jun-17, Volume: 42, Issue:12	Design and synthesis of modified quinolones as antitumoral acridones.
AID145436	Antitumor activity against human ovarian OVCAR-3 cell lines.	1996	Journal of medicinal chemistry, Dec-06, Volume: 39, Issue:25	2-[2'-(Dimethylamino)ethyl]-1,2-dihydro- 3H-dibenz[de,h]isoquinoline-1,3-diones with substituents at positions 4, 8, 9, 10, and 11. Synthesis, antitumor activity, and quantitative structure-activity relationships.
AID625283	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID236916	Percentage of mass balance in hexadecane membranes model	2005	Journal of medicinal chemistry, Jan-27, Volume: 48, Issue:2	Exploring the role of different drug transport routes in permeability screening.
AID625284	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID227413	Dose modifying factor expressed as the ratio of IC50 for the chemotherapy drug to IC50 for drug + GG918; Range = 1.2-1850	2004	Bioorganic & medicinal chemistry letters, Feb-23, Volume: 14, Issue:4	Inhibitors of multidrug resistance (MDR) have affinity for MDR substrates.
AID216273	In vitro extracellular concentration required to reduce cell population to 50% against Walker 256 (WS) carcinoma cells	1992	Journal of medicinal chemistry, Apr-17, Volume: 35, Issue:8	Anthracene-9,10-diones as potential anticancer agents. Synthesis, DNA-binding, and biological studies on a series of 2,6-disubstituted derivatives.
AID436875	Inhibition of TEM-1 using nitrocefin as substrate at 25 uM after 15 mins by microtiter plate assay	2009	Bioorganic & medicinal chemistry, Jul-15, Volume: 17, Issue:14	Inhibitors of VIM-2 by screening pharmacologically active and click-chemistry compound libraries.
AID83794	Percent inhibition at S phase of cell cycle at a dose of 25 ng/mL after 72 hours of induction in HT-29 cell line	1999	Journal of medicinal chemistry, Sep-09, Volume: 42, Issue:18	8,11-dihydroxy-6-[(aminoalkyl)amino]-7H-benzo[e]perimidin-7-ones with activity in multidrug-resistant cell lines: synthesis and antitumor evaluation.
AID57199	In vitro inhibition of partially purified human ovarian carcinoma topoisomerase II of kDNA decatenation	1995	Journal of medicinal chemistry, Oct-27, Volume: 38, Issue:22	Topoisomerase II-mediated DNA cleavage by adocia- and xestoquinones from the Philippine sponge Xestospongia sp.
AID683861	Antiproliferative activity against human HL60/MX2 cells after 72 hrs by SRB assay	2012	Bioorganic & medicinal chemistry letters, Oct-01, Volume: 22, Issue:19	New derivatives of 11-methyl-6-[2-(dimethylamino)ethyl]-6H-indolo[2,3-b]quinoline as cytotoxic DNA topoisomerase II inhibitors.
AID1349105	Induction of apoptosis in human Caco2 cells assessed as necrotic cells at 1 uM after 16 hrs by Annexin V-FITC/propidium iodide staining-based flow cytometric analysis (Rvb = 0.12%)	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	Structure-based identification of a NEDD8-activating enzyme inhibitor via drug repurposing.
AID81643	Relative cytotoxicity against Human promyelocytic Leukemia(HL-60) cells; Value is in range, activity expressed as IC90	1999	Journal of medicinal chemistry, Jun-17, Volume: 42, Issue:12	Design and synthesis of modified quinolones as antitumoral acridones.
AID1053264	Antagonist activity at human recombinant dopamine D1 receptor expressed in CHOK1 cells assessed as inhibition of agonist-induced cAMP accumulation at 100 uM preincubated for 10 mins prior to agonist addition measured after 30 mins by HTRF assay relative t	2013	Journal of medicinal chemistry, Nov-14, Volume: 56, Issue:21	Experimental confirmation of new drug-target interactions predicted by Drug Profile Matching.
AID320442	Cytotoxicity against human SF268 cells after 48 hrs by SRB assay	2008	Bioorganic & medicinal chemistry, Jan-15, Volume: 16, Issue:2	Synthesis, DNA binding, and cytotoxicity of 1,4-bis(2-amino-ethylamino)anthraquinone-amino acid conjugates.
AID595062	Cytotoxicity against human MES-SA cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay	2011	Bioorganic & medicinal chemistry letters, May-15, Volume: 21, Issue:10	Design, synthesis and antiproliferative activity of novel aminosubstituted benzothiopyranoisoindoles.
AID1130164	Antineoplastic activity against mouse L1210 cells allografted in CDF1 mouse assessed as survival at 10.8 mg/kg qd for 9 days	1979	Journal of medicinal chemistry, May, Volume: 22, Issue:5	Structural modification study of bis(substituted aminoalkylamino)anthraquinones. An evaluation of the relationship of the [2-[(2-hydroxyethyl)amino]ethyl]amino side chain with antineoplastic activity.
AID1079941	Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID1711997	Toxicity in Kunming mouse implanted with mouse H22 cells assessed as change in body weight at 0.4 mg/kg, iv administered for 7 consecutive days starting from day 11 post inoculation and measured after 18 days (Rvb = 5.2 %)	2016	European journal of medicinal chemistry, Oct-04, Volume: 121	Synthesis and biological properties of polyamine modified flavonoids as hepatocellular carcinoma inhibitors.
AID594151	Antiproliferative activity against human RKOp27 cells after 48 hrs by XTT assay	2011	Bioorganic & medicinal chemistry letters, May-15, Volume: 21, Issue:10	Synthesis and antiproliferative activity of new cytotoxic azanaphthoquinone pyrrolo-annelated derivatives: Part II.
AID216435	Tested for inhibitory activity against a sensitive strain of human colon carcinoma WiDr using sulforhodamine B assay (it is MRP positive but non-P-glycoprotein).	2000	Journal of medicinal chemistry, Aug-10, Volume: 43, Issue:16	Analogues of amonafide and azonafide with novel ring systems.
AID681508	TP_TRANSPORTER: efflux in MCF7/VP and MCF cells	2001	Cancer research, Jul-15, Volume: 61, Issue:14	Resistance to mitoxantrone in multidrug-resistant MCF7 breast cancer cells: evaluation of mitoxantrone transport and the role of multidrug resistance protein family proteins.
AID1430727	Toxicity in Balb/c mouse implanted with mouse 4T1.2 cells assessed as body weight loss at 3 mg/kg, iv encapsulated within cucurbit[8]uril administered twice weekly for 2 weeks	2017	ACS medicinal chemistry letters, May-11, Volume: 8, Issue:5	Encapsulation of Mitoxantrone within Cucurbit[8]uril Decreases Toxicity and Enhances Survival in a Mouse Model of Cancer.
AID1079947	Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID102172	In vitro cytotoxicity was tested against human colon adenocarcinoma LoVo cell line	1999	Journal of medicinal chemistry, Jul-15, Volume: 42, Issue:14	2,3-Dihydro-1H,7H-pyrimido[5,6,1-de]acridine-1,3,7-trione derivatives, a class of cytotoxic agents active on multidrug-resistant cell lines: synthesis, biological evaluation, and structure-activity relationships.
AID1711976	Antitumor activity against mouse H22 cells implanted in Kunming mouse assessed as tumor growth inhibition at 0.4 mg/kg, iv administered for 7 consecutive days starting from day 8 post inoculation and measured after 16 days relative to control	2016	European journal of medicinal chemistry, Oct-04, Volume: 121	Synthesis and biological properties of polyamine modified flavonoids as hepatocellular carcinoma inhibitors.
AID1474540	Resistance index, ratio of IC50 for human HL60/MX2 cells to IC50 for human HL60 cells	2017	European journal of medicinal chemistry, May-26, Volume: 132	Novel phosphonate analogs of sulforaphane: Synthesis, in vitro and in vivo anticancer activity.
AID98312	Dose level for 50% inhibition of L1210 cell growth was measured after 48 hr.	1988	Journal of medicinal chemistry, Apr, Volume: 31, Issue:4	Synthesis, molecular modeling, DNA binding, and antitumor properties of some substituted amidoanthraquinones.
AID10007	Cytotoxic potency required to inhibit A2780 cell growth by 50% after cell drug contact for 96 hrs	1997	Journal of medicinal chemistry, Nov-07, Volume: 40, Issue:23	1-[(omega-aminoalkyl)amino]-4-[N-(omega-aminoalkyl)carbamoyl]-9-oxo-9, 10-dihydroacridines as intercalating cytotoxic agents: synthesis, DNA binding, and biological evaluation.
AID1903852	Antitumor immunity against human U2OS cells assessed as decrease in ATP by measuring reduction in quinacrine green fluorescence intensity at 3 uM pretreated for 24 hrs by live fluorescence microscopic analysis	2022	Journal of medicinal chemistry, 03-24, Volume: 65, Issue:6	Biological Investigation of a Water-Soluble Isoginkgetin-Phosphate Analogue, Targeting the Spliceosome with
AID1506796	Inhibition of ROS1 in human HCC78 cells assessed as reduction in STAT3 phosphorylation incubated for 48 hrs by Western blot method	2017	MedChemComm, Mar-01, Volume: 8, Issue:3	Identification of mitoxantrone as a new inhibitor of ROS1 fusion protein in non-small cell lung cancer cells.
AID115197	The percent increase in life span of compound was measured against P388 Leukemia cells in mice at at a dose of 1.6 mg/kg on days 1,5 and 9	1995	Journal of medicinal chemistry, Mar-17, Volume: 38, Issue:6	Amino-substituted 2-[2'-(dimethylamino)ethyl]-1,2-dihydro-3H- dibenz[de,h]isoquinoline-1,3-diones. Synthesis, antitumor activity, and quantitative structure--activity relationship.
AID1221965	Transporter substrate index of efflux ratio in human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 1 uM of P-gp inhibitor LY335979	2011	Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2	Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID272511	Antiproliferative activity against multidrug resistant MDA435/LCC6 cells in presence of 5 uM verapamil by ELISA	2006	Journal of medicinal chemistry, Nov-16, Volume: 49, Issue:23	Flavonoid dimers as bivalent modulators for P-glycoprotein-based multidrug resistance: synthetic apigenin homodimers linked with defined-length poly(ethylene glycol) spacers increase drug retention and enhance chemosensitivity in resistant cancer cells.
AID214779	Antitumor activity against human melanoma UACC375 cell line.	1996	Journal of medicinal chemistry, Dec-06, Volume: 39, Issue:25	2-[2'-(Dimethylamino)ethyl]-1,2-dihydro- 3H-dibenz[de,h]isoquinoline-1,3-diones with substituents at positions 4, 8, 9, 10, and 11. Synthesis, antitumor activity, and quantitative structure-activity relationships.
AID1221957	Apparent permeability from basolateral to apical side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis	2011	Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2	Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID1506774	Induction of apoptosis in human HCC78 cells incubated fro 48 hrs by Annexin-V FITC and propidium iodide staining based flow cytometry	2017	MedChemComm, Mar-01, Volume: 8, Issue:3	Identification of mitoxantrone as a new inhibitor of ROS1 fusion protein in non-small cell lung cancer cells.
AID589896	Cytotoxicity against human A549 cells after 72 hrs	2011	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 21, Issue:7	Cytotoxic and antioxidant activities of diterpenes and sterols from the Vietnamese soft coral Lobophytum compactum.
AID1130155	Antineoplastic activity against mouse B16 cells allografted in BDF1 mouse at 0.25 mg/kg qd for 9 days relative to control	1979	Journal of medicinal chemistry, May, Volume: 22, Issue:5	Structural modification study of bis(substituted aminoalkylamino)anthraquinones. An evaluation of the relationship of the [2-[(2-hydroxyethyl)amino]ethyl]amino side chain with antineoplastic activity.
AID85581	Inhibitory activity against human tumor cell line HT1080.	1995	Journal of medicinal chemistry, Feb-03, Volume: 38, Issue:3	Chromophore-modified antitumor anthracenediones: synthesis, DNA binding, and cytotoxic activity of 1,4-bis[(aminoalkyl)amino]benzo[g]-phthalazine-5,10-diones.
AID1550886	Induction of immunogenic cell death in mouse H22 cells assessed as extracellular ATP level at 2 uM measured after 24 hrs by chemiluminescence-based assay	2019	European journal of medicinal chemistry, Jun-01, Volume: 171	Naphthyl quinoxaline thymidine conjugate is a potent anticancer agent post UVA activation and elicits marked inhibition of tumor growth through vaccination.
AID322370	Inhibition of human BCRP mediated mitoxantrone accumulation in mitoxantrone resistant MCF7 cells at 5 uM by flow cytometry	2008	Bioorganic & medicinal chemistry, Jan-01, Volume: 16, Issue:1	Functionalized chalcones as selective inhibitors of P-glycoprotein and breast cancer resistance protein.
AID1656522	Stabilization of [32P]-labelled dsDNA (unknown origin) assessed as drug-DNA adduct formation at 5 uM in presence of formaldehyde incubated for 12 hrs by phosphorimaging analysis relative to control	2020	Bioorganic & medicinal chemistry, 02-01, Volume: 28, Issue:3	Formaldehyde-activated WEHI-150 induces DNA interstrand crosslinks with unique structural features.
AID1221960	Apparent permeability from apical to basolateral side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 1 uM of P-gp inhibitor LY335979	2011	Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2	Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID1236570	Cytotoxicity against human MCF7 cells	2015	Journal of medicinal chemistry, Aug-13, Volume: 58, Issue:15	Progress Toward the Development of Noscapine and Derivatives as Anticancer Agents.
AID152516	Activity against P388 leukemia cells in mice, by intraperitoneal dosing and net log tumor cell kill was reported	1987	Journal of medicinal chemistry, Jan, Volume: 30, Issue:1	Anthrapyrazole anticancer agents. Synthesis and structure-activity relationships against murine leukemias.
AID135060	In vivo antileukemic activity towards P388 Murine Leukemia at a dose of 0.4 mg/kg, expressed as long time survivors tested in 12 animals	1999	Journal of medicinal chemistry, Sep-09, Volume: 42, Issue:18	8,11-dihydroxy-6-[(aminoalkyl)amino]-7H-benzo[e]perimidin-7-ones with activity in multidrug-resistant cell lines: synthesis and antitumor evaluation.
AID101787	In vitro cytotoxic activity against human breast MDA-MB-231 cell line ( standard deviation in parenthesis)	2002	Journal of medicinal chemistry, Jun-06, Volume: 45, Issue:12	Design, synthesis, and antiproliferative activity of some new pyrazole-fused amino derivatives of the pyranoxanthenone, pyranothioxanthenone, and pyranoacridone ring systems: a new class of cytotoxic agents.
AID1079944	Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID1474166	Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index	2016	Drug discovery today, Apr, Volume: 21, Issue:4	DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID97056	In vivo effect of dosing on L1210 leukemia measured as range at 0.4 mg/kg (cumulative dose 6.8 mg/Kg) with ip day 1,5&9 (once daily); value range 15 to 20	1988	Journal of medicinal chemistry, Apr, Volume: 31, Issue:4	Synthesis, molecular modeling, DNA binding, and antitumor properties of some substituted amidoanthraquinones.
AID1711971	Antitumor activity against mouse H22 cells implanted in Kunming mouse assessed as reduction in tumor weight at 0.4 mg/kg, iv administered for 7 consecutive days starting from day 8 post inoculation and measured after 16 days (Rvb = 2.15 +/- 0.51 g)	2016	European journal of medicinal chemistry, Oct-04, Volume: 121	Synthesis and biological properties of polyamine modified flavonoids as hepatocellular carcinoma inhibitors.
AID733200	Antiproliferative activity against human KB/HeLa cells after 48 hrs	2013	Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6	Synthesis and biological evaluation of new cytotoxic indazolo[4,3-gh]isoquinolinone derivatives.
AID647959	Inhibition of human TERT expression in H1299 cells at 1 uM after 24 hrs by secreted alkaline phosphatase reporter gene assay relative to control	2012	European journal of medicinal chemistry, Apr, Volume: 50	Design, synthesis and evaluation of telomerase inhibitory, hTERT repressing, and anti-proliferation activities of symmetrical 1,8-disubstituted amidoanthraquinones.
AID1349111	Induction of apoptosis in human Caco2 cells assessed as early apoptotic cells at 10 uM after 16 hrs by Annexin V-FITC/propidium iodide staining-based flow cytometric analysis (Rvb = 1.40%)	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	Structure-based identification of a NEDD8-activating enzyme inhibitor via drug repurposing.
AID455589	Cytotoxicity against human HL60 cells by MTT assay	2010	Bioorganic & medicinal chemistry letters, Jan-01, Volume: 20, Issue:1	Dammarane-type saponins from the flower buds of Panax ginseng and their effects on human leukemia cells.
AID647962	Cytotoxicity against human H1299 cells assessed as cell growth at 1 uM after 48 hrs by MTT assay	2012	European journal of medicinal chemistry, Apr, Volume: 50	Design, synthesis and evaluation of telomerase inhibitory, hTERT repressing, and anti-proliferation activities of symmetrical 1,8-disubstituted amidoanthraquinones.
AID1430721	Drug uptake in mouse 4T1.2 cell nucleus at 5 uM encapsulated within cucurbit[8]uril after 4 hrs by laser scanning confocal microscopic method	2017	ACS medicinal chemistry letters, May-11, Volume: 8, Issue:5	Encapsulation of Mitoxantrone within Cucurbit[8]uril Decreases Toxicity and Enhances Survival in a Mouse Model of Cancer.
AID1586109	Antiproliferative activity against human SGC7901 cells after 72 hrs by sulforhodamine B assay	2018	Journal of natural products, 12-28, Volume: 81, Issue:12	A Pair of Enantiomeric Bis- seco-abietane Diterpenoids from Cryptomeria fortunei.
AID436874	Inhibition of TEM-1 using nitrocefin as substrate after 15 mins by microtiter plate assay	2009	Bioorganic & medicinal chemistry, Jul-15, Volume: 17, Issue:14	Inhibitors of VIM-2 by screening pharmacologically active and click-chemistry compound libraries.
AID592675	Cytotoxicity against human HCT116 cells by MTT assay	2011	Bioorganic & medicinal chemistry, Apr-15, Volume: 19, Issue:8	Cytotoxic and anti-inflammatory cembranoids from the Vietnamese soft coral Lobophytum laevigatum.
AID687161	Ratio of IC50 for human HL60/ADR cells to IC50 for human HL60 cells	2012	Journal of medicinal chemistry, Jun-14, Volume: 55, Issue:11	Structure-activity relationship (SAR) study of ethyl 2-amino-6-(3,5-dimethoxyphenyl)-4-(2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate (CXL017) and the potential of the lead against multidrug resistance in cancer treatment.
AID1349087	Inhibition of SAE (unknown origin) assessed as decrease in SAE-mediated Ubc9-SUMO conjugation levels up to 10 uM preincubated for 10 mins followed by ATP and Mg2+ addition measured after 60 mins by Western blot analysis	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	Structure-based identification of a NEDD8-activating enzyme inhibitor via drug repurposing.
AID635081	Cytotoxicity against human PC3 cells after 48 hrs by SRB assay	2012	European journal of medicinal chemistry, Jan, Volume: 47, Issue:1	Synthesis, antiproliferative activities and telomerase inhibition evaluation of novel asymmetrical 1,2-disubstituted amidoanthraquinone derivatives.
AID538150	Binding affinity to calf thymus DNA assessed as ratio of final absorbance area to absorbance of compound at 100 uM after 24 hrs by UV spectrophotometer analysis	2010	European journal of medicinal chemistry, Nov, Volume: 45, Issue:11	Structural modifications on the phenazine N,N'-dioxide-scaffold looking for new selective hypoxic cytotoxins.
AID153900	In vivo antitumor activity against P388 leukemia cells at a dose of 1.5 mg/kg as a single injection and 3 mg/kg as a total	1984	Journal of medicinal chemistry, Mar, Volume: 27, Issue:3	5-[(Aminoalkyl)amino]-substituted anthra[1,9-cd]pyrazol-6(2H)-ones as novel anticancer agents. Synthesis and biological evaluation.
AID10019	In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780	1999	Journal of medicinal chemistry, Sep-09, Volume: 42, Issue:18	8,11-dihydroxy-6-[(aminoalkyl)amino]-7H-benzo[e]perimidin-7-ones with activity in multidrug-resistant cell lines: synthesis and antitumor evaluation.
AID1883026	Antitumor activity against mouse 4T1 cells implanted in Balb/c mouse assessed as TUNEL positive cells at 50 mg/kg administered intratumorally every four days for 14 days in the presence of liquid cyanoacrylate by TUNEL staining analysis	2022	European journal of medicinal chemistry, Jul-05, Volume: 237	Design, synthesis, and evaluation of a novel series of mono-indolylbenzoquinones derivatives for the potential treatment of breast cancer.
AID1209593	Dissociation constant, pKa of the acidic compound by capillary electrophoresis-mass spectrometry analysis	2011	Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3	Measurement of unbound drug exposure in brain: modeling of pH partitioning explains diverging results between the brain slice and brain homogenate methods.
AID1132489	Antitumor activity against mouse P388 cells allografted in BDF1 mouse assessed as mouse survival at 0.5 mg/kg administered 24 hrs post challenge relative to control	1978	Journal of medicinal chemistry, Mar, Volume: 21, Issue:3	Antineoplastic agents. Structure-activity relationship study of bis(substituted aminoalkylamino)anthraquinones.
AID320439	Ratio of GI50 for human HL60/MX2 cells to GI50 for human HL60 cells	2008	Bioorganic & medicinal chemistry, Jan-15, Volume: 16, Issue:2	Synthesis, DNA binding, and cytotoxicity of 1,4-bis(2-amino-ethylamino)anthraquinone-amino acid conjugates.
AID102331	Tested in vitro for cytotoxic activity against Doxorubicin resistant Human colon Adenocarcinoma sensitive cell line	1994	Journal of medicinal chemistry, Mar-18, Volume: 37, Issue:6	6,9-Bis[(aminoalkyl)amino]benzo[g]isoquinoline-5,10-diones. A novel class of chromophore-modified antitumor anthracene-9,10-diones: synthesis and antitumor evaluations.
AID678804	TP_TRANSPORTER: ATP hydrolysis in membrane vesicle from BCRP-expressing Sf9 cells	2001	Biochemical and biophysical research communications, Jul-06, Volume: 285, Issue:1	Functional characterization of the human multidrug transporter, ABCG2, expressed in insect cells.
AID102334	In vitro cytotoxicity was tested against human colon adenocarcinoma LoVo/Dx resistant cell line	1999	Journal of medicinal chemistry, Jul-15, Volume: 42, Issue:14	2,3-Dihydro-1H,7H-pyrimido[5,6,1-de]acridine-1,3,7-trione derivatives, a class of cytotoxic agents active on multidrug-resistant cell lines: synthesis, biological evaluation, and structure-activity relationships.
AID97831	Effective concentration required to inhibit by 50% the growth of L1210 cells	1988	Journal of medicinal chemistry, Oct, Volume: 31, Issue:10	Synthesis and antineoplastic evaluation of 1,4-bis(aminoalkanamido)-9,10-anthracenediones.
AID202924	Number of mice dead with toxic dose was measured on S180 tumor cell at 0.75 mg/kg (cumulative dose 16 mg/kg) introduced (in vivo) ip	1988	Journal of medicinal chemistry, Apr, Volume: 31, Issue:4	Synthesis, molecular modeling, DNA binding, and antitumor properties of some substituted amidoanthraquinones.
AID83789	Percent inhibition at G1 phase of cell cycle at a dose of 100n g/mL after 72 hours of induction in HT-29 cell line	1999	Journal of medicinal chemistry, Sep-09, Volume: 42, Issue:18	8,11-dihydroxy-6-[(aminoalkyl)amino]-7H-benzo[e]perimidin-7-ones with activity in multidrug-resistant cell lines: synthesis and antitumor evaluation.
AID1233374	Antiproliferative activity against human MES-SA/Dx5 cells after 72 hrs by MTT assay	2015	Bioorganic & medicinal chemistry letters, Jul-01, Volume: 25, Issue:13	Synthesis and antiproliferative activity of some novel benzo-fused imidazo[1,8]naphthyridinones.
AID733186	Binding affinity to calf thymus DNA up to 5 mM	2013	Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6	Synthesis and biological evaluation of new cytotoxic indazolo[4,3-gh]isoquinolinone derivatives.
AID1525936	Cytotoxicity against human HEK293 cells assessed as reduction in cell viability after 5 days by MTS/PMS assay	2019	Journal of medicinal chemistry, 09-26, Volume: 62, Issue:18	Triazole Bridged Flavonoid Dimers as Potent, Nontoxic, and Highly Selective Breast Cancer Resistance Protein (BCRP/ABCG2) Inhibitors.
AID9065	Inhibitory concentration of compound against proliferation of lung carcinoma A549 cell line	2002	Bioorganic & medicinal chemistry letters, Jun-03, Volume: 12, Issue:11	Design and synthesis of some new pyranoxanthenone aminoderivatives with cytotoxic activity.
AID678965	TP_TRANSPORTER: drug resistance in BCRP-expressing PA317 cells	2003	International journal of cancer, Dec-10, Volume: 107, Issue:5	Single amino acid substitutions in the transmembrane domains of breast cancer resistance protein (BCRP) alter cross resistance patterns in transfectants.
AID1439470	Selectivity index, ratio of IC50 for mouse NIH/3T3 cells to IC50 for mouse L1210 cells	2017	European journal of medicinal chemistry, Mar-31, Volume: 129	Allylic isothiouronium salts: The discovery of a novel class of thiourea analogues with antitumor activity.
AID106265	In vivo antitumor activity was measured on MX-1 human mammary carcinoma cells. TWI%=tumor weight inhibition. Optimal dose at 3 mg/kg/day	1998	Journal of medicinal chemistry, Dec-31, Volume: 41, Issue:27	Synthesis and antitumor evaluation of 2,5-disubstituted-indazolo[4, 3-gh]isoquinolin-6(2H)-ones (9-aza-anthrapyrazoles).
AID1430722	Drug uptake in mouse 4T1.2 cell lysosomes at 5 uM encapsulated within cucurbit[8]uril after 20 mins by LysoTracker Green staining based laser scanning confocal microscopic method	2017	ACS medicinal chemistry letters, May-11, Volume: 8, Issue:5	Encapsulation of Mitoxantrone within Cucurbit[8]uril Decreases Toxicity and Enhances Survival in a Mouse Model of Cancer.
AID1430731	Antitumor activity against mouse 4T1.2 cells implanted in Balb/c mouse assessed as mouse survival rate at 2 mg/kg, iv administered twice weekly for 2 weeks measured up to 33 days (rvb = 30%)	2017	ACS medicinal chemistry letters, May-11, Volume: 8, Issue:5	Encapsulation of Mitoxantrone within Cucurbit[8]uril Decreases Toxicity and Enhances Survival in a Mouse Model of Cancer.
AID721747	Inhibition of human MATE1-mediated [14]-metformin uptake expressed in HEK293 cells after 1.5 mins by scintillation counting analysis	2013	Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3	Discovery of potent, selective multidrug and toxin extrusion transporter 1 (MATE1, SLC47A1) inhibitors through prescription drug profiling and computational modeling.
AID1130151	Antineoplastic activity against mouse B16 cells allografted in BDF1 mouse at 1 mg/kg qd for 9 days relative to control	1979	Journal of medicinal chemistry, May, Volume: 22, Issue:5	Structural modification study of bis(substituted aminoalkylamino)anthraquinones. An evaluation of the relationship of the [2-[(2-hydroxyethyl)amino]ethyl]amino side chain with antineoplastic activity.
AID1349103	Induction of apoptosis in human Caco2 cells assessed as early apoptotic cells at 1 uM after 16 hrs by Annexin V-FITC/propidium iodide staining-based flow cytometric analysis (Rvb = 1.40%)	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	Structure-based identification of a NEDD8-activating enzyme inhibitor via drug repurposing.
AID1349106	Induction of apoptosis in human Caco2 cells assessed as viable cells at 5 uM after 16 hrs by Annexin V-FITC/propidium iodide staining-based flow cytometric analysis (Rvb = 98.4%)	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	Structure-based identification of a NEDD8-activating enzyme inhibitor via drug repurposing.
AID248024	Cytotoxicity against human LoVo cancer cell line was determined after 144 hr	2004	Journal of medicinal chemistry, Oct-07, Volume: 47, Issue:21	Rational design, synthesis, and biological evaluation of bis(pyrimido[5,6,1-de]acridines) and bis(pyrazolo[3,4,5-kl]acridine-5-carboxamides) as new anticancer agents.
AID680981	TP_TRANSPORTER: intracellular accumulation in MCF-7 and MCF-7 AdVp3000 cells	2000	Journal of cell science, Jun, Volume: 113 ( Pt 11)	The multidrug-resistant phenotype associated with overexpression of the new ABC half-transporter, MXR (ABCG2).
AID230915	Ratio of antilog(mean log IC50 in bone marrow sample) and antolog(mean log IC90) in HL-60)	1999	Journal of medicinal chemistry, Jun-17, Volume: 42, Issue:12	Design and synthesis of modified quinolones as antitumoral acridones.
AID129074	Antileukemic activity towards P388 Murine Leukemia at a dose of 0.4 mg/kg, expressed as body weight change	1999	Journal of medicinal chemistry, Sep-09, Volume: 42, Issue:18	8,11-dihydroxy-6-[(aminoalkyl)amino]-7H-benzo[e]perimidin-7-ones with activity in multidrug-resistant cell lines: synthesis and antitumor evaluation.
AID171537	Cardiotoxicity measured by the ATP/protein ratio compared with untreated controls using neonatal rat heart myocyte assay.	1996	Journal of medicinal chemistry, Dec-06, Volume: 39, Issue:25	2-[2'-(Dimethylamino)ethyl]-1,2-dihydro- 3H-dibenz[de,h]isoquinoline-1,3-diones with substituents at positions 4, 8, 9, 10, and 11. Synthesis, antitumor activity, and quantitative structure-activity relationships.
AID680980	TP_TRANSPORTER: intracellular accumulation in S1 and S1-M1-80 cells	2000	Journal of cell science, Jun, Volume: 113 ( Pt 11)	The multidrug-resistant phenotype associated with overexpression of the new ABC half-transporter, MXR (ABCG2).
AID1070859	Inhibition of human tert transcriptional activity assessed as SEAP activity at 100 uM after 24 hrs by SEAP reporter assay	2013	European journal of medicinal chemistry, Nov, Volume: 69	Structure-based design, synthesis and biological evaluation of novel anthra[1,2-d]imidazole-6,11-dione homologues as potential antitumor agents.
AID1711992	Antimetastatic activity against mouse H22 cells implanted in Kunming mouse assessed as inhibition of metastasis at 0.4 mg/kg, iv administered for 7 consecutive days starting from day 11 post inoculation and measured after 18 days relative to control	2016	European journal of medicinal chemistry, Oct-04, Volume: 121	Synthesis and biological properties of polyamine modified flavonoids as hepatocellular carcinoma inhibitors.
AID154570	Percent ratio of the medium survival time for P388 murine leukemia in CDF1 mice at 12 mg/kg	1989	Journal of medicinal chemistry, Aug, Volume: 32, Issue:8	Synthesis of unsymmetrically substituted 1,4-bis[(aminoalkyl)amino]anthracene-9,10-diones as potential antileukemic agents.
AID1070862	Cytotoxicity against human H1299 cells assessed as cell viability at 100 uM after 48 hrs by MTT assay	2013	European journal of medicinal chemistry, Nov, Volume: 69	Structure-based design, synthesis and biological evaluation of novel anthra[1,2-d]imidazole-6,11-dione homologues as potential antitumor agents.
AID96628	Antitumor activity against L1210 lymphocytic cells in vitro	1984	Journal of medicinal chemistry, Mar, Volume: 27, Issue:3	5-[(Aminoalkyl)amino]-substituted anthra[1,9-cd]pyrazol-6(2H)-ones as novel anticancer agents. Synthesis and biological evaluation.
AID1233370	Antiproliferative activity against human FM3 cells after 72 hrs by MTT assay	2015	Bioorganic & medicinal chemistry letters, Jul-01, Volume: 25, Issue:13	Synthesis and antiproliferative activity of some novel benzo-fused imidazo[1,8]naphthyridinones.
AID1221963	Transporter substrate index ratio of permeability from apical to basolateral side in human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 1 uM of P-gp inhibitor LY335979	2011	Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2	Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID1883018	Protection of Balb/c mouse spleen implanted with mouse 4T1 cells at 50 mg/kg administered intratumorally every four days for 14 days in the presence of liquid cyanoacrylate	2022	European journal of medicinal chemistry, Jul-05, Volume: 237	Design, synthesis, and evaluation of a novel series of mono-indolylbenzoquinones derivatives for the potential treatment of breast cancer.
AID312292	Cytotoxicity against human K562 cells after 5 days by XTT assay	2007	Journal of natural products, Dec, Volume: 70, Issue:12	Curcumin induces high levels of topoisomerase I- and II-DNA complexes in K562 leukemia cells.
AID39734	Compound was tested against sc B16 melanoma at % tumor growth inhibition(TGI) in mice at 3.2 mg/kg dosage.	1996	Journal of medicinal chemistry, Apr-12, Volume: 39, Issue:8	6- and 7-substituted 2-[2'-(dimethylamino)ethyl]-1,2-dihydro-3H-dibenz[de,h] isoquinoline-1,3-diones: synthesis, nucleophilic displacements, antitumor activity, and quantitative structure-activity relationships.
AID84118	Percent inhibition at S phase of cell cycle at a dose of 250 ng/mL after 72 hours of induction in HT-29/Mx cell line	1999	Journal of medicinal chemistry, Sep-09, Volume: 42, Issue:18	8,11-dihydroxy-6-[(aminoalkyl)amino]-7H-benzo[e]perimidin-7-ones with activity in multidrug-resistant cell lines: synthesis and antitumor evaluation.
AID1130172	Antineoplastic activity against mouse P388 cells allografted in CDF1 mouse assessed as survival at 2 mg/kg qd for 9 days	1979	Journal of medicinal chemistry, May, Volume: 22, Issue:5	Structural modification study of bis(substituted aminoalkylamino)anthraquinones. An evaluation of the relationship of the [2-[(2-hydroxyethyl)amino]ethyl]amino side chain with antineoplastic activity.
AID1236574	Cytotoxicity against human MCF-7 FLV1000 cells expressing ABCB2	2015	Journal of medicinal chemistry, Aug-13, Volume: 58, Issue:15	Progress Toward the Development of Noscapine and Derivatives as Anticancer Agents.
AID1506780	Induction of apoptosis in human HCC78 cells assessed as early apoptotic cells level at 5 nM incubated fro 48 hrs by Annexin-V FITC and propidium iodide staining based flow cytometry (Rvb = 6.33%)	2017	MedChemComm, Mar-01, Volume: 8, Issue:3	Identification of mitoxantrone as a new inhibitor of ROS1 fusion protein in non-small cell lung cancer cells.
AID721745	Ratio of Cmax unbound to IC50 for human MATE1-mediated ASP+ uptake expressed in HEK293 cells	2013	Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3	Discovery of potent, selective multidrug and toxin extrusion transporter 1 (MATE1, SLC47A1) inhibitors through prescription drug profiling and computational modeling.
AID1550891	Induction of immunogenic cell death in mouse H22 cells assessed as increase in calreticulin level in cell surface at 2 uM incubated for 5 hrs by Hoechst staining based fluorescence microscopic analysis	2019	European journal of medicinal chemistry, Jun-01, Volume: 171	Naphthyl quinoxaline thymidine conjugate is a potent anticancer agent post UVA activation and elicits marked inhibition of tumor growth through vaccination.
AID1349113	Induction of apoptosis in human Caco2 cells assessed as necrotic cells at 10 uM after 16 hrs by Annexin V-FITC/propidium iodide staining-based flow cytometric analysis (Rvb = 0.12%)	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	Structure-based identification of a NEDD8-activating enzyme inhibitor via drug repurposing.
AID1349107	Induction of apoptosis in human Caco2 cells assessed as early apoptotic cells at 5 uM after 16 hrs by Annexin V-FITC/propidium iodide staining-based flow cytometric analysis (Rvb = 1.40%)	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	Structure-based identification of a NEDD8-activating enzyme inhibitor via drug repurposing.
AID1656521	Stabilization of [32P]-labelled dsDNA (unknown origin) assessed as drug-DNA adduct formation by measuring adduct half life incubated for 12 hrs in presence of formaldehyde by phosphorimaging analysis	2020	Bioorganic & medicinal chemistry, 02-01, Volume: 28, Issue:3	Formaldehyde-activated WEHI-150 induces DNA interstrand crosslinks with unique structural features.
AID248858	Cytotoxicity is determined as the concentration required to inhibit the growth of human colon adenocarcinoma (HT-29) cell line	2004	Journal of medicinal chemistry, Oct-07, Volume: 47, Issue:21	Rational design, synthesis, and biological evaluation of bis(pyrimido[5,6,1-de]acridines) and bis(pyrazolo[3,4,5-kl]acridine-5-carboxamides) as new anticancer agents.
AID1053266	Agonist activity at human recombinant dopamine D1 receptor expressed in CHOK1 cells assessed as stimulation of cAMP accumulation at 100 uM after 30 mins by HTRF assay relative to SKF81297	2013	Journal of medicinal chemistry, Nov-14, Volume: 56, Issue:21	Experimental confirmation of new drug-target interactions predicted by Drug Profile Matching.
AID1851419	Antiproliferative activity against human K562 cells assessed as inhibition of cell growth	2022	Bioorganic & medicinal chemistry letters, 10-01, Volume: 73	Synthesis and antitumor activity of a series of novel N-aryl-5-(2,2,2-trifluoroethoxy)-1,5-dihydro-2H-pyrrol-2-ones derivatives.
AID46169	Inhibitory concentration against ethidium:Calf thymus DNA(0.1:1) binding at pH 5	1997	Journal of medicinal chemistry, Nov-07, Volume: 40, Issue:23	1-[(omega-aminoalkyl)amino]-4-[N-(omega-aminoalkyl)carbamoyl]-9-oxo-9, 10-dihydroacridines as intercalating cytotoxic agents: synthesis, DNA binding, and biological evaluation.
AID1132520	Antitumor activity against mouse B16 cells allografted in BDF1 mouse assessed as increase in survival time at 0.5 mg/kg administered 24 hrs post challenge relative to control	1978	Journal of medicinal chemistry, Mar, Volume: 21, Issue:3	Antineoplastic agents. Structure-activity relationship study of bis(substituted aminoalkylamino)anthraquinones.
AID381808	Resistance factor, ratio of IC50 for etoposide-resistant human K/VP.5 cells to IC50 for human K562 cells	2008	Bioorganic & medicinal chemistry, Apr-01, Volume: 16, Issue:7	The structure-based design, synthesis and biological evaluation of DNA-binding bisintercalating bisanthrapyrazole anticancer compounds.
AID212421	Inhibition of Taq polymerase at 10 uM (Slight inhibition)	1998	Journal of medicinal chemistry, Aug-13, Volume: 41, Issue:17	1,4- and 2,6-disubstituted amidoanthracene-9,10-dione derivatives as inhibitors of human telomerase.
AID1130158	Antineoplastic activity against mouse Colon 26 cells allografted in CDF1 mouse assessed as survival at 0.69 mg/kg qd for 9 days	1979	Journal of medicinal chemistry, May, Volume: 22, Issue:5	Structural modification study of bis(substituted aminoalkylamino)anthraquinones. An evaluation of the relationship of the [2-[(2-hydroxyethyl)amino]ethyl]amino side chain with antineoplastic activity.
AID1430729	Antitumor activity against mouse 4T1.2 cells implanted in Balb/c mouse assessed as tumor growth inhibition at 3 mg/kg, iv encapsulated within cucurbit[8]uril administered twice weekly for 2 weeks	2017	ACS medicinal chemistry letters, May-11, Volume: 8, Issue:5	Encapsulation of Mitoxantrone within Cucurbit[8]uril Decreases Toxicity and Enhances Survival in a Mouse Model of Cancer.
AID1130176	Antineoplastic activity against mouse P388 cells allografted in CDF1 mouse assessed as survival at 0.5 mg/kg qd for 9 days	1979	Journal of medicinal chemistry, May, Volume: 22, Issue:5	Structural modification study of bis(substituted aminoalkylamino)anthraquinones. An evaluation of the relationship of the [2-[(2-hydroxyethyl)amino]ethyl]amino side chain with antineoplastic activity.
AID679126	TP_TRANSPORTER: transepithelial transport (basal to apical) in MDR1-expressing MDCKII cells	2004	European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, Jan, Volume: 21, Issue:1	Exploring the quantitative relationship between the level of MDR1 transcript, protein and function using digoxin as a marker of MDR1-dependent drug efflux activity.
AID1349090	Inhibition of NAE (unknown origin) assessed as decrease in NAE-mediated Ubc12-NEDD8 conjugation levels at 10 uM treated for 10 mins post ATP and Mg2+ addition measured after 60 mins by Western blot analysis	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	Structure-based identification of a NEDD8-activating enzyme inhibitor via drug repurposing.
AID153418	Compound was tested against P388 leukemia at % increase in life span (ILS) in mice at 1.6 mg/kg dosage.	1996	Journal of medicinal chemistry, Apr-12, Volume: 39, Issue:8	6- and 7-substituted 2-[2'-(dimethylamino)ethyl]-1,2-dihydro-3H-dibenz[de,h] isoquinoline-1,3-diones: synthesis, nucleophilic displacements, antitumor activity, and quantitative structure-activity relationships.
AID98202	Antitumor activity against murine L1210 resistant cell line by using MTT assay	1995	Journal of medicinal chemistry, Mar-17, Volume: 38, Issue:6	Amino-substituted 2-[2'-(dimethylamino)ethyl]-1,2-dihydro-3H- dibenz[de,h]isoquinoline-1,3-diones. Synthesis, antitumor activity, and quantitative structure--activity relationship.
AID100166	Number of mice dead with 0.75 mg/kg dose (in vivo)	1988	Journal of medicinal chemistry, Apr, Volume: 31, Issue:4	Synthesis, molecular modeling, DNA binding, and antitumor properties of some substituted amidoanthraquinones.
AID733189	Antiproliferative activity against human RKOp27IND cells after 48 hrs	2013	Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6	Synthesis and biological evaluation of new cytotoxic indazolo[4,3-gh]isoquinolinone derivatives.
AID1349099	Inhibition of NAE in human Caco2 cells assessed as decrease in cyclin D1 protein levels at 0.1 to 10 uM after 16 hrs by Western blot analysis	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	Structure-based identification of a NEDD8-activating enzyme inhibitor via drug repurposing.
AID1070864	Cytotoxicity against human H1299 cells assessed as cell viability at 1 uM after 48 hrs by MTT assay	2013	European journal of medicinal chemistry, Nov, Volume: 69	Structure-based design, synthesis and biological evaluation of novel anthra[1,2-d]imidazole-6,11-dione homologues as potential antitumor agents.
AID101603	Inhibitory activity against human tumor cell line MCF-7 breast adenocarcinoma.	1995	Journal of medicinal chemistry, Feb-03, Volume: 38, Issue:3	Chromophore-modified antitumor anthracenediones: synthesis, DNA binding, and cytotoxic activity of 1,4-bis[(aminoalkyl)amino]benzo[g]-phthalazine-5,10-diones.
AID1396797	Resistance index, ratio of IC50 for antiproliferative activity against human HL60/MX2 cells to IC50 for antiproliferative activity against human HL60 cells	2018	Bioorganic & medicinal chemistry letters, 08-15, Volume: 28, Issue:15	Phosphorus-containing isothiocyanate-derived mercapturic acids as a useful alternative for parental isothiocyanates in experimental oncology.
AID1349089	Competitive inhibition of NAE (unknown origin) assessed as decrease in NAE-mediated Ubc12-NEDD8 conjugation levels at 10 uM preincubated for 10 mins followed by Mg2+ and various concentrations of ATP addition measured after 60 mins by Lineweaver-Burk plot	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	Structure-based identification of a NEDD8-activating enzyme inhibitor via drug repurposing.
AID683862	Resistance index, ratio of IC50 for human HL60/MX2 cells to IC50 for human HL60 cells	2012	Bioorganic & medicinal chemistry letters, Oct-01, Volume: 22, Issue:19	New derivatives of 11-methyl-6-[2-(dimethylamino)ethyl]-6H-indolo[2,3-b]quinoline as cytotoxic DNA topoisomerase II inhibitors.
AID1349114	Cytotoxicity against human Caco2 cells after 72 hrs by MTT assay	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	Structure-based identification of a NEDD8-activating enzyme inhibitor via drug repurposing.
AID687160	Ratio of IC50 for human HL60/MX2 cells to IC50 for human HL60 cells	2012	Journal of medicinal chemistry, Jun-14, Volume: 55, Issue:11	Structure-activity relationship (SAR) study of ethyl 2-amino-6-(3,5-dimethoxyphenyl)-4-(2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate (CXL017) and the potential of the lead against multidrug resistance in cancer treatment.
AID1430720	Drug uptake in mouse 4T1.2 cell nucleus at 5 uM after 4 hrs by laser scanning confocal microscopic method	2017	ACS medicinal chemistry letters, May-11, Volume: 8, Issue:5	Encapsulation of Mitoxantrone within Cucurbit[8]uril Decreases Toxicity and Enhances Survival in a Mouse Model of Cancer.
AID1349088	Inhibition of UAE1 (unknown origin) assessed as decrease in UAE1-mediated Ubc10-ubiquitin conjugation levels up to 10 uM preincubated for 10 mins followed by ATP and Mg2+ addition measured after 60 mins by Western blot analysis	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	Structure-based identification of a NEDD8-activating enzyme inhibitor via drug repurposing.
AID140019	The compound was tested for antitumor activity against P388 murine leukemia at 3 (mg/kg/day) dose; 12/132 -no. of toxic deaths/no. of mice	1994	Journal of medicinal chemistry, Mar-18, Volume: 37, Issue:6	6,9-Bis[(aminoalkyl)amino]benzo[g]isoquinoline-5,10-diones. A novel class of chromophore-modified antitumor anthracene-9,10-diones: synthesis and antitumor evaluations.
AID1525933	Inhibition of BCRP in human HEK293/R2 cells assessed as reduction in cell viability after 5 days by MTS/PMS assay	2019	Journal of medicinal chemistry, 09-26, Volume: 62, Issue:18	Triazole Bridged Flavonoid Dimers as Potent, Nontoxic, and Highly Selective Breast Cancer Resistance Protein (BCRP/ABCG2) Inhibitors.
AID55805	In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line DU145	1999	Journal of medicinal chemistry, Sep-09, Volume: 42, Issue:18	8,11-dihydroxy-6-[(aminoalkyl)amino]-7H-benzo[e]perimidin-7-ones with activity in multidrug-resistant cell lines: synthesis and antitumor evaluation.
AID687164	Ratio of IC50 for doxorubicin-resistant human K562 cells to IC50 for human K562 cells	2012	Journal of medicinal chemistry, Jun-14, Volume: 55, Issue:11	Structure-activity relationship (SAR) study of ethyl 2-amino-6-(3,5-dimethoxyphenyl)-4-(2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate (CXL017) and the potential of the lead against multidrug resistance in cancer treatment.
AID96755	Effect of dosing on L1210 leukemia in vivo measured as mean at 0.4 mg/kg (cumulative dose 6.8 mg/Kg) with ip day 1,5&9 (once daily)	1988	Journal of medicinal chemistry, Apr, Volume: 31, Issue:4	Synthesis, molecular modeling, DNA binding, and antitumor properties of some substituted amidoanthraquinones.
AID404699	Cytotoxicity against human mitoxantrone-sensitive HL60 cells after 72 hrs	2008	Journal of medicinal chemistry, Jun-26, Volume: 51, Issue:12	Synthesis, cytotoxicity, DNA interaction, and topoisomerase II inhibition properties of novel indeno[2,1-c]quinolin-7-one and indeno[1,2-c]isoquinolin-5,11-dione derivatives.
AID589897	Cytotoxicity against human HL60 cells after 72 hrs	2011	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 21, Issue:7	Cytotoxic and antioxidant activities of diterpenes and sterols from the Vietnamese soft coral Lobophytum compactum.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635	Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID720501	qHTS for Inhibitors of Polymerase Kappa: Confirmatory Assay for Cherry-picked Compounds	2012	PloS one, , Volume: 7, Issue:10	A comprehensive strategy to discover inhibitors of the translesion synthesis DNA polymerase κ.
AID1811	Experimentally measured binding affinity data derived from PDB	2006	FEBS letters, May-29, Volume: 580, Issue:13	The structure of PknB in complex with mitoxantrone, an ATP-competitive inhibitor, suggests a mode of protein kinase regulation in mycobacteria.
AID977608	Experimentally measured binding affinity data (IC50) for protein-ligand complexes derived from PDB	2006	FEBS letters, May-29, Volume: 580, Issue:13	The structure of PknB in complex with mitoxantrone, an ATP-competitive inhibitor, suggests a mode of protein kinase regulation in mycobacteria.
AID1159607	Screen for inhibitors of RMI FANCM (MM2) intereaction	2016	Journal of biomolecular screening, Jul, Volume: 21, Issue:6	A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1347411	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347412	qHTS assay to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: Counter screen cell viability and HiBit confirmation	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1745855	NCATS anti-infectives library activity on the primary C. elegans qHTS viability assay	2023	Disease models & mechanisms, 03-01, Volume: 16, Issue:3	In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1745854	NCATS anti-infectives library activity on HEK293 viability as a counter-qHTS vs the C. elegans viability qHTS	2023	Disease models & mechanisms, 03-01, Volume: 16, Issue:3	In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1346063	Human DNA topoisomerase II alpha (5.99.1.2 DNA Topoisomerases)	2008	Bioorganic & medicinal chemistry, Apr-01, Volume: 16, Issue:7	The structure-based design, synthesis and biological evaluation of DNA-binding bisintercalating bisanthrapyrazole anticancer compounds.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	634 (14.73)	18.7374
1990's	1184 (27.52)	18.2507
2000's	1362 (31.65)	29.6817
2010's	939 (21.82)	24.3611
2020's	184 (4.28)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	1,042 (22.88%)	5.53%
Reviews	392 (8.61%)	6.00%
Case Studies	373 (8.19%)	4.05%
Observational	12 (0.26%)	0.25%
Other	2,736 (60.07%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (312)

Trial Overview

Trial	Phase	Enrollment	Study Type	Start Date	Status
A Phase 3 Randomized Trial for Patients With De Novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 With GO, and the Addition of the FLT3 Inhibitor Gilteritinib for Patients With FLT3 Mutations [NCT04293562]	Phase 3	1,400 participants (Anticipated)	Interventional	2020-07-21	Recruiting
"A Phase III Trial Comparing ARA-C/High-Dose Mitoxantrone (ALL-2') to A Standard Vincristine/Prednisone Based Regimen ('L-20') as Induction Therapy For Adult Patients With Acute Lymphoblastic Leukemia (ALL): The ALL-4 Protocol" [NCT00002766]	Phase 3	170 participants (Actual)	Interventional	1996-03-31	Completed
A Clinical Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Mitoxantrone Hydrochloride Liposome Injection Combined With Chemotherapy in Previously Untreated de Novo Acute Myeloid Leukemia [NCT05941585]		90 participants (Anticipated)	Interventional	2023-07-31	Not yet recruiting
CLAG-M or FLAG-Ida Chemotherapy Followed Immediately by Related/Unrelated Reduced-Intensity Conditioning (RIC) Allogeneic Hematopoietic Cell Transplantation for Adults With Myeloid Malignancies at High Risk of Relapse: A Phase 1 Study [NCT04375631]	Phase 1	120 participants (Anticipated)	Interventional	2020-12-03	Recruiting
A Phase I Study of Azacitidine Combined With Mitoxantrone and Etoposide (A-NOVE) Chemotherapy for Patients' Age ≥ 60 With Poor Prognosis Acute Myeloid Leukemia (AML) [NCT01260714]	Phase 1	13 participants (Actual)	Interventional	2010-12-31	Terminated(stopped due to Inadequate accrual rate)
A Phase Ⅰ Clinical Study of Mitoxantrone Hydrochloride Liposome Injection in Combination With Bortezomib and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma [NCT05052970]	Phase 1	60 participants (Anticipated)	Interventional	2021-10-20	Recruiting
Prexasertib in Combination With Mitoxantrone, Etoposide and Cytarabine (MEC) in Relapsed/Refractory Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS) - a Phase I Trial [NCT03735446]	Phase 1	2 participants (Actual)	Interventional	2019-01-18	Terminated(stopped due to Sponsor Decision)
A Phase 1 Study of MLN9708 in Combination With MEC (Mitoxantrone, Etoposide, and Intermediate-Dose Cytarabine) for Relapsed/ Refractory Acute Myelogenous Leukemia (AML) [NCT02070458]	Phase 1	30 participants (Actual)	Interventional	2014-10-08	Completed
Phase I Dose Escalation Study of Mitoxantrone Hydrochloride Liposome Injection in Patients With Malignant Lymphoma [NCT02131688]	Phase 1	30 participants (Anticipated)	Interventional	2013-05-31	Recruiting
A Phase Ib/II Trial of Combined SGN-35 (BrentuximabVedotin) Therapy With Cyclophosphamide, Procarbazine, Prednisone, Etoposide and Mitoxantrone (BrEPEM) for Older Patients With Untreated Hodgkin Lymphoma (HL) [NCT03576378]	Phase 1/Phase 2	41 participants (Actual)	Interventional	2018-08-08	Active, not recruiting
A Randomized, Risk and Age Adapted Comparison of the Dose-Dense Regimen S-HAM (Sequential High Dose Cytosine Arabinoside and Mitoxantrone) Versus Standard Double Induction for Initial Chemotherapy of Adult Patients With Acute Myeloid Leukemia [NCT01382147]	Phase 3	396 participants (Actual)	Interventional	2009-07-01	Completed
Multicenter Randomised Clinical Trial in Acute Myeloid Leukemia Treatment Based on Three Anthracyclines, Comparing Two Types of Consolidation With Different ARA-C Doses Followed by One Year Maintenance [NCT01587430]	Phase 4	245 participants (Anticipated)	Interventional	2010-01-31	Active, not recruiting
Phase I Study of the Combination of Midostaurin, Bortezomib, and Chemotherapy in Relapsed/Refractory Acute Myeloid Leukemia [NCT01174888]	Phase 1	34 participants (Actual)	Interventional	2010-08-31	Completed
A Phase III Randomized Trial of Gemtuzumab Ozogamicin (Mylotarg) Combined With Conventional Chemotherapy for De Novo Acute Myeloid Leukemia (AML) in Children, Adolescents, and Young Adults [NCT00372593]	Phase 3	1,070 participants (Actual)	Interventional	2006-08-31	Completed
Addition of Sorafenib to G-CSF, Cladribine, Cytarabine and Mitoxantrone (G-CLAM) in Adults With Newly-Diagnosed Acute Myeloid Leukemia (AML) Independent of FLT3-ITD Status: A Phase 1/2 Study [NCT02728050]	Phase 1/Phase 2	84 participants (Actual)	Interventional	2016-12-01	Completed
TINI 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia II [NCT05848687]	Phase 1/Phase 2	90 participants (Anticipated)	Interventional	2023-11-01	Not yet recruiting
A Phase III Study for Patients With Newly Diagnosed Acute Promyelocytic Leukemia (APL) Using Arsenic Trioxide and All-Trans Retinoic Acid [NCT02339740]	Phase 3	158 participants (Actual)	Interventional	2015-07-21	Active, not recruiting
Clinical Pharmacokinetics of Mitoxantrone Hydrochloride Liposome Injection in Recurrent/Refractory Lymphoma Subjects [NCT05173545]	Phase 1	24 participants (Actual)	Interventional	2019-07-29	Completed
An Open Label Study to Evaluate the Feasibility of CPI-613 Given With High Dose Cytarabine and Mitoxantrone in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) [NCT02484391]	Phase 2	50 participants (Anticipated)	Interventional	2015-09-30	Completed
Open-label Multicenter Trial of Glivec® (Imatinib Mesylate, Formerly Known as STI571) in Combination With Chemotherapy (MTC) in Patients With Refractory or Relapsed Acute Myeloid Leukemia (AML) [NCT00744081]	Phase 2	130 participants (Anticipated)	Interventional	2004-07-31	Completed
A Phase II, Open-label, Single Arm Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Twice Daily Midostaurin (PKC412) Combined With Standard Chemotherapy and as a Single Agent Post-consolidation Therapy in Children With Untreated FLT3-mutate [NCT03591510]	Phase 2	23 participants (Anticipated)	Interventional	2019-03-13	Recruiting
Study Impact, on Clinical Outcomes, Quality of Life and Costs of 2 Therapeutic Strategy (Monthly Natalizumab Versus Mitoxantrone Then Immunomodulator) at 3 Years of Follow-up for Aggressive Remitting Multiple Sclerosis [NCT01065727]		250 participants (Anticipated)	Interventional	2010-02-28	Recruiting
Evaluation of the Efficacy of Induction-consolidation Treatment Using a Double Induction in Patients With AML <60 Years Old, Depending on the Percentage of Blasts in the 14 Day, Residual Disease and Leukemic Hematopoietic Cells [NCT02072811]	Phase 3	400 participants (Anticipated)	Interventional	2014-02-28	Recruiting
A Randomized, Open-Label Study of Oral CEP-701 Administered in Sequence With Standard Chemotherapy to Patients With Relapsed Acute Myeloid Leukemia (AML) Expressing FLT-3 Activating Mutations [NCT00079482]	Phase 2	224 participants (Actual)	Interventional	2003-10-31	Completed
Dose Finding Safety Run-in Phase Followed by a Randomized Phase II Trial of Intensive Chemotherapy With or Without Volasertib (BI 6727) Administered Prior or After Chemotherapy in Patients With Newly Diagnosed High-Risk Myelodysplastic Syndrome (MDS) and [NCT02198482]	Phase 2	6 participants (Actual)	Interventional	2016-02-29	Terminated(stopped due to development program of study drug volasertib was stopped by Boehringer Ingelheim due to manufacturing problems)
A Phase 1b/2 Study to Assess the Safety and Efficacy of AMG 102 in Combination With Mitoxantrone and Prednisone in Subjects With Previously Treated Castrate Resistant Prostate Cancer [NCT00770848]	Phase 1/Phase 2	162 participants (Actual)	Interventional	2008-11-30	Completed
Adjuvant Androgen Deprivation Versus Mitoxantrone Plus Prednisone Plus Androgen Deprivation in Selected High-Risk Prostate Cancer Patients Following Radical Prostatectomy [NCT00004124]	Phase 3	983 participants (Actual)	Interventional	1999-10-15	Completed
Phase 1b/2 Study of Carfilzomib in Combination With Induction Chemotherapy in Children With Relapsed or Refractory Acute Lymphoblastic Leukemia [NCT02303821]	Phase 1	130 participants (Anticipated)	Interventional	2015-02-16	Recruiting
National Multicenter, Controlled, Single-blind Study With Two Parallel Groups Evaluating the Safety and Efficacy of Sequential Treatment With Mitoxantrone and Interferon Beta-1a (REBIF 44mg 3 Times / Week) Versus Interferon Alone in Patients With Strong R [NCT02937285]	Phase 3	35 participants (Actual)	Interventional	2010-12-06	Completed
Dose-Finding Run-in Phase I Followed by a Phase III, Multicenter, Randomized, Double-Blind, Placebo-controlled Study of Crenolanib in Combination With Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia and Activating FLT3 Mutation [NCT02298166]	Phase 3	9 participants (Actual)	Interventional	2016-11-17	Terminated(stopped due to The manufacturer Arog Pharmaceuticals Inc has terminated the Agreement Concerning the Support of an Investigator Initiated Trial this became valid on 2020/03/09)
Risk-Stratified Randomized Phase III Testing of Blinatumomab (NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL) [NCT02101853]	Phase 3	669 participants (Actual)	Interventional	2014-12-17	Active, not recruiting
A Phase I Study of Bortezomib in Combination With MEC (Mitoxantrone, Etoposide, and Intermediate-Dose Cytarabine) for Relapsed/ Refractory Acute Myelogenous Leukemia (AML) [NCT01127009]	Phase 1	3 participants (Actual)	Interventional	2010-07-31	Completed
A Phase 1 Study of Intravenous EGFR-ErbituxEDVsMIT (EEDVsMit) in Children With Recurrent / Refractory Solid or CNS Tumours Expressing Epidermal Growth Factor Receptor (EGFR) (ECREST Study) [NCT02687386]	Phase 1	9 participants (Actual)	Interventional	2016-02-08	Terminated(stopped due to Study medication no longer in production)
A Multicentre, Open-label, Single-arm, Phase I/II Clinical Study to Evaluate the Safety, Efficacy and Pharmacokinetic Characteristics of Liposomal Mitoxantrone Hydrochloride Injection Combined With Pegaspargase in the Treatment of NKTCL [NCT04509466]	Phase 1/Phase 2	104 participants (Anticipated)	Interventional	2020-08-15	Not yet recruiting
Single-arm, Open and Multi-center Phase II Study of Liposome-entrapped Mitoxantrone Hydrochloride Injection in Relapsed/Refractory Peripheral T-cell Lymphoma and NK/T-cell Lymphoma [NCT03776279]	Phase 2	106 participants (Anticipated)	Interventional	2018-04-02	Recruiting
Isolated Thoracic Perfusion With Hemofiltration (ITP-F) for Pretreated and Progressive Malignant Pleural Mesothelioma [NCT02467426]		23 participants (Actual)	Observational	2009-09-30	Completed
Fludarabine, Mitoxantrone, and Dexamethasone (FND) Plus Chimeric Anti-CD20 Monoclonal Antibody (Rituximab) for Stage IV Indolent Lymphoma [NCT00577993]	Phase 3	210 participants (Actual)	Interventional	1998-03-16	Completed
Effect of Priming With Granulocyte-Macrophage Colony-Stimulating Factor During Chemotherapy and Comparison of Timed Sequential Chemotherapy vs 4 Courses of High Dose Cytarabine as Consolidation in Younger Adults With Newly Diagnosed AML [NCT00880243]	Phase 3	473 participants (Actual)	Interventional	1999-03-31	Completed
A Phase II, Open-Label, Single- Center Study to Assess the Activity of Oshadi D and Oshadi R in Combination With Salvage Chemotherapy for Relapsed or Refractory Acute Myeloid Leukemia (AML) or Lymphoid Leukemia (ALL) Patients [NCT02462265]	Phase 2	15 participants (Anticipated)	Interventional	2017-01-31	Suspended
A PALG Prospective Multicenter Clinical Trial to Compare the Efficacy of Two Standard Induction Therapies (DA-90 vs DAC) and Two Standard Salvage Regimens (FLAG-IDA vs CLAG-M) in AML Patients ≤ 60 Years Old [NCT03257241]	Phase 3	582 participants (Anticipated)	Interventional	2017-07-03	Recruiting
A Phase II Study of Double Induction Chemotherapy for Newly Diagnosed Non-L3 Adult Acute Lymphoblastic Leukemia With Investigation of Minimal Residual Disease and Risk of Relapse Following Maintenance Chemotherapy [NCT00109837]	Phase 2	79 participants (Actual)	Interventional	2005-04-30	Completed
A Multicenter, Open-label, Phase Ib Study of Mitoxantrone Hydrochloride Liposome Injection in Subjects With Advanced Bone and Soft Tissue Sarcoma Who Has Failed At Least One Prior Line of Therapy [NCT04900766]	Phase 1	50 participants (Anticipated)	Interventional	2021-06-30	Not yet recruiting
A Phase III Randomized Trial for Patients With De Novo AML Using Bortezomib and Sorafenib (NSC# 681239, NSC# 724772) for Patients With High Allelic Ratio FLT3/ITD [NCT01371981]	Phase 3	1,645 participants (Actual)	Interventional	2011-06-20	Active, not recruiting
A Prospective, Single-arm, Multicenter Clinical Study of Mitoxantrone Hydrochloride Liposome Combined With Rituximab and Lenalidomide in the Treatment of Relapsed and Refractory Diffuse Large B-cell Lymphoma [NCT05575973]	Phase 2	55 participants (Anticipated)	Interventional	2022-10-10	Not yet recruiting
A Randomized, Double-blind, Placebo-controlled Phase Ⅱ Clinical Study to Evaluate the Efficacy and Safety of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Neuromyelitis Optica Spectrum Disorder (NMOSD) [NCT05551598]	Phase 2	45 participants (Anticipated)	Interventional	2022-11-15	Not yet recruiting
A Collaboration Phase 2 Study of Venetoclax in Combination With Conventional Chemotherapy in Pediatric Patients With Acute Myeloid Leukemia [NCT05955261]	Phase 2	70 participants (Anticipated)	Interventional	2023-07-25	Recruiting
Clinical Study of Venetoclax Combined With Mitoxantrone Liposome in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia [NCT05522192]	Phase 1/Phase 2	70 participants (Anticipated)	Interventional	2022-07-21	Recruiting
Phase I Study of Induction Therapy With Cytarabine, High-Dose Mitoxantrone and Dasatinib for Patients With Philadelphia-Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia (ALL): ALL-6 Protocol [NCT00940524]	Phase 1	7 participants (Actual)	Interventional	2009-07-31	Completed
A Phase II Trial to Evaluate the Rate of Immune Response Using Idiotype Immunotherapies Produced by Molecular Biological Means for Treatment of Aggressive B Cell Lymphoma [NCT00004197]	Phase 2	0 participants	Interventional	1999-06-25	Completed
Phase I Investigator Sponsored Study to Assess the Tolerability and Efficacy of Selinexor in Combination With High Dose Cytarabine (HiDAC) and Mitoxantrone Chemotherapy for Remission Induction in Acute Myelogenous Leukemia (AML) [NCT02573363]	Phase 1	25 participants (Actual)	Interventional	2015-10-07	Completed
Venetoclax-Navitoclax With Cladribine-based Salvage Therapy in Patients With Relapsed/Refractory Acute Myeloid Leukemia [NCT06007911]	Phase 1	36 participants (Anticipated)	Interventional	2024-02-29	Not yet recruiting
A Phase I Study of Intravenous Plerixafor in Combination With Mitoxantrone Etoposide and Cytarabine for Relapsed or Refractory Acute Myeloid Leukemia [NCT01027923]	Phase 1	6 participants (Actual)	Interventional	2010-05-31	Terminated(stopped due to Withdrawal of support from sponsor)
The Efficacy and Safety of Chidamide Combined With VDDT Regimen（Vinorelbine，Liposomal Doxorubicin，Dexamethasone and Thalidomide） in Relapse and Refractory Patients With Diffuse Large B Cell Lymphoma [NCT02733380]	Phase 2	20 participants (Anticipated)	Interventional	2016-05-31	Recruiting
A Multicenter, Open-label, Phase I Dose-escalation and Dose-expansion Study of Mitoxantrone Hydrochloride Liposome Injection Combination Therapy in Chinese Patients With Advanced Solid Tumors [NCT05344742]	Phase 1	116 participants (Anticipated)	Interventional	2022-04-30	Not yet recruiting
Phase I/II Study of the Combination of Mitoxantrone, Etoposide and Gemtuzumab Ozogamicin for Patients With Acute Myeloid Leukemia Refractory to Initial Standard Induction Therapy (UPCI 07-154) [NCT00660036]	Phase 1	5 participants (Actual)	Interventional	2008-09-30	Terminated(stopped due to due to new safety information)
ALLR3: An International Collaborative Trial for Relapsed and Refractory Acute Lymphoblastic Leukaemia (ALL) [NCT00967057]	Phase 3	470 participants (Anticipated)	Interventional	2002-10-31	Completed
A Phase I Study of Combination Chemotherapy With Mitoxantrone and Etoposide (VP-16) Combined With an Autophagy Inhibitor, Hydroxychloroquine (HCQ), for the Treatment of Patients With Relapsed Acute Myelogenous Leukemia (AML) [NCT02631252]	Phase 1	1 participants (Actual)	Interventional	2016-08-18	Terminated(stopped due to Inability to accrue)
A Multi-Center, Randomized, Open Label Study To Evaluate Safety, Tolerability And Efficacy Of Treatment With Mitoxantrone; Pre-Treatment With Glatiramer Acetate (GA) Versus Treatment With GA Alone In Relapsing Forms Of Multiple Sclerosis. [NCT00203073]	Phase 2	40 participants (Actual)	Interventional	2003-06-30	Completed
Liposomal Mitoxantrone Hydrochloride, Gemcitabine, Vinorelbine With or Without Rituximab (GVM±R) in Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma [NCT05299164]	Phase 1	24 participants (Anticipated)	Interventional	2022-05-15	Not yet recruiting
A Phase 3 Open-Label, Multicenter, Randomized Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FLT3 Mutation [NCT02421939]	Phase 3	371 participants (Actual)	Interventional	2015-10-20	Active, not recruiting
A Phase I/II Study of AMD3100 With Mitoxantrone, Etoposide and Cytarabine (AMD3100+MEC) in Relapsed or Refractory AML [NCT00512252]	Phase 1/Phase 2	52 participants (Actual)	Interventional	2007-07-31	Completed
A Phase 2, Multicenter, Open-Label Study of CNTO 328 (Anti-IL-6 Monoclonal Antibody) in Combination With Mitoxantrone Versus Mitoxantrone in Subjects With Metastatic Hormone-Refractory Prostate Cancer (HRPC) [NCT00385827]	Phase 2	106 participants (Actual)	Interventional	2006-11-30	Terminated(stopped due to Prematurely stopped after Independent Data Monitoring Committee (IDMC) evaluation for lack of efficacy.)
Title: A Pilot Study Evaluating the Safety and Feasibility of Custirsen (OGX-011) in Combination With Second Line Chemotherapy in Patients With Hormone Refractory Prostate Cancer [NCT00327340]	Phase 2	70 participants (Actual)	Interventional	2006-07-31	Completed
A Phase I-II Study of Pentostatin, Cyclophosphamide, Rituximab, and Mitoxantrone in Previously Treated Patients With Chronic Lymphocytic Leukemia and Other Low Grade B-Cell Neoplasms [NCT00546377]	Phase 1/Phase 2	50 participants (Actual)	Interventional	2005-07-31	Completed
Phase II Trial of Combined Immunochemotherapy With Fludarabine, Mitoxantrone, Cyclophosphamide and Alemtuzumab (FMC-Alemtuzumab) in Patients With Previously Treated or Untreated T-Prolymphocytic Leukemia [NCT01186640]	Phase 2	16 participants (Actual)	Interventional	2010-06-30	Completed
Risk Adapted Treatment of Newly Diagnosed Childhood Acute Promyelocytic Leukemia (APL) Using Arsenic Trioxide (Trisenox® ) During Consolidation [NCT00866918]	Phase 3	106 participants (Actual)	Interventional	2009-03-09	Completed
A Randomized Phase II Study of Mitoxantrone vs. Mitoxantrone With Cetuximab in Metastatic Androgen Independent Prostate Cancer (AIPC) Previously Treated With Docetaxel-based Chemotherapy [NCT00661492]	Phase 2	115 participants (Actual)	Interventional	2008-05-31	Completed
A Phase 2, Multicenter, Randomized Study of IMC-A12 or IMC-1121B Plus Mitoxantrone and Prednisone in Metastatic Androgen-Independent Prostate Cancer (AIPC) Following Disease Progression on Docetaxel-Based Chemotherapy [NCT00683475]	Phase 2	138 participants (Actual)	Interventional	2008-08-31	Completed
Risk-Stratified Therapy for Acute Myeloid Leukemia in Down Syndrome [NCT02521493]	Phase 3	312 participants (Anticipated)	Interventional	2015-12-23	Active, not recruiting
Clofarabine, Etoposide, and Mitoxantrone for Relapsed and Refractory Acute Leukemias [NCT00882076]	Phase 1	22 participants (Actual)	Interventional	2009-03-31	Terminated(stopped due to study closed prematurely)
A Phase II Multicenter Open-label Study of MabThera(Rituximab) Addition to Regularly Prescribed Chemotherapy in Patients With Untreated Mantle Cell Lymphoma [NCT01144403]	Phase 2	8 participants (Actual)	Interventional	2010-06-30	Terminated
A Multicenter and Randomized Prospective Study for Improving the Outcome of Childhood Acute Promyeloid Leukemia [NCT02200978]	Phase 4	176 participants (Actual)	Interventional	2011-09-30	Completed
Phase II Study of Treatment of Relapsed Agressive Lymphomas [NCT00842595]	Phase 2	50 participants (Actual)	Interventional	2003-12-31	Completed
Impact of Treatment Intensity on Survival, Quality of Life, and Resource Utilization in Medically Less Fit Adults With Acute Myeloid Leukemia and Analogous Myeloid Neoplasms: A Randomized Pilot Study [NCT03012672]	Phase 2	50 participants (Actual)	Interventional	2016-12-30	Completed
A Phase 1 Study of Temsirolimus in Combination With Intensive Re-induction Therapy for Children With Relapsed Acute Lymphoblastic Leukemia and Non-Hodgkin Lymphoma [NCT01403415]	Phase 1	13 participants (Actual)	Interventional	2011-09-30	Completed
Combination of Mitoxantrone, Etoposide and Gemtuzumab Ozogamicin (MEGO) for Patients With Acute Myeloid Leukemia Refractory to Initial Standard Induction Therapy [NCT03839446]	Phase 2	16 participants (Actual)	Interventional	2019-02-28	Completed
An Open-label, Randomized, Phase 3 Study Of Inotuzumab Ozogamicin (Cmc-544) Administered In Combination With Rituximab Compared To A Defined Investigator's Choice Therapy In Subjects With Relapsed Or Refractory, Cd22- Positive, Follicular B-cell Non Hodgk [NCT00562965]	Phase 3	29 participants (Actual)	Interventional	2007-11-30	Terminated(stopped due to See termination reason in detailed description.)
A Phase I Study of M3814 in Combination With MEC in Patients With Relapsed or Refractory Acute Myeloid Leukemia [NCT03983824]	Phase 1	48 participants (Anticipated)	Interventional	2020-05-05	Recruiting
A Prospective Single Institution Pilot Study Evaluating the Pharmacokinetics of Sirolimus in Combination With MEC (Mitoxantrone + Etoposide + Cytarabine) in Patients With High Risk Leukemias [NCT00780104]	Phase 1	16 participants (Actual)	Interventional	2007-07-31	Completed
Multicenter Trial for Treatment of Acute Lymphoblastic Leukemia in Adults (05/93) [NCT00199069]	Phase 4	720 participants	Interventional	1993-04-30	Completed
Treatment of Relapsed / Refractory Chronic Lymphocytic Leukemia (CLL) WITH Bendamustine / Mitoxantrone (BM) [NCT00274963]	Phase 2	60 participants (Anticipated)	Interventional	2004-10-31	Completed
A Single-arm, Open, Multi-center Phase II Clinical Trial of Mitoxantrone HCL Liposome Injection in Subjects With Relapsed Diffuse Large B-cell Lymphoma and and Peripheral T/NK Lymphomas [NCT02597387]	Phase 2	50 participants (Anticipated)	Interventional	2015-08-31	Recruiting
A PHASE I-II MULTICENTER STUDY OF THE CLORETAZINE-DAUNORUBICIN-ARACYTINE COMBINATION FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA (AML) WITH UNFAVORABLE CYTOGENETICS [NCT00840684]	Phase 1/Phase 2	135 participants (Anticipated)	Interventional	2009-01-31	Completed
Phase I and Pharmacokinetic Study of Mitoxantrone Hydrochloride Liposome Injection in Patients With Solid Tumor [NCT02043756]	Phase 1	20 participants (Actual)	Interventional	2011-08-31	Completed
A Randomized Trial for Patients With Acute Myeloid Leukemia or High Risk Myelodysplatic Syndrome Aged 60 or Over [NCT00005823]	Phase 3	2,000 participants (Anticipated)	Interventional	1998-12-31	Completed
Treatment of High Risk Adult Acute Lymphoblastic Leukemia [NCT00853008]	Phase 4	100 participants (Anticipated)	Interventional	2003-01-31	Completed
Primed Peripheral Blood Stem Cell Autologous Transplantation for Lymphoma and Hodgkin's Disease [NCT00005985]	Phase 2	213 participants (Actual)	Interventional	2000-08-31	Completed
First Line Treatment of Metastatic Hormone Refractory Prostate Cancer With a Combination of Novantrone-Navelbine [NCT00006114]	Phase 2	0 participants	Interventional	1999-05-31	Active, not recruiting
Autologous Transplantation for Non-Hodgkin's Lymphoma and Hodgkin's Disease Using Retrovirally Marked Peripheral Blood Progenitor Cells Obtained After In Vivo Mobilization Using Hematopoietic Cytokines Plus Chemotherapy [NCT00005998]	Phase 2	0 participants (Actual)	Interventional	2000-01-31	Withdrawn(stopped due to Withdrawn because study never enrolled patients)
"RANDOMIZED COMPARISON OF ALTERNATING TRIPLE THERAPY (ATT) VERUS CHOP IN PATIENTS WITH INTERMEDIATE GRADE LYMPHOMAS AND IMMUNOBLASTIC LYMPHOMAS WITH INTERNATIONAL INDEX 2-5" [NCT00002565]	Phase 3	61 participants (Actual)	Interventional	1994-05-25	Completed
A Single-arm, Open, Multi-center Phase II Clinical Trial of Mitoxantrone HCL Liposome Injection in Subjects With Relapsed Cutaneous T Cell Lymphomas [NCT02597153]	Phase 2	1 participants (Actual)	Interventional	2015-10-31	Terminated(stopped due to Just one subject enrolled in this trial during one and a half years.)
Study Of The Survival Without Degradation To The Quality Of Life During Chemotherapy For Metastatic Breast Cancer In Women [NCT00010075]	Phase 2	0 participants	Interventional	2000-01-31	Active, not recruiting
Autologous Transplantation for Multiple Myeloma: A Research Study of Multiple Myeloma Using Chemotherapy Plus Growth Factor Primed Peripheral Blood Stem Cells Followed by Autologous Transplantation and Post-Transplant Immunotherapy [NCT00005987]	Phase 2	87 participants (Actual)	Interventional	2000-08-31	Terminated(stopped due to Withdrawn because treatment guidelines changed)
A Randomized, Open-label, Positive-controlled, Single-institutional, Phase Ⅱ of Mitoxantrone Hydrochloride Liposome Injection in Advanced Recurrent or Metastatic Breast Cancer [NCT02596373]	Phase 2	60 participants (Anticipated)	Interventional	2015-06-30	Recruiting
A Phase II Study of Gemzar, Novantrone and Rituxan in Relapsed or Refractory Mantle Cell Lymphoma (MCL) (B9E-US-X436) [NCT00656084]	Phase 2	16 participants (Actual)	Interventional	2004-12-31	Completed
A Double-Blind, Three-Armed, Randomized Phase-III-Study, to Compare the Efficacy, Tolerability and Safety of Three Doses of Mitoxantrone in the Treatment of Patients With Secondary Progressive Multiple Sclerosis [NCT00146159]	Phase 3	336 participants (Anticipated)	Interventional	2005-03-31	Terminated
An Open, Single-arm, Multi-center Clinical Trial of Molecular Subtype-guided R-MINE+X Regimen in the Treatment of Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) [NCT05784987]		60 participants (Anticipated)	Interventional	2023-04-15	Not yet recruiting
AML2003 - Randomized Comparison Between Standard-Therapy and Intensified Therapy for Adult Acute Myeloid Leukemia Patients <= 60 Years. A Prospective, Randomized, Multi-center Therapy-Optimizing-Study. [NCT00180102]	Phase 4	600 participants (Anticipated)	Interventional	2003-12-31	Completed
A Phase II Study of R-FND, Followed by Zevalin Radioimmunotherapy, and Subsequent Maintenance Rituximab for Advanced Stage Follicular Lymphoma With High-Risk Features [NCT00290511]	Phase 2	49 participants (Actual)	Interventional	2004-06-29	Completed
A Collaborative Trial for the Treatment of Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplasia [NCT00136084]	Phase 3	238 participants (Actual)	Interventional	2002-08-31	Completed
A Phase II Study of Bortezomib in Combination With Rituximab, Fludarabine, Mitoxantrone, and Dexamethasone (VR-FND) for Relapsed or Refractory Follicular Lymphoma [NCT00510887]	Phase 2	14 participants (Actual)	Interventional	2007-01-31	Terminated(stopped due to Low accrual.)
Phase I/II Trial of Epothilone Analog BMS-247550 (Ixabepilone), Mitoxantrone, and Prednisone in Hormone Refractory Prostate Cancer (HRPC) Patients Previously Treated With Chemotherapy [NCT00331344]	Phase 1/Phase 2	100 participants (Actual)	Interventional	2006-04-30	Completed
A Phase II Study of Gemcitabine/ Mitoxantrone in Patients With Acute Myeloid Leukemia in First Relapse [NCT00268242]	Phase 2	24 participants (Actual)	Interventional	2006-01-31	Terminated(stopped due to If
A Phase I Study of Lenalidomide Therapy Prior to Re-induction Chemotherapy With Mitoxantrone, Etoposide, and Cytarabine (MEC) for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia (AML) [NCT01904643]	Phase 1	17 participants (Actual)	Interventional	2014-02-28	Terminated(stopped due to Accrual factor)
A Pilot Study of Mitoxantrone for the Treatment of Recurrent Neuromyelitis Optica (Devic's Disease) [NCT00304291]	Phase 4	5 participants	Interventional	2001-08-31	Completed
A Phase 2, Single-arm, Multicenter Trial to Evaluate the Efficacy and Safety of Mitoxantrone Hydrochloride Liposome Injection in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) [NCT05875428]	Phase 2	104 participants (Anticipated)	Interventional	2023-06-01	Not yet recruiting
Evaluation of a New Therapeutic Strategy in Early and Active Relapsing-Remitting Multiple Sclerosis: Induction Treatment With Mitoxantrone Followed by Long-Term Treatment With Interferon-beta1b [NCT00219908]	Phase 2	124 participants	Interventional	1999-07-31	Terminated
Pilot Study of Crenolanib Combined With Standard Salvage Chmetherapy in Subjects With Relapsed/Refractory Acute Myeloid Leukemia [NCT02626338]	Phase 1/Phase 2	16 participants (Actual)	Interventional	2016-02-29	Completed
An Open, Single-arm, Multicenter Study of R-CMOP Protocol for Primary Treatment of Diffuse Large B-cell Lymphoma Based on Cardiac Function Screening [NCT05777369]		30 participants (Anticipated)	Interventional	2023-03-31	Not yet recruiting
A Phase 1/2 Study of Mitoxantrone Hydrochloride Liposome Infusion in Patients With Non-Hodgkin's Lymphoma [NCT02856685]	Phase 1/Phase 2	60 participants (Anticipated)	Interventional	2016-08-31	Recruiting
Efficacy and Safety of Mitoxantrone in Patients With Refractory Neuromyelitis Optica and Spectrum Disorders [NCT02021825]	Phase 4	50 participants (Anticipated)	Interventional	2009-03-31	Recruiting
Phase III, Randomized, Multicenter Study to Assess the Efficacy and Safety of HuM195 (Recombinant Humanized Anti-CD33 Monoclonal Antibody) in Combination With Standardized Chemotherapy Compared to Standardized Chemotherapy Alone in the Treatment of Patien [NCT00006045]	Phase 3	0 participants	Interventional	2000-03-31	Active, not recruiting
Randomized Trial of MCD Versus FMD in Untreated Advanced Follicular Lymphoma [NCT00006250]	Phase 3	500 participants (Anticipated)	Interventional	2000-05-31	Active, not recruiting
A Phase II Trial of Brief Duration Combination Chemotherapy and Rituximab With Prophylactic Pegfilgrastim, Followed by Maintenance Rituximab, in Elderly/Poor Performance Status Patients With Large B-Cell Non-Hodgkin's Lymphoma [NCT00193479]	Phase 2	51 participants (Actual)	Interventional	2003-04-30	Completed
Programma di Terapia Per Pazienti Affetti da Linfoma Diffuso a Grandi Cellule B CD20 Positive [NCT00556127]	Phase 2	94 participants (Actual)	Interventional	2002-06-30	Completed
A Phase II Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia [NCT03164057]	Phase 2	206 participants (Actual)	Interventional	2017-06-15	Active, not recruiting
Cyclosporine Modulation of Drug Resistance in Combination With Pravastatin, Mitoxantrone, and Etoposide for Adult Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML): A Phase 1/2 Study [NCT01342887]	Phase 1/Phase 2	6 participants (Actual)	Interventional	2011-04-30	Terminated
A Randomized, Open Label Multi-Center Study of XRP6258 at 25 mg/m^2 in Combination With Prednisone Every 3 Weeks Compared to Mitoxantrone in Combination With Prednisone For The Treatment of Hormone Refractory Metastatic Prostate Cancer Previously Treated [NCT00417079]	Phase 3	755 participants (Actual)	Interventional	2007-01-31	Completed
A Single-arm, Multi-center Phase II Clinical Study on Pegaspargase Combined With Gemcitabine, Etoposide, Liposomal Mitoxantrone Hydrochloride and Dexamethasone (P-GEMD) in the Treatment of Untreated Early Non-upper Respiratory Tract or Advanced Extranodal [NCT05774028]	Phase 2	50 participants (Anticipated)	Interventional	2023-04-30	Not yet recruiting
A Phase 2 Multicenter Study of First-line Dasatinib Plus Conventional Chemotherapy in Adults With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia [NCT01004497]	Phase 2	51 participants (Actual)	Interventional	2010-03-31	Completed
Clinical Study of Mitoxantrone Hydrochloride Liposome Injection Combined With Capecitabine in Patients With HER-2 Negative Advanced Breast Cancer [NCT06156761]		24 participants (Anticipated)	Interventional	2023-11-28	Not yet recruiting
International Randomised Phase III Clinical Trial in Children With Acute Myeloid Leukaemia - Incorporating an Embedded Dose Finding Study for Gemtuzumab Ozogamicin in Combination With Induction Chemotherapy [NCT02724163]	Phase 3	700 participants (Anticipated)	Interventional	2016-04-30	Recruiting
Phase 2 Randomized Study Evaluating 3 Chemotherapy Regimens as Second-line Treatment in Patients With Hormone-refractory Metastatic Prostate Cancer [NCT00627354]	Phase 2	90 participants (Anticipated)	Interventional	2006-09-30	Completed
A Phase 1 Clinical Study of DSP-2033 (Alvocidib) in Combination With Cytarabine/Mitoxantrone or Cytarabine/Daunorubicin (7+3) in Patients With Acute Myeloid Leukemia [NCT03563560]	Phase 1	10 participants (Actual)	Interventional	2018-05-15	Completed
A Randomized Phase 2 Study of Human Anti-PDGFRα Monoclonal Antibody IMC-3G3 Plus Mitoxantrone Plus Prednisone or Mitoxantrone Plus Prednisone in Metastatic Castration-Refractory Prostate Cancer Following Disease Progression or Intolerance on Docetaxel-bas [NCT01204710]	Phase 2	123 participants (Actual)	Interventional	2010-10-31	Completed
Optimal Treatment Strategy Based on Prognostic Groups for Pediatric de Novo Acute Myeloid Leukemia [NCT02848183]	Phase 2	350 participants	Interventional	2016-01-31	Recruiting
A Phase II Study of Bendamustine, Mitoxantrone, and Rituximab (BMR) for Patients With Untreated High Risk Follicular Lymphoma [NCT00901927]	Phase 2	14 participants (Actual)	Interventional	2009-05-31	Terminated(stopped due to Study was closed early due to toxicity)
Chemosensitization With Plerixafor Plus G-CSF in Relapsed or Refractory Acute Myeloid Leukemia [NCT00906945]	Phase 1/Phase 2	39 participants (Actual)	Interventional	2011-02-28	Completed
A Randomized, Open-label, Active Controlled, Multi-center Phase 3 Clinical Study to Compare the Efficacy and Safety of Mitoxantrone Hydrochloride Liposome Injection With Chidamide in Patients With Relapsed/Refractory PTCL. [NCT04668690]	Phase 3	190 participants (Anticipated)	Interventional	2021-01-01	Not yet recruiting
A Phase 2 Study of Chidamide, Azacitidine Combined With GM Regimen for Patients With Relapsed and Refractory DLBCL [NCT05823701]	Phase 2	23 participants (Anticipated)	Interventional	2022-09-30	Recruiting
An Multicenter, Randomized Study of Comparison of Docetaxel Plus Prednisone With Mitoxantrone Plus Prednisone in the Patients With Hormone-refractory (Androgen-independent) Metastatic Prostate Cancer [NCT00436839]	Phase 3	228 participants (Actual)	Interventional	2007-01-31	Completed
Gemtuzumab Ozogamicin (CMA-676) Followed or Not by Intensive Chemotherapy as Initial Treatment for Elderly Patients With Acute Myeloid Leukemia: An EORTC-LG Pilot Phase II Study [NCT00006122]	Phase 2	106 participants (Actual)	Interventional	2000-06-30	Completed
An Open Label, Multicenter, Non Randomized Phase II Study to Evaluate Anti-tumor Activity and Safety of a Combination of Fludarabine, Mitoxantrone and Rituximab in Relapsed or Primary Failing Advanced Follicular Non-Hodgkin's Lymphoma. [NCT00169208]	Phase 2	50 participants (Actual)	Interventional	2001-04-30	Completed
Risk-Adapted Therapy for Patients With Untreated Age-Adjusted International Prognostic Index Low-Intermediate Risk, High-Intermediate Risk, or High Risk Diffuse Large B Cell Lymphoma [NCT00712582]	Phase 2	96 participants (Actual)	Interventional	2008-07-01	Completed
High-dose Cytarabine/Mitoxantrone Followed by Autotransplantation for Therapy-Related Myelodysplastic Syndrome/Therapy -Related Acute Myeloid Leukemia [NCT00774046]	Phase 2	32 participants (Actual)	Interventional	2002-12-31	Completed
Treatment of Newly Diagnosed Patients With Acute Promyelocytic Leukemia (PETHEMA LPA 2005): Remission Induction With ATRA + Idarubicin. Risk-adapted Consolidation With ATRA and Anthracycline-based Chemotherapy (Idarubicin/Mitoxantrone) With Addition of Ar [NCT00408278]	Phase 4	300 participants (Anticipated)	Interventional	2005-07-31	Completed
AIDA2000 - Risk-Adapted Therapy for Patients With Acute Promyelocytic Leukemia(APL) [NCT00180128]	Phase 4	80 participants (Anticipated)	Interventional	2000-01-31	Recruiting
Dose-Finding (Phase 1) Study of Continuous Infusion Cladribine, Cytarabine and Mitoxantrone (CI-CLAM) for Adults With Relapsed/Refractory Acute Myeloid Leukemia or Other High-Grade Myeloid Neoplasms Treated at UW/SCCA [NCT04196010]	Phase 1	13 participants (Actual)	Interventional	2020-05-08	Terminated(stopped due to Terminated due to unfavorable risk-benefit ratio of investigational regimen.)
Phase I Study of a Pharmacologically Derived Hybrid Bolus-Infusion Schedule of Flavopiridol (NSC 649890, IND 46,211) Given in Timed Sequential Combination With Cytosine Arabinoside (Ara-C) and Mitoxantrone for Adults With Relapsed and Refractory Acute Leu [NCT00470197]	Phase 1	35 participants (Actual)	Interventional	2007-04-30	Completed
A Randomized Phase II Trial of Fludarabine, Cyclophosphamide and Mitoxantrone (FCM) With or Without Rituximab in Previously Treated Chronic Lymphocytic Leukemia [NCT00337246]	Phase 2	56 participants (Anticipated)	Interventional	2005-07-31	Completed
Phase II Study of DN-101 (High Dose Pulse Calcitriol), Mitoxantrone, Prednisone in Androgen-Independent Prostate Cancer (AIPC) [NCT00182741]	Phase 2	19 participants (Actual)	Interventional	2004-09-30	Completed
A Pilot Phase II Trial of Combination Therapy With Fludarabine, Mitoxantrone and Rituximab in Mantle Cell Lymphoma [NCT00183989]	Phase 2	30 participants (Anticipated)	Interventional	2000-08-31	Terminated(stopped due to Insufficient accrual)
Phase II Trial to Assess the Activity of Ketoconazole and Mitoxantrone Plus GM-CSF in Patients With Progressive Hormone Refractory Prostate Cancer [NCT00447473]	Phase 2	31 participants (Actual)	Interventional	2006-07-31	Terminated(stopped due to PI decision)
Phase II Study of Fludarabine and Mitoxantrone, Followed by GM-CSF(Granulocyte-macrophage Colony-stimulating Factor) and Rituximab in Patients With Low Grade Non-Hodgkins Lymphoma: An Analysis of Efficacy and Tolerability [NCT00208975]	Phase 2	15 participants (Actual)	Interventional	2002-07-31	Terminated(stopped due to slow accrual)
Phase I Investigation of the Feasibility of Combining 5-azacytidine With Highdose Cytarabine (HiDAC) and Mitoxantrone Chemotherapy in a Sequential Manner for Remission Induction in High-risk Acute Myelogenous Leukemia (AML) [NCT01839240]	Phase 1	50 participants (Actual)	Interventional	2012-06-06	Completed
A Phase 1 Study of Azacitidine in Combination With MEC (Mitoxantrone, Etoposide, Cytarabine) in Relapsed and Refractory Acute Myeloid Leukemia [NCT01249430]	Phase 1	24 participants (Actual)	Interventional	2011-01-20	Completed
Study Phase II Non-randomized Prospective Open to Assess the Combination of Rituximab, Bendamustine, Mitoxantrone, Dexamethasone (R-BMD) in Patients With Follicular Lymphoma Refractory or Relapsed [NCT01133158]	Phase 2	61 participants (Actual)	Interventional	2009-07-31	Completed
LAL-Ph-2000: Treatment of Acute Lymphoblastic Leukemia Chromosome Philadelphia Positive [NCT00526305]	Phase 4	100 participants (Anticipated)	Interventional	2000-01-31	Completed
International Collaborative Treatment Protocol for Infants Under One Year With Acute Lymphoblastic or Biphenotypic Leukemia [NCT00550992]		445 participants (Anticipated)	Interventional	2006-01-31	Recruiting
A Phase I/II, Open-label Multicenter Trial to Determine Safety, Pharmacokinetics and Efficacy of GMI-1271 in Combination With Chemotherapy in Patients With Acute Myeloid Leukemia [NCT02306291]	Phase 1/Phase 2	91 participants (Actual)	Interventional	2015-03-31	Completed
Phase I Trial of Brentuximab Vedotin With Re-induction Chemotherapy in Patients With Relapsed, CD30 Expressing, Acute Myeloid Leukemia (AML) [NCT01830777]	Phase 1	22 participants (Actual)	Interventional	2013-05-31	Completed
The Clinical Observationg on HAM for Acute Myeloid Leukemia [NCT04024241]		250 participants (Anticipated)	Observational	2017-09-01	Recruiting
MITOXANTRONE (N) VS. 5-FLUOROURACIL, EPIRUBICIN AND CYCLOPHOSPHAMIDE AS FIRST-LINE CHEMOTHERAPY FOR PATIENTS WITH METASTATIC BREAST CANCER AND AN UNFAVORABLE PROGNOSIS [NCT00002544]	Phase 3	300 participants (Anticipated)	Interventional	1993-05-31	Completed
A PHASE II STUDY OF MITOXANTRONE AND HIGH-DOSE ARA-C FOLLOWED BY INTENSIVE CONSOLIDATION WITH CYCLOPHOSPHAMIDE AND ETOPOSIDE FOR MYELOID BLAST CRISIS OF CHRONIC MYELOGENOUS LEUKEMIA (CML) [NCT00002598]	Phase 2	30 participants (Anticipated)	Interventional	1994-06-30	Completed
ACUTE MYELOID LEUKAEMIA TRIAL 12 [NCT00002658]	Phase 3	2,000 participants (Anticipated)	Interventional	1994-01-31	Active, not recruiting
AML-MVPCYA: ADDITION OF CYCLOSPORIN A TO THE COMBINATION OF MITOXANTRONE AND ETOPOSIDE (VP 16,213) TO OVERCOME RESISTANCE TO CHEMOTHERAPY IN REFRACTORY AML: A RANDOMIZED PHASE II STUDY [NCT00002688]	Phase 2	25 participants (Anticipated)	Interventional	1995-02-28	Active, not recruiting
A RANDOMIZED PHASE III TRIAL COMPARING DEXAMETHASONE WITH PREDNISONE IN INDUCTION TREATMENT AND BONE MARROW TRANSPLANTATION WITH INTENSIVE MAINTENANCE TREATMENT IN ADOLESCENT AND ADULT ACUTE LYMPHOBLASTIC LEUKEMIA (ALL-4) [NCT00002700]	Phase 3	392 participants (Anticipated)	Interventional	1995-08-31	Completed
A Phase II Trial of Adjuvant Mitoxantrone (NSC #301739) for High Risk Patients Following Radical Prostatectomy [NCT00003858]	Phase 2	0 participants (Actual)	Interventional		Withdrawn(stopped due to The study was not activated.)
Chemotherapy (CT) Followed by Donor Lymphocyte Infusion (DLI) Plus Interleukin 2 (IL-2) for Patients With Relapse Acute Myeloid or Lymphoid Leukemia After Allogeneic Hematopoietic Transplant [NCT00005802]	Phase 1/Phase 2	0 participants	Interventional	1999-06-30	Completed
A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination With Induction Therapy and Consolidation Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia With an IDH1 and/or IDH2 Mutation [NCT02632708]	Phase 1	153 participants (Actual)	Interventional	2015-12-31	Active, not recruiting
Intensive Induction for Newly Diagnosed Acute Myelogenous Leukemia [NCT00274807]	Phase 2	40 participants (Actual)	Interventional	2001-06-30	Completed
Abbreviated Fludarabine / Mitoxantrone / Rituximab Chemotherapy Followed by Zevalin for Relapsed Mantle Cell Lymphoma [NCT00119730]	Phase 2	30 participants (Actual)	Interventional	2005-02-28	Completed
A Clinical Study Was Conducted to Evaluate the Efficacy and Safety of the RCMOP Regimen Sequential Therapy as a First-line Treatment for Patients With Intermediate-to-high Risk Diffuse Large B-cell Lymphoma Who Had Incomplete Remission. [NCT05990985]		20 participants (Anticipated)	Interventional	2023-09-01	Not yet recruiting
Phase I Dose Escalation and Pharmacokinetics Clinical Trial of Mitoxantrone Hydrochloride Liposome in Children With Relapsed and Refractory Lymphoma and Solid Tumors [NCT05620862]	Phase 1	68 participants (Anticipated)	Interventional	2022-10-25	Recruiting
Phase I Cinical Sudy of Lposomal Mitoxantrone Hydrochloride Combined With Cyclophosphamide, Vincristine, Etoposide and Prednisone (CMOEP) in Previously Untreated Peripheral T-cell Lymphoma [NCT05458180]	Phase 1	18 participants (Anticipated)	Interventional	2022-07-07	Not yet recruiting
Three-Arm Randomized Phase II Clinical Study of Irofulven/Prednisone, Irofulven/Capecitabine/Prednisone or Mitoxantrone/Prednisone in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer Patients [NCT00124566]	Phase 2	135 participants (Actual)	Interventional	2004-06-30	Completed
Phase I Study of Adoptive Immunotherapy With CD8 Minor Histocompatibility (H) Antigen-Specific CTL Clones for Patients With Relapsed of AML or ALL After Allogeneic Hematopoietic Stem Cell Transplant [NCT00107354]	Phase 1	0 participants	Interventional	1998-12-31	Completed
A Randomised Multicentric Phase III Study for the Treatment of Young Patients With High Risk (IPI 2-3) Diffuse Large B-Cell Lymphoma. Dose Dense Chemotherapy + Rituximab +/- Intensified High Dose Chemoimmunotherapy With Support of Peripheral Autologous St [NCT00499018]	Phase 3	399 participants (Anticipated)	Interventional	2006-01-31	Active, not recruiting
A Phase I Study Investigating the Combination of RAD001 With Standard Induction and Consolidation Therapy in Older Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) [NCT01154439]	Phase 1	11 participants (Actual)	Interventional	2010-10-31	Completed
Phase II Study on Gemtuzumab Ozogamicin in Combination With All-trans-Retinoic Acid, High-dose Cytarabine and Mitoxantrone in Patients With Primary Refractory Acute Myeloid Leukemia [NCT00143975]	Phase 2	95 participants (Actual)	Interventional	2004-06-30	Completed
A Pilot Study of Mitoxantrone in Combination With Clofarabine (MITCL) in Children, Adolescents and Young Adults (CAYA) With Refractory/Relapsed Acute Leukemia or High Grade Non-Hodgkin Lymphoma [NCT01842672]	Phase 1/Phase 2	41 participants (Actual)	Interventional	2013-03-31	Completed
A Pilot, Pharmacodynamic Correlate, Multi-Institutional Trial of Sirolimus in Combination With Chemotherapy (Mitoxantrone, Etoposide, Cytarabine) for the Treatment of High Risk, Acute Myelogenous Leukemia [NCT01184898]		36 participants (Actual)	Interventional	2010-07-31	Completed
Phase III Trial Comparing CHOP ot PMitCEBO in Good Risk Patients With Histologically Aggresive Non Hodgkin's Lymphoma [NCT00005867]	Phase 3	310 participants (Anticipated)	Interventional	1998-01-31	Completed
Phase II Trial of CLAG-M in Relapsed ALL [NCT01513603]	Phase 2	50 participants (Anticipated)	Interventional	2012-01-31	Recruiting
A Phase II Study of Bortezomib and Vorinostat in Patients With Refractory or Relapsed MLL Rearranged Hematologic Malignancies [NCT02419755]	Phase 2	12 participants (Actual)	Interventional	2015-04-14	Terminated(stopped due to Accrual goals were no longer feasible based on restrictions imposed by the DSMB.)
Brief Induction Chemoimmunotherapy With Rituximab + Bendamustine + Mitoxantrone Followed by Rituximab in Elderly Patients With Advanced Stage Previously Untreated Follicular Lymphoma [NCT01523860]	Phase 2	76 participants (Actual)	Interventional	2009-06-30	Completed
Phase II Study of High Dose Cyclophosphamide, Mitoxantrone, and Carboplatin With Autologous Bone Marrow Transplantation in Refractory or Relapsed Ovarian Carcinoma [NCT00002474]	Phase 2	0 participants	Interventional	1991-02-28	Completed
CMF AND MITOXANTRONE IN ELDERLY PATIENTS WITH ADVANCED BREAST CANCER, A RANDOMIZED PHASE II STUDY [NCT00002498]	Phase 2	0 participants	Interventional	1992-07-31	Active, not recruiting
Study of Topoisomerase Inhibition in the Treatment of Acute Leukemia [NCT00100477]	Phase 2	10 participants (Actual)	Interventional	1998-08-31	Completed
MULTICENTRE TRIAL OF INTENSIFIED THERAPY FOR ADULT ALL (O5/93) [NCT00002531]	Phase 2	0 participants	Interventional	1993-01-31	Active, not recruiting
Pilot Study Of PMitCEBO Plus G-CSF In Good-Prognosis HIV-Related Lymphoma [NCT00032149]	Phase 1/Phase 2	30 participants (Anticipated)	Interventional	2001-10-31	Active, not recruiting
A Phase II Study of the Recombinant Human Monoclonal Anti-Vascular Endothelial Growth Factor Antibody (rhuMAB VEGF) Bevacizumab (NSC #704865, IND # 7,921) Administered in Times Sequential Combination With Cytosine Arabinoside (Ara-C) and Mitoxantrone for [NCT00015951]	Phase 2	0 participants	Interventional	2001-04-30	Completed
A Phase 1/2 Trial of G-CSF, Cladribine, Cytarabine, and Dose-Escalated Mitoxantrone (G-CLAM) in Adults With Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndromes (MDS) [NCT02044796]	Phase 1/Phase 2	199 participants (Actual)	Interventional	2014-01-23	Completed
High Dose Cytarabine And Mitoxantrone Therapy For Relapsed And Refractory Acute Myeloid And Lymphocytic Leukemia: Effects Of GM-CSF Versus G-CSF On Dendritic Cells And Leukemia Associated Antigen-Specific T-Lymphocytes [NCT00053131]	Phase 2	0 participants	Interventional	1999-01-31	Completed
A Randomized Phase II Study Of BMS 247550 Or Mitoxantrone And Prednisone In Patients With Taxane Resistant Hormone Refractory Prostate Cancer [NCT00058084]	Phase 2	80 participants (Actual)	Interventional	2003-03-31	Completed
Treatment of Newly Diagnosed Childhood Acute Myeloid Leukemia (AML) Using Intensive MRC-Based Therapy and Gemtuzumab Ozogamicin (GMTZ): A COG Pilot Study [NCT00070174]	Phase 2	350 participants (Actual)	Interventional	2003-12-31	Completed
A Phase II Study VEPEMB In Patients With Hodgkin's Lymphoma Aged ≥ 60 Years; Vinblastine, Cyclophosphamide, Procarbazine, Prednisolone, Etoposide, Mitoxantrone, and Bleomycin in Treating Older Patients With Hodgkin's Lymphoma [NCT00079105]	Phase 2	175 participants (Actual)	Interventional	2004-01-31	Completed
A Prospective, Open-label, Single-arm Clinical Study of Mitoxantrone Hydrochloride Liposome Injection Combined With Daratumumab and Dexamethasone in the Treatment of Relapsed/Refractory Multiple Myeloma [NCT05857982]	Phase 1/Phase 2	20 participants (Anticipated)	Interventional	2023-05-20	Recruiting
A Phase I/II Study of Flavopiridol (NSC 649890, IND 46,211) in Timed Sequential Combination With Cytosine Arabinoside (Ara-C) and Mitoxantrone for Adults With Poor-Risk Acute Leukemias [NCT00016016]	Phase 1/Phase 2	53 participants (Anticipated)	Interventional	2001-02-28	Completed
[NCT00024492]	Phase 1	40 participants	Interventional	2001-08-31	Completed
A Dose Finding Study of the Safety of Gemtuzumab Ozogamicin Combined With Conventional Chemotherapy for Patients With Relapsed or Refractory Acute Myeloid Leukemia [NCT00028899]	Phase 1	47 participants (Actual)	Interventional	2002-07-31	Completed
A Multicenter, Single-arm, Open Clinical Efficacy Observational Study of Cidapenem Combined With Azacitidine and Mitoxantrone Liposome (CAM) Regimen for Relapsed/Refractory Intra-nodal Follicular Adjuvant T-cell Lymphoma (nTFHL) [NCT05772728]		23 participants (Anticipated)	Interventional	2023-04-30	Not yet recruiting
Gemtuzumab Ozogamicin (GO) Combined With Standard Intensive Chemotherapy Versus Standard Intensive Chemotherapy Alone For Induction/Consolidation In Patients 61-75 Years Old With Previously Untreated AML: A Randomized Phase III Trial (AML-17) Of The EORTC [NCT00052299]	Phase 3	472 participants (Actual)	Interventional	2002-09-30	Completed
Phase I Study of Weekly Intravenous PS-341 (Bortezomib) Plus Mitoxantrone in Patients With Advanced Androgen-Independent Prostate Cancer (AI-PCa) [NCT00059631]	Phase 1	42 participants (Actual)	Interventional	2003-03-20	Completed
A Pilot Study Of Cytarabine And High-Dose Mitoxantrone For Relapsed Or Refractory Hematologic Malignancies [NCT00047021]	Phase 2	3 participants (Actual)	Interventional	2001-11-30	Completed
Phase III - Study on All-Trans Retinoic Acid in Combination With Standard Induction and Consolidation Therapy in Older Patients With Newly Diagnosed Acute Myeloid Leukemia [NCT00151255]	Phase 3	500 participants (Anticipated)	Interventional	2004-06-30	Completed
Phase I/II Trial of VELCADE® (Bortezomib) in Combination With Mitoxantrone and Etoposide for Relapsed or Refractory Acute Leukemias [NCT00410423]	Phase 1/Phase 2	55 participants (Actual)	Interventional	2006-01-31	Completed
Mitoxantrone, Prednisone Plus Sorafenib in Taxane-Refractory Metastatic Hormone Refractory Prostate Cancer (HRPC) [NCT00452387]	Phase 2	22 participants (Actual)	Interventional	2007-05-31	Terminated(stopped due to Early stopping rule)
Cytosine Arabinoside and Mitoxantrone for Patients With Juvenile Myelomonocytic Leukemia Receiving Repeat Stem Cell Transplantation [NCT00609739]	Phase 1/Phase 2	1 participants (Actual)	Interventional	1999-06-30	Terminated(stopped due to Low accrual)
The Efficiency of CAMS-2016 Trial for the Newly Diagnosed Pediatric Acute Myeloid Leukemia: A Prospective Single Centre Trial From China [NCT03173612]		132 participants (Anticipated)	Interventional	2016-08-31	Recruiting
"A Feasibility Study of Early Allogeneic Hematopoietic Cell Transplantation for Relapsed or Refractory High-Grade Myeloid Neoplasms" [NCT02756572]	Phase 2	30 participants (Actual)	Interventional	2016-09-22	Completed
An Multicenter, Randomized, Controlled, Prospective Clinical Study of Mitoxantrone Liposome Combined With PTCy as Conditioning Regimen in Allo-HSCT in Acute Leukemia [NCT05739630]	Phase 2/Phase 3	60 participants (Anticipated)	Interventional	2023-01-01	Recruiting
Clinical Study to Evaluate the Safety, Tolerability, Efficacy and Pharmacokinetics of Liposomal Mitoxantrone Hydrochloride Injection Combined With Cyclophosphamide, Vincristine and Prednisone in the Treatment of Untreated PTCL [NCT04548700]	Phase 1	63 participants (Anticipated)	Interventional	2020-12-24	Recruiting
Treatment of Poor Prognosis Acute Myeloid Leukemia and Blastic Crisis Chronic Myelogenous Leukemia With Mylotarg, High-Dose Cytarabine, Mitozantrone and Ethyol AML/CML 2000-06. [NCT00003407]	Phase 2	0 participants (Actual)	Interventional	2001-02-13	Withdrawn(stopped due to The P.I deceased.)
A Phase I Study of Lenalidomide Plus Chemotherapy With Mitoxantrone, Etoposide, and Cytarabine for the Reinduction of Patients With Acute Myelogenous Leukemia [NCT01681537]	Phase 1	36 participants (Actual)	Interventional	2012-09-30	Completed
Treatment of Advanced Chronic Lymphocytic Leukemia (CLL) Fludarabine, Mitoxantrone and Cyclophosphamide With or Without G-CSF [NCT00416910]	Phase 3	83 participants (Actual)	Interventional	1999-07-31	Terminated(stopped due to low recruitment)
A Multicenter, Open-label, Single-arm, Phase Ib Study to Evaluate the Safety and Efficacy of Mitoxantrone Hydrochloride Liposome Injection in Subjects With Platinum-Resistant or Platinum-Refractory Relapsed Ovarian Cancer [NCT04718376]	Phase 1	30 participants (Anticipated)	Interventional	2021-01-12	Recruiting
Consolidation With Campath-1H After FMC Induction in Patients With T-cell Chronic Lymphocytic Leukemia [NCT00278213]	Phase 2	17 participants (Anticipated)	Interventional	2002-09-30	Completed
A Multicenter, Open-label, Single-arm, Phase Ib Study to Evaluate the Safety and Efficacy of Mitoxantrone Hydrochloride Liposome Injection in Subjects With Advanced Gastric Carcinoma [NCT04718402]	Phase 1	30 participants (Anticipated)	Interventional	2021-03-30	Recruiting
A Phase I Study of Lintuzumab-Ac225 in Combination With CLAG-M Chemotherapy in Patients With Relapsed/Refractory Acute Myeloid Leukemia [NCT03441048]	Phase 1	26 participants (Actual)	Interventional	2018-05-22	Active, not recruiting
A Phase II Proof of Concept Study Evaluating the Reduction of Mitoxantrone-induced Cardiotoxicity and Neurological Outcome in the Combined Use of Mitoxantrone and Dexrazoxane (Cardioxane®) in Multiple Sclerosis (MSCardioPro) [NCT01627938]	Phase 2	50 participants (Anticipated)	Interventional	2012-04-30	Active, not recruiting
Sequencing of Chemotherapy and Radiotherapy in Adjuvant Breast Cancer [NCT00003893]	Phase 3	2,250 participants (Anticipated)	Interventional	1998-07-31	Completed
A Phase II Study of the Efficacy and Pharmacogenomics of Cladribine-based Salvage Chemotherapy in Patients With Relapse/Refractory and Secondary Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS) [NCT03150004]	Phase 2	90 participants (Anticipated)	Interventional	2017-06-14	Recruiting
An Open Label, Dose-Escalation Study to Evaluate Safety, Tolerability, Maximum Tolerated Dose (MTD), Efficacy, and Pharmacokinetics (PKs) of CPI-613 Given With High Dose Cytarabine and Mitoxantrone in Patients With Relapsed or Refractory Acute Myeloid Leu [NCT01768897]	Phase 1	67 participants (Actual)	Interventional	2013-01-31	Completed
HLA-mismatched Allogeneic Cellular Therapy (HMMACT) After Chemotherapy in High Risk Acute Myeloid Leukemia [NCT01801046]	Phase 1	10 participants (Actual)	Interventional	2013-03-06	Terminated(stopped due to Insufficient Accrual)
NOPHO-DBH AML 2012 Protocol. Research Study for Treatment of Children and Adolescents With Acute Myeloid Leukaemia 0-18 Years [NCT01828489]	Phase 3	300 participants (Anticipated)	Interventional	2013-03-31	Recruiting
"Randomized Phase II Trial of Timed Sequential Therapy (TST) With Alvocidib (Flavopiridol), Ara-C and Mitoxantrone (FLAM) vs. 7+3 for Adults Age 70 and Under With Newly Diagnosed Acute Myelogenous Leukemia (AML)" [NCT01349972]	Phase 2	172 participants (Actual)	Interventional	2011-04-30	Completed
Phase 1/2 Study of Concurrent Decitabine in Combination With G-CSF, Cladribine, Cytarabine, and Mitoxantrone (G-CLAM) in Adults With Newly Diagnosed Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndromes (MDS) [NCT02921061]	Phase 1/Phase 2	28 participants (Actual)	Interventional	2016-11-17	Completed
A Phase II Study of Therapy for Pediatric Relapsed or Refractory Precursor B-Cell Acute Lymphoblastic Leukemia and Lymphoma [NCT01700946]	Phase 2	80 participants (Actual)	Interventional	2013-04-15	Completed
A Multicenter, Randomized, Open-label, Phase Ib Study to Evaluate the Safety, Efficacy and Pharmacokinetic Characteristics of Mitoxantrone Hydrochloride Liposome Injection in Subjects With Advanced Solid Tumor [NCT04719065]	Phase 1	90 participants (Anticipated)	Interventional	2021-01-13	Active, not recruiting
Phase II Study of Intravenous Novantrone(R) in the Treatment of AIDS Related Kaposi's Sarcoma [NCT00002259]	Phase 2	0 participants	Interventional		Completed
IDA VS MTZ IN INDUCTION AND INTENSIFICATION TREATMENT OF AML OR MDS IN CHILDREN, A PHASE III RANDOMIZED STUDY [NCT00002517]	Phase 3	0 participants	Interventional	1993-03-31	Completed
A Phase I/II Trial Using Weekly Mitoxantrone Chemotherapy and G-CSF for the Treatment of Metastatic Hormone Refractory Prostate Cancer [NCT00003183]	Phase 1/Phase 2	64 participants (Anticipated)	Interventional	1997-03-31	Active, not recruiting
A Phase II Randomized Trial of Carboplatin and Topotecan; Flavopiridol, Mitoxantrone and Cytosine Arabinoside; and Sirolimus, Mitoxantrone, Etoposide and Cytosine Arabinoside for the Treatment of Adults With Primary Refractory or Initial Relapse of Acute [NCT00634244]	Phase 2	92 participants (Actual)	Interventional	2008-10-31	Completed
Treateament of Newly Diagnosed Acute Monocytic Leukemia in Children： A Prospective Multicenter Study in South China [NCT05313958]	Phase 2/Phase 3	43 participants (Anticipated)	Interventional	2021-12-01	Recruiting
A Single-arm, Multicenter, Prospective Clinical Study of Mitoxantrone Hydrochloride Liposome Injection Combined With Chidamide and Azacitidine in the Treatment of Relapsed and Refractory Peripheral T-cell Lymphoma [NCT05495100]	Phase 2	45 participants (Anticipated)	Interventional	2022-08-11	Recruiting
A Phase II Study Incorporating Panobinostat, Bortezomib and Liposomal Vincristine Into Re-Induction Therapy for Relapsed Pediatric T-Cell Acute Lymphoblastic Leukemia or Lymphoma [NCT02518750]	Phase 2	3 participants (Actual)	Interventional	2016-11-23	Terminated(stopped due to Due to slow accrual)
A Randomized Phase III Study to Compare Arsenic Trioxide (ATO) Combined to ATRA and Idarubicin Versus Standard ATRA and Anthracyclines-based Chemotherapy (AIDA Regimen) for Patients With Newly Diagnosed, High-risk Acute Promyelocytic Leukemia [NCT02688140]	Phase 3	280 participants (Anticipated)	Interventional	2016-06-30	Active, not recruiting
CYTOREDUCTIVE CHEMOTHERAPY WITH MITOXANTRONE, CYTOSINE ARABINOSIDE AND ETOPOSIDE FOLLOWED BY RECOMBINANT HUMAN G-CSF FOR MOBILIZATION OF PERIPHERAL BLOOD STEM CELLS IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA [NCT00002674]	Phase 2	30 participants (Anticipated)	Interventional	1994-10-31	Completed
Study of Combinative Effect of Induction Therapy With Mitoxantrone and Plasmapheresis to Treat Patients With Aggressive Multiple Sclerosis [NCT01214317]		40 participants (Actual)	Interventional	2010-01-31	Completed
Medical Research Council Working Party on Leukaemia in Childhood Acute Myeloid Leukaemia Trial 12 [NCT00003436]	Phase 3	2,000 participants (Anticipated)	Interventional	1998-07-31	Completed
Randomized Placebo-Controlled Trial of Mitoxantrone/Prednisone and Clodronate Versus Mitoxantrone/Prednisone Alone in Patients With Hormone Refractory Metastatic Prostate Cancer and Pain [NCT00003232]	Phase 3	227 participants (Actual)	Interventional	1997-11-24	Completed
A Randomized Controlled Study on the Efficacy and Safety of MA-BUCY2 Protocol in the Conditioning of Haploidentical Stem Cell Transplantation in Patients With High-risk Acute Myeloid Leukemia [NCT05814731]		264 participants (Anticipated)	Interventional	2023-04-15	Not yet recruiting
Safety, Tolerability, Pharmacokinetics and Efficacy of Mitoxantrone Hydrochloride Liposome Injection in Chinese Patients With Advanced Solid Tumors: A Multicenter, Open-label, Phase I Dose-escalation and Dose-expansion Study [NCT04921878]	Phase 1	104 participants (Anticipated)	Interventional	2021-06-30	Not yet recruiting
Evaluation of the Impact of Remission Induction Chemotherapy Prior to Allogeneic Stem Cell Transplantation in Relapsed and Poor-response Patients With AML [NCT02461537]	Phase 3	281 participants (Actual)	Interventional	2015-09-17	Completed
Phase 1 Study of Selinexor in Combination With Topoisomerase-II Inhibition in Acute Myeloid Leukemia [NCT02299518]	Phase 1	23 participants (Actual)	Interventional	2015-05-18	Completed
Phase I/II Study of Neoadjuvant Weekly Docetaxel and Mitoxantrone Prior to Prostatectomy in Patients With High Risk Localized Prostate Cancer [NCT00017563]	Phase 2	57 participants (Actual)	Interventional	2000-09-30	Completed
Mitoxantrone, Etoposide, and Cytarabine (MEC) Following Epigenetic Priming With Decitabine in Adults With Relapsed/Refractory Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndromes (MDS): A Phase 1/2 Study [NCT01729845]	Phase 1/Phase 2	52 participants (Actual)	Interventional	2012-12-20	Completed
A Study of Therapy for Pediatric Relapsed or Refractory Acute Lymphoblastic Leukemia [NCT00186875]	Phase 2	47 participants (Actual)	Interventional	2003-11-30	Completed
Clofarabine, Cytarabine and Mitoxantrone (CLAM) for Relapsed or Refractory AML [NCT02686593]	Phase 2	50 participants (Actual)	Interventional	2016-02-01	Completed
A Phase II Investigation of Vorinostat in Combination With Intravenous Fludarabine, Mitoxantrone, and Dexamethasone in Patients With Relapsed or Refractory Mantle Cell Lymphoma [NCT01578343]	Phase 2	20 participants (Actual)	Interventional	2012-06-30	Terminated(stopped due to we collected data of a total of 19 patients for an interim analysis. but there are less than 7 responses out of the initial 19 patients.)
A Phase I Study of Cabazitaxel, Mitoxantrone, and Prednisone (CAMP) for Patients With Metastatic Castration-Resistant Prostate Cancer and no Prior Chemotherapy [NCT01594918]	Phase 1	25 participants (Actual)	Interventional	2012-06-30	Completed
Phase 3 Open-label, Multicenter, Randomized Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FLT3 Mutation [NCT03182244]	Phase 3	276 participants (Actual)	Interventional	2018-01-15	Active, not recruiting
Treatment Protocol for Relapsed Anaplastic Large Cell Lymphoma of Childhood and Adolescence [NCT00317408]		96 participants (Anticipated)	Interventional	2004-04-30	Active, not recruiting
A RANDOMIZED PROSPECTIVE TRIAL OF CHOP VERSUS MCOP IN ELDERLY PATIENTS WITH INTERMEDIATE AND HIGH GRADE NON-HODGKIN'S LYMPHOMA (AGED 65 YEARS AND OVER) [NCT00002576]	Phase 3	200 participants (Anticipated)	Interventional	1992-11-30	Completed
A Single-arm, Open-label, Single-center Phase Ib Study to Evaluate the Safety and Efficacy of Liposome-entrapped Mitoxantrone Hydrochloride Injection (PLM60) in Advanced Hepatocellular Carcinoma (HCC) [NCT04331743]	Phase 1	18 participants (Anticipated)	Interventional	2021-06-05	Not yet recruiting
A PHASE I COOPERATIVE AGREEMENT PEDIATRIC TRIAL OF MITOXANTRONE, ETOPOSIDE AND PSC-833 (PSC-ME) THERAPY IN PATIENTS WITH RELAPSED AND REFRACTORY ACUTE LEUKEMIA [NCT00002912]	Phase 1	3 participants (Actual)	Interventional	1997-01-31	Completed
A Randomized Trial of High-Dose Chemotherapy and Autologous Stem Cell Therapy Versus Standard Therapy in Women With Metastatic Breast Cancer Who Have Responded to Anthracycline or Taxane-Based Induction Chemotherapy [NCT00003032]	Phase 3	224 participants (Actual)	Interventional	1997-04-25	Completed
An Out Patient Dose Escalation Trial of High Dose Mitoxantrone, Thiotepa and Cyclophosphamide Plus Autologous Blood Cell Rescue and Amifostine Cytoprotection [NCT00003068]	Phase 2	30 participants (Anticipated)	Interventional	1997-06-30	Completed
A Phase I Trial of Sequential High Dose Chemotherapy Regimens Followed by Autologous or Syngeneic Peripheral Blood Stem Cell (PBSC) Rescue in Patients With Persistent Stage III/IV Ovarian Cancer [NCT00003080]	Phase 1	0 participants	Interventional	1996-09-30	Completed
INDUCTION WITH ALL-TRANS RETINOIC ACID IN COMBINATION WITH IDARUBICIN AND INTENSIVE CONSOLIDATION FOLLOWED BY BONE MARROW TRANSPLANTATION OR A RANDOMIZED MAINTENANCE TREATMENT DEPENDING UPON THE AMOUNT OF MINIMAL RESIDUAL DISEASE IN ACUTE PROMYELOCYTIC LE [NCT00002701]	Phase 3	750 participants (Anticipated)	Interventional	1995-10-31	Active, not recruiting
RANDOMIZED PHASE III STUDY TO EVALUATE THE VALUE OF rHuG-CSF IN INDUCTION AND OF AN ORAL SCHEDULE AS CONSOLIDATION TREATMENT IN ELDERLY PATIENTS WITH ACUTE MYELOGENOUS LEUMEKIA (AML-13 PROTOCOL) [NCT00002719]	Phase 3	500 participants (Anticipated)	Interventional	1995-12-31	Completed
A Randomised Study Comparing an Oral Regimen (Idarubicin and Etoposide) With an Intravenous Regimen (MAE) for Consolidation in Patients Over 55 Years With Acute Myeloid Leukaemia in First Complete Remission [NCT00003602]	Phase 3	400 participants (Anticipated)	Interventional	1998-03-31	Active, not recruiting
Phase III Study of Combination Chemotherapy in Children With T Cell and Pre-B Cell Non-Hodgkin's Lymphoma [NCT00003650]	Phase 3	179 participants (Actual)	Interventional	1997-02-28	Completed
The Value of Dexamethasone Versus Prednisolone During Induction and Maintenance Therapy of Prolonged Versus Conventional Duration of L-Asparaginase Therapy During Consolidation and Late Intensification, and of Corticosteroid + VCR Pulses During Maintenanc [NCT00003728]	Phase 3	1,500 participants (Anticipated)	Interventional	1998-12-31	Active, not recruiting
PROSPECTIVE NON-RANDOMIZED STUDY WITH CHEMOTHERAPY FOR RELAPSED OR REFRACTORY HIV-RELATED NON-HODGKIN'S LYMPHOMA: VMP REGIMEN FOR RELAPSED PATIENTS, CDE REGIMEN FOR REFRACTORY PATIENTS [NCT00002905]	Phase 2	20 participants (Anticipated)	Interventional	1995-06-30	Active, not recruiting
A Randomized Phase II Trial of Navelbine/Epirubicin Versus Navelbine/Mitozantrone Versus Cyclophosphamide/Adriamycin as Preoperative Chemotherapy in Patients With > or = 3cm Diameter Early Breast Cancer [NCT00004237]	Phase 2	0 participants	Interventional	1998-10-31	Completed
A Randomized, Double-Blind, Placebo-Controlled, Phase III Study of the Matrix Metalloprotease Inhibitor AG3340 in Combination With Mitoxantrone and Prednisone With Provision for Subsequent Change in Therapy in Patients Having Hormone-Refractory Prostate C [NCT00003343]	Phase 3	525 participants (Anticipated)	Interventional	1998-03-31	Completed
Phase 2, Randomized, Biomarker-driven Clinical Study in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With MCL-1 Dependence ≥30% [NCT02520011]	Phase 2	104 participants (Actual)	Interventional	2016-03-14	Terminated(stopped due to Due to slow enrollment, the extensive time projected to conclude the study hypothesis rendered the study no longer reasonably feasible to complete.)
Phase II Study of Novantrone(R) (Mitoxantrone) and Etoposide in Patients With HIV Associated Large Cell and Immunoblastic Lymphomas [NCT00002003]	Phase 2	0 participants	Interventional		Completed
RANDOMIZED PHASE III STUDY OF INDUCTION (ICE VS MICE VS DCE) AND INTENSIVE CONSOLIDATION (IDIA VS NOVIA VS DIA) FOLLOWED BY BONE MARROW TRANSPLANTATION IN ACUTE MYELOGENOUS LEUKEMIA: AML 10 PROTOCOL [NCT00002549]	Phase 3	1,520 participants (Anticipated)	Interventional	1993-11-30	Active, not recruiting
A Pilot Clinical Trial of Mitomycin C Modulation of Multidrug Resistance Proteins and a Phase I Evaluation of Mitomycin C and Mitoxantrone in Patients With Acute Myelogenous Leukemia [NCT00003003]	Phase 1	29 participants (Anticipated)	Interventional	1996-09-30	Completed
Treatment Protocol for Patients With Standard Risk Acute Myelogenous Leukemia and Its Variants: Induction Using High-Dose Cytarabine, Mitoxantrone and Ethyol; Consolidation With Cytarabine and Idarubicin and Maintenance With 13 Cis Retinoic Acid and Alpha [NCT00003405]	Phase 2	0 participants (Actual)	Interventional	1998-04-30	Withdrawn(stopped due to No enrollment)
Phase 3 Multicenter Randomized Trial to Evaluate Efficacy and Safety of CPI-613 in Combination With HD Cyt. and Mito. vs HD Cyt. and Mito. Therapy and Control Sub-groups in Older Patients With R/R AML [NCT03504410]	Phase 3	200 participants (Actual)	Interventional	2018-11-12	Terminated(stopped due to Futile)
A Phase Ⅱ Study to Evaluate the Safety and Efficacy of Mitoxantrone Hydrochloride Liposome Injection for Relapsing Multiple Sclerosis [NCT05496894]	Phase 2	0 participants (Actual)	Interventional	2022-08-31	Withdrawn(stopped due to Due to the company's project adjustment, decided to stop this study)
Acute Myeloid Leukemia Salvage Therapy for Patients in First Relapse or Who Fail to Achieve an Initial Remission or Who Develop AML as a Second Malignant Neoplasm [NCT00002805]	Phase 2	115 participants (Actual)	Interventional	1997-08-31	Completed
Phase I/II Study of High Dose Topotecan, Mitoxantrone and Thiotepa (TMT) Followed by Autologous Stem Cell Transplant in Patients With Recurrent Platinum Resistant Ovarian Cancer [NCT00003297]	Phase 1/Phase 2	50 participants (Anticipated)	Interventional	1997-12-31	Completed
A Randomized Prospective Study of Early Intensification Versus Alternating Triple Therapy for Patients With Poor Prognosis Lymphoma [NCT00002835]	Phase 3	116 participants (Actual)	Interventional	1995-10-30	Completed
A Phase II Trial of Multiple Cycles of Sequential High Dose Chemotherapy for Patients With Chemotherapy Sensitive Relapsed Non-Hodgkin's Lymphoma [NCT00003957]	Phase 2	3 participants (Actual)	Interventional	1998-12-31	Completed
Treatment of Prostate Cancer by Induction of Alternate Cell Death Pathways: A Phase I Trial of Docetaxel, Estramustine, Mitoxantrone and Prednisone [NCT00003633]	Phase 1	12 participants (Anticipated)	Interventional	1998-08-31	Active, not recruiting
A Randomized, Open-Label Phase II/III Study of SU101 Plus Mitoxantrone/Prednisone Compared to Mitoxantrone/Prednisone Alone in Patients With Hormone-Refractory Prostate Cancer [NCT00004071]	Phase 2/Phase 3	0 participants	Interventional	1999-08-31	Completed
A Pilot Study of Mitoxantrone-Based Four Drug Reinduction in Combination With Bortezomib for Relapsed or Refractory Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma in Children and Young Adults [NCT02535806]	Phase 2	2 participants (Actual)	Interventional	2015-07-31	Terminated(stopped due to Funding source discontinued)
Phase 3 Randomized Trial of DFP-10917 vs Non-Intensive Reinduction (LoDAC, Azacitidine, Decitabine, Venetoclax Combination Regimens) or Intensive Reinduction (High & Intermediate Dose Cytarabine Regimens) for Acute Myelogenous Leukemia Patients in Second, [NCT03926624]	Phase 3	450 participants (Anticipated)	Interventional	2019-11-22	Recruiting
Phase I/II Clinical Study of Mitoxantrone Hydrochloride Liposomes in Combination With Gemcitabine, Dexamethasone, and Cisplatin in Relapsed/Refractory Peripheral T-cell Lymphoma [NCT05441761]	Phase 1/Phase 2	60 participants (Anticipated)	Interventional	2022-05-01	Recruiting
Phase Ib Trial of Gilteritinib in Combination With Mitoxantrone, Cladribine, Cytarabine and Filgrastim (GM-CLAG) for Relapsed/Refractory FLT3-mutated Acute Myeloid Leukemia [NCT05330377]	Phase 1	0 participants (Actual)	Interventional	2023-03-31	Withdrawn(stopped due to Sponsor withdrew funding)
Phase 2 Study of Mitoxantrone, Etoposide, and Cytarabine (MEC) Plus Lenalidomide for the Treatment of Adult Patients With Relapsed or Refractory Acute Myeloid Leukemia [NCT03118466]	Phase 2	41 participants (Actual)	Interventional	2017-09-25	Active, not recruiting
AN OPEN-LABEL, RANDOMIZED PHASE 3 STUDY OF INOTUZUMAB OZOGAMICIN COMPARED TO A DEFINED INVESTIGATOR'S CHOICE IN ADULT PATIENTS WITH RELAPSED OR REFRACTORY CD22-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) [NCT01564784]	Phase 3	326 participants (Actual)	Interventional	2012-08-02	Completed
Phase II Study of Granulocyte-Macrophage Colony Stimulating Factor Plus Mitoxantrone for the Treatment of Hormone Refractory Prostate Cancer [NCT00477087]	Phase 2	10 participants (Actual)	Interventional	2006-07-31	Terminated(stopped due to Low accrual)
Open-Label, PhaseIb/Ⅱ Study of Tislelizumab and Mitoxantrone Hydrochloride Liposome Combination Treatment in Patients With Relapsed or Refractory Extranodal Natural Killer/T Cell Lymphoma（ALLIANCE-022） [NCT05464433]	Phase 1/Phase 2	46 participants (Anticipated)	Interventional	2022-07-30	Recruiting
Venetoclax Combining Chidamide and Azacitidine (VCA) Regimen Followed by Dicitabine Combined With Liposome Mitoxantrone, Cytarabine, and G-CSF (D-MAG) Regimen on the Treatment of Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) : A Multi [NCT05603884]	Phase 2	66 participants (Anticipated)	Interventional	2022-12-01	Recruiting
A Multicenter, Open-label, Single-arm, Phase Ib Study to Evaluate Safety and Efficacy of Mitoxantrone Hydrochloride Liposome Injection in Subjects With Recurrent/Metastatic Head and Neck Cancers [NCT04902027]	Phase 1	30 participants (Anticipated)	Interventional	2021-07-01	Not yet recruiting
A Multicenter, Single-arm, Prospective Phase I/II Trial of Mitoxantrone Hydrochloride Liposome Injection Combined With Chidamide in Relapsed or Refractory Peripheral T-cell Lymphoma [NCT05527275]	Phase 1/Phase 2	78 participants (Anticipated)	Interventional	2022-10-01	Not yet recruiting
Phase I-II Study of Crenolanib Combined With Standard Salvage Chemotherapy, and Crenolanib Combined With 5-Azacitidine in Acute Myeloid Leukemia Patients With FLT3 Activating Mutations [NCT02400281]	Phase 1/Phase 2	28 participants (Actual)	Interventional	2015-09-30	Completed
Safety, Tolerability, and Efficacy of Mitoxantrone Hydrochloride Liposome Injection in Patients With Advanced Pancreatic Cancer: A Multicenter, Open-label, Phase Ⅱ Study [NCT05100329]	Phase 2	38 participants (Anticipated)	Interventional	2021-11-30	Not yet recruiting
A Randomized Phase II Trial of Mitoxantrone, Estramustine and Navelbine or 13-cis Retinoic Acid, Interferon and Paclitaxel in Patients With Metatstatic Hormone Refractory Prostate Cancer [NCT00005847]	Phase 2	0 participants	Interventional	2001-04-05	Completed
Total Therapy for Infants With Acute Lymphoblastic Leukemia (ALL) I [NCT02553460]	Phase 1/Phase 2	50 participants (Actual)	Interventional	2016-01-29	Active, not recruiting
A Phase I/II Study to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetics of Mitoxantrone Hydrochloride Liposome Injection in Subjects With Acute Myeloid Leukemia [NCT05345938]	Phase 1/Phase 2	90 participants (Anticipated)	Interventional	2022-05-30	Not yet recruiting
Dasatinib Plus Multi-agent Chemotherapy for New Diagnosed Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia [NCT02523976]	Phase 2	30 participants (Actual)	Interventional	2015-08-01	Completed
Multicenter Randomized Controlled Clinical Study of Mitoxantrone Hydrochloride Liposome Injection Combined With Carmustine, Etoposide and Cytarabine (Modified BEAM Protocol) for T Cell Lymphoma Underwent Autologous Stem Cell Transplantation [NCT05814718]		122 participants (Anticipated)	Interventional	2023-04-15	Not yet recruiting
A Phase 1 Single-Center Trial Combining Venetoclax With G-CSF, Cladribine, Cytarabine, and Mitoxantrone (CLAG-M) for Patients With AML and High-Grade Myeloid Neoplasms [NCT04797767]	Phase 1	20 participants (Anticipated)	Interventional	2022-02-04	Recruiting
Open-label, Single-arm Trial to Evaluate Antitumor Activity, Safety, and Pharmacokinetics of Isatuximab Used in Combination With Chemotherapy in Pediatric Patients From 28 Days to Less Than 18 Years of Age With Relapsed/Refractory B or T Acute Lymphoblast [NCT03860844]	Phase 2	67 participants (Actual)	Interventional	2019-08-06	Terminated(stopped due to Study was prematurely stopped due to sponsor decision (stage 2 efficacy criteria not met); not due to safety concerns.)
A Single-Center Phase 1/2 Study of Single- or Fractioned-Dose Gemtuzumab Ozogamicin in Combination With G-CSF, Cladribine, Cytarabine, and Mitoxantrone for Previously Untreated Adult Acute Myeloid Leukemia or High-Grade Myeloid Neoplasm [NCT03531918]	Phase 1/Phase 2	66 participants (Actual)	Interventional	2018-09-14	Completed
Phase 2 Study of the Activity and Safety of Fludarabine, Cyclophosphamide, and Mitoxantrone Plus Rituximab (FCM-R) With Pegfilgrastim (Neulasta) as Frontline Therapy for Patients < 70 Years With Chronic Lymphocytic Leukemia [NCT00254410]	Phase 2	30 participants (Actual)	Interventional	2005-03-14	Completed
A Phase 3, Randomized, Double-blind, Controlled Trial of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer [NCT01522443]	Phase 3	119 participants (Actual)	Interventional	2012-03-31	Terminated(stopped due to Stopped after the outcome of cabozantinib Phase 3 CRPC study XL184-307.)
Phase II Study of Adult Acute Lymphoblastic Leukaemia (ALL): Imatinib in Combination With Chemotherapy in Ph+ Patients, and Post-remissional Treatment Intensification in High-risk Ph- Patients, With Minimal Residual Disease Monitoring. [NCT00458848]	Phase 2	470 participants (Actual)	Interventional	2004-10-31	Completed
Randomized Phase 2 Trial of CPX-351 (Vyxeos) vs. CLAG-M (Cladribine, Cytarabine, G-CSF, and Mitoxantrone) in Medically Less-Fit Adults With Acute Myeloid Leukemia (AML) or Other High-Grade Myeloid Neoplasm [NCT04195945]	Phase 2	60 participants (Anticipated)	Interventional	2020-03-11	Recruiting
A Phase I Dose Escalation Study of Clofarabine Given in Combination With Multi-agent Therapy for Remission Induction in Pediatric Patients With Acute Lymphoblastic Leukemia in First Relapse or Refractory to First Line Therapy - [NCT01279096]	Phase 1	20 participants (Actual)	Interventional	2010-01-31	Completed
A Multicenter, Open-label, Single-arm, Phase II Study of Mitoxantrone Hydrochloride Liposome Injection in Patients With Advanced HER2 Negative Breast Cancer [NCT04927481]	Phase 2	73 participants (Anticipated)	Interventional	2021-06-11	Recruiting
A Phase 2 Multi-Arm Study of Magrolimab Combinations in Patients With Myeloid Malignancies [NCT04778410]	Phase 2	59 participants (Anticipated)	Interventional	2021-06-28	Active, not recruiting
An Open-label, Multi-center Phase II Clinical Trial to Evaluate the Cardiac Safety of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Advanced Malignant Tumor [NCT05089461]	Phase 2	120 participants (Anticipated)	Interventional	2022-03-07	Suspended(stopped due to sponsor decided to stop)
A RANDOMIZED, CONTROLLED TRIAL OF SALVAGE THERAPY WITH PACLITAXEL AND CARBOPLATIN VERSU SALVAGE THERAPY WITH STEM CELL SUPPORTED HIGH-DOSE CARBOPLATIN, MITOXANTRONE AND CYCLOPHOSPHAMIDE IN PATIENTS WITH PERSISTENT LOW VOLUME OVARIAN CANCER AND RESPONSE TO [NCT00002819]	Phase 3	0 participants	Interventional	1996-11-30	Terminated
Standard Chemotherapy (CHOP Regimen) Versus Sequential High-Dose Chemotherapy With Autologous Stem Cell Transplantation in Patients With Newly Diagnosed Aggressive Non-Hodgkin's Lymphomas and Poor Prognostic Factors: A Randomized Phase III Study (MISTRAL) [NCT00003215]	Phase 3	400 participants (Anticipated)	Interventional	1997-04-30	Completed
Docetaxel and Estramustine Versus Mitoxantrone and Prednisone for Advanced, Hormone Refractory Prostate Cancer [NCT00004001]	Phase 3	770 participants (Actual)	Interventional	1999-10-31	Completed
Phase II Study of Alvocidib (NSC 649890, Flavopiridol) in Timed Sequential Combination With Cytosine Arabinoside (Ara-C) and Mitoxantrone for Adults With Newly Diagnosed, Previously Untreated, Poor-Risk Acute Myelogenous Leukemias [NCT00407966]	Phase 2	45 participants (Actual)	Interventional	2006-10-31	Completed
A Phase I Study of Neoadjuvant Chemotherapy Involving Cabazitaxel, Docetaxel, Mitoxantrone or Satraplatin (CDMS) Followed by Surgery for Patients With High Risk Localized Prostate Cancer [NCT03258320]	Phase 1	50 participants (Anticipated)	Interventional	2015-01-31	Recruiting
Randomized Phase II Study Comparing Two Administration Schedules of Flavopiridol (Alvocidib, NSC 649890, IND 46, 211) Given in Timed Sequential Combination With Cytosine Arabinoside (Ara-C) and Mitoxantrone Hydrochloride for Adults With Newly Diagnosed, P [NCT00795002]	Phase 2	78 participants (Actual)	Interventional	2008-11-30	Completed
Phase III Randomized, Double-blind, Placebo-controlled Study Investigating the Efficacy of the Addition of Crenolanib to Salvage Chemotherapy Versus Salvage Chemotherapy Alone in Subjects ≤ 75 Years of Age With Relapsed/Refractory FLT3 Mutated Acute Myelo [NCT03250338]	Phase 3	322 participants (Anticipated)	Interventional	2018-06-05	Recruiting
An Open-label, Multi-center Phase Ib/II Study to Evaluate the Tolerance and Efficacy of Mitoxantrone Hydrochloride Liposome Injection Combined With Cytarabine in Patients With Acute Myeloid Leukemia (AML) [NCT05100303]	Phase 1/Phase 2	58 participants (Anticipated)	Interventional	2021-12-31	Not yet recruiting
A Pilot Study of Decitabine and Vorinostat With Chemotherapy for Relapsed ALL [NCT01483690]	Phase 1/Phase 2	23 participants (Actual)	Interventional	2011-12-31	Terminated(stopped due to Toxicity)
A Prospective, Randomized, Controlled Trial of Decitabine Versus Conventional Chemotherapy for Maintenance Therapy of Patients With Acute Myeloid Leukemia With t(8;21) [NCT03026842]	Phase 4	180 participants (Anticipated)	Interventional	2017-01-31	Active, not recruiting
A Biomarker Validation Study to Establish Whether Serial Flow Cytometric Measurements Predict Clinical Response to Sirolimus and MEC (Mitoxantrone Etoposide Cytarabine) Treatment in Patients With High-Risk Acute Myelogenous Leukemia [NCT02583893]	Phase 2	39 participants (Actual)	Interventional	2015-10-07	Completed
A Randomized, Open-label, Positive-controlled, Multicenter Phase Ш Study Comparing Mitoxantrone Hydrochloride Liposome Injection Combined With Capecitabine Versus Capecitabine Monotherapy in Patients With Recurrent Metastatic Nasopharyngeal Carcinoma Who [NCT05717764]	Phase 3	500 participants (Anticipated)	Interventional	2023-02-28	Not yet recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Trial	Outcome
NCT00002766 (1) [back to overview]	Complete Remission (CR)
NCT00004124 (3) [back to overview]	Compare Qualitative and Quantitative Toxicities of These Regimens in These Patients
NCT00004124 (3) [back to overview]	Disease Free Survival
NCT00004124 (3) [back to overview]	Overall Survival
NCT00017563 (1) [back to overview]	Number of Participants With 5-year Freedom From Prostate Specific Antigen (PSA) Recurrence.
NCT00109837 (2) [back to overview]	Continuous Complete Remission at 1 Year
NCT00109837 (2) [back to overview]	Toxicity
NCT00136084 (7) [back to overview]	Relationship of Inhibition of DNA Synthesis and Clinical Response
NCT00136084 (7) [back to overview]	To Assess Whether Inhibition of DNA Synthesis is Greater After High-dose Ara-C (HDAC) Than After Low-dose Ara-C (LDAC) Therapy
NCT00136084 (7) [back to overview]	Minimal Residual Disease (MRD).
NCT00136084 (7) [back to overview]	Proportion of Minimal Residual Disease (MRD)+ Patients Who Become MRD- After One Course of Gemtuzumab Ozogamicin (GO)
NCT00136084 (7) [back to overview]	To Estimate the Overall Event-free Survival (EFS) of AML Patients Who Undergo Risk-adapted and Genotype-directed Therapy
NCT00136084 (7) [back to overview]	Proportion of MRD Reduction After One Course of Cytarabine + Daunomycin + Etoposide (ADE) + GO
NCT00136084 (7) [back to overview]	Proportion of Patients Experienced Toxicity of Cytarabine + Daunomycin + Etoposide (ADE) + GO.
NCT00186875 (4) [back to overview]	Overall Survival (OS)
NCT00186875 (4) [back to overview]	Minimal Residual Disease (MRD) Compared With Historical Data From TOTXV Protocol (NCT00137111)
NCT00186875 (4) [back to overview]	Minimal Residual Disease (MRD) Compared With Historical Data From TOTXV Protocol (NCT00137111)
NCT00186875 (4) [back to overview]	Response Rate
NCT00193479 (1) [back to overview]	Overall Response Rate (ORR), the Percentage of Patients Who Experience an Objective Benefit From Treatment
NCT00208975 (1) [back to overview]	Number of Patients's Who Had Complete Response and Partial Response to the Treatment of Fludarabine and Cyclophosphamide Followed by GM-CSF and Rituximab.
NCT00254410 (4) [back to overview]	Molecular Response Rate at 3 Months
NCT00254410 (4) [back to overview]	Clinical Response Rate at 6 Months
NCT00254410 (4) [back to overview]	Clinical Response Rate at 3 Months
NCT00254410 (4) [back to overview]	Molecular Response Rate at 6 Months
NCT00268242 (6) [back to overview]	Complete Response Rate
NCT00268242 (6) [back to overview]	White Blood Cell Count at Time of Relapse
NCT00268242 (6) [back to overview]	Disease-free and Overall Survival
NCT00268242 (6) [back to overview]	Laboratory Correlates: Immunohistochemistry
NCT00268242 (6) [back to overview]	Duration of the First Complete Response
NCT00268242 (6) [back to overview]	Percentage of Patients Making it to Bone Marrow Transplant.
NCT00290511 (7) [back to overview]	Tolerance and Efficacy of Maintenance Therapy With Yttrium-90 Ibritumomab Tiuxetan (YIT)
NCT00290511 (7) [back to overview]	Tolerance and Efficacy of Maintenance Therapy With Rituximab
NCT00290511 (7) [back to overview]	Number of Participants With Time to Progression (TTP)
NCT00290511 (7) [back to overview]	Progression Free Survival at 10 Years
NCT00290511 (7) [back to overview]	Percentage of Participants With Overall Survival Rate at 10 Years
NCT00290511 (7) [back to overview]	Median Progression Free Survival
NCT00290511 (7) [back to overview]	Overall Survival
NCT00327340 (4) [back to overview]	Safety and Tolerability of Custirsen (OGX-011) in Combination With Either Docetaxel/Prednisone or Mitoxantrone/Prednisone as Second-line Chemotherapy.
NCT00327340 (4) [back to overview]	Feasibility of Treatment With Custirsen (OGX-011) in Combination With Second-line Chemotherapy Based on Prostate Specific Antigen (PSA) Response
NCT00327340 (4) [back to overview]	Feasibility of Treatment With OGX-011 in Combination With Either Docetaxel/Prednisone or Mitoxantrone/Prednisone as Second Line Chemotherapy Based on Time to Pain Progression
NCT00327340 (4) [back to overview]	Relationship Between Changes in Serum Clusterin Levels and Change in Serum PSA Levels When OGX-011 in Combination With Either Docetaxel/Prednisone or Mitoxantrone/Prednisone is Administered as Second Line Chemotherapy.
NCT00331344 (4) [back to overview]	Proportion Responding to Treatment With of the Combination of Ixabepilone and Mitoxantrone Hydrochloride With Prednisone in Hormone Refractory Prostate Cancer Patients Who Have Had Prior Taxane Chemotherapy Based Upon a PSA Decline of > 50% (Phase II)
NCT00331344 (4) [back to overview]	Dose Limiting Toxicities for Each Dose Level of Ixabepilone, Mitoxantrone Hydrochloride, and Prednisone in Patients With Hormone-refractory Metastatic Prostate Cancer That Progressed During or After Taxane-based Chemotherapy (Phase I).
NCT00331344 (4) [back to overview]	Time to Progression (Phase II)
NCT00331344 (4) [back to overview]	Safety of the Combination of Ixabepilone, Mitoxantrone Hydrochloride, and Prednisone in Patients With Hormone-refractory Metastatic Prostate Cancer That Progressed During or After Taxane-based Chemotherapy (Phase I)
NCT00372593 (7) [back to overview]	Event-free Survival at 3 Years
NCT00372593 (7) [back to overview]	Mortality
NCT00372593 (7) [back to overview]	Overall Survival at 3 Years
NCT00372593 (7) [back to overview]	Remission Induction Rate After 2 Courses of Induction Therapy
NCT00372593 (7) [back to overview]	Toxicities, Including Infectious Complications
NCT00372593 (7) [back to overview]	Time to Marrow Recovery
NCT00372593 (7) [back to overview]	Disease-free Survival (DFS)
NCT00385827 (5) [back to overview]	Overall Survival (OS)
NCT00385827 (5) [back to overview]	Number of Participants With Prostate Specific Antigen (PSA) Response
NCT00385827 (5) [back to overview]	Time to Clinical Deterioration (TtCD)
NCT00385827 (5) [back to overview]	Part 1: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
NCT00385827 (5) [back to overview]	Part 2: Progression Free Survival (PFS)
NCT00407966 (1) [back to overview]	Complete Response
NCT00410423 (2) [back to overview]	Complete Response Rate to 1.3mg/m^2 of Bortezomib With Mitoxantrone and Etoposide in Phase II
NCT00410423 (2) [back to overview]	Number of Participants With Dose Limiting Toxicity in Phase I
NCT00417079 (8) [back to overview]	PSA (Prostate-Specific Antigen) Response
NCT00417079 (8) [back to overview]	Overall Survival
NCT00417079 (8) [back to overview]	Overall Tumor Response
NCT00417079 (8) [back to overview]	Pain Response
NCT00417079 (8) [back to overview]	Time to Pain Progression
NCT00417079 (8) [back to overview]	Time to Progression Free Survival (PFS)
NCT00417079 (8) [back to overview]	Time to Prostatic Specific Antigen (PSA) Progression
NCT00417079 (8) [back to overview]	Time to Tumor Progression
NCT00452387 (3) [back to overview]	Quality of Life (QoL)
NCT00452387 (3) [back to overview]	Correlation of Biochemical Criteria (PSA, Prostate-specific Antigen) With Objective Imaging
NCT00452387 (3) [back to overview]	Median Overall Survival (OS)
NCT00458848 (3) [back to overview]	Percentage of Participants Reaching Overall Survival
NCT00458848 (3) [back to overview]	Percentage of Participants Reaching Disease Free Survival
NCT00458848 (3) [back to overview]	Number of Patients Reaching Complete Hematological Response After Induction Therapy
NCT00477087 (3) [back to overview]	Overall Survival (OS)
NCT00477087 (3) [back to overview]	Progression-free Survival (PFS)
NCT00477087 (3) [back to overview]	Number of Participants With > 50% Decrease in Prostate-specific Antigen Levels (PSA Response)
NCT00510887 (6) [back to overview]	Complete and Partial Response
NCT00510887 (6) [back to overview]	Number of Participants With Neuropathy, Any Grade
NCT00510887 (6) [back to overview]	Duration of Response
NCT00510887 (6) [back to overview]	Number of Participants With a Grade 3-4 Hematologic Toxicity.
NCT00510887 (6) [back to overview]	Percentage of Subjects Experiencing Overall Survival
NCT00510887 (6) [back to overview]	Percentage of Subjects Experiencing Progression Free Survival
NCT00512252 (10) [back to overview]	Time to Platelet Recovery
NCT00512252 (10) [back to overview]	Time to Neutrophil Recovery
NCT00512252 (10) [back to overview]	Relapse-free Survival
NCT00512252 (10) [back to overview]	Treatment Failure
NCT00512252 (10) [back to overview]	Safety and Tolerability of AMD3100 + MEC.
NCT00512252 (10) [back to overview]	Phase II Only: Complete Response Rate of AMD3100 + MEC
NCT00512252 (10) [back to overview]	Characterize the Mobilization of Leukemic Cells With AMD3100 by Measuring the Peak Mobilization of Total Leukocytes (Phase I)
NCT00512252 (10) [back to overview]	Characterize the Mobilization of Leukemic Cells With AMD3100 by Measuring the Peak Mobilization of AML Blasts (Phase I)
NCT00512252 (10) [back to overview]	Phase I Only: Optimal Dose of AMD3100 Plus MEC in Patients With Relapsed or Refractory AML
NCT00512252 (10) [back to overview]	Overall Survival
NCT00546377 (2) [back to overview]	Maximum Tolerated Dose (MTD) of Mitoxantrone
NCT00546377 (2) [back to overview]	Overall Response
NCT00562965 (7) [back to overview]	Progression-Free Survival (PFS)
NCT00562965 (7) [back to overview]	Number of Participants With Clinically Significant Change From Baseline in Vital Signs
NCT00562965 (7) [back to overview]	Number of Participants With Grade 3 or 4 Treatment Emergent Adverse Events (TEAEs)
NCT00562965 (7) [back to overview]	Number of Participants With Clinically Significant Change From Baseline in QT Interval Findings
NCT00562965 (7) [back to overview]	Percentage of Participants With Objective Response (OR)
NCT00562965 (7) [back to overview]	Overall Survival Probability at Months 6, 12 and 24
NCT00562965 (7) [back to overview]	Number of Participants With Clinically Significant Change From Baseline in Laboratory Findings
NCT00577993 (2) [back to overview]	Number of Participants With Progression Free Survival (10 Years) by Treatment
NCT00577993 (2) [back to overview]	Number of Participants With Overall Survival (10 Years) by Treatment
NCT00609739 (4) [back to overview]	Patients With Graft-Versus-Host-Disease
NCT00609739 (4) [back to overview]	Patients Who Relapsed
NCT00609739 (4) [back to overview]	Patients With Regimen-Related Toxicity
NCT00609739 (4) [back to overview]	Disease-free Survival
NCT00634244 (2) [back to overview]	The Rate of Treatment Failure
NCT00634244 (2) [back to overview]	The Rate of Complete Remission (CR+CRi)
NCT00656084 (4) [back to overview]	Duration of Response
NCT00656084 (4) [back to overview]	Objective Response Rate (CR + PR)
NCT00656084 (4) [back to overview]	Progression-free Survival Rate at 1 Year.
NCT00656084 (4) [back to overview]	Overall Survival (OS) Rate at 1 Year
NCT00661492 (8) [back to overview]	Prostate-specific Antigen (PSA) Response Rate
NCT00661492 (8) [back to overview]	Prostate-specific Antigen (PSA) Doubling Time
NCT00661492 (8) [back to overview]	Objective Response Rate (ORR)
NCT00661492 (8) [back to overview]	Median Time to Prostate-specific Antigen (PSA) Progression
NCT00661492 (8) [back to overview]	Median Time to Progression (TTP)
NCT00661492 (8) [back to overview]	Median Overall Survival (OS)
NCT00661492 (8) [back to overview]	2-year Radiographically Evident Progression-free Survival (REPFS).
NCT00661492 (8) [back to overview]	Median Progression-free Survival (PFS)
NCT00683475 (9) [back to overview]	Objective Response Rate (ORR)
NCT00683475 (9) [back to overview]	Prostate Specific Antigen (PSA) Response Rate
NCT00683475 (9) [back to overview]	Composite Progression-free Survival (cPFS) at 12-months
NCT00683475 (9) [back to overview]	Composite Progression-free Survival (cPFS)
NCT00683475 (9) [back to overview]	Overall Survival (OS)
NCT00683475 (9) [back to overview]	Composite Progression-free Survival (cPFS) at 9-months
NCT00683475 (9) [back to overview]	Composite Progression-free Survival (cPFS) at 6-months
NCT00683475 (9) [back to overview]	Summary Listing of Participants Reporting Treatment-Emergent Adverse Events
NCT00683475 (9) [back to overview]	Time to Radiographic Evidence of Disease Progression
NCT00712582 (2) [back to overview]	2-year PFS From the Start of Induction Therapy Conditional
NCT00712582 (2) [back to overview]	Overall Survival at 1 Year
NCT00774046 (7) [back to overview]	Response to Induction Chemotherapy (CR or PR)
NCT00774046 (7) [back to overview]	Disease-free Survival in Patients Undergoing Autologous Stem Cell Transplant
NCT00774046 (7) [back to overview]	Relapse-free Survival
NCT00774046 (7) [back to overview]	Feasibility of Stem Cell Collection
NCT00774046 (7) [back to overview]	Numbers of Stem Cells Collected
NCT00774046 (7) [back to overview]	Overall Survival
NCT00774046 (7) [back to overview]	Overall Survival in Patients Undergoing Autologous Stem Cell Transplant
NCT00795002 (3) [back to overview]	Complete Response
NCT00795002 (3) [back to overview]	Disease-free Survival
NCT00795002 (3) [back to overview]	Number of Participants Experiencing Death From Any Cause Within 60 Days of Starting FLAM
NCT00866918 (4) [back to overview]	Hematologic Remission Rate
NCT00866918 (4) [back to overview]	Overall Survival (OS)
NCT00866918 (4) [back to overview]	Hematologic, Molecular, and Cytogenetic Remission Rate
NCT00866918 (4) [back to overview]	Event-free Survival (EFS)
NCT00901927 (3) [back to overview]	Participants With Adverse Events
NCT00901927 (3) [back to overview]	Complete Response Rate of the Combination of BMR (Bendamustine + Mitoxantrone + Rituximab)
NCT00901927 (3) [back to overview]	Time to Progression (TTP) for Participants Treated With BMR (Bendamustine, Mitoxantrone, and Rituximab)
NCT00906945 (13) [back to overview]	Characterize the Mobilization of Leukemic Cells With Plerixafor Plus G-CSF as Measured by Fold Change in AML Blast Count
NCT00906945 (13) [back to overview]	Characterize the Mobilization of Leukemic Cells With Plerixafor Plus G-CSF as Measured by Fold Change in White Blood Cells
NCT00906945 (13) [back to overview]	Overall Survival
NCT00906945 (13) [back to overview]	Phase I: Maximum Tolerated Dose of Plerixafor Plus G-CSF When Combined With MEC
NCT00906945 (13) [back to overview]	Phase II: Complete Response Rate (CR+CRi)
NCT00906945 (13) [back to overview]	Relapse Free-survival Rate
NCT00906945 (13) [back to overview]	Time to Hematologic Recovery as Measured by Time to Neutrophil Recovery
NCT00906945 (13) [back to overview]	Time to Hematologic Recovery as Measured by Time to Neutrophil Recovery
NCT00906945 (13) [back to overview]	Time to Hematologic Recovery as Measured by Time to Platelet Recovery
NCT00906945 (13) [back to overview]	Time to Hematologic Recovery as Measured by Time to Platelet Recovery
NCT00906945 (13) [back to overview]	Phase I and Phase II: Safety and Tolerability of Regimen as Measured by Grade and Frequency of Adverse Events Exceeding 10% in Total Frequency
NCT00906945 (13) [back to overview]	Characterize the Effects of Plerixafor Plus G-CSF on Fold Change in CXCR4 Clone 12G5 Relative Mean Fluorescent Intensity
NCT00906945 (13) [back to overview]	Characterize the Effects of Plerixafor Plus G-CSF on Fold Change in CXCR4 Clone 1D9 Relative Mean Fluorescent Intensity
NCT01133158 (2) [back to overview]	Secondary Endpoints Included an Assessment of the Following Parameters: Progression-Free Survival, Disease-Free Survival, Global Survival, Duration of the Response.
NCT01133158 (2) [back to overview]	Response Rate
NCT01144403 (4) [back to overview]	Number of Participant With Adverse Event (AE)
NCT01144403 (4) [back to overview]	Overall Response Rate (ORR)
NCT01144403 (4) [back to overview]	Overall Survival (OS)
NCT01144403 (4) [back to overview]	Progression-free Survival (PFS)
NCT01184898 (4) [back to overview]	Complete Response in the Absence of Platelet Recovery
NCT01184898 (4) [back to overview]	Association Between the Magnitude of mTOR Target Inhibition Post-treatment in Leukemic Blasts and Clinical Response in Patients With High Risk AML Treated With Sirolimus MEC
NCT01184898 (4) [back to overview]	Partial Response
NCT01184898 (4) [back to overview]	Complete Response
NCT01204710 (11) [back to overview]	PFS Based on Baseline Circulating Tumor Cells (CTC) Counts
NCT01204710 (11) [back to overview]	Percentage of Participants With Anti-Olaratumab Antibody Assessment (Immunogenicity)
NCT01204710 (11) [back to overview]	Percentage of Participants With a ≥50% Decrease in Prostate Specific Androgen (PSA) From Pretreatment to Any Time
NCT01204710 (11) [back to overview]	Summary Listing of Participants Reporting Treatment-Emergent Adverse Events (TEAE)
NCT01204710 (11) [back to overview]	Percentage of Participants Who Achieved a Best Overall Response of Complete Response (CR) or Partial Response (PR) [Objective Response Rate (ORR)]
NCT01204710 (11) [back to overview]	Overall Survival (OS)
NCT01204710 (11) [back to overview]	OS Based on Baseline CTC Counts
NCT01204710 (11) [back to overview]	Percentage of Participants With a ≥30% Decrease in PSA From Pretreatment to Week 12
NCT01204710 (11) [back to overview]	Progression-Free Survival (PFS)
NCT01204710 (11) [back to overview]	Number of Participants Who Died During Study
NCT01204710 (11) [back to overview]	Number of Participants With Negative Platelet-Derived Growth Factor Receptor Alpha (PDGFRα) Protein Expression by Immunohistochemistry (IHC)
NCT01214317 (2) [back to overview]	Expanded Disability Status Score
NCT01214317 (2) [back to overview]	Change From Baseline in Mean Number of MS Plaques Found on Brain MRI
NCT01342887 (1) [back to overview]	Maximum Tolerated Doses Mitoxantrone Hydrochloride and Etoposide When Combined With Cyclosporine and Pravastatin Sodium
NCT01349972 (6) [back to overview]	Complete Response Rate
NCT01349972 (6) [back to overview]	Progression-free Survival
NCT01349972 (6) [back to overview]	Overall Survival
NCT01349972 (6) [back to overview]	Disease-free Survival
NCT01349972 (6) [back to overview]	Incidence of Toxicities, Characterized by Number of Events by Treatment and Grade
NCT01349972 (6) [back to overview]	Number of Patients With Minimal Residual Disease
NCT01371981 (18) [back to overview]	Sorafenib Steady State Concentration
NCT01371981 (18) [back to overview]	Total Scale Score From Parent-reported Cancer Module
NCT01371981 (18) [back to overview]	OS for Patients on Arm C, Cohort 2
NCT01371981 (18) [back to overview]	Total Scale Score From Parent-reported Multidimensional Fatigue Scale Module
NCT01371981 (18) [back to overview]	EFS for Patients on Arm C, Cohort 2
NCT01371981 (18) [back to overview]	EFS for Patients on Arm C, Cohort 1
NCT01371981 (18) [back to overview]	OS for Patients on Arm C, Cohort 1
NCT01371981 (18) [back to overview]	Change in Shortening Fraction
NCT01371981 (18) [back to overview]	Change in Ejection Fraction
NCT01371981 (18) [back to overview]	OS for Patients on Arm C, Cohort 3
NCT01371981 (18) [back to overview]	Proportion of High Risk Children Without HR FLT3/ITD+ Converting From Positive MRD at End of Induction I to Negative MRD at the End of Induction II
NCT01371981 (18) [back to overview]	Total Scale Score From Parent-reported Pediatric Quality of Life Inventory Module
NCT01371981 (18) [back to overview]	Bortezomib Clearance
NCT01371981 (18) [back to overview]	Overall Survival (OS) for Patients Without High Allelic Ratio FLT3/ITD+ Mutations
NCT01371981 (18) [back to overview]	Event-free Survival (EFS) for Patients Without High Allelic Ratio FLT3/ITD+ Mutations
NCT01371981 (18) [back to overview]	EFS for Patients on Arm C, Cohort 3
NCT01371981 (18) [back to overview]	Proportion of Patients Experiencing Grade 3 or Higher Non-hematologic Toxicities and Infections While on Protocol Therapy
NCT01371981 (18) [back to overview]	Relapse Rate for Patients Without High Allelic Ratio FLT3/ITD+ Mutations
NCT01483690 (2) [back to overview]	Disease Response Rate After Treatment.
NCT01483690 (2) [back to overview]	Number of Participants Who Experienced a Dose Limiting Toxicity (DLT).
NCT01522443 (3) [back to overview]	Pain Response at Week 6 Confirmed at Week 12, Week 12 Reported
NCT01522443 (3) [back to overview]	Bone Scan Response (BSR)
NCT01522443 (3) [back to overview]	Overall Survival (OS)
NCT01564784 (12) [back to overview]	Duration of Remission (DoR) for Participants Who Achieved CR/CRi (Per Investigator Assessment)
NCT01564784 (12) [back to overview]	Cytogenetic Status (Based on Local Laboratory Analysis) of Participants With CR/CRi (Per EAC Assessment)
NCT01564784 (12) [back to overview]	Overall Survival (OS)
NCT01564784 (12) [back to overview]	Maximum Observed Inotuzumab Ozogamicin Serum Concentration (Cmax) and Pre-Dose Inotuzumab Ozogamicin Serum Concentration (Ctrough) Following Single and Multiple Dosing
NCT01564784 (12) [back to overview]	Change From Baseline in EuroQol 5 Dimension Health Questionnaire (EQ-5D) Index Score
NCT01564784 (12) [back to overview]	Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire, Core 30 (EORTC QLQ-C30) Score
NCT01564784 (12) [back to overview]	Change From Baseline in EQ-5D VAS
NCT01564784 (12) [back to overview]	Progression-Free Survival (PFS)
NCT01564784 (12) [back to overview]	Percentage of Participants With Veno-Occlusive Liver Disease (VOD)/Sinusoidal Obstruction Syndrome (SOS) Following Post Study HSCT
NCT01564784 (12) [back to overview]	Percentage of Participants With Hematologic Remission (Complete Remission [CR]/Complete Remission With Incomplete Hematologic Recovery [CRi]) as Assessed by the Endpoint Adjudication Committee (EAC)
NCT01564784 (12) [back to overview]	Percentage of Participants Who Had a Hematopoietic Stem-Cell Transplant (HSCT)
NCT01564784 (12) [back to overview]	Percentage of Participants Achieving MRD Negativity (Based on Central Laboratory Analysis) in Participants Achieving a CR/CRi (Per EAC Assessment)
NCT01700946 (4) [back to overview]	3-year Overall Survival Rate of Patients With Relapsed ALL
NCT01700946 (4) [back to overview]	Median CD20 Expression Levels
NCT01700946 (4) [back to overview]	Mean of CD20 Expression Levels
NCT01700946 (4) [back to overview]	3-year Event-free Survival Rates in Patients With Relapsed ALL
NCT01729845 (4) [back to overview]	Remission Rate Including CR and CRp
NCT01729845 (4) [back to overview]	Duration of Relapse-free Survival (for Patients Achieving CR or CRp)
NCT01729845 (4) [back to overview]	Overall Survival
NCT01729845 (4) [back to overview]	Most Efficacious and Tolerated Dosage of Decitabine (Period 1)
NCT02044796 (4) [back to overview]	Minimal Residual Disease Negative Complete Remission Rate in Patients With Newly Diagnosed Disease (Phase II)
NCT02044796 (4) [back to overview]	Number of Participants With Dose Limiting Toxicities of Mitoxantrone (Phase I, Dose Level 4)
NCT02044796 (4) [back to overview]	Remission Rate (Complete Remission and Complete Remission With Incomplete Platelet Count Recovery) of This Regimen in Patients With Relapsed/Refractory Disease (Phase II)
NCT02044796 (4) [back to overview]	Overall Survival (Phase II)
NCT02101853 (4) [back to overview]	Disease Free Survival (DFS) of Low Risk (LR) Relapse Patients
NCT02101853 (4) [back to overview]	Disease Free Survival (DFS) of High-risk (HR) and Intermediate-risk (IR) Relapse Patients
NCT02101853 (4) [back to overview]	Overall Survival (OS) of HR and IR Relapse Patients
NCT02101853 (4) [back to overview]	Overall Survival (OS) of LR Relapse Patients
NCT02339740 (2) [back to overview]	EFS in High Risk APL Patients
NCT02339740 (2) [back to overview]	Event-free Survival (EFS) in Standard Risk Acute Promyelocytic Leukemia (APL) Patients
NCT02419755 (1) [back to overview]	Number of Relevant Toxicities Related to Therapy
NCT02421939 (12) [back to overview]	Duration of Overall Survival (OS)
NCT02421939 (12) [back to overview]	Percentage of Participants Who Achieved Transfusion Conversion and Maintenance
NCT02421939 (12) [back to overview]	Change From Baseline in Brief Fatigue Inventory (BFI)
NCT02421939 (12) [back to overview]	Percentage of Participants With Composite Complete Remission (CRc Rate)
NCT02421939 (12) [back to overview]	Percentage of Participants With Complete Remission (CR) With Partial Hematological Recovery (CRh)
NCT02421939 (12) [back to overview]	Percentage of Participants With Complete Remission (CR) Rate
NCT02421939 (12) [back to overview]	Duration of Event-Free Survival (EFS)
NCT02421939 (12) [back to overview]	Percentage of Participants Who Underwent Hematopoietic Stem Cell Transplant
NCT02421939 (12) [back to overview]	Duration of Remission
NCT02421939 (12) [back to overview]	Number of Participants With Adverse Events
NCT02421939 (12) [back to overview]	Percentage of Participants With Complete Remission and Complete Remission With Partial Hematological Recovery (CR/CRh) in the Gilteritinib Arm
NCT02421939 (12) [back to overview]	Duration of Leukemia-Free Survival (LFS)
NCT02520011 (2) [back to overview]	Complete Response (CR) Rate in Patients With Relapsed or Refractory AML
NCT02520011 (2) [back to overview]	Response to Treatment
NCT02535806 (4) [back to overview]	2-year Overall Survival Seen With Using Bortezomib in Combination With the ALL R3 Re-induction Regimen in Pediatric Patients With Relapsed or Refractory ALL or LL.
NCT02535806 (4) [back to overview]	Post-induction Level of Minimal Residual Disease Seen With Using Bortezomib in Combination With the ALL R3 Re-induction Regimen in Pediatric Patients With Relapsed or Refractory ALL or LL.
NCT02535806 (4) [back to overview]	Remission Rate Seen With Using Bortezomib in Combination With the ALL R3 Re-induction Regimen in Pediatric Patients With Relapsed or Refractory ALL or LL.
NCT02535806 (4) [back to overview]	Number of Subject With Adverse Events
NCT02553460 (1) [back to overview]	Percentage of Treatment-related Mortality (TRM)
NCT02626338 (1) [back to overview]	Clinical Response to Crenolanib With Standard Salvage Chemotherapy
NCT02728050 (8) [back to overview]	Overall Response Rate (ORR)
NCT02728050 (8) [back to overview]	Overall Survival (OS)
NCT02728050 (8) [back to overview]	Phase 1: Maximum Tolerated Dose (MTD)/Recommended Phase 2 Dose (RP2D) of Mitoxantrone
NCT02728050 (8) [back to overview]	Phase 1: Maximum Tolerated Dose (MTD)/Recommended Phase 2 Dose (RP2D) of Sorafenib
NCT02728050 (8) [back to overview]	Phase I and II: Rate of Minimal Residual Disease Negative (MRDneg) Complete Response (CR)
NCT02728050 (8) [back to overview]	Relapse-free Survival (RFS)
NCT02728050 (8) [back to overview]	Number of Participants With Adverse Events
NCT02728050 (8) [back to overview]	Event-free Survival (EFS)
NCT02756572 (19) [back to overview]	Feasibility of Early Allogeneic Hematopoietic Cell Transplant Assessed by Relapsed-free Survival 6 Months After Transplant
NCT02756572 (19) [back to overview]	Overall Survival (OS) Among Patients Who Received Early Transplant.
NCT02756572 (19) [back to overview]	Overall Survival (OS) Among Patients Who Did Not Receive Early Transplant
NCT02756572 (19) [back to overview]	Overall Survival (OS) Among Patients Who Did Not Receive Early Transplant
NCT02756572 (19) [back to overview]	Factors That Distinguish Patients Who Received Early Transplant From Those Who Did Not - TREATMENT RELATED MORTALITY
NCT02756572 (19) [back to overview]	Factors That Distinguish Patients Who Received Early Transplant From Those Who Did Not - AGE
NCT02756572 (19) [back to overview]	Event-free Survival (EFS) Among Patients Who Received Early Transplant
NCT02756572 (19) [back to overview]	Demonstrate the Feasibility of Collecting Resource Utilization Data for Trial Participants
NCT02756572 (19) [back to overview]	Response Assessments After Early Allogeneic Hematopoietic Cell Transplant, Day 84
NCT02756572 (19) [back to overview]	Response Assessments After Early Allogeneic Hematopoietic Cell Transplant, Day 28
NCT02756572 (19) [back to overview]	Overall Survival (OS) Among Patients Who Received Early Transplant.
NCT02756572 (19) [back to overview]	Relapse-free Survival (RFS) Among Patients Who Received Early Transplant
NCT02756572 (19) [back to overview]	Feasibility of Early Allogeneic Hematopoietic Cell Transplant Assessed by Enrollment and Incidence of Early Transplant
NCT02756572 (19) [back to overview]	Factors That Distinguish Patients Who Received Early Transplant From Those Who Did Not - GENDER
NCT02756572 (19) [back to overview]	Demonstrate the Feasibility of Collecting Patient-reported Outcomes for Trial Participants
NCT02756572 (19) [back to overview]	Treatment Related Mortality Among Patients Who Received Early Transplant vs Patients Who Did Not Receive Early Transplant
NCT02756572 (19) [back to overview]	Relapse-free Survival (RFS) Among Patients Who Received Early Transplant
NCT02756572 (19) [back to overview]	Event-free Survival (EFS) Among Patients Who Received Early Transplant
NCT02756572 (19) [back to overview]	Acute Graft Versus Host Disease Among Patients Who Received Early Transplant
NCT02921061 (6) [back to overview]	Number of Participants With Event-free Survival
NCT02921061 (6) [back to overview]	Number of Participants Who Achieved Remission (Complete Remission [CR]/CR With Incomplete Peripheral Blood Count Recovery [CRi])
NCT02921061 (6) [back to overview]	Number of Participants Experiencing Dose Limiting Toxicities (DLTs) at the Maximum Tolerated Dose (MTD) for Decitabine When Given Together With G-CLAM Toxicities (DLTs) (Phase I)
NCT02921061 (6) [back to overview]	Number of Participants With Relapse-free Survival
NCT02921061 (6) [back to overview]	Number of Participants With Overall Survival
NCT02921061 (6) [back to overview]	Number of Participants With Minimal Residual Disease Negative (MRDneg) Complete Remission (Phase II)
NCT03118466 (6) [back to overview]	Number of Patients That Achieved ANC Recovery
NCT03118466 (6) [back to overview]	Number of Patients That Achieved Platelet Recovery
NCT03118466 (6) [back to overview]	Overall Survival
NCT03118466 (6) [back to overview]	Treatment-related Mortality
NCT03118466 (6) [back to overview]	Transfusion Support: Number of Red Blood Cell and Platelet Transfusions
NCT03118466 (6) [back to overview]	Complete Response Rate
NCT03504410 (1) [back to overview]	Complete Remission (CR)
NCT03531918 (10) [back to overview]	Measurable Residual Disease (MRD) and Remission Rates: Alapasia (MRDneg)
NCT03531918 (10) [back to overview]	Measurable Residual Disease (MRD) and Remission Rates: CRi (MRDneg)
NCT03531918 (10) [back to overview]	Measurable Residual Disease (MRD) and Remission Rates: MLFS (MRDneg)
NCT03531918 (10) [back to overview]	Overall Survival
NCT03531918 (10) [back to overview]	Relapse-free Survival of GO3 Cohort
NCT03531918 (10) [back to overview]	Event-free Survival (EFS) Rate (Phase 2)
NCT03531918 (10) [back to overview]	Measurable Residual Disease (MRD) Rates and Remission Rates: CR
NCT03531918 (10) [back to overview]	Maximum Tolerated Dose (MTD) of Gemtuzumab Ozogamicin (GO) When Added to GCLAM (Phase 1)
NCT03531918 (10) [back to overview]	30-day All-cause Mortality
NCT03531918 (10) [back to overview]	Measurable Residual Disease (MRD) and Remission Rates: CR/CRi
NCT03860844 (13) [back to overview]	Number of Participants With Infusion Reactions (IRs)
NCT03860844 (13) [back to overview]	Overall Response Rate (ORR)
NCT03860844 (13) [back to overview]	Percentage of Participants With Complete Response (CR) Rate
NCT03860844 (13) [back to overview]	AML: AUC of Isatuximab
NCT03860844 (13) [back to overview]	AML: Ceoi of Isatuximab
NCT03860844 (13) [back to overview]	AML: Plasma Concentration Reached by Isatuximab Before Next Dose Administration (Ctrough)
NCT03860844 (13) [back to overview]	B-ALL and T-ALL: Area Under the Concentration Time Curve (AUC) of Isatuximab
NCT03860844 (13) [back to overview]	B-ALL and T-ALL: Concentrations at the End of Infusion (Ceoi) of Isatuximab
NCT03860844 (13) [back to overview]	B-ALL and T-ALL: Plasma Concentration Reached by Isatuximab Before Next Dose Administration (Ctrough)
NCT03860844 (13) [back to overview]	CD38 Receptor Occupancy
NCT03860844 (13) [back to overview]	CD38 Receptor Occupancy
NCT03860844 (13) [back to overview]	Cluster of Differentiation (CD)38 Receptor Density
NCT03860844 (13) [back to overview]	Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs)

Complete Remission (CR)

complete remission (CR) Disappearance of all clinical evidence of leukemia for a minimum of four weeks. The patient should have a neutrophil count > 1,000 x 10^6/1, a platelet count > 100,000 x 10^9/1, no circulating blasts, and < than or = to blasts on bone marrow differential in a qualitatively normal or hypercellular marrow. Progressive disease or failure: Increasing bone marrow infiltrate or development of organ failure or extramedullary infiltrates due to leukemia. (NCT00002766)
Timeframe: 2 years

Intervention	participants (Number)
	Complete Remission	Complete Response (CR)	Failure	Failure-Progression	Relapse
All-2	50	14	5	8	1
L-20	50	11	14	10	0

Intervention	Participants (Number)
	Abdominal pain/cramping	Abscess	Alkaline phosphatase increase	Allergic reaction	Allergic rhinitis	Alopecia	Anal incontinence	Anemia	Anorexia	Anxiety/agitation	Apnea	Arrhythmia, NOS	Arthralgia	Arthritis	Ataxia (incoordination)	Bilirubin increase	Blurred vision	Bone pain	Bruising	CPK increase	Cardiac ischemia/infarction	Cardiovascular-other	Cataract	Cerebrovascular ischemia	Chest pain,not cardio or pleur	Conduction abnormality/block	Confusion	Conjunctivitis	Constipation/bowel obstruction	Cough	Creatinine increase	Cushingoid appearance	Dehydration	Depression	Diarrhea without colostomy	Dizziness/light headedness	Dry eye	Dry skin	Dysmenorrhea	Dyspepsia/heartburn	Dyspnea	Dysuria	Ear-other	Edema	Endocrine-other	Epistaxis	Erectile impotence	Eryth/rash/eruption/desq, NOS	Esophagitis/dysphagia	Eye-other	Fatigue/malaise/lethargy	Febrile neutropenia	Feminization of male	Fever without neutropenia	Fever, NOS	Flatulence	Flu-like symptoms-other	Flushing	GGT increase	GI Mucositis, NOS	GI-other	GU-other	Gastritis	Gastritis/ulcer, NOS	Glaucoma	Gynecomastia	Headache	Hematologic-other	Hematuria	Hemolysis	Hemoptysis	Hemorrhage-other	Hiccoughs	Hot flashes	Hypercalcemia	Hypercholesterolemia	Hyperglycemia	Hyperkalemia	Hypermagnesemia	Hypernatremia	Hypertension	Hypertriglyceridemia	Hypoalbuminemia	Hypocalcemia	Hypoglycemia	Hypokalemia	Hypomagnesemia	Hyponatremia	Hypotension	Hypothyroidism	Hypoxia	Incontinence	Infection w/o 3-4 neutropenia	Infection with 3-4 neutropenia	Infection, unk ANC	Inner ear-hearing loss	Insomnia	Invol. movement/restlessness	Joint,muscle,bone-other	LVEF decrease/CHF	Leukopenia	Libido loss	Local injection site reaction	Lung-other	Lymphopenia	Male infertility	Melena/ GI bleeding	Memory loss	Metabolic-other	Middle ear-hearing loss/otitis	Mood/consciousness change, NOS	Mouth dryness	Muscle weakness (not neuro)	Myalgia	Myalgia/arthralgia, NOS	Myocarditis	Nail changes	Nausea	Neuro-other	Neuropathic pain	Neutropenia/granulocytopenia	PRBC transfusion	Pain-other	Palpitations	Pelvic pain	Pericar. effusion/pericarditis	Personality/behavioral change	Phlebitis	Pigmentation changes/yellowing	Pleural effusions	Pneumonitis/infiltrates	Proctitis	Proteinuria	Pruritus	RT-GI mucositis, NOS	RT-focal dermatitis, NOS	RT-late bladder morbidity	RT-late intestinal morbidity	RT-pain	Rash/desquamation	Rectal bleeding/hematochezia	Rectal/perirectal pain	Respiratory infect w/o neutrop	Respiratory infection, unk ANC	Rigors/chills	SGOT (AST) increase	SGPT (ALT) increase	Salivary change, NOS	Second primary	Seizures	Sensory neuropathy	Sexual/reproductive-other	Sinus bradycardia	Skin-other	Speech impairment	Stomatitis/pharyngitis	Supraventricular arrhythmia	Surgery-wound infection	Sweating	Syncope	Taste disturbance	Tearing	Thrombocytopenia	Thrombosis/embolism	Tremor	Troponin T (cTnT) increase	Urinary frequency/urgency	Urinary retention	Urinary tr infect w/ neutrop	Urinary tr infect w/o neutrop	Urinary tr infection, unk ANC	Urine color change	Urticaria	Ventricular arrhythmia	Vertigo	Vision,NOS	Voice change/stridor/larynx	Vomiting	Weakness (motor neuropathy)	Weight gain	Weight loss
Arm I: Bicalutamide + Goserelin	19	0	11	1	2	91	2	52	7	52	1	0	43	17	1	5	3	19	1	0	1	0	5	1	11	1	6	0	57	10	7	0	0	80	55	33	1	11	0	7	21	14	0	40	3	0	181	0	2	1	258	0	1	0	1	2	2	5	1	0	12	9	2	0	2	140	37	1	9	0	0	1	0	439	4	5	44	0	0	0	38	2	1	1	0	8	1	3	3	2	0	88	5	0	1	3	79	2	11	0	14	163	11	0	4	2	0	15	0	0	2	10	55	26	1	0	4	26	5	0	11	0	112	1	9	0	12	0	0	0	0	4	3	13	0	3	1	2	1	46	12	7	1	1	7	42	22	0	0	1	37	2	0	11	0	5	0	0	138	0	1	0	3	2	0	0	86	13	0	1	3	3	3	1	1	0	0	10	3	179	12
Arm II: Mitoxantrone + Prednisone + Bivalutamid + Goserelin	41	1	11	5	16	131	2	141	41	62	1	1	64	17	1	20	6	34	14	2	1	5	6	0	19	0	14	4	117	34	17	8	6	85	75	71	5	28	1	44	49	11	2	56	2	2	146	2	13	6	357	2	0	9	6	3	6	4	0	10	20	9	0	1	0	100	82	1	13	1	1	4	4	422	5	2	78	4	1	4	38	0	6	7	1	11	1	2	11	0	4	71	10	2	4	2	92	2	27	8	317	133	17	2	49	3	2	12	1	1	3	13	77	45	12	1	57	205	4	1	239	3	127	6	11	1	11	5	3	1	1	4	1	23	1	1	0	1	0	63	10	5	7	8	24	42	26	1	6	1	57	1	4	11	1	49	2	1	129	3	46	6	35	5	2	1	101	7	1	2	2	44	4	0	1	1	6	51	6	151	29

Intervention	Participants with a given type of AE (Number)
	ALT, SGPT (serum glutamic pyruvic transaminase)	AST, SGOT (serum glut oxaloacetic transaminase)	Albumin, serum-low (hypoalbuminemia)	Alkaline phosphatase	Anorexia	Ascites (non-malignant)	Bilirubin (hyperbilirubinemia)	Calcium, serum-low (hypocalcemia)	Cholecystitis	Cholesterol, serum-high (hypercholesterolemia)	Coagulation-Other (Specify)	Colitis, infectious (e.g., Clostridium difficile)	Constipation	DIC (disseminated intravascular coagulation)	Death not assoc with CTCAE term-Multi-organ fail	Edema: limb	Fatigue (asthenia, lethargy, malaise)	Febrile neutropenia	Fever (in the abs of neutropenia)	Fibrinogen	Glucose, serum-high (hyperglycemia)	Glucose, serum-low (hypoglycemia)	Hemoglobin	Hypertension	Hypotension	Hypoxia	Ileus, GI (functional obstruction of bowel)	Infec(doc clin or mibio) w/ Gr 3/4 neut-Anal	Infec(doc clin or mibio) w/ Gr 3/4 neut-Bladder	Infec(doc clin or mibio) w/ Gr 3/4 neut-Blood	Infec(doc clin or mibio) w/ Gr 3/4 neut-Bronchus	IInfec(doc clin or mibio) w/ Gr 3/4 neut-Catheter	Infec(doc clin or mibio) w/ Gr 3/4 neut-Eye NOS	Infec(doc clin or mibio) w/ Gr 3/4 neut-Lung	Infec(doc clin or mibio) w/ Gr 3/4 neut-Nose	Infec(doc clin or mibio) w/ Gr 3/4 neut-Pharynx	Infec(doc clin or mibio) w/ Gr 3/4 neut-Ur tract	Infec with nor ANC or Gr 1/2 neut-Lung (pneumonia)	Infection-Other (Specify)	Leukocytes (total WBC)	Lipase	Liver dysfunction/failure (clinical)	Lymphopenia	Magnesium, serum-high (hypermagnesemia)	Mucositis/stomatitis (clinical exam) - Oral cavity	Mucositis/stomatitis (funct/symp) - Oral cavity	Mucositis/stomatitis (func/symp) - Pharynx	Muscle weak,gen spec area-Whole body	Nausea	Neuropathy: motor	Neutrophils/granulocytes (ANC/AGC)	Pain - Abdomen NOS	Pain - Bone	Pain - Neck	Pancreatic endocrine: glucose intolerance	Pancreatitis	Phosphate, serum-low (hypophosphatemia)	Platelets	Potassium, serum-high (hyperkalemia)	Potassium, serum-low (hypokalemia)	Rash/desquamation	Renal failure	Sodium, serum-low (hyponatremia)	Thrombosis/thrombus/embolism	Thrombotic microangiopathy	Triglyceride, serum-high (hypertriglyceridemia)	Tumor lysis syndrome	Typhlitis (cecal inflammation)	Uric acid, serum-high (hyperuricemia)	Vomiting
Induction	17	13	3	2	2	1	6	7	1	2	1	1	1	2	1	1	3	18	1	11	16	1	33	2	3	2	1	1	1	11	1	1	1	1	1	1	2	2	1	43	1	2	19	1	2	1	1	2	3	1	47	1	1	1	1	1	1	44	1	7	1	2	6	1	2	1	5	1	1	1

Intervention	Participants (Number)
	Experienced Grade 3 or 4 toxicities	Did not experience Grade 3 or 4 toxicities
Overall	27	3

Intervention	Participants (Count of Participants)
	Negative <0.01%	Positive ≥0.01%
High Risk	2	10
Standard Risk	11	11
TOTXV Participants	191	297

Intervention	proportion of participants (Number)
	Complete remission	Failure to reach complete remission
High Risk	0.786	0.214
Standard Risk	0.846	0.154

Intervention	participants (Number)
	Complete Response	Partial Response	Stable Disease
Chronic Lymphocytic Leukemia	4	2	1
Non Hodgkin Lymphoma	5	2	0

Intervention	participants (Number)
	Patients dead >30 days post-tx, no relapse	Patients alive with no evidence of disease relapse	Patient death on Day 1 of Protocol Therapy	Patients dead >30 days post-tx, after relapse
Gemcitabine + Mitoxantrone	1	4	1	18

Intervention	percentage of participants (Number)
	Participants with GSTP1 Gene Expression	Participants with SLC29A2 Gene Expression	Participants with MRP1 Gene Expression	Participants with LRP1 Gene Expression	Participants with MDR1 Gene Expression
Gemcitabine + Mitoxantrone	70	55	43	35	22

Intervention	Participants (Count of Participants)
	Complete Response (CR)	Progressive Disease
R-FIND + Zevalin	37	1

Intervention	Participants (Count of Participants)
	Complete Response (CR)	Progression Disease (PD)
R-FIND + Zevalin	38	3

Intervention	Participants (Count of Participants)
	Complete Response (CR)	Partial Response (PR)
R-FIND + Zevalin	42	4

Intervention	percentage of participants (Number)
	Percent of Subjects with Serious Adverse Events	Percent of Subjects with Grade 5 Adverse Events	Percent of Subjects with Grade 4 Adverse Events	Percent of Subjects with Grade 3 Adverse Events	Percent of Subjects with Grade 2 Adverse Events	Percent of Subjects with Grade 1 Adverse Events	Percent of Subjects who Discontinued Study Drug
OGX-011 + Docetaxel + Prednisone	26	4	15	52	98	100	17
OGX-011 + Mitoxantrone + Prednisone	26	13	26	70	83	100	22

Intervention	percentage of participants (Number)
OGX-011 / Mitoxantrone/Prednisone	17
OGX-011 / Docetaxel/Prednisone	31

Intervention	percentage of participants (Number)
	Minimum clusterin level < or = to 45 mcg/mL	Minimum clusterin level > 45 mcg/mL
OGX-011 + Docetaxel + Prednisone	24	7
OGX-011 + Mitoxantrone + Prednisone	22	4

Intervention	Participants (Count of Participants)
Phase I Group I	0
Phase Group II	0
Phase I Group III	0
Phase I Group IV	1
Phase I Group V	2
Phase I Group VI	2
Phase I Group Va	0
Phase I Group VIa	1

Intervention	percentage of participants (Number)
Arm A: Standard Arm - No GMTZ, AML Pts w/Out Down Syndrome	46.9
Arm B: Experimental - With GMTZ, AML Pts w/Out Down Syndrome	53.1
Arm A: Standard Arm - No GMTZ, AML Patients With Down Syndrome	50.0

Intervention	percentage of participants (Number)
Arm A: Standard Arm - No GMTZ, AML Pts w/Out Down Syndrome	65.4
Arm B: Experimental - With GMTZ, AML Pts w/Out Down Syndrome	69.4
Arm A: Standard Arm - No GMTZ, AML Patients With Down Syndrome	50.0

Intervention	Proportion of participants (Number)
Arm A: Standard Arm - No GMTZ, AML Pts w/Out Down Syndrome	0.851324
Arm B: Experimental - With GMTZ, AML Pts w/Out Down Syndrome	0.882716
Arm A: Standard Arm - No GMTZ, AML Patients With Down Syndrome	0.666667

Intervention	Mean days (Mean)
	During Induction I (days 0 - 28 of therapy)	During Induction II (days 29 - 56 of therapy)	During Intensification I (days 57 - 84 of therapy)
Arm A: Standard Arm - No GMTZ, AML Patients With Down Syndrome	29.17	26.6	24.5
Arm A: Standard Arm - No GMTZ, AML Pts w/Out Down Syndrome	30.56	28.54	27.51
Arm B: Experimental - With GMTZ, AML Pts w/Out Down Syndrome	30.56	28.52	28.10

Intervention	Percentage participants DFS at 3 years (Number)
Arm A: Standard Arm - No GMTZ, AML Pts w/Out Down Syndrome	56.6
Arm B: Experimental - With GMTZ, AML Pts w/Out Down Syndrome	63.0
Arm A: Standard Arm - No GMTZ, AML Patients With Down Syndrome	75.0

mitoxantrone

Description

Cross-References

Synonyms (166)

Research Excerpts

Overview

Effects

Actions

Treatment

Toxicity

Pharmacokinetics

Compound-Compound Interactions

Bioavailability

Dosage Studied

Roles (2)

Drug Classes (1)

Protein Targets (147)

Potency Measurements

Inhibition Measurements

Activation Measurements

Other Measurements

Biological Processes (663)

Molecular Functions (193)

Ceullar Components (144)

Bioassays (933)

Research

Studies (4,303)

Market Indicators

Research Demand Index: 61.03

Study Types

Clinical Trials (312)

Trial Overview

Trial Outcomes

Complete Remission (CR)

Compare Qualitative and Quantitative Toxicities of These Regimens in These Patients

Disease Free Survival

Overall Survival

Number of Participants With 5-year Freedom From Prostate Specific Antigen (PSA) Recurrence.

Continuous Complete Remission at 1 Year

Toxicity

Relationship of Inhibition of DNA Synthesis and Clinical Response

To Assess Whether Inhibition of DNA Synthesis is Greater After High-dose Ara-C (HDAC) Than After Low-dose Ara-C (LDAC) Therapy

Minimal Residual Disease (MRD).

Proportion of Minimal Residual Disease (MRD)+ Patients Who Become MRD- After One Course of Gemtuzumab Ozogamicin (GO)

To Estimate the Overall Event-free Survival (EFS) of AML Patients Who Undergo Risk-adapted and Genotype-directed Therapy

Proportion of MRD Reduction After One Course of Cytarabine + Daunomycin + Etoposide (ADE) + GO

Proportion of Patients Experienced Toxicity of Cytarabine + Daunomycin + Etoposide (ADE) + GO.

Overall Survival (OS)

Minimal Residual Disease (MRD) Compared With Historical Data From TOTXV Protocol (NCT00137111)

Minimal Residual Disease (MRD) Compared With Historical Data From TOTXV Protocol (NCT00137111)

Response Rate

Overall Response Rate (ORR), the Percentage of Patients Who Experience an Objective Benefit From Treatment

Number of Patients's Who Had Complete Response and Partial Response to the Treatment of Fludarabine and Cyclophosphamide Followed by GM-CSF and Rituximab.

Molecular Response Rate at 3 Months

Clinical Response Rate at 6 Months

Clinical Response Rate at 3 Months

Molecular Response Rate at 6 Months

Complete Response Rate

White Blood Cell Count at Time of Relapse

Disease-free and Overall Survival

Laboratory Correlates: Immunohistochemistry

Duration of the First Complete Response

Percentage of Patients Making it to Bone Marrow Transplant.

Tolerance and Efficacy of Maintenance Therapy With Yttrium-90 Ibritumomab Tiuxetan (YIT)

Tolerance and Efficacy of Maintenance Therapy With Rituximab

Number of Participants With Time to Progression (TTP)

Progression Free Survival at 10 Years

Percentage of Participants With Overall Survival Rate at 10 Years

Median Progression Free Survival

Overall Survival

Safety and Tolerability of Custirsen (OGX-011) in Combination With Either Docetaxel/Prednisone or Mitoxantrone/Prednisone as Second-line Chemotherapy.

Feasibility of Treatment With Custirsen (OGX-011) in Combination With Second-line Chemotherapy Based on Prostate Specific Antigen (PSA) Response

Feasibility of Treatment With OGX-011 in Combination With Either Docetaxel/Prednisone or Mitoxantrone/Prednisone as Second Line Chemotherapy Based on Time to Pain Progression

Relationship Between Changes in Serum Clusterin Levels and Change in Serum PSA Levels When OGX-011 in Combination With Either Docetaxel/Prednisone or Mitoxantrone/Prednisone is Administered as Second Line Chemotherapy.

Proportion Responding to Treatment With of the Combination of Ixabepilone and Mitoxantrone Hydrochloride With Prednisone in Hormone Refractory Prostate Cancer Patients Who Have Had Prior Taxane Chemotherapy Based Upon a PSA Decline of > 50% (Phase II)

Dose Limiting Toxicities for Each Dose Level of Ixabepilone, Mitoxantrone Hydrochloride, and Prednisone in Patients With Hormone-refractory Metastatic Prostate Cancer That Progressed During or After Taxane-based Chemotherapy (Phase I).

Time to Progression (Phase II)

Safety of the Combination of Ixabepilone, Mitoxantrone Hydrochloride, and Prednisone in Patients With Hormone-refractory Metastatic Prostate Cancer That Progressed During or After Taxane-based Chemotherapy (Phase I)

Event-free Survival at 3 Years

Mortality

Intervention	days (Median)
Part 1: Mitoxantrone + Prednisone + Siltuximab	368.0
Part 2: Mitoxantrone + Prednisone	394.0
Part 2: Mitoxantrone + Prednisone + Siltuximab	311.0

Intervention	days (Median)
Part 1: Mitoxantrone + Prednisone + Siltuximab	199.0
Part 2: Mitoxantrone + Prednisone	298.0
Part 2: Mitoxantrone + Prednisone + Siltuximab	183.0

Intervention	days (Median)
Part 2: Mitoxantrone + Prednisone	228.0
Part 2: Mitoxantrone + Prednisone + Siltuximab	97.0

Intervention	Participants (Count of Participants)
Phase 1 - Bortezomib 0.7mg/m^2	0
Phase 1 - Bortezomib 1.0 mg/m^2	0
Phase 1 - Bortezomib 1.3mg/m^2	0

Intervention	units on a scale (Mean)
	Baseline	Cycle 1	Cycle 2	Cycle 3	Cycle 4	Cycle 5	Cycle 6	Cycle 7	Cycle 8	Cycle 9	Cycle 10	Cycle 11	Cycle 12	Cycle 13	End of Study (at treatment discontinuation)
Treatment Group: Mitoxantrone, Prednisone, Plus Sorafenib	50.21	49.71	51.06	51.20	51.66	51.22	49.73	49.50	48.20	54.34	55.88	54.95	54.02	54.65	45.13

Intervention	Participants (Number)
	PSA response (> 50% reduction)	PSA response (< or = 50% reduction)
Imaging Response (Favorable)	3	6
Imaging Response (Unfavorable)	0	13

Intervention	participants (Number)
	Persistent leukemia	Death during aplasia	Unknown
>= Second Relapse/Salvage	3	0	0
First Relapse, First Salvage	12	1	1
Primary Refractory	6	2	0
Total	21	3	1

Intervention	participants (Number)
	Sepsis	Adverse transfusion reaction w/febrile neutropenia
Phase II Dose Treatment	2	1

Intervention	percentage of participants (Number)
	CR + CRi	CR only
>= Second Relapse/Salvage	25	25
First Relapse, First Salvage	56	47
Primary Refractory	20	20
Total	46	39

Intervention	cells x 10^3/microliter (Median)
	Total leukocytes at 0 hours	Total leukocytes at 1 hour	Total leukocytes at 2 hours	Total leukocytes at 4 hours	Total leukocytes at 6 hours	Total leukocytes at 8 hours	Total leukocytes at 12 hours	Total leukocytes at 24 hours
Phase I Dose Escalation - Dose Level 1	2.5	4.3	4	4.7	4.8	4.5	5.1	4.3
Phase I Dose Escalation - Dose Level 2	4.7	7.0	8.5	9.4	11.3	12.0	12.1	7.9
Phase I Dose Escalation - Dose Level 3	3.5	6.4	7.5	8.3	9.5	8.9	7.8	5.8